poster session - American Association for Cancer Research

Transcription

13_15AM_Tue_Layout 1 3/27/15 12:24 PM Page 437
TUESDAY, APRIL 21 AT-A-GLANCE
All sessions eligible for CME credit unless otherwise noted.
7:00 a.m.-8:00 a.m.
Meet-the-Expert Sessions
439-442
8:00 a.m.-12:00 p.m.
Poster Session
443-475
8:00 a.m.-12:00 p.m.
Late-Breaking and Clinical Trials Poster Sessions
476
8:15 a.m.-10:15 p.m.
Plenary Session
477
8:30 a.m.-2:00 p.m.
Professional Advancement Session
478
9:00 a.m.-10:00 a.m.
Meet the MCT Editor-in-Chief
479
10:30 a.m.-11:30 a.m.
AMC Career Conversations
480
10:30 a.m.-12:00 p.m.
NCI/NIH-Sponsored Session
481
10:30 a.m.-12:40 p.m.
Clinical Trials Plenary Session
482
10:30 a.m.-12:30 p.m.
Major Symposia
483-487
10:30 a.m.-12:30 p.m.
AMC Professional Advancement Session
488
10:30 a.m.-12:30 p.m.
Recent Advances in Diagnostics and
Therapeutics Research
489-490
10:30 a.m.-12:30 p.m.
Recent Advances in Epidemiology and
Prevention Research
491
10:30 a.m.-12:30 p.m.
Recent Advances in Organ Site Research
492-493
10:30 a.m.-12:30 p.m.
Special Sessions
494-495
12:00 p.m.-1:00 p.m.
Meet the CIR Editor-in-Chief
496
12:00 p.m.-1:30 p.m.
496
12:30 p.m.-1:00 p.m.
AACR-Elion Award Lecture
497
12:30 p.m.-3:00 p.m.
Therapeutics Research (dedicated to Eddie Reed)
498-499
1:00 p.m.-2:00 p.m.
AMC Career Conversations
500
1:00 p.m.-3:00 p.m.
Major Symposia
501-504
1:00 p.m.-3:00 p.m.
AMC Professional Advancement Session
505
1:00 p.m.-3:00 p.m.
Therapeutics Research
506
April 18-22, 2015 • Philadelphia, PA
437
TUESDAY, APRIL 21 AT-A-GLANCE
All sessions eligible for CME credit unless otherwise noted.
1:00 p.m.-3:00 p.m.
Recent Advances in Epidemiology and
Prevention Research
507
1:00 p.m.-3:00 p.m.
Recent Advances in Organ Site Research
508-509
1:00 p.m.-3:00 p.m.
Regulatory Science and Policy Session
510
1:00 p.m.-5:00 p.m.
Poster Sessions
511-544
1:00 p.m.-5:00 p.m.
Late-Breaking Poster Sessions
545
1:30 p.m.-3:00 p.m.
546
2:30 p.m.-3:30 p.m.
Meet the Mentor: Undergraduate Focus
547
3:00 p.m.-4:00 p.m.
AACR-CICR Award Lecture
548
3:00 p.m.-4:00 p.m.
AACR-ACS Award Lecture
549
3:00 p.m.-4:40 p.m.
Clinical Trials Minisyposium
550
3:00 p.m.-5:00 p.m.
Major Symposia
551-552
3:00 p.m.-5:00 p.m.
Minisymposia
553-557
3:00 p.m.-5:00 p.m.
Regulatory Science and Policy Sessions
558-559
3:30 p.m.-4:30 p.m.
Meet the Director and Staff of the NCI
560
4:00 p.m.-5:00 p.m.
Meet the CD Editors-in-Chief
561
4:15 p.m.-5:15 p.m.
AACR Award Lecture
562
4:15 p.m.-5:15 p.m.
AACR-Burchenal Award Lecture
563
5:00 p.m.-6:30 p.m.
Forums
564-565
5:00 p.m.-6:30 p.m.
566
5:00 p.m.-6:30 p.m.
Regulatory Science and Policy Session
567
5:00 p.m.-6:30 p.m.
Special Session
568
5:00 p.m.-6:30 p.m.
AACR-CRI Award Lecture
569
6:30 p.m.-8:30 p.m.
TME Town Meeting
570
438
AACR ANNUAL MEETING 2015
MEET-THE-EXPERT SESSIONS
Tuesday, 7:00 a.m.-8:00 a.m.
Room 118, Pennsylvania Convention Center
Cell Polarity, Epithelial Homeostasis,
and Metastasis
Ian G. Macara, Vanderbilt University Medical College,
Nashville, TN
Cancers are caused by mutations but are also diseases of
cell behavior. Oncogenic mutations can often be tolerated
within a normal epithelial tissue environment, and we
propose that release from homeostatic constraints permits
the display of the tumorigenic phenotype. Most human
cancers arise from epithelial cells or their progenitors, and
a key feature of these cells is apical/basal polarity. Polarity
signaling through the Par3 protein suppresses tumor
growth and dissemination in several mouse models, and
Par3 protein expression is suppressed in human breast
cancers. In normal mammary tissue, the loss of Par3
triggers two contradictory responses - rapid cell death
through apoptosis and hyper-proliferation. Oncogenic
activation blocks apoptosis and reveals the proliferative
response, driving increased tumor growth. This session and
the ensuing discussion will address the impact of collective
epithelial cell behavior on the tumor phenotype, and
possible directions towards new therapies.
describe a comprehensive program to identify and
characterize the functional consequences and therapeutic
liabilities engendered by specific aberrations found in
patient tumors for the effective implementation of
personalized cancer therapy.
Drugging the Undruggable Using
Fragment-Based Methods
Stephen W. Fesik, Vanderbilt University School of Medicine,
Nashville, TN
Only about 10% of the 30,000 proteins in the human
genome are thought to be druggable with small molecules.
Thus, many proteins that could serve as excellent targets
for therapeutic intervention may be difficult or impossible
to drug. One approach for discovering small molecules
against these challenging targets is fragment-based
methods. In this presentation, the theoretical and practical
aspects of fragment-based methods will be described. In
addition, examples will be presented that illustrate the
power of this approach for targeting challenging cancer
targets that exert their effects through protein-protein
interactions.
Terrace Ballroom I (400 Level), Pennsylvania
Convention Center
Delivering on the Promise of Personalized
Cancer Therapy
Terrace Ballroom IV (400 Level), Pennsylvania
Convention Center
Gordon B. Mills, The University of Texas MD Anderson
Cancer Center, Houston, TX
Genomic Approaches to Cancer
Drug Discovery
The realization of the promise of personalized molecular
medicine requires efficient development and
implementation of novel targeted therapeutics linked to
molecular markers able to identify patients most likely to
benefit. The plethora of aberrations present in each tumor,
the need to distinguish drivers from passengers, and the
combinatorial effects of aberrations on critical cellular
functions represent key challenges to the successful
implementation of personalized medicine. To optimally
benefit patients, we must manage patients based on the
functional consequences of the specific aberrations
present in their tumor. Indeed, even in a known cancer
gene, aberrations can be passengers, hypermorphs
(increased activity), hypomorphs (decreased activity), or
neomorphs that mediate novel functions that require
different personalized management approaches. I will
Todd R. Golub, Broad Institute of MIT and Harvard,
Cambridge, MA
Genomic approaches are now becoming possible not just
to characterize cancer genomes, but to facilitate the
process of drug discovery. In particular, the testing of drug
sensitivity across a large panel of genetically characterized
cancer cell lines can be powerful. We will discuss a new
approach to such cell line profiling, termed, PRISM,
whereby pools of molecularly barcoded cell lines are
profiled as mixtures of cell lines. In addition, high
throughput gene expression profiling as part of the
Connectivity Map/LINCS project can be used as a means to
gain insights into small-molecule mechanism-of-action.
The use of the Connectivity Map to support discovery will
be discussed.
439
Tuesday, 7:00 a.m.-8:00 a.m.
Heterogeneity of Hepatocellular
Carcinoma: From Bench to Bedside
Hongyang Wang, Eastern Hepatobiliary Institute, Shanghai,
China
The heterogeneity of the tumor is a big obstacle for
personalized therapy. Hepatocellular carcinoma (HCC) is an
extraordinarily heterogeneous disease because, in addition
to the common intrinsic cancer heterogeneity resulting
from genome instability, a number of epigenetic alterations
occur, induced by host microenvironment and several
etiologies (virus infection, sexual susceptibility, metabolic
disorder, gut microbiome, alcohol intake, and nonalcoholic
steatohepatitis). Although many efforts have been devoted
to identifying genes responsible for tumorigenesis in the
past few decades, the questions of when to treat, what to
target, in which patient, and how to monitor the cancer
recurrence are still unsolved. Hence, a better
understanding of the more sophisticated crosstalk between
diversified tumor subpopulations and their dynamic
environments in driving HCC progression is critical for
personalized prevention and treatment for HCC patients.
Terrace Ballroom II-III (400 Level), Pennsylvania
Convention Center
MYC and Metabolism Meet on the
Road to Cancer
Chi Van Dang, Abramson Cancer Center of the University
of Pennsylvania, Philadelphia, PA
MYC is one of the most frequently amplified genes in
human cancers, accounting for over 30% of ovarian cancer
and well over 15% of uterine, breast, and esophageal
cancers. MYC is pathognomically activated by
chromosomal translocation in Burkitt lymphoma. Its
ectopic deregulated expression in transgenic mice resulted
in tumorigenesis in a broad range of tissues, attesting to its
tumorigenic role in vivo. MYC encodes the Myc
transcription factor that dimerizes with Max to bind and
regulate target genes. Comprehensive biological, genomic,
chromatin immunoprecipition, and metabolomic studies
revealed that Myc is an oncogenic transcription factor that
amplifies gene expression in a nonlinear fashion to
coordinate nutrient acquisition with macromolecular
synthesis, redox homeostasis, and ribosome biogenesis for
cell growth and division. The role of Myc in regulating
glutamine metabolism and fatty acid synthesis will be
discussed in the context of potential therapeutic
opportunities directed at cancer metabolism.
mTOR Complex 1, Metabolism, and
Therapeutic Opportunities
John Blenis, Weill Cornell Medical College, New York, NY
The mTOR Complex 1 (mTORC1) signaling pathway has
evolved to sense and respond to cellular energy status,
nutrient availability, and surrounding oxygen
concentrations. In addition, mTORC1 can be further
activated by mitogen- and hormone-activated AGC kinases
including Akt and RSK, and suppressed by S6K1 via a
variety of negative feedback loops. The integration of
these multiple inputs control the strength and duration of
downstream signaling, which is important in differentially
regulating mTORC1-dependent processes such as protein
synthesis and cellular metabolism. I will discuss how
mTORC1 and S6K1 regulate aspects of nutrient metabolism,
mRNA metabolism, and protein production; biological
processes critical to the control of cell growth while at the
same time creating vulnerabilities that may provide
important therapeutic opportunities in cancers with
activated mTORC1 signaling.
440
Myeloid-Derived Suppressor Cells in
MDS Pathogenesis
Alan F. List, Moffitt Cancer Center and Research Institute,
Tampa, FL
Despite the diversity of somatic genetic events in
myelodysplastic syndromes (MDS), these disorders share
common biological features of accelerated attrition of
hematopoietic progenitors in an inflammatory bone
marrow (BM) microenvironment. Mounting evidence
implicates sustained activation of innate immune signaling
in both hematopoietic senescence and the pathobiology of
MDS. In particular, BM expansion and activation of myeloidderived suppressor cells (MDSC) have emerged as key
cellular effectors with a pathogenetic role in hematopoietic
impairment. MDS-MDSC are clonally distinct from the
neoplastic clone, indicating that these cells derive from
non-neoplastic myeloid progenitors that precede
emergence of the genetically distinct MDS clone. MDSC
generate hematopoietic suppressive cytokines and
function as potent cytocidal effectors targeting autologous
hematopoietic progenitors. BM expansion of MDSC is
driven by interaction of the pro-inflammatory dangerassociated molecular pattern (DAMP) heterodimer
S100A8/S100A9 with its native receptors, CD33 and TLR-4.
Evidence from an S100A9 transgenic mice model shows
that forced BM expansion of MDSC by S100A9 is sufficient
for MDS development manifested as multilineage
cytopenias and cytological dysplasia, thereby
phenocopying human MDS. In vitro neutralization of
S100A9 in primary human MDS BM specimens markedly
improves colony-forming capacity and decreases cell
death. Therapeutic interventions that promote MDSC
maturation or disrupt S100A9 signaling may improve
hematopoiesis in MDS.
Noninvasive Diagnostic Approaches:
Circulating Tumor Cells
Mehmet Toner, Massachusetts General Hospital,
Charlestown, MA
Viable tumor-derived circulating tumor cells (CTCs) have
been identified in peripheral blood from cancer patients
and are probably the origin of intractable metastatic
disease. However, the ability to isolate CTCs has proven to
be difficult due to the exceedingly low frequency of CTCs
in circulation. We introduced several microfluidic methods
to improve the sensitivity of rare event CTC isolation, a
strategy that is particularly attractive because it can lead
to efficient purification of viable CTCs from unprocessed
whole blood. Our most recent technology is a tumor
marker free (or antigen-independent) approach for sorting
of CTCs based on the inertial focusing strategy, which
allows positioning of cells in a near-single file line, such
that they can be precisely deflected using minimal
magnetic force. We applied this microfluidic platform to
blood samples obtained from lung, prostate, breast, colon,
melanoma, and pancreatic cancer patients. This
presentation will share our integrated strategy to
simultaneously advance the engineering and microfluidics
of CTC-Chip development, the biology of these rare cells,
the potential clinical applications of circulating tumor cells.
Precision Medicine: Intentional and
Incidental Germline Testing
Judy E. Garber, Dana-Farber Cancer Institute, Boston, MA
Germline genetics has entered a new era with the use of
next-generation sequencing. Germline testing for cancer
susceptibility is more often performed using “panel” tests
of multiple genes. Targeted gene testing may be an interim
strategy before whole exome/whole genome, or may be
best for this purpose once optimized. This strategy ensures
that fewer individuals will remain uncharacterized, and that
estimates of penetrance and the range of tumors
associated with germline mutations in specific genes will
be revised, as the populations tested become less and less
selected. The number of variants of uncertain significance
is larger for the expanded number of genes examined, but
this is a temporary problem. The identification of potential
germline predisposition mutations in the course of tumor
genomic analysis is an increasingly common occurrence in
precision medicine. The germline findings increase the
power and utility of genomics in cancer medicine.
Strategies for communication of test results that include
germline data benefit from advanced planning.
Radiation and Immunotherapy: From
Preclinical Models to Cancer Patients
Silvia C. Formenti, New York University, New York, NY
Ionizing radiation can induce immunogenic cell death of
tumors, an effect likely to contribute to the success
associated with radiotherapy (RT) of cancer. Recent
discovery suggests that radiotherapy can be applied as a
powerful adjuvant to immunotherapy and contribute to
convert the irradiated tumor into an in situ vaccine,
resulting in specific immunity against metastases.
Preclinical models of syngeneic tumors have reliably
predicted clinical success, in several distinct tumor settings
and immunotherapy/radiation combinations. For instance,
the success of anti-CTLA4 antibody and RT in a syngeneic
murine model of mammary carcinoma was mirrored by
systemic responses in metastatic melanoma and lung
cancer patients irradiated to one metastatic site, during
anti-CTLA-4 monoclonal antibody ipilimumab. While
promising, this evidence remains preliminary and this
session will discuss research opportunities to define the
optimal immunotherapy/RT combinations.
441
Tuesday, 7:00 a.m.-8:00 a.m.
Stem Cells
XBP1 Promotes Triple-Negative Breast
Cancer By Controlling the HIF1
Transcriptional Program
Catriona H. M. Jamieson, UCSD Moores Cancer Center, La
Jolla, CA
Clinical translation of stem cell research-related discoveries
is predicated on developing novel tools that can detect and
genetically correct stem cell defects, enhance self-renewal
of normal stem cells, and rejuvenate aged stem cells as
well as eradicate malignant stem cells. The hematopoietic
system has served as a paradigm for defining genetic and
epigenetic regulators of self-renewal in protective stem cell
niches in both normal and malignant hematopoiesis.
However, the plethora of changes that occur in other
tissue-specific stem cells in the context of heritable as well
as somatic mutations and epigenetic alterations during
aging and malignant transformation have yet to be clearly
understood or corrected. The ultimate goals of the
regenerative medicine field include defining seminal gene
correction methods to reengineer genetically defective
stem cells to adopt normal cell fate decisions, identifying
genetic and epigenetic regulators capable of promoting
normal-tissue-specific stem cell regeneration that will
enable development of optimal expansion technologies,
and elucidating the factors that promote stem-cell
rejuvenation in an aged host. In addition, early detection
and elimination of cells that have co-opted stem cell
pathways and thus have been reprogrammed to behave
like cancer stem cells has been a major focus of the field. In
this session, recent research insights into stem cell gene
correction, self-renewal, and rejuvenation will be discussed
with an emphasis on improving tissue homeostasis and
stem cell dynamics in response to injury and aging as well
as in the setting of inflammation and cancer.
442
Laurie Glimcher, Weill Cornell Medical College of Cornell
University, New York, NY
Triple-negative breast cancer (TNBC), a form of breast
cancer in which tumor cells do not express the genes for
estrogen receptor, progesterone receptor, and Her2/neu, is
a highly aggressive malignancy with limited treatment
options. We have recently reported that XBP1, a key
component of endoplasmic reticulum (ER) stress and the
Unfolded Protein Response (UPR), is activated in TNBC
and plays a pivotal role in the tumorigenicity and
progression of this human breast cancer subtype.
Depletion of XBP1 inhibited tumor growth and tumor
relapse by reducing the chemotherapy-resistant
CD44high/CD24low population, while enforced XBP1
expression in CD44low/CD24high cells conferred tumorinitiating properties on them. Hypoxia-inducing factor
(HIF)1α is known to be hyperactivated in TNBCs and also
required for the self-renewal of breast TICs3-6 . Genomewide mapping of the XBP1 transcriptional regulatory
network revealed that XBP1 drives TNBC tumorigenicity by
assembling a transcriptional complex with HIF1α that
regulates the expression of HIF1α targets via the
recruitment of RNA polymerase II. Analysis of independent
cohorts of patients with TNBC revealed a specific XBP1
gene expression signature that was highly correlated with
HIF1α and hypoxia-driven signatures and that strongly
associated with poor prognosis. Our findings reveal a key
function for the XBP1 branch of the UPR in TNBC and imply
that targeting this pathway may offer alternative treatment
strategies for this aggressive subtype of breast cancer.
POSTER SESSION
Poster Section 1 • Tuesday, 8:00 AM-12:00 PM
Molecular and Cellular Biology
Autophagy and Metabolic Interactions between Epithelial and Stromal Cells
(not eligible for CME credit)
Poster
Board
1.
3.
4.
5.
6.
7.
8.
Abstract
Number
2897 Phosphatidylcholine synthesis is required for
autophagosome membrane formation and maintenance
during autophagy. Gabriela Andrejeva, Gigin Lin, Harry G.
Parkes, James Mui, Anne-Christine L. Wong Te Fong, Gema
Vizcay-Barrena, Roland Fleck, Martin O. Leach, Yuen-Li
Chung.
2899 Mitophagy imparts enzalutamide resistance in
prostate cancer. Hirak S. Basu, Cynthia L. Schrieber, Jamie M.
Sperger, Maryanne Naundorf, Ashley M. Weichman, Farideh
Mehraein-Ghomi, Dawn R. Church, Joshua M. Lang, George
Wilding.
2900 Biochemical alterations in BRAF inhibitor (BRAFi)
resistant melanoma cells increase their vulnerability to
arginine deprivation. Ying-Ying Li, Niramol Savaraj,
Chunjing Wu, Shumei Chen, Medhi Wangpaichitr, Macus T.
Kuo, Lynn G. Feun.
2901 The role of basal and BRAF inhibitor-induced
autophagy-driven secretion in remodeling the melanoma
tumor secretome. Adam Kraya, David W. Speicher, Ravi
Amaravadi.
2902 The effectiveness of autophagy inhibition in
sensitizing triple-negative breast cancer cells to
chemotherapy. Svetlana Bortnik, Suganthi Chittaranjan, Jing
Xu, Wieslawa H. Dragowska, Jianghong An, Adrienne Kyle,
Nancy E. Go, Lubomir Vezenkov, Courtney Choutka, Amy
Leung, Suzana Kovacic, Damien Bosc, Karen Gelmon, Marcel
Bally, Steven Jones, Robert Young, Sharon Gorski.
2903 Differential regulation of LC3 A and B, GABARAPL
1 and 2 autophagy genes by micro-environmental stress
and role in breast cancer survival. Christos E. Zois, Syed
Haider, Simon Wigfield, Alexandra Giatromanolaki, Efthimios
Sivridis, Karl Morten, Ioannis Roxanis, Russel Leek, Francesca
Buffa, Michael Koukourakis, Adrian L. Harris.
2904 Induction of autophagy reveals a cytoprotective
mechanism by which DNA polymerase gamma (pol-␥)
prevents UVB-induced skin cancer. Sanjit K. Dhar, Vasu
Bakthavachalu, Tadahide Izumi, Jing Chen, Haining Zhu,
Daret K. St. Clair.
April 18 –22, 2015 • Philadelphia, PA
Poster
Board
Abstract
Number
9.
2905 HSP27 as a potential factor to determine the fate
of Gemcitabine- induced autophagy in osteosarcoma:
Survival vs. death. Janice M. Santiago-O’Farrill, Mario
Hollomon, Eugenie Kleinerman, Nancy Gordon.
10.
2906 Role of autophagy in Wnt5A-mediated melanoma
invasion and metastasis. Abibatou Ndoye, Anna Budina,
Marie Webster, Amanpreet Kaur, Reeti Behera, Maureen
Murphy, Ashani T. Weeraratna.
11.
2907 AMPK induction, lysosomal acidification and
melanoma survival increased by p53 dysfunction are
counteracted by inhibiting autophagy. Valery ChavezPerez, Mary Strasberg-Rieber, Manuel Rieber.
12.
2908 A sensitive immunohistochemistry method for in
vivo autophagy biomarker detection and
pharmacodynamic studies. Yu Yang, Natalie R. D’Amore,
Jouhara Chouitar, Jie Yu, Kristine Burke, Zhongmin Xiang,
Lunyin Yu, Kerri Lasky, James Brownell, Chris Simpson, Evan
Luongo, Doug Bowman, Stephen Tirrell, Helen He.
13.
2909 LC3 protein expression associates with UV
exposure in melanoma histopathology. Kirsten A. White,
Salina Torres, Todd A. Thompson, Chien-An A. Hu, Orrin
Myers, Marianne Berwick.
14.
2910 The dual role of autophagy in cadmium induced
prostate carcinogenesis. Trinath P. Das, Arokya M. John,
Suman Suman, Murali Ankem, Chendil Damodaran.
15.
2911 Leptin Notch VEGFR-2 axis influences cancer
stromal cell behavior. Viola Lanier, Merle Jeffers, Johannes
Walterberger, Leonard Anderson, Ruben Gonzalez.
16.
2912 Nitric oxide mediates metabolic coupling of
omentum-derived adipose to ovarian and endometrial
cancer cells. Bahar Salimian Rizi, Kevin Chen, Inka C. Didelija,
Juan Marini, Ann H. Klopp, Deepak Nagrath.
17.
2913 Transcriptional reprogramming of pancreatic
stroma induces metabolic changes in pancreatic tumor
cells. Joelle Baddour, Lifeng Yang, Abhinav Achreja, Seth
Padmabandu, Pari Shah, Rebecca N. Curtis, Thomas
Plackemeier, Radina Khalid, Juan C. Marini, Janusz FrancoBarraza, Edna Cukierman, Chaoxin Hu, Anirban Maitra,
Deepak Nagrath.
Poster
:LJ[PVU
1
1
443
POSTER SESSION
Poster
:LJ[PVU
2
2
Cell Death Therapies 1
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
444
Abstract
Number
2914 Gold magneto nanoparticles induced apoptosis in
liver cancer cells through changes of Ca channel pump
detected by LIBS Technique and RT-PCR array. Ola Ahmed,
Hisham Imam, Abdel-Rahman N. Zekri.
2915 Identification of the mechanisms of
radiosensitization by human papillomavirus (HPV) in head
and neck cancer cell lines. Vanesa Bol.
2916 Tumor wound healing in response to treatmentinduced tumor cell death increases tumor metastasis.
Rebecca S. Cook.
2917 Caspase-8 expression is predictive of tumor
response to death receptor 5 agonist antibody
conatumumab in Ewing’s sarcoma. Zhigang Kang, D S.
Goldstein, Yunkai Yu, Paul S. Meltzer, David M. Loeb, Liang
Cao.
2918 Peptide probe-based in vivo imaging of
apoptosis and early decision on stomach tumor response
to treatment. Fatima Khan, Smriti Gurung, Hyun-Kyung
Jung, Moon-Chang Baek, Yong Woo Choi, In San Kim, Byung
Heon Lee.
2919 A novel J-series prostamide mediates
anandamide-induced endoplasmic reticulum stressapoptosis in tumorigenic keratinocytes. Eman Soliman,
Rukiyah Van Dross, Allison Danell.
2920 Excess of cytoplasmic NPM-ALK driven oncogenic
signaling is toxic and promotes cellular apoptosis and
drug dependency. Monica Ceccon, Maria Elena Boggio
Merlo, Luca Mologni, Lydia Varesio, Teresa Poggio, Matteo
Menotti, Silvia Bombelli, Roberta Rigolio, Andrea Manazza,
Chiara Ambrogio, Giovanni Giudici, Cesare Casati, Mara
Compagno, Suzanne Turner, Carlo Gambacorti Passerini,
Roberto Chiarle, Claudia Voena.
2921 Preclinical characteristics of NP137, a first-inclass monoclonal antibody directed against netrin-1 and
inducing dependence receptors-mediated cell death.
Benjamen Ducarouge, Jean-Guy Delcros, Riad Abès, David
Goldschneider, Benjamin Gibert, John Blachier, David Neves,
Patrick Mehlen, Agnès Bernet, Stéphane Depil.
2922 Development of Bcl2 BH4 antagonist for cancer
therapy. Bingshe Han, Dongkyoo Park, Rui Li, Maohua Xie,
Taofeek Owonikoko, Gabriel Sica, Chunyong Ding, Jia Zhou,
Andrew Magis, Suresh Ramalingam, Fadlo Khuri, Walter
Curran, Xingming Deng.
2923 A novel cell-penetrating peptide targeting ATF5
(CP-d/n-ATF5) exerts anti-cancer activity in vitro and in
vivo against a broad spectrum of human cancers. Georg
Karpel-Massler, Chang Shu, Lily Chau, James M. Angelastro,
Lloyd A. Greene, Markus D. Siegelin.
2924 Suppressing SET reactivates PP2A function in
EGFR wide-type NSCLC and synergizes with taxol to exert
anti-cancer effects. Man-Hsin Hung, Chung-Wai Shiau,
Yung-Jen Hsiao, Hui-Chuan Yu, Wei-Tien Tai, Chun-Yu Liu,
Cheng-Yi Wang, Kuen-Feng Chen.
2925 WAVE3 is associated with chemoresistance in
TNBC by activating tumor angiogenesis downstream of the
STAT1/Hif-1␣/VEGF-A signaling axis. Gangarao Davuluri,
Edward F. Plow, William P. Schiemann, Khalid Sossey-Alaoui.
2926 DR5-targeting sensitizes Lgr5+ stem cells to p53
and Chk2-dependent chemotherapy-induced cell death
and produces dose-limiting gastrointestinal toxicity (GIT).
Niklas K. Finnberg, Prashanth Gokare, Arunasalam Navaraj,
Krystle A. Lang Kuhs, George Cerniglia, Hideo Yagita,
Kazuyoshi Takeda, Noboru Motoyama, Wafik S. El-Deiry.
Poster
Board
14.
15.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Abstract
Number
2927 Targeting p53 with Bak and Bax mitochondrial
targeting signals for the treatment of ovarian cancer.
Phong Lu.
2928 Withanolide E sensitizes renal carcinoma cells to
TRAIL-induced apoptosis by increasing cFLIP degradation.
Brooks D. Alan, Curtis J. Henrich, Karen L. Erickson, Cheryl L.
Thomas, Heidi R. Bokesch, Poonam Tewary, Candace R.
Thompson, Richard J. Pompei, Kirk R. Gustafson, James B.
McMahon, Thomas J. Sayers.
2930 Differential tumour response to birinapant and
irinotecan revealed by non-invasive MRI. Efthymia
Papaevangelou, Gilberto S. Almeida, Yann Jamin, Simon P.
Robinson, Nandita M. deSouza.
2931 Calmodulin-DR5 binding in breast cancer:
Independent of TRA-8 sensitivity. Romone M. Fancy,
Donald J. Buchsbaum, Tong Zhou, Yuhua Song.
2932 Role of death receptor 5 (DR5) in apoptosis
induced by anticancer agents in colon cancer cells.
Jingshan Tong, Jian Yu, Lin Zhang.
2933 The apoptotic mechanism of action of SKI-178, a
novel Sphingosine kinase 1 selective inhibitor. Taryn E.
Dick, Jeremy Hengst, Vijay Kale, Ashley Colledge, Jong K.
Yun.
2934 TRAIL-resistance in pancreatic cancer stem cells
can be regulated through JNK pathway inhibition without
impacting resident stem cell physiology. Alejandro Recio
Boiles, Matthias Ilmer, Jody Vykoukal, Eckhard Alt.
2935 A novel HSP70 inhibitor demonstrates potent
anti-myeloma activity. Charvann K. Bailey, Anna Budina,
Maureen Murphy, Yulia Nefedova.
2936 Mitochondria dysfunction-mediated apoptosis
resistance associates with defective heat shock protein
response in African American prostate cancer. Ajay K.
Chaudhary, Tariq A. Bhatt, Sandeep Kumar, Willie
Underwood, Shahriar Koochekpour, Mojgan Shourideh, Neelu
Yadav, Dhyan Chandra.
2937 MEK/ERK inhibitor GDC-0623 dephosphorylates
and accumulates BIM that enables a synergistic apoptosis
with the Bcl-xL antagonist, ABT-263, in mutant KRAS
colorectal cancer cells. Aziz Zaanan, Koichi Okamoto, Hisato
Kawakami, Shengbing Huang, Frank Sinicrope.
2938 BMI-1 inhibition by PTC-209 induces
mitochondrial apoptosis in acute myeloid leukemia cells.
Kensuke Kojima, Yuki Nishida, Aya Maeda, Dhruv Chachad,
Hiroaki Kitamura, Jo Ishizawa, Michael Andreeff, Shinya
Kimura.
2939 Induction of apoptosis in prostate cancer cells by
altering cell metabolism. Gonzalo Torga, Steven Mooney,
Jelani C. Zarif, Kenneth J. Pienta.
2940 Identifying the minimal region of the ING1 tumor
suppressor capable of efficiently killing cancer cells.
Oleksandr Boyko, Karl T. Riabowol.
2941 Targeting MCL1-dependent cancers through RNA
splicing modulation. Eun Sun Park, Michelle Aicher, Daniel
Aird, Silvia Buonamici, Betty Chan, Cheryl Eifert, Peter
Fekkes, Craig Furman, Baudouin Gerard, Craig Karr, Gregg
Keaney, Kaiko Kunii, Linda Lee, Ermira Pazolli, Sudeep
Prajapati, Takashi Satoh, Peter Smith, John Yuan Wang,
Karen Wang, Markus Warmuth, Lihua Yu, Ping Zhu,
Yoshiharu Mizui, Laura B. Corson.
2942 TRAIL pathway inducer ONC201/TIC10 primes
multiple myeloma cells (MM) for apoptosis by
downregulating X-linked inhibitor of apoptosis. Christina
Leah Kline, Amriti R. Lulla, David Dicker, Joshua E. Allen,
Wafik El-Deiry.
POSTER SESSION
DNA Methylation 2
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
2943 Novel combination therapy of DNMT inhibitor
SGI-110 and PARP inhibitor BMN-673 (talazoparib) for
BRCA-proficient ovarian cancer. Nicholas Pulliam, Pietro
Taverna, John Lyons, Kenneth P. Nephew.
2.
3.
4.
Poster
Board
Abstract
Number
13.
2944 5-azacytidine nucleosides and their derivatives:
Molecular hallmarks of drug resistance & alternative
therapeutic regimen. Khushboo Agrawal, Petr Vojta, Dušan
Holub, Ivo Frydrych, Petr Džubák, Miroslav Otmar, Marcela
Krečmerová, Marián Hajdúch.
2955 The effects of the environmental carcinogen
dibenzo[a,l]pyrene on genome-wide methylation and the
impact of dietary black raspberry in mouse oral tissues.
Yuan-Wan Sun, Kun-Ming Chen, Yuka Imamura Kawasawa,
Anna Salzberg, Cesar Aliaga, Krishnegowda Gowdahalli,
Shantu Amin, Gary Stoner, Karam El-Bayoumy.
14.
2945 Nilotinib abrogates DNMT1-depenent DNA
methylation: A novel mechanism for induction of AML
leukemia regression. Na Shen, Fei Yan, Jiuxia Pang,
Naseema Gangat, Mark R. Litzow, Aref Al-Kali, Shujun Liu.
2956 A targeted bisulfite sequencing method
combining microfluidics-based PCR with Next-Gen
sequencing. Emily Putnam, Lam Nguyen, Hunter Chung,
Peisheng Shi, Xueguang Sun, Marc E. Van Eden, Xi-Yu Jia.
15.
2946 Effects of two novel quinoline-based nonnucleoside DNA methyltransferase inhibitors against bone
sarcomas. Maria Cristina Manara, Sergio Valente, Camilla
Cristalli, Cristina Baricordi, Clemens Zwergel, Paola B
Arimondo, Piero Picci, Antonello Mai, Katia Scotlandi.
2957 Investigating methyl-CpG DNA recognition in
cancer. Tommy W. Terooatea, Megan J. Wallace, Marta W.
Szulik, Alan C. Chugg, Sven Miller, Bethany A. BuckKoehntop.
16.
2958 Discovering therapeutic epigenetic targets using
whole genome siRNA screening. Yasuyuki Okamoto,
Woonbok Chung, Judith Garriga, Jaroslav Jelinek, JeanPierre J. Issa.
17.
2959 Differential DNA methylation in peripheral blood
DNA as a biomarker of hepatocellular carcinoma risk.
Katarzyna Lubecka-Pietruszewska, Lucinda Kurzava, Hannah
Buvala, Kirsty Flower, Samer Gawrieh, Jennifer Mansfield,
Naga Chalasani, James M. Flanagan, Barbara Stefanska.
18.
2960 DNA promoter hypermethylation of genes as
potential diagnostic and prognostic biomarkers for
ovarian cancer. Blanca L. Valle, Elisabetta Kuhn, David
Sidransky, Rafael Guerrero-Preston.
19.
2961 Characterization of methylation profiles reveals
distinct epigenomic patterns in SCLC and NSCLC. Seema
Mukherjee, Bonnie S. Glisson, John D. Minna, Robert
J. Cardnell, Luc Girard, Adi Gazdar, Lixia Diao, Jing Wang,
Lauren A. Byers.
20.
2962 LRH-1 expression in breast cancer tissue and its
association with phenotype and DNA methylation. Jia-Min
Pang, Ashwini Chand, Kevin Knower, Elena Takano, David
Byrne, Evelien Sprenkeler, Ramyar Molania, Ewan Millar,
Soon Lee, Sandra O’Toole, Colin Clyne, Alexander Dobrovic,
Stephen Fox.
5.
2947 Pharmacodynamic (PD) and pharmacokinetic
(PK) results of the second-generation hypomethylating
agent, SGI-110, in patients with hepatocellular carcinoma
(HCC) after progression on sorafenib. Anthony El-Khoueiry,
Mary F. Mulcahy, Tanios Bekaii-Saab, Richard Kim, Crystal
Denlinger, Rakesh Goel, Shweta Gupta, Simone Jueliger,
Aram Oganesian, Harold Keer, John Nemunaitis.
6.
2948 Combination treatment of PARP inhibitor, BMN
673 and DNMT inhibitor, Azacytidine: A potential therapy
for BRCA negative and positive, triple negative breast
cancers. Khadiza Chowdhury, Rena G. Lapidus, Eun Yong
Choi, Feyruz V. Rassool, Stephen Baylin.
8.
2950 Epigenetic silencing BCL6B inactivates p53
signaling and causes human hepatocellular carcinoma cell
resist to 5-FU. Xin Li, Jie Yu, Malcolm Brock, Qian Tao, James
Herman, Ping Liang, Mingzhou Guo.
9.
2951 Evaluation of methylation biomarkers for colon
cancer using normal tissues. Carmen Sapienza, May M.
Truongcao, Jayashri Ghosh.
10.
2952 Determinants of hypomethylation and clinical
responses in relapsed/refractory AML patients treated
with SGI-110, a novel hypomethylating agent in a phase
1/2 study. Woonbok Chung, Pietro Taverna, John Lyons,
Yong Hao, Mohammad Azab, Hagop Kantarjian, Patricia
Kropf, Jean-Pierre Issa.
21.
2953 Genomic DNA hypomethylation as an
independent risk factor for renal cell carcinoma. Julia
Mendoza Perez, Jian Gu, Nizar M. Tannir, Surena Matin, Jose
A. Karam, David W. Chang, Luis A. Herrera, Christopher G.
Wood, Xifeng Wu.
2963 5-hydroxymethylcytosine alterations at H3K9me3
marked genomic regions serve as potential biomarker for
renal cell carcinoma patients. Wei Meng, Tim
Lautenschlaeger, David Frankhouser, Zhenqing Ye, Alexander
Huebner, Victor Jin, Pearlly Yan, Arnab Chakravarti.
22.
2964 Histology-specific patterns of DNA methylation in
Lynch-associated and sporadic ovarian cancer. Anni
Niskakoski, Sippy Kaur, Synnove Staff, Laura RenkonenSinisalo, Heini Lassus, Heikki J. Järvinen, Jukka-Pekka
Mecklin, Ralf Bützow, Päivi Peltomäki.
23.
2965 Identification of SMARCA4/BRG1 mutation types
in NSCLC cell lines and tumors. Wei Zhang, Yibing Yao,
Yunyun Zhou, Xiaotu Ma, Jingsheng Yan, Tao Wang, Luc
Girard, John Minna, Guanghua Xiao, Yang Xie, Adi Gazdar.
11.
12.
2954 Low level methylation (1-20%) or methylation
seeds is a distinct epigenetic regulator of gene expression
and is a strong predictor of methylation gains in AML and
MDS patients. Priyanka Madireddi, Jaroslav Jelinek, Justin
Lee, Matteo Cesaroni, Rodrigo Rodrigues, Yan Zhang, JeanPierre Issa.
3
3
445
POSTER SESSION
Poster
:LJ[PVU
4
4
Genomics 1
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
446
Abstract
Number
2966 The mutational landscape of localized gleason 6 and 7 prostate
cancer. Michael E. Fraser, Veronica Y. Sabelnykova, Takafumi N. Yamaguchi,
Alice Meng, Lawrence E. Heisler, Junyan Zhang, Julie Livingstone, Vincent
Huang, Andre P. Masella, Fouad Yousif, Michael Xie, Nicholas J. Harding, Xihui
Lin, Haiying Kong, Stephenie D. Prokopec, Alejandro Berlin, Dominique Trudel,
Xuemei Luo, Timothy E. Beck, Richard de Borja, Alister D’Costa, Robert E.
Denroche, Natalie S. Fox, Emilie Lalonde, Ada Wong, Taryne Chong, Michelle
Sam, Jeremy Johns, Lee Timms, Nicholas Buchner, Michele Orain, Valerie Picard,
Helene Hovington, Kenneth C. Chu, Christine P’ng, Bryan Lo, Francis Nguyen,
Kathleen E. Houlahan, Christopher Cooper, Shaylan K. Govind, Clement Fung,
Louis Lacombe, Colin C. Collins, Yves Fradet, Bernard Tetu, Theodorus van der
Kwast, John McPherson, Thomas J. Hudson, Rob G. Bristow, Paul Boutros.
2966A A comprehensive investigation of insertional variations of
human endogenous retrovirus elements in tumor tissues. Tomoaki Kahyo,
Hidetaka Yamada, Hong Tao, Yusuke Inoue, Nobuya Kurabe, Haruhiko
Sugimura.
2968 Exome sequencing of desmoplastic melanoma reveals recurrent
NFKBIE promoter mutations and diverse MAPK/PI3K pathway activating
mutations. Alan H. Shain, Maria Garrido, Thomas Botton, Eric Talevich, Iweh
Yeh, Zack Sanborn, Jongsuk Chung, Nicholas Wang, Hojabr Kakavand, Graham
Mann, John Thompson, Thomas Wiesner, Ritu Roy, Adam Olshen, Alexander
Gagnon, Joe Gray, Nam Huh, Joe Hur, Klaus Busam, Richard Scolyer, Raymond
Cho, Rajmohan Murali, Boris Bastian.
2969 Progress in The Cancer Genome Atlas bladder cancer project.
John N. Weinstein, Jaegil Kim, Chad J. Creighton, Rehan Akbani, Katherine A.
Hoadley, William Y. Kim, Margaret B. Morgan, Toshinori Hinoue, Andrew
Cherniack, Xiaoping Su, Andrew J. Mungall, Michael C. Ryan, Dean F. Bajorin,
Jonathan E. Rosenberg, Bogdan Czerniak, Donna Hansel, Victor E. Reuter, Brian
D. Robinson, Hikmat A. Al-Ahmadie, Jeffrey S. Damrauer, Wei Zhang, Yuexin
Liu, Dmitry R. Gordenin, Joshua M. Stuart, Nikolaus Schultz, Gordon Robertson,
Steven J. Jones, Raju R. Kucherlapati, David J. McConkey, Peter W. Laird,
Gordon B. Mills, David J. Kwiatkowski, Seth P. Lerner, TCGA Bladder Cancer
Working Group, TCGA Research Network.
2970 Whole genome sequencing analysis of multiple liver cancer
nodules for determination of causal events for multi-occurrence. Mayuko
Furuta, Akihiro Fujimoto, Masaki Ueno, Shinya Hayami, Yoshi-iku Kawakami,
Kunihito Gotoh, Tatsuhiko Tsunoda, Satoru Miyano, Hideki Ohdan, Kazuaki
Chayama, Hiroki Yamaue, Hidewaki Nakagawa.
2971 Whole exome sequencing reveals heterogeneity within lobular
carcinoma in situ (LCIS) and clonal selection in the progression to malignant lesions.
Michail Schizas, Rita A. Sakr, Britta Weigelt, Charlotte K. Ng, Jose Victor S. Carniello, Dilip
Giri, Salvatore Piscuoglio, Luciano G. Martelotto, Russell Towers, Victor P. Andrade,
Raymond Lim, David B. Solit, Jorge S. Reis-Filho, Tari A. King.
2972 Genomic classification of cutaneous melanoma. Ian R. Watson,
Chang-Jiun Wu, Lihua Zou, Jeffrey E. Gershenwald, Lynda Chin, on behalf of the
Melanoma Analysis Working Group and The Cancer Genome Analysis Research
Network.
2973 Exome sequencing of 243 liver tumors identifies new mutational
signatures and potential therapeutic targets. Kornelius Schulze, Sandrine
Imbeaud, Eric Letouzé, Ludmil B. Alexandrov, Julien Calderaro, Sandra
Rebouissou, Gabrielle Couchy, Clément Meiller, Jayendra Shinde, Shalini Datta,
Frederic Soysouvanh, Anna-Line Calatayud, Roser Pinyol, Laura Pelletier,
Charles Balabaud, Alexis Laurent, Jean-Frederic Blanc, Viccenzo Mazzaferro,
Fabien Calvo, Augusto Villanueva, Jean-Charles Nault, Paulette Bioulac-Sage,
Michael R. Stratton, Josep M. Llovet, Jessica Zucman-Rossi.
2974 Comprehensive and integrative genomic characterization of
diffuse lower grade gliomas. Daniel J. Brat, The Cancer Genome Atlas (TCGA)
Research Network.
2975 Comprehensive analysis of genetic alterations and DNA copy
number in Borrmann type IV gastric cancer. Makiko Yasumoto, Sachiko
Ogasawara, Jun Akiba, Hironori Kusano, Akiko Sumi, Taro Isobe, Junya Kizaki,
Yoshito Akagi, Takuji Torimura, Etsuko Sakamoto, Hiraku Itadani, Tsutomu
Kobayashi, Shinji Mizuarai, Shinji Oie, Hirohisa Yano.
2976 Comprehensive Pan-Genomic characterization of adrenocortical
carcinoma. Siyuan Zheng, Andrew D. Cherniack, Ninad Dewal, Richard A.
Moffitt, Ludmila Danilova, Bradley A. Murray, Antonio M. Lerario, Tobias Else,
Theo A. Knijnenburg, Giovanni Ciriello, Seungchan Kim, Guillaume Assie, Olena
Morozova, Rehan Akbani, Juliann Shih, Katherine A. Hoadley, Toni K. Choueiri,
Jens Waldmann, Ozgur Mete, Gordon A. Robertson, Matthew Meyerson, Michael
J. Demeure, Felix Beuschlein, Anthony Gill, Ana C. Latronico, Maria C. Fragosa,
Leslie Cope, Electron Kebebew, Mouhammed A. Habra, Timothy G. Whitsett,
Kimberly J. Bussey, William E. Rainey, Sylvia Asa, Jérôme Bertherat, Martin
Fassnacht, David A. Wheeler, The Cancer Genome Atlas Research Network, Gary
D. Hammer, Thomas J. Giordano, Roel Verhaak.
Poster
Board
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
2977 Most patients with acquired aplastic anemia develop clonal
hematopoiesis early in disease. Daria V. Babushok, Nieves Perdigones, Juan C.
Perin, Timothy S. Olson, Wenda Ye, Jacquelyn J. Roth, Curt Lind, Carine Cattier,
Yimei Li, Helge Hartung, Michele E. Paessler, Dale M. Frank, Hongbo M. Xie, Tracy
M. Busse, Shanna Cross, Gregory M. Podsakoff, Dimitrios Monos, Jaclyn A.
Biegel, Philip J. Mason, Monica Bessler.
2978 An integrated comparative analysis of TCGA lung adenocarcioma
and lung squamous cell carcinoma copy number and RNA-Seq expression
data. Andrea J. OHara, Raja Keshavan, Zhiwei Che, Soheil Shams.
2979 A web portal of ‘next-generation’ clustered heat maps for userfriendly, interactive exploration of patterns in TCGA data. John N. Weinstein,
Rehan Akbani, David W. Kane, James M. Melott, Tod D. Casasent, Rong Yao, Paul L.
Roebuck, Gordon B. Mills, Michael C. Ryan, Christopher Wakefield, Bradley M. Broom.
2980 Relapsed neuroblastomas show frequent RAS-MAPK pathway
mutations. Derek A. Oldridge, Thomas F. Eleveld, Virginie Bernard, Jan Koster, Leo C.
Daage, Sharon J. Diskin, Linda Schild, Nadia B. Bentahar, Angela Bellini, Mathieu
Chicard, Eve Lapouble, Valérie Combaret, Patricia Legoix-Né, Jean Michon, Trevor J.
Pugh, Lori S. Hart, JulieAnn Rader, Edward F. Attiyeh, Jun S. Wei, Shile Zhang, Arlene
Naranjo, Julie M. Gastier-Foster, Michael D. Hogarty, Malcolm A. Smith, Jaime G.
Auvil, Thomas B. Watkins, Danny A. Zwijnenburg, Marli E. Ebus, Peter van Sluis, Anne
Hakkert, Esther van Wezel, C. Ellen van der Schoot, Ellen M. Westerhout, Johannes H.
Schulte, Godelieve A. Tytgat, M. Emmy M. Dolman, Isabelle Janoueix-Lerosey,
Daniela S. Gerhard, Huib N. Caron, Olivier Delattre, Javed Khan, Rogier Versteeg,
Gudrun Schleiermacher, John M. Maris, Jan J. Molenaar.
2981 The epithelial to mesenchymal transition (EMT) produces
colorectal cancer subpopulations with strikingly different mutation profiles.
Mingli Yang, Michael J. Schell, Norman H. Lee, Timothy J. Yeatman.
2982 Genome sequencing reveals the multicentric nature of multiple
synchronous lung adenocarcinomas. Jianjun Zhang, Yu Liu, Lin Li, Jianhua Zhang,
Guangliang Yin, Dongmei Lin, Xiangyang Liu, Hannah Cheung, Sahil Seth, Xingzhi
Song, Xizeng Mao, Jiexin Zhang, Shujun Cheng, Andrew Futreal, Yanning Gao.
2983 In silico prescription of anticancer drugs to cohorts of 28 tumor
types reveals novel targeting opportunities. Carlota Rubio-Perez, David
Tamborero, Michael P. Schroeder, Albert A. Antolin, Jordi Deu-Pons, Christian
Perez-Llamas, Jordi Mestres, Abel Gonzalez-Perez, Nuria Lopez-Bigas.
2984 Heterogeneous mechanisms of acquired resistance in high grade
serous ovarian cancer. David D. Bowtell.
2985 Systematic identification of sex-linked molecular alterations and
therapeutic strategies in cancer. Jonathan Ma, Sadhika Malladi, Andrew H. Beck.
2986 Meta-analysis of whole exome sequencing data reveals the
mutational spectrum of testicular germ cell tumors. Kevin Litchfield, Richard
S. Houlston, Robert Huddart, Brenda Summersgill, Janet Shipley, Clare Turnbull.
2987 Next generation sequencing analysis of genetically engineered
mouse models of human cancers. Wei-Jen Chung, Jason Long, Jason Cheng,
Chris Tran, Anwesha Dey, Anneleen Daemen, Melissa Junttila.
2988 International cancer genome consortium (ICGC). Jennifer L.
Jennings, Thomas J. Hudson.
2989 Intra-tumor heterogeneity and clonal changes in the progression
of DCIS to invasiveness: Combined tumor bulk and single cell analysis. Rita A.
Sakr, Luciano G. Martelotto, Timour Baslan, Charlotte K. Ng, Jude Kendall, Linda
Rodgers, Hilary Cox, Mike Riggs, Sean D’Itali, Asya Stepansky, Narciso Olvera,
Tari A. King, Britta Weigelt, Jorge S. Reis-Filho, James Hicks.
2990 Evidence for diverse mechanisms of tumorigenesis in breast and
ovarian tumors of BRCA1/2 carriers. Kara N. Maxwell, Daniel De Sloover,
Bradley Wubbenhorst, Brandon Wenz, Nicole Lunceford, Lyndsey Emery, Kurt
D’Andrea, Robert D. Daber, Michael D. Feldman, Susan M. Domchek, Katherine L.
Nathanson.
2991 Detection of gene rearrangements using OncoPanel: a targeted
next-generation sequencing assay. Elizabeth P. Garcia, Azra H. Ligon, Ryan P.
Abo, Paola S. Dal Cin, Stanislawa Weremowicz, Priyanka Shivdasani, Phani K.
Davineni, Dimity L. Zepf, Matthew D. Ducar, Paul Van Hummelen, Yonghui Jia,
Frank C. Kuo, Lynette M. Sholl, Laura E. MacConaill, Neal I. Lindeman.
2992 The landscape of long non-coding RNAs in cancer. Yashar S.
Niknafs, Matthew K. Iyer, Arul M. Chinnaiyan.
2993 The landscape of DNA allelic imbalance in the normal-appearing
airway field of cancerization. Yasminka Jakubek, Wenhua Lang, Selina Vattathil,
Melinda Garcia, Lili Huang, Wei Lu, Chi-Wan Chow, Zachary Weber, Gareth E. Davies,
Carmen Behrens, Neda Kalhor, Cesar Moran, Junya Fujimoto, Reza J. Mehran, Jerry
Fowler, Erik A. Ehli, Ignacio I. Wistuba, Paul Scheet, Humam Kadara.
2994 Clinical applications of comprehensive genome analysis of
papillary renal cell carcinoma, type II. Ji-Yeon Kim, Se-Hoon Lee, Soojin Cha,
Kyung Chul Moon, Jong-Il Kim, Dae Seog Heo.
2995 Loss of SHISA3 is an early event of the epithelial-tomesenchymal transition associated with chemoresistance in prostate cancer.
Nicolas J. Martin, Sophie Cotteret, Catherine Gaudin, Marine Garrido, Safae
Aarab-Terrisse, Nader al Nakouzi, Lucas Gentilini, Daniel Compagno, Vasily
Ogryzko, Guillaume Meurice, Karim Fizazi, Anne Chauchereau.
POSTER SESSION
Hypoxia
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
2996 Hypoxia pathway activation in HPV-associated
OSCC. Jens P. Klussmann, JeJennifer Knuth, Steffen Wagner.
2.
2997 Upregulation of S100P by caveolin-1 drives
tumorigenesis and metastasis in hepatocellular carcinoma
under hypoxic stress. Xiaowen Mao, Sivia Yuen-sze Wong,
Frankie Chi Fat Ko, Judy Wai Ping Yam.
3.
2998 MLN4924 inhibition of Cullin-Ring ligases
activates a hypoxic response and secretion of tumor
promoting factors in human MCF7 breast cancer cells.
James Rivard, Amy James, Erin Eleria, Neal Lee, Kathy
Brumbaugh, Greta Wegner, Kevin Reagan.
4.
5.
6.
2999 DEC1 and DEC2 crosstalk between circadian
rhythm and tumor progression. Fuyuki Sato, Yasuteru
Muragaki.
3000 Hypoxic primary tumor stress microenvironments
prime DTCs in lungs for dormancy. Georg Fluegen, Alvaro
Avivar-Valderas, Yarong Wang, Michael Padgen, Yeriel
Estrada, James K. Williams, David Entenberg, Kevin Eliceiri,
Patricia J. Keely, James Castracane, Vladislav V. Verkhusha,
John Condeelis, Julio A. Aguirre-Ghiso.
3001 Alternatively spliced tissue factor promotes
pancreatic cancer progression via carbonic anhydrase IX.
Divya Ramchandani, Dusten Unruh, Vladimir Y. Bogdanov,
Georg F. Weber.
Poster
Board
Abstract
Number
8.
3003 OMX-4.80P, a novel H-NOX oxygen carrier that
oxygenates hypoxic tumors in multiple tumor models and
canine cancer patients, downregulates HIF-1 pathway and
increases response to radiation therapy leading to cures.
Ana Krtolica, Natacha Le Moan, Jen Getz, Tina Davis, Sarah Ng,
Catherine Bedard, Andrew Davis, Philberta Leung, Laura Serwer,
Kevin Tanaka, Tim Keating, Feng Yan, Teri Guerrero, Michael
Kent, Peter Dickinson, Jonathan Winger, Stephen P. Cary.
9.
3004 Contextual RNAi screen identifies ACLY and ACC1
as mediators of hypoxia-induced apoptosis through
metabolic and transcriptional mechanisms. Melissa M.
Keenan, Beiyu Liu, Xiaohu Tang, Jianli Wu, Derek Cyr, Robert
D. Stevens, Olga Ilkayeva, Joseph Lucas, Deborah M. Muoio,
So Young Kim, Jen-Tsan Chi.
10.
3005 Investigating the impact of hypoxia-induced
changes in splicing on tumor microenvironment. Lauren
Brady, Vladimir Popov, Mircea Ivan, MIlan Radovich,
Constantinos Koumenis.
11.
3006 Hyperoxia may be a treatment option for NSCLC.
Junko Hamamoto, Hiroyuki Yasuda, Ichiro Nakachi, Michael
G. Edwards, Masayoshi Miyawaki, Makoto Nishino, Aoi
Kuroda, Tetsuo Tani, Daisuke Arai, Kota Ishioka, Ichiro
Kawada, Katsuhiko Naoki, Tomoko Betsuyaku, Kenzo
Soejima.
12.
3007 Intracellular detection of hypoxia in live cells.
Bhaskar S. Mandavilli, Michael O’Grady.
5
5
447
POSTER SESSION
Poster
:LJ[PVU
6
6
Mechanisms of Genomic Instability in Cancers
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
16.
448
Abstract
Number
3008 CEP55 is a determinant of genomic instability in
aneuploid breast cancer cells and facilitates anti-mitotic
drugs resistance by interacting directly with HSF1.
Murugan Kalimutho, Nicola Waddell, Jessie Jeffry, Sriganesh
Srihari, Kum Kum Khanna.
3009 ATRX validated as tumor suppressor in a novel
mouse model of pediatric and young adult GBM. Carl
Koschmann, Alexandra Calinescu, Daniel Thomas, Felipe J.
Nunez, Marta Dzaman, Johnny Krasinkiewicz, Rosie Lemons,
Neha Kamran, Flor Mendez, Soyeon Roh, David Ferguson,
Pedro R. Lowenstein, Maria G. Castro.
3010 Meiotic cohesin REC8 associates with
chromosome instability in melanoma. Julia Escandon, Scott
Lindsey, Mark S Eller, James M Grichnik.
3011 Two-sided story of DNA repair proteins MRE11
and RAD51 in breast cancer. Shyng-Shiou F. Yuan, Amos
Hung, Ming-Feng Hou.
3012 The Snm1B/Apollo DNA nuclease functions in
resolution of replication stress and maintenance of
genome stability. Ishita Das, Jennifer Mason, JoAnn
Sekiguchi.
3013 RNF126 promotes homologous recombination via
regulating E2F1-mediated BRCA1 expression. Ying Wang,
Ou Deng, Zhihui Feng, Zhanwen Du, Xiahui Xiong, Ceshi
Chen, Zhefu Ma, Junran Zhang.
3014 Identification of the NDP kinase critical for DNA
repair. Ning Tsao, Yu-Jyun Deng, Zee-Fen Chang, Wei
Zhang.
3015 BCL10 is a novel DNA damage response factor
whose expression inversely correlates with the clinical
outcome of breast invasive ductal carcinoma. Min Zhu,
Hongchang Zhao, Xingzhi Xu.
3016 APOBEC3 enzymes induce damage to the cellular
genome during DNA replication. Abby M. Green, Sebastien
Landry, James P. Evans, Sophia Shalhout, Ashok S. Bhagwat,
Matthew D. Weitzman.
3017 Ribonucleotide reductase promotes uracilmediated genome instability in tumor progression. ChihWei Chen, Ning Tsao, Yun Yen, Christine E. Lehman, Yuh-Hwa
Wang, Chian-Feng Chen, Tse-Hsiang Wu, Sui-Chih Tien,
Ming-Hsiang Lee, Zee-Fen Chang.
3018 FANCF, a Fanconi anemia core protein, functions
outside of monoubiquitinating FANCD2 in DNA interstrand
crosslink repair. Muriel W. Lambert, Deepa Sridharan, Pan
Zhang.
3019 GIPC high expression rescues BRCA2 deficiency
and promotes tumorigenesis. Xia Ding, Shyam K. Sharan.
3020 Homology-directed repair in mouse mammary
tissue. Elizabeth Kass, Mary Ellen Moynahan, Maria Jasin.
3021 FoxP1 increases nucleotide excision repair
capacity through activating xeroderma pigmentosum
group C in human breast cancer. Haesung Kim, Lee-Su Kim,
Jae-yong Lee, Jeong-Hyeon Kim, Jeong-Min Lee, Chea-Ha
Kim.
3023 Chromatin accessibility underlies the tumor
suppressor role of BAF (mSWI/SNF) complexes in many
human cancers. Courtney Hodges, Diana C. Hargreaves, Erik
L. Miller, Gerald R. Crabtree.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Abstract
Number
3024 Lack of CK1␦ increases DNA damage and genomic
instability due to defects in DNA repair and mitotic
checkpoints. Yoshimi E. Greer, Bo Gao, Yingzi Yang, Stanley
Lipkowitz, Jeff S. Rubin.
3025 Characterization of CDK9/BRCA1 complex in DNA
damage response. Thales Nepomuceno, Vanessa Fernandes,
Thiago Gomes, Giuliana De Gregoris, Renato Carvalho,
Guilherme Kurtz, Álvaro Monteiro, Marcelo A. Carvalho.
3026 Gastric cancer associated variant of DNA
polymerase Beta (Leu22Pro) induce genomic instability
and cellular transformation. Dawit Kidane, Jenna Rozacky,
Joann B. Sweasy.
3027 Investigating the function of NONO, a novel
double strand break repair factor, and exploring its
potential role as a biomarker for melanoma. Shuyi Li,
Fengjue Shu, Mohammad K. Khan, Brian P. Pollack, Zhentian
Li, Morgan McLemore, William S. Dynan.
3028 Tolerance and intolerance of proximal thymine
glycol in DNA double-strand break repair by
nonhomologous end joining. Duaa Bafail, Sri Lakshmi
Chalasani, Mohammed Al mohaini, Konstantin Akopiants,
Lawrence F. Povirk.
3029 Role of eIF3a expression in cellular sensitivity to
radiation treatment. Rima A. Tumia.
3030 De novo engineering of chromosomal
amplifications in human cells. Josh Lauring.
3031 Replication stress and DNA damage promote
genomic instability in near-tetraploid colorectal cancer
cells. Isabel Quintanilla, Darawalee Wangsa, Markus Brown,
Amaia Ercilla, Greg Klus, Maria Vila, Juan José Lozano, Zoltan
Szallsi, Neus Agell, Antoni Castells, Thomas Ried, Jordi
Camps.
3032 Genomic deregulation and therapeutic role of the
cell-cycle kinase TLK2 in more aggressive breast cancers.
Jin-Ah KIM, Ying Tan, Xian Wang, Xixi Cao, Jamunarani
Veeraraghavan, Yulong Liang, Dean P. Edwards, Xuewen
Pan, Kaiyi Li, Rachel Schiff, Xiaosong Wang.
3033 Generation of a mouse model of young adult
glioblatoma: In vivo expression of mutated IDH1-R132H
gene using the sleeping beauty transposase system. Felipe
J. Nunez, Flor M. Mendez, Carl Koschmann, Alexandra
Calinescu, Pedro R. Lowenstein, Maria G. Castro.
3034 A high-content screen to identify novel
chromosome instability genes. Laura L. Thompson, Allison
Baergen, Zelda Lichtensztejn, Kirk J. McManus.
3035 HDAC8 is recruited to DNA double strand breaks
sites and affects the homologous recombination efficiency
in multiple myeloma. Maria Gkotzamanidou, Masood
Shammas, Jesús Martín Sánchez, Mehmet Mehmet Kemal
Samur, Stephane Minvielle, Florence Magrangeas, Herve
Avet-Loiseau, Athanasios-Meletios Dimopoulos, Kenneth C.
Anderson, Nikhil C. Munshi.
3036 The SUMO-targeted ubiquitin ligase RNF4
regulates BLM helicase’s function in dormant origin firing.
Nathan A. Ellis, Wei-Chih Yang, Mary Yagle, Jianmei Zhu, Jing
Huang, Michael Seidman, Michael J. Matunis.
POSTER SESSION
Mitochondrial Function
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
3038 G quadruplex stabilization induces mitophagy in
S. cerevisiae. Jennifer Stundon.
2.
3039 Targeting mitochondrial DNA polymerase gamma
(POLG) as a novel therapeutic strategy for acute myeloid
leukemia (AML). Sanduni Liyanage, Rose Hurren, Rebecca
Laposa, Aaron Schimmer.
3.
3040 NANOG metabolically reprograms tumorinitiating stem-like cells in oxidative phosphorylation and
fatty acid metabolism. Chia-Lin Chen, Dinesh Babu Uthaya
Kumar, Vasu Punj, Jun Xu, Linda Sher, Sonja Hess, Keigo
Machida.
4.
3041 Lymphocyte-specific protein tyrosine kinase
(Lck) interacts with CR6-interacting factor 1 (CRIF1) in
mitochondria to repress oxidative phosphorylation.
Shahrooz Vahedi, Fu-Yu Chueh, Chao-Lan Yu.
5.
3042 A novel integrated approach for deciphering the
mitochondrial mutation enigma in glioblastoma. Rhiannon
E. Lloyd, Kathleen Keatley, Anais Laleve, Samantha C.
Higgins, Stavros Polyzoidis, Keyoumars Ashkan, Helen L.
Fillmore, Simon J. Heales, John E. McGeehan, Iain
Hargreaves, Brigitte Meunier, Geoffrey J. Pilkington.
6.
3043 Discovery of a novel mitochondrial protein
complex containing pro-apoptotic Noxa in leukemia.
Jeffrey S. Gaynes, Eric A. Hanse, Ameeta Kelekar.
7.
3044 The ability of tubulin to close mitochondrial VDAC
pores depends on beta tubulin isotype. Kely L. Sheldon,
Dan L. Sackett.
8.
3045 Novel altered mitochondrial genes in prostate
cancer progression. Tanya C. Burch, J. S. Rhim, Julius O.
Nyalwidhe.
9.
3046 Glutamate dehydrogenase 1 signals through
antioxidant glutathione peroxidase 1 to regulate redox
homeostasis and tumor growth. Lingtao Jin, Dan Li, Gina
Alesi, Jun Fan, Hee-Bum Kang, Lu Zhou, Titus Boggon, Kelly
Magliocca, Chuan He, Martha Arellano, Hanna Khoury, Dong
Shin, Fadlo Khuri, Sumin Kang.
10.
3047 Mitochondrial DNA copy variation and TFAM
expression in astrocytoma. Suely K. Marie, Roseli Silva,
Antonio Lerario, Miyuki Uno, Sueli M. Oba-Shinjo.
11.
3048 Study of mitochondria in multi-drug resistance
and Polyphyllin D anti-cancer effect in hepatocellular
carcinoma. Brandon Ho Ngai, Jacky Fong Chuen Loo, Siu Kai
Kong.
Poster
Board
Abstract
Number
12.
3049 BRAF status and low glutamine/glucose influence
glutamine addiction modulated by oxidative stress in
human melanoma cells. Manuel Rieber, Valery ChavezPerez, Mary Strasberg-Rieber.
14.
3051 Functional bioenergetic signature predicts
therapeutic responses to BPM 31510. Anne R. Diers, Michael
A. Kiebish, Arleide Lee, Rakibou Ouro-Djobo, Stephane Gesta,
Vivek K. Vishnudas, Rangaprasad Sarangarajan, Niven R.
Narain.
15.
3052 NAMPT inhibition induces mitochondrial
dysfunction leading to apoptosis in chronic lymphocytic
leukemia cells. Eric D. Bouchard, Edgard M. Mejia, Iris
Gehrke, Armando G. Poeppl, Donna Hewitt, James B.
Johnston, Spencer B. Gibson, Grant M. Hatch, Versha Banerji.
16.
3053 Knockout of UCP2 suppresses skin
carcinogenesis. Annapoorna Sreedhar, Chunjing Zhang,
Yunfeng Zhao.
17.
3054 Bioenergetic signature of stromal cells defines
the aggressiveness of prostate cancer. Praveen K. Vayalil,
Aimee Landar.
18.
3055 Regulation of mitochondria-nuclear crosstalk in
triple negative breast cancer. Jun H. Park, Sajna A.
Vithayathil, Nagireddy Putluri, Efrosini Tsouko, Taraka R.
Donti, Daniel E. Frigo, Chad J. Creighton, Michael T. Lewis,
Arun Sreekumar, Lee-Jun Wong, Benny A. Kaipparettu.
19.
3056 Mitochondrial DNA copy number and risk of
second primary tumors in long-term breast cancer
survivors. Miguel Santibanez, Alma Rodriguez, Michelle A.
Hildebrandt, David W. Chang, Xifeng Wu.
20.
3057 Potentiation of LPS-induced toxicity in human
hepatoma HepG2 cells by aspirin and its protection by
N-acetyl cysteine. Haider Raza, Annie John, Jasmin shafarin.
21.
3058 Oxidative phosphorylation-dependent regulation
of cancer cell apoptosis in response to anticancer agents.
Sandeep Kumar, Neelu Yadav, Tim Marlowe, Ajay Chaudhary,
Jianmin Wang, Jordan O’Malley, Patrick Boland, Srinivas
Jayanthi, Thallapuranam K. Kumar, Nagendra Yadava, Dhyan
Chandra.
7
7
449
POSTER SESSION
Poster
:LJ[PVU
8
8
Oncomirs
Poster
Board
1.
2.
3.
4.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
450
Abstract
Number
3059 miR-518c-5p promotes the metastasis of oral
cancer cells in a CXCR4-dependent and -independent
manner. Makoto Kinouchi, Daisuke Uchida, Nobuyuki
Kuribayashi, Tetsuya Tamatani, Hirokazu Nagai, Hitoshi
Kawamata, Youji Miyamoto.
3060 The role of miR-135b in clinical outcome and
metastasis in colorectal cancer. Wei-Ran Wang, Yawen
Cheng, Nan-Yung Hsu Hsu.
3061 In vivo role of miR-32 in prostate cancer. Leena
Latonen, Mauro Scaravilli, Fuping Zhang, Pekka Ruusuvuori,
Matti Poutanen, Tapio Visakorpi.
3062 miR-671-5p promotes epithelial-tomesenchymal transition by downregulating FOXM1
expression in breast cancer. Xiaohui Tan, Yebo Fu, Liang
Chen, Shejuan An, Woojin Lee, Yinglei Lai, Katayoon Rezaei,
Sana Tabbara, Christine B. Teal, Yan-gao Man, Robert Siegel,
Rachel F. Brem, Sidney W. Fu.
3064 MicroRNA-21 enhances the effect of ionizing
radiation via alteration of the DNA damage response. Tu
Dan, Ajay Palagani, Tiziana DeAngelis, Sunny Han, Lance
Liotta, Richard Pestell, Nicole Simone.
3065 MicroRNA-137 confers chemoresistance by
suppressing CASP3 in lung cancer cells. Te-Jen Shu,
Sung-Liang Yu, Jeremy J. W. Chen.
3066 Regulation of oncogenic Zeb1 by microRNA-23b
in bladder cancer. Shahana Majid, Altaf A. Dar, Sharanjot
Saini, Soichiro Yamamura, Varahram Shahryari, Yozo Mitsui,
Yuichiro Tanaka, Rajvir Dahiya, Guoren Deng.
3067 Expression of miR-301a regulates metastasis and
act as a lethal marker for prostate cancer. Trinath P. Das,
Suman Suman, Arokya M. PapuJohn, Akhila Ankhem,
Sandhya R. Rao, Jamie C. Messer, Houda Alatassi, Murali M.
Ankhem, Chendil Damodaran.
3068 Integrative tcga analyses identify key microRNAs
involved in chemoresistance. Fangrong Shen, Sehgal
Vasudha, Sherry Wu, Ehsanipour, Ehsan A, Olson Robert C,
Ivan, Cristina, Baggerly, Keith A, Ram, Prahlad, Sood, Anil K.
3069 The role of miR-30c-2* in clinical outcome and
drug resistance in HPV-infected non-small cell lung cancer.
Ya-Wen Cheng, Hsiao-Ching Lin.
3070 MicroRNA-155 directly targets PDCD4 and
activates BIC promoter through AP-1 dependent
transcription to replenish miR-155 expression in SAS cells.
shabir A. zargar, Devarajan Karunagaran.
3071 MicroRNA-486 (miR-486) promotes invasion by
targeting RECK in nasopharyngeal carcinoma cells. ChinTarng Lin, Cheng-Der Wu.
3072 miR-551b amplification regulates STAT3
expression and resistance to anoikis of ovarian cancer
cells. Pradeep Chaluvally Raghavan, Sunila Pradeep, Yiling
Lu, Anil Sood, Gordon Mills.
3073 Reorganization of metastamiRs in the evolution
of metastatic aggressive high-risk neuroblastoma. Faizan
H. Khan, SatishKumar Ramraj, Sheeja Aravindan, Mohan
Natarajan, Terence H. Herman, Natarajan Aravindan.
3074 A novel microRNA promoting colon cancer
metastasis and relapse by forming a positive feedback
between cancer and stromal cells. Pengcheng Bu, Lihua
Wang, Xiling Shen.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Abstract
Number
3075 miRNA-10a* enhances invasiveness via
suppression of HDAC5 in lung cancer. Pin-Yen Hsu, BingChing Ho, Chiou-Ling Cheng, Hsuan-Yu Chen, Sung-Liang Yu,
Guan-Tarn Huang.
3076 Post-transcriptional regulatory mechanisms
contributing to the evolution of paclitaxel resistance in
breast cancer model cell line, SKBR3. Sambasivarao
Damaraju, Preethi Krishnan, Marc S. George, Jack Tuszynski,
Carol Cass, IngSwie Goping, Olga Kovalchuk.
3077 Dysregulation of microRNA-mRNA regulatory
networks in the bronchial airway epithelium of smokers
with lung cancer. Ana Brandusa Pavel, Joshua D. Campbell,
Gang Liu, Sherry Zhang, Hanqiao Liu, Lingqi Luo, Ji Xiao, Kate
Porta, Duncan Whitney, Steven Dubinett, David Elashoff,
Marc E. Lenburg, Avrum Spira.
3078 Epigenetic regulation of miR-138 confers cancer
stem cell characteristics of renal cell carcinoma. Eun-Jin
Yun, Jiancheng Zhou, Chun-Jung Lin, Elizabeth Hernandez,
John Santoyo, Jer-Tsong Hsieh.
3079 Mechanism of hsa-miR-15a in EMT and
chemoresistance in colorectal cancer. Andrew Fesler,
Haiyan Zhai, Jingfang Ju.
3080 Definition of the Ewing sarcoma specific oncomir1 targetome. Raphaela Schwentner, David Herrero-Martin,
Maximilian Kauer, Heinrich Kovar.
3081 miRNA regulation of neuroblastoma cell viability.
Zhenze Zhao, Xiuye Ma, Liqin Du, Alexander Pertsemlidis.
3082 miR-155-5p expression is associated with
response to neoadjuvant paclitaxel treatment of locally
advanced breast cancer. Anne Hege Straume, Einar
Birkeland, Stian Knappskog, Per Eystein Lønning.
3083 Global gene expression profiling of mice tumorderived organoids identifies key microRNAs and metabolic
genes involved in CRC progression. Mahnaz Darvish
Damavandi, Chiara Braconi, Luciano Cascione, Andrea
Lampis, Jens Hahne, Claudio Murgia, Michele Ghidini, Gift
Nyamundanda, Anguraj Sadanandam, Carlo Croce, Owen
Sansom, Nicola Valeri.
3084 MicroRNA involvement in DNA damage response
and BCR signaling in malignant B cells. Katerina Cerna, Jan
Oppelt, Lenka Radova, Katerina Musilova, Vaclav Seda,
Gabriela Pavlasova, Michal Jez, Nikola Tom, Filip Pardy, Jitka
Malcikova, Karla Plevova, Boris Tichy, Yvona Brychtova,
Michael Doubek, Martin Trbusek, Jiri Mayer, Jaroslav Koca,
Raffaele Calogero, Sarka Pospisilova, Marek Mraz.
3085 MicroRNA-186 inhibition alters cell proliferation
and colony formation in prostate cancer. Dominique Z.
Jones, Katharine R. Hobbing, M. L. Schmidt, Geoffrey J. Clark,
LaCreis R. Kidd.
3086 From profiling to function: A role for microRNA
miR-888 in promoting prostate cancer progression. Holly
Lewis, Tsuyoshi Hasegawa, Garrison Glavich, Raymond
Lance, O. John Semmes, Hind Beydoun, Richard Drake,
Aurora Esquela-Kerscher.
3087 MicroRNA 141: A novel regulator of brain
metastasis from breast cancer. Bisrat G. Debeb, Lara
Lacerda, Simone Anfossi, Parmesh Diagaradjane, Khoi Chu,
Lei Huo, Caimiao Wei, Richard Larson, Adam Wolfe, Wei Xu,
Li Li, Daniel Smith, Cristina Ivan, Pamela Allen, Savitri
Krishnamurthy, George Calin, Xiang Zhang, Thomas
Buchholz, Naoto Ueno, James Reuben, Wendy Woodward.
POSTER SESSION
Targeting Cyclin-Dependent Kinases and Checkpoint Kinases for Cancer Therapy
Poster
Board
Abstract
Number
Poster
Board
Abstract
Number
1.
3088
Robb.
Inhibition of CDK5 in colorectal cancer. Caroline M.
10.
2.
3089 CDKN2A and p53 status predicts response to
CDK4/6 inhibition in melanoma. Claire A. Martin, Laura
Kirby, Stephen Wong, Grant A. McArthur, Karen E. Sheppard.
3097 CDKs inhibitor: potential monotherapy for
treatment of triple-negative breast cancer. Sandeep
Rajput, Zhanfang Guo, Cynthia Ma.
11.
3098 The effects of a pan-cyclin dependent kinase
(CDK) inhibitor and its combination with cisplatin in
nasopharyngeal carcinoma (NPC). Pei Li Lim, John SW Low,
Gerhard Siemeister, Boon Cher Goh, Wen-son Hsieh.
12.
3099 Longitudinal genomic and transcriptomic analysis
of mantle cell lymphoma in a targeted combination trial of
a selective CDK4/6 inhibitor. Priyanka Vijay, Pedro Blecua,
Maurizio Di Liberto, David Chiron, Xiangao Huang, Olivier
Elemento, Peter Martin, John P. Leonard, Christopher E.
Mason, Selina Chen-Kiang.
13.
3100 Characterisation of novel chalcone derivatives,
CTR compounds as tubulin polymerisation inhibitors.
Indeewari K. Lindamulage, Hai-Yen Vu, Dr. Piyush Trivedi, Dr.
Hoyun Lee.
14.
3101 In-vitro characterization of Abemaciclib
pharmacology in ER+ breast cancer cell lines. Maria Jose
Lallena, Karsten Boehnke, Raquel Torres, Ana Hermoso,
Joaquin Amat, Bruna Calsina, Alfonso De Dios, Sean
Buchanan, Jian Du, Richard P. Beckmann, Xueqian Gong, Ann
Mcnulty.
15.
3102 AZD1152HQPA Accurin™ nanoparticles inhibit
growth of diffuse large B-cell lymphomas and small cell
lung cancer. Susan Ashton, Paula Taylor, Nicola Curtis, James
Pilling, Thierry Dorval, Jeff Hrkach, Philip J. Jewsbury, Simon
T. Barry.
16.
3103 Cyclin E amplification predicts sensitivity of
primary Uterine Serous Carcinoma (USC) cell lines to the
cdk2 inhibitor CYC065. Emiliano Cocco, Stefania Bellone,
Salvatore Lopez, Elena Bonazzoli, Federica Predolini,
Jonathan D. Black, Alessandro D. Santin.
17.
3104 Molecular features that determine the sensitivity
of cancer cells to abemaciclib, an inhibitor of CDK4 and
CDK6. Xueqian Gong, Li-Chun Chio, MaryJo Lallena, Farhana
Merzoug, Shaoyou Chu, Yue Webster, Jack Dempsey, Xiwen
Ma, Alfonso De Dios, Richard Beckman, Sean G. Buchanan.
3.
3090 Novel Mps1 kinase inhibitors with potent antitumor activity. Antje M. Wengner, Gerhard Siemeister,
Marcus Koppitz, Volker Schulze, Dirk Kosemund, Ulrich Klar,
Detlef Stoeckigt, Roland Neuhaus, Philip Lienau, Benjamin
Bader, Stefan Prechtl, Olaf Doehr, Marian Raschke, Oliver von
Ahsen, Cem Elbi, Ingmar Bruns, Martin Michels, Bertolt Kreft,
Franz von Nussbaum, Michael Brands, Dominik Mumberg,
Karl Ziegelbauer.
4.
3091 Targeting low molecular weight (LMW) cyclin
E-Cdk2 pathway for the prevention of breast cancer. Said
Akli, Dong Yang, Tuyen N. Bui, Khandan Keyomarsi.
5.
3092 In-situ Kinome wide profiling of Palbociclib
treated COLO-205 human tumor xenograft samples. Geeta
Sharma, Subha Vogeti, Wendy Grant, Shuzhen Wu, Christa
Dias, Tyzoon Nomanbhoy, Jiangyue Wu, Arwin Aban.
6.
3093 CDK4 amplification reduces sensitivity to CDK4/6
inhibition in fusion-positive rhabdomyosarcoma. Mary E.
Olanich, Wenyue Sun, Stephen M. Hewitt, Zied Abdullaev,
Svetlana D. Pack, Frederic G. Barr.
7.
3094 Sprouty and cell proliferation in colorectal cancer.
Qiong Zhang, Katherine Shim, Kevin Wright, Alexander
Jurkevich, Sharad Khare.
8.
3095 Longitudinal integrative whole transcriptome and
exome sequencing identifies genes that reprogram
lymphoma cells for clinical response to CDK4/6 inhibition
in combination therapy. Maurizio Di Liberto, Peter Martin,
David Chiron, Priyanka Vijay, Xiangao Huang, Pedro Blecua,
Scott Ely, Olivier Elemento, John P. Leonard, Christopher E.
Mason, Selina Chen-Kiang.
9.
3096 CDK4/6 as a therapeutic target in malignant
melanoma. Jessica L. Teh, Andrew Aplin.
Poster
:LJ[PVU
9
9
451
POSTER SESSION
Poster
:LJ[PVU
10
10
Tumor Suppressor miRNAs
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
452
Abstract
Number
3105 MiR-199a-5p confers tumor suppressive role by
inhibiting stenmness characteristics in triple-negative
breast cancers. Jiawei Chen, Man-Ting Siu, John Chi-Wang
Ho, Vivian Yvonne Shin, Ava Kwong.
3106 Elucidating molecular mechanisms linking
microRNA-206 loss to tumor progression and metastasis.
Kathleen D. Watt, Peter Truesdell, Andrew W. Craig.
3107 MicroRNA-1289 is a novel tumor suppressive
microRNA in human oral squamous cell carcinoma. Kazuki
Iwamoto, Koh-ichi Nakashiro, Hiroshi Tnaka, Norihiko
Tokuzen, Hiroyuki Hamakawa.
3108 MicroRNA-200B inhibits arsenic-transformed cell
migration by targeting protein kinase C␣ signaling
pathway. Zhishan Wang, Brock Humphries, Chengfeng Yang.
3109 A functional microRNA screening approach that
identifies microRNAs affecting melanoma cell invasion.
Claudia E. Weber, Chonglin Luo, Agnes Hotz-Wagenblatt,
Wolfram Osen, Tim Holland-Letz, Stefan B. Eichmüller.
3110 Urinary miR-1825 and miR-484: An oncogene and
a tumor- suppressor gene among prostate cancer patients.
Moemen Abdalla, Taha A. Haj-Ahmad, Yousef Haj-Ahmad.
3111 JNK/c-Jun- and NF-␬B-mediated microRNA-221
governs tumor suppressor HDAC6 to potentiate malignant
progression of liver cancer. Hyung Seok Kim, Qingyu Shen,
Jung Woo Eun, Woo Chan Shin, Hee Doo Yang, Won Sang
Park, Joung Young Lee, Suk Woo Nam.
3112 Decrease of microRNA-122 is a key event during
hepatocarcinogenesis from non-alcoholic steatohepatitis.
Hidetsugu Saito, Yoko Takaki, Azusa Takasugi, Shoji Yamada,
Toshihide Muramatsu, Masaki Kimura, Kazuo Sugiyama,
Hiromu Suzuki, Yae Kanai, Yoshimasa Saito.
3113 Primate-specific miR-663 suppresses
glioblastoma progression and predicts patient prognosis.
Yu Shi, Yi-fang Ping, Xiu-wu Bian.
3114 MicroRNA-205 signaling regulates mammary
stem cell fate and tumorigenesis. Meng-Ju Wu, Chun-Ju
Chang.
3115 miR-30a-5p functions as a tumor suppressor gene
in gastric cancer. Jimin Min, Tae-su Han, Boram Choi, Keun
Hur, Hyuk-Joon Lee, Han-Kwang Yang.
3116 MiR-215 is a tumor suppressor in colorectal
cancer in vitro and in vivo. Petra Vychytilova-Faltejskova,
Jana Merhautova, Jitka Mlcochova, Lenka Radova, Robert
Iliev, Marek Svoboda, Rostislav Vyzula, Ondrej Slaby.
3117 Hsa-miR-140-5p inhibits colorectal cancer stem
cell invasion and metastasis by suppressing Smad2 and
autophagy. Haiyan Zhai, Andrew Fesler, Jingfang Ju.
3118 Identification of tumor suppressive microRNA451a in hypopharyngeal squamous cell carcinoma based
on microRNA expression signature. Ichiro Fukumoto,
Takashi Kinoshita, Toyoyuki Hanazawa, Naoko Kikkawa,
Takeshi Chiyomaru, Hideki Enokida, Noriko Yamamoto,
Yusuke Goto, Rika Nishikawa, Masayuki Nakagawa, Yoshitaka
Okamoto, Naohiko Seki.
3119 miR-296-5p and miR-874-3p control cell
proliferation and apoptosis in HCC via regulation of PIN1
expression. Ka Wai Leong, Chi Wai Cheng, Chun Ming Wong,
Oi Lin Irene Ng, Yok Lam Kwong, Eric Wai Choi Tse.
Poster
Board
16.
17.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
3120 miR-489 function as tumor suppressor miRNA by
targeting HER2 in HER2-positive breast cancer. Yogin
Patel, Nirav Shah, Racheal Botbyl, Jishin Lee, Hexin Chen.
3121 Hypoxia-related microRNA, miR-199a-3p,
displays tumor suppressor function in ovarian cancer.
Yasuto Kinose, Kenjiro Sawada, Koji Nakamura, Akihiko
Yoshimura, Erika Nakatsuka, Seiji Mabuchi, Tadashi Kimura.
3123 miR-520b inhibits malignancy of head-neck
cancer through suppression of cancer stemness by
targeting to CD44 molecule. Ya-Ching Lu, Ann-Joy Cheng.
3124 Synergistic modulation of microRNAs for
treatment of glioblastoma cancer initiating cells. Kimberly
Ornell, Yuan Yin, Alexander Alexander Beliveau, Anjana Jain.
3125 miR-9-3p plays a tumor-suppressor role by
targeting TAZ (WWTR1) in hepatocellular carcinoma cells.
Takaaki Higashi, Hiromitsu Hayashi, Hideaki Takeyama,
Takayoshi Kaida, Kota Arima, Katsunobu Taki, Hirohisa
Okabe, Hidetoshi Nitta, Daisuke Hashimoto, Akira Chikamoto,
Toru Beppu, Hideo Baba.
3126 Survival in glioblastoma cancer patients is
predicted by miR-340, that regulates key cancer hallmarks
by inhibiting NRAS. Danilo Fiore, Cristina Quintavalle, Elvira
Donnarumma, Giuseppina Roscigno, Margherita Iaboni,
Valentina Russo, Assunta Adamo, Fabio De Martino, Adelaide
Greco, Giulia Romano, Soini Ylermi, Arturo Brunetti, Carlo
Maria Croce, Gerolama Condorelli.
3127 Small but lethal, miR-137 acts as a tumor
suppressive microRNA in colorectal cancer. Amber R.
Smith, Rebecca Marquez, Bryan Tsao, Alexandria Roy, Bailey
Wilkerson, Surajit Pathak, Kristi Neufeld, Xiao-Feng Sun,
Liang Xu.
3128 MicroRNA-mediated reprogramming of myeloid
cells by targeting TGF␤ signaling and its associated
molecular network. Suman K. Vodnala.
3129 miR-340 is a modulator of oncogenic signaling in
melanoma. Ashley M. Poenitzsch Strong, Emily G. Adochio,
Vijayasaradhi Setaluri, Vladimir S. Spiegelman.
3130 Discovery of tumor suppressor microRNA using
smoking-related lung carcinogenesis cell model. Jae Sook
Sung, Jong Won Lee, Yeul Hong Kim.
3131 Prognostic significance of miR-34a and its inverse
correlation with c-MET and CDK6 in lung adenocarcinoma.
Ji Hyung Hong, Kang San Roh, Sung-Suk Suh, Suk Chan Lee,
Jae Ho Byun, Myung ah Lee, Jin Hyoung Kang.
3132 Suppressor microRNA-145 is epigenetically
regulated by promoter hypermethylation in esophageal
squamous cell carcinoma. kazuto harada, Yoshifumi Baba,
Keisuke Kosumi, Ryuma Tokunaga, Daisuke Izumi, Mayuko
Ouchi, Kennichi Nakamura, Yuki Kiyozumi, Junji Kurashige,
Yukiharu Hiyoshi, Shiro Iwagami, Yuji Miyamoato, Yasuo
Sakamoto, Naoya Yoshida, Masayuki Watanabe, Hideo Baba.
3133 Deciphering the novel role and underlying
mechanism of let-7i repression in stem-like properties of
head and neck cancer cells. Tsai-Tsen Liao, Muh-Hwa Yang.
3134 MicroRNA located in frequently deleted locus
8p21 regulates prostate cancer EMT, progression and
metastasis. Shinichiro Fukuhara, Nathan Bucay, Shahana
Majid, Varahram Shahryari, Laura Z. Tabatabai, Kirsten
Greene, Soichiro Yamamura, Yozo Mitsui, Yuichiro Tanaka,
Guoren Deng, Rajvir Dahiya, Sharanjot Saini.
POSTER SESSION
Immunology
Adoptive Cell Therapies
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
12.
13.
Abstract
Number
3135 HER2 specific adoptive T cells shown to localize
and infiltrate all sites of disease using combined SPECT
and PET imaging. Sasha E. Stanton, Janet Eary, Edmond
Marzbani, David Mankoff, Lupe Salazar, Doreen Higgins,
Jessica Reichow, Yushe Dang, Mary L. Disis.
3136 Adoptive transfer of bone marrow T cells induces
antitumor immune responses in murine models of
melanoma and neuroblastoma. Krithika N. Kodumudi, Amy
Weber, Ellen Moore, Amod Sarnaik, Shari Pilon-Thomas.
3137 A novel expansion method for functional natural
killer cells and its clinical application. Takeshi Ishikawa,
Naoyuki Sakamoto, Tetsuya Okayama, Kaname Oka, Satoshi
Kokura, Mitsuko Ideno, Akiko Kato, Tatsuji Enoki, Masanari
Kitagawa, Junichi Mineno, Tomoyo Yasuda, Toshifumi Doi,
Yuji Naito, Yoshito Itoh, Toshikazu Yoshikawa.
3138 Cotargeting the tumor and associated vasculature
in triple-negative breast cancer using TEM8 specific T cells.
Tiara Byrd, Kristen Fousek, Antonella Pignata, Christopher
Szot, Kevin Bielamowicz, Amanda Wakefield, Steven
Seaman, Bradley Fletcher, Meenakshi Hegde, Brad St Croix,
Nabil Ahmed.
3139 CD33 directed chimeric antigen receptor T cell
therapy as a novel regimen prior to allogeneic stem cell
transplantation in acute myeloid leukemia. Saad S.
Kenderian, Marco Ruella, Olga Shestova, Michael Klichinsky,
John Scholler, Decheng Song, David L. Porter, Martin Carroll,
Carl H. June, Saar Gill.
3140 Antigen-induced downmodulation is associated
with diminished efficacy of a novel chimeric antigen
receptor targeting anaplastic lymphoma kinase. Alec J.
Walker, Ling Zhang, Adrienne H. Long, Rimas J. Orentas,
Crystal L. Mackall.
3141 Restricting aerobic glycolysis provides functional
improvement of chimeric antigen receptor (CAR)modified T cells. Jillian P. Smith, Adrienne H. Long, Crystal L.
Mackall.
3142 Inhibition of the transcription factor Ikaros
augments the tumoricidal capacity of CD8+ T cells
expressing chimeric antigen receptors. Shaun O’Brien,
Liang-Chuan Wang, Kheng Newick, Rajan M. Thomas,
Andrew Wells, Steven M. Albelda.
3143 Alternative splicing of CD19 mRNA in leukemias
escaping CART-19 immunotherapy eliminates the cognate
epitope and contributes to treatment failure. Elena Sotillo,
David Barrett, Aseb Bagashev, Kathryn Black, Caludia
Lanauze, Derek Oldridge, Robyn Sussman, Colleen
Harrington, Elaine Y. Chung, Ted J. Hofmann, Shannon L.
Maude, Nicole M. Martinez, Pichai Raman, Marco Ruella,
David Allman, Elad Jacoby, Terry Fry, Yoseph Barash, Kristen
W. Lynch, Crystal Mackall, John Maris, Stephen A. Grupp,
Andrei Thomas-Tikhonenko.
3144 Development of immunotherapy for anaplastic
large cell lymphoma (ALCL) using CSF1R retargeted
human T lymphocytes. Daniela Achkova, James Spicer, John
Maher.
3146 T cell therapy targeting a neoantigen reduces
in vivo tumour growth. Else M. Inderberg-Suso, Sebastien
Wälchli, Marit R. Myhre, Mengyu Wang, Hilde Almåsbak,
Gunnar Kvalheim, Gustav Gaudernack.
3147 Generation of exhaustion-resistant memory CD8
T-cells by simultaneous downmodulation of mTORC1 and
PD-1 in activated CD8 T-cells. Alexey Berezhnoy, Agata
Levay, Anugraha Rajagopalan, Yvonne Puplampu-Dove, Eli
Gilboa.
Poster
Board
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
Abstract
Number
3148 Implication of highly cytotoxic natural killer cells
for esophageal cancer treatment. Kee Siang Lim, Ley Fang
Kua, Kosaku Mimura, Kensuke Shiraishi, Wee Joo Chng, Wei
Peng Yong, Dario Campana, Koji Kono.
3149 Chimeric antigen receptor-modified T cells
against several target antigens in multiple myeloma. LungJi Chang, Yuchen Liu, Hao-Hsiang Kuo, Shih-Ting Tsao, Jan S.
Moreb.
3150 GD2-specific chimeric antigen receptor T cells
targeting retinoblastoma. Jatuporn Sujjitjoon, La-ong Sri
Atchaneeyasakul, Shih-Ting Tsao, Elias Sayour, Pa-thai
Yenchitsomanus, Lung-Ji Chang.
3151 T cells engineered to express a chimeric antigen
receptor targeting chondroitin sulfate proteoglycan 4
(CSPG4) specifically kill medulloblastoma and produce
inflammatory cytokines. Christopher M. Rota, Nicholas
Tschernia, Steven Feldman, Crystal Mackall, Daniel W. Lee.
3152 Genetic modification of T cells with a novel
bispecific chimeric antigen receptor to enhance the control
of solid tumors with varying expression of HER2 and GD2.
Kristen Fousek, Amanda Wakefield, Tiara T. Byrd, Daniel
Landi, Ben Bleiberg, Helen Heslop, Stephen Gottschalk, Eric
Yvon, Gianpietro Dotti, Matthew Baker, Nabil Ahmed,
Meenakshi Hegde.
3153 Critical roles of chemo-resistant effector and
regulatory T cells in cancer immunotherapy during
hemostatic proliferation. Ko Sato, Satoshi Watanabe, Yu
Saida, Tomohiro Tanaka, Junko Baba, Aya Ohtsubo, Satoshi
Shoji, Daisuke Ishikawa, Rie Kondo, Masaaki Okajima, Satoru
Miura, Junta Tanaka, Hiroshi Kagamu, Hirohisa Yoshizawa,
Ichiei Narita.
3154 Identification of CD4+ T cell epitopes specific for
the breast cancer associated antigen NY-BR-1. Adriane
Gardyan, Wolfram Osen, Maria Agawal, Inka Zörnig, Eliana
Ruggiero, Manfred Schmidt, Andreas Schneeweiss, Dirk
Jäger, Stefan B. Eichmüller.
3155 Neuroblastoma (NB), Medulloblastoma (MB), and
Ewing’s sarcoma (ES) express ROR1 and can be effectively
targeted with NK cells modified to express an anti ROR1
chimeric antigen receptor (CAR). Mona Elmacken,
Aradhana Awasthi, Janet Ayello, Carmella VanDeVen, Wen
Luo, Yanling Liao, Stanley Riddell, Mitchell S. Cairo.
3156 Construction and validation of an activating and
inhibitory chimeric antigen receptor (CAR) system.
Leonardo Chicaybam, Martin H. Bonamino.
3157 Novel GD2-specific chimeric antigen receptormodified T cells targeting osteosarcoma. Monrat
Chulanetra, Elias Sayour, Lamis Eldjerou, Joanne Lagmay,
Rowan Milner, William Slayton, Lung-Ji Chang.
3158 Ex vivo expansion and activation of human
lymphocytes with a selective agonist of the intermediateaffinity IL-2 receptor. Jared E. Lopes, Jan L. Fisher, Heather
C. Losey, Marc S. Ernstoff, Juan C. Alvarez.
3159 In vitro characterization of third-generation
chimeric antigen receptor T cells directed toward GD2expressing and BRAF-inhibitor resistant melanoma target
cells. Tessa Gargett, Michael P. Brown.
3160 Fine-tuned T cell receptors for cancer
immunotherapy. Bent Jakobsen.
3161 Predictive Immunotherapy Models: Overcoming
the challenge of T cells gene transfer. Pascale Bouillé,
Christine Duthoit, Régis Gayon, Vincent Feuillet, Cédric
Auffray.
12
12
453
POSTER SESSION
Immunology
Poster
:LJ[PVU
13
13
Inflammation and Cancer Progression
Poster
Board
1.
2.
3.
3162 NOD1 augments cancer cell metastatic potential
through p38 MAP kinase activation. Henry Jiang, Sara
Najmeh, Julie Berube, Arielle Leone, Paul Savage, Betty
Giannias, France Bourdeau, Simon Rousseau, Morag Park,
Lorenzo E. Ferri.
3163 Diet-induced obesity is associated with increased
levels of IL-4 and IL-13, macrophage infiltration, fibrosis,
and pancreatic neoplasia in the conditional KrasG12D
mouse model. Chiara Birtolo, Guido Eibl, Aune Moro,
Xiaoman Jung, Susan Morvaridi, Richard Waldron, Aurelia
Lugea, Vay L. Go, Stephen J. Pandol.
3164 Inflammasomes: fanning the flames of malignant
mesothelioma initiation. Joyce K. Thompson, Maximilian B.
MacPherson, Stacie L. Beuschel, Arti Shukla.
4.
3165 Galectin-4, a key regulator of inflammation and
cancer of the intestine. U.S. Rao, Prema S. Rao.
5.
3166 The role of CD4 T cells in murine model of NASHpromoted HCC. Chi Ma, Dean Felsher, Tim Greten.
6.
3167 CCL2 recruits inflammatory monocytes to
facilitate perineural invasion. Richard Bakst, Huizhong
Xiong, Chun-Hao Chen, Sylvie Deborde, Yi Zhou, William
McNamara, Sei Young Lee, Eric Pamer, Richard J. Wong.
7.
3168 A role for tumor-derived CCL2 in directing
leukocyte infiltration and stromal heterogeneity in
pancreatic ductal adenocarcinoma. Graham M. Tooker,
Whitney L. Gladney, Gregory Beatty.
8.
3169 Influence of systemic and local immune response
on overall survival after hepatic resection of colorectal
liver metastasis. Takeomi Hamada, Ishizaki Hidenobu,
Yukihiro Haruyama, Rouko Hamada, Koichi Yano, Kazuhiro
Otani, Yoshiro Fujii, Kazuhiro Kondo, Hiroaki Kataoka.
9.
10.
11.
12.
454
Abstract
Number
3170 IL17 favours carcinogenesis and limits the antitumor responses in pancreatic cancer. Paola Cappello,
Roberta Curto, Gianluca Mucciolo, Simona Rolla, Elisabetta
Tonoli, Francesco Novelli.
3171 IL-25/IL-17E does not induce breast tumor cell
apoptosis and both IL-17A and IL-25/IL-17E contribute to
breast cancer survival and proliferation associated with
generation of pro-oncogenic low molecular forms of cyclin
E. Jérôme Giustiniani, Hervé Curé, Christian Garbar, Yacine
Merrouche, Nathalie Bonnefoy, Jérémy Bastid, Gilles Alberici,
Jean-François Eliaou, Armand Bensussan.
3172 CCL9 induction in myeloid cells of the
premetastatic niche enhances tumor cell survival and
metastatic colonization. Hannah H. Yan, Yanli Pang, Kent
Hunter, Chand Khanna, Li Yang.
3173 The NLRC4 inflammasome promotes breast
cancer progression in diet-induced obese mice. Ryan Kolb,
Nicholas Borcherding, Yinghong Liu, Fang Yuan, Qing Xie,
Fayyaz Sutterwala, Weizhou Zhang.
13.
3174 Retinoblastoma protein 1 implication in the
monocytic - granulocytic transition. Jerome Mastio,
Thomas Condamine, Dmitry Gabrilovich.
14.
3175 CD38-expressing myeloid-derived suppressor
cells promote tumor growth in a murine model of
esophageal cancer. Tatiana A. Karakasheva, Todd J.
Waldron, Evgeniy Eruslanov, Ju-Seog Lee, Shaun O’Brien,
Devraj Basu, Sunil Singhal, Fabio Malavasi, Anil K. Rustgi.
Poster
Board
Abstract
Number
15.
3176 Linking suppressive activity and ER-Stress in
Myeloid Derived Suppressor Cells. Thomas C. Condamine,
Vinit Kumar, Dmitry I. Gabrilovich.
16.
3177 In vitro cellular inflammation caused by
Caco2BBE and HepG2 cells secreted exosomes. Jenniffer L.
Stetler, Brandon S. Canup, Russell P. Puckett, XiangXiao
Meng, Ma Qiang, Hamed Laroui.
17.
3178 Targeting CXCR2 signaling inhibits KRAS(G12D)
induced autocrine growth transformation by suppressing
ERK activation in pancreatic cancer. Abhilasha Purohit,
Michelle Varney, Satya Rachagani, Pavan Myneni, Michel
Ouellette, Surinder K. Batra, Rakesh K. Singh.
18.
3179 Enhanced pancreatic tumor progression in
p48Cre-KrasG12D mice is regulated by natural killer T
(NKT) cells dependent on mPGES-1 in tumor-associated
macrophages. Naveena B. Janakiram, Altaf Mohammed,
Taylor Bryant, Rebekah Ritchie, Gopal Pathuri, Stan Lightfoot,
Mark L. Lang, Chinthalapally V. Rao.
19.
3180 Regulation of stem cells by the tumor suppressor
PP2A-B56␣. Mahnaz Janghorban, Derek Zachman, Xiaoyan
Wang, Anupriya Agarwal, William Fleming, Rosalie Sears.
20.
3181 EGFR and KRAS activation generate discrete
inflammatory responses within the lung tumor
microenvironment. Stephanie E. Busch, Mark L. Hanke,
Kyoung H. Kim, Julia Kargl, A. McGarry Houghton.
21.
3182 Reduced tumor burden and mortality in IL-17RAdeficient EGFR mutant mice. Mark L. Hanke, Stephanie E.
Busch, Julia Kargl, Kyoung H. Kim, A M. Houghton.
22.
3183 Role of danger signals in tumor elicited
inflammation. Ralph Francescone, Debora VendraminiCosta, Oxana Dmitrieva, Vivi Hou, David Posocco, Sergei
Grivennikov.
23.
3184 Tumor-entrained dendritic cells promote ICOS/
ICOSL-dependent Th17-like responses in pancreatic
adenocarcinoma. Rocky M. Barilla, Raul Caso Caso, Antonina
Avanzi, Anjlee Panjwani, Xiaopei L. Zeng, Steve Matthews,
Daniel M. Tippens, Lena Tomkoetter, Elliot M. Levie, Alejandro
Torres-Hernandez, Donnele Daley, George Miller.
24.
3185 Complement C5 promotes male bias of pancreatic
neuroendocrine tumor metastasis. Tanupriya Contractor,
Chang Chan, Shinta Kobayashi, Richard Clausen, Yvonne Sun,
Edaise da Silva, Evan Vosburgh, Arnold J. Levine, Laura Tang,
Chris R. Harris.
25.
3186 Role of Interleukin 1 signaling in tumor elicited
inflammation and colon cancer. Oxana Dmitrieva, David
Possoco, Ralph A. Francescone, Vivianty Hou, Debora B.
Vendramini-Costa, Sergey Grivennikov.
26.
3187 Depleting cells expressing fibroblast activation
protein disrupts tumor-promoting desmoplasia. Albert Lo,
Liang-Chuan S. Wang, John Scholler, James Monslow, Diana
Avery, Rebecca A. Evans, David J. Bajor, Amy C. Durham,
Elizabeth L. Buza, Robert H. Vonderheide, Carl H. June,
Steven M. Albelda, Ellen Puré.
27.
3188 MEK and TAK1 signaling interactions coordinately
regulate inflammation and apoptosis in KRAS dependent
colon cancer cells. Kelsey L. McNew, William J. Whipple,
Anita K. Mehta, Trevor Grant, Anurag Singh.
POSTER SESSION
Tumor Biology
Dynamic Regulation of the Tumor Microenvironment
Poster
Board
1.
2.
3.
4.
5.
6.
7.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
3189 Tunneling nanotube formation is significantly
upregulated in invasive cancer cells. Snider Desir, Subbaya
Subramanian, Clifford Steer, Emil Lou.
3190 Characterization of the mechanistic and
functional link between tumor microenvironment and
cancer cells using metabolic flux analysis. Hongyun Zhao,
Lifeng Yang, Abhinav Achreja, Tyler Moss, Thavisha Tudawe,
Juan Marini, Donna Peehl, Prahlad T. Ram, Deepak Nagrath.
3191 The role of rigidity in myeloid-tumor cell
interactions in bone. Denise Buenrostro, Ushashi Dadwal,
Scott Guelcher, Julie Sterling.
3192 Cooperation between adenosinergic and hypoxic
signals in shaping chronic lymphocytic leukemia
microenvironment. Sara Serra, Davide Brusa, Roberta
Buonincontri, Valentina Audrito, Tiziana Vaisitti, Simon
Robson, Silvia Deaglio.
3193 Expression analysis reveals candidate genes
involved in highly invasive high-hyaluronan binding
subpopulations of prostate cancer cell lines. Sean J. Leith,
Ann F. Chambers, James B. McCarthy, Joseph L. Chin, Eva A.
Turley.
3194 Inhibition of breast cancer - fibroblast interaction
by specific micronutrient combinations. Neha Shanker, M.
Waheed Roomi, Aleksandra Niedzwiecki, Matthias Rath.
3195 STAT3 inhibition using shRNA inhibits GBM
proliferation, cell migration, anchorage-independent
growth of mouse, rat, and human stem-like cells in vitro;
and it induces long term survival and anti-GBM immunity
in vivo. Nathan T. VanderVeen, Nicholas Raja, Elizabeth Yi,
James Curtin, Peter Chockley, Hikmat Assi, Jonathan
Savakus, Tom Mikkelsen, Samuel Rabkin, Pedro R.
Lowenstein, Maria G. Castro.
3197 Exosome secretion in ovarian carcinoma. Esther C.
Broner, Tali Tavor Re’em, Claes Tropé, Ben Davidson, Reuven
Reich.
3198 The impact of aerobic exercise on oxygenation
and vascularity in breast cancer models. Jennifer M.
Wiggins, Jennifer A. Lee, Lori Rice, Dietmar Siemann.
3199 Stable isotope resolved metabolomics (SIRM) on
fresh human tissues as a preclinical drug testing platform.
Andrew N. Lane, Teresa W. Fan, Alexander C. Belshoff,
Richard M. Higashi, Jeremiah Martin, Michael Bousamra.
3200 Acidic microenvironment activates endoplasmic
reticulum stress pathways through GPR4 in human
vascular endothelial cells. Lixue Dong, Elizabeth A.
Krewson, Li V. Yang.
3201 Complement component C3 and complement
factor B regulate growth of cutaneous squamous cell
carcinoma. Pilvi Riihila, Mehdi Farshchian, Markku Kallajoki,
Atte Kivisaari, Seppo Meri, Reidar Grenman, Ritva
Heljasvaara, Taina Pihlajaniemi, Juha Peltonen, Sirkku
Peltonen, Veli-Matti Kahari.
3202 Single cell analysis of ascites macrophages in
ovarian cancer. Huanhuan Mahsa He, Feiqiao Brian Yu,
Stephen R. Quake, Oliver Dorigo.
3203 Multiple myeloma microenvironment and obesity.
Erica Bullwinkle.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
3204 Tissue engineered models of metastatic bone
disease for the study of prostate cancer cell dormancy.
Yanwan Liao, Jun Jie Aaron Tan, Sahaana Tamilselvan, Jerry
Chan, Ruowen Ge, Lui Shiong Lee, Mark Chong.
3205 Breast cancer cell quiescence in bone is
modulated by Osteo-TAFs. Karen M. Bussard, Frank C.
Marini.
3206 SPARC in tumor microenvironment induces
dormancy of prostate cancer in bone. Sambad Sharma, Fei
Xing, Yin Liu, Kerui Wu, Aya Kobayashi, Kounosuke Watabe.
3207 The roles of cancer-associated fibroblasts in
stemness maintenance of lung cancer cells. Chih-An Lin,
Chao-Chi Ho, Jeremy J. Chen.
3208 Stromal up-regulation of gene expression in
prostate cancer cells: Role of microenvironment. Shingo
Ashida, Chiaki Kawada, Keiji Inoue, Taro Shuin.
3209 The expression of SLC7A11 transporter in lung
and pancreatic cancer tissues at different stages of
development. Jonathan A. Moreno, Maria P. Lambros.
3210 Level of Osteoprotegerin expression is breast
cancer subtype specific. Stephanie Tsang, Ashleigh Renaud,
Kim Roseman, Yuko Imaizumi, Nalini Yadav, Michael
Weichhaus, Linda Connelly.
3211 Heterogeneity of PPAR␤/␦ expression in
colorectal tumor stroma. Eddie H. Tan, Ming Keat Sng,
Jeremy S. Chan, Nguan Soon Tan.
3212 Metastatic breast cancer cell communication
within a pro-dormancy bone marrow niche. Trevor T. Price,
Clara H. Lee, Qing Cheng, H. K. Lyerly, William E. Fogler, John
L. Magnani, Dorothy A. Sipkins.
3213 Extracellular acidosis alters polarization of
macrophages. Asmaa E. El-Kenawi, Arig A. Ibrahim-Hashim,
Kimberly A. Luddy, Shari A. Pilon-Thomas, Robert A.
Gatenby, Robert J. Gillies.
3214 Genome-wide analysis of stroma-tumor crosstalk
pathways in lung cancer: therapeutic implications. Hyejin
Choi, Jianting Shen, Anna Durrans, Tina El Rayes, Kari Fischer,
Dingcheng Gao, Steve Wong, Nasser Altorki, Vivek Mittal.
3215 Microenvironmental impact on breast cancer cell
dormancy and drug sensitivity in a 3D model. Bo Han,
Josephine Fang, Shih-Jye Tan, Yi-Chen Wu.
3216 Immunogenicity and genomic profiling reveal
sub-clonal diversity of a murine acute myeloid leukemia
(AML) cell line. Carine Brinster, Virginie DRISS, Bruno
Quesnel, Martin Figeac, Frédéric Leprêtre, Céline Villenet,
Isabelle Briche.
3217 NextGen strategies for mapping genetic modifiers
in the tumor microenvironment. Michael Flister, Angela
Lemke, Michael Dwinell, Carmen Bergom, James Shull,
Howard Jacob.
3218 Transcriptome characterization by RNA
sequencing identifies molecular and clinical subgroups in
high risk neuroblastoma. Shile Zhang, Jun S. Wei, Rajesh
Patidar, Young K. Song, Sivasish Sindiri, Xinyu Wen, Shahab
Asgharzadeh, Robert C. Seeger, John M. Maris, Jamie M.
Guidry Auvil, Daniela S. Gerhard, Javed Khan.
Poster
:LJ[PVU
14
14
455
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
15
15
Human-in-Mouse Models of Cancer 2
Poster
Board
1.
3219 A patient-centric repository of PDX models for translational
oncology research. Tin O. Khor, Ido Ben Zvi, Amanda Katz, David
Vasquez-Dunddel, Ido Sloma, Daniel Ciznadija, David Sidransky, Keren
Paz.
2.
3220 Establishment and characterization of patientderived tumor xenograft using gastroscopic biopsies in
gastric cancer. Jing Gao, Lin Shen, Yan Zhu, Tiantian Tian.
3221 Development of patient-derived xenograft (PDX)
models for gastrointestinal stromal tumors (GIST) as a preclinical platform for drug development. Jill Ricono, Chelsea
Mullins, Praveen Nair, Cyrus Mirsaidi, Thomas Broudy.
3222 Biomarker discovery through bioinformatic
analysis of genomic profiles of PDX models with different
responses to cancer therapies. Jingjing Jiang, Tengfei Yu,
Ying Yan, Wei Du, Tingting Tan, Xuqin Yang, Jiali Gu, Liang
Hua, Katherine X. Ye, Zhenyu Gu.
3223 A true orthotopic ovarian cancer patient-derived
xenograft (PDX) model. Hongmei Cui, Yingyan He, Clemens
Krepler, Janos Tanyi, Mark A. Morgan, Robert A. Burger,
Sarah Kim, Emily Ko, Tan Ince, Meenhard Herlyn, Fiona
Simpkins.
3224 Molecular Response LLC tumor bank and patientderived tumor xenograft models: a powerful translational
engine for discovery and development of novel oncology
therapeutics. Thomas Broudy, Jill Ricono, Colleen Scott,
Praveen Nair, Jayant Thatte, Cyrus Mirsaidi.
3225 Identification of predictive drug resistance
markers in preclinical xenograft models (PDX) of soft
tissue sarcomas. Jana Rolff, Frank Traub, Per-Ulf Tunn, Jens
Hoffmann, Iduna Fichtner.
3226 Patient-derived xenograft (PDX) models for
triple negative breast cancer (TNBC): A pre-clinical
platform for drug discovery. Jayant Thatte, Miguel Meza, Jill
Ricono, Cyrus Mirsaidi, Thomas Broudy.
3227 Advanced imaging with PET and MRI in Temozolomide
sensitive and resistant subcutaneous and orthotopic patientderived xenograft (PDX) glioblastoma models. Mette K.
Nedergaard, Carsten H. Nielsen, Kyriakos P. Papadopoulos,
Anthony W. Tolcher, Michael J. Wick, Andreas Kjaer.
3228 Establishment and characterization of orthotopic
mouse models for human uveal melanoma hepatic
metastases. Shinji Ozaki, Mizue Terai, Ken Kageyama, Hanyin
Cheng, Masahiro Ohara, Andrew E. Aplin, Michael J.
Mastranjelo, Takami Sato.
3229 Distinct types of cetuximab resistant KRAS
mutant of colorectal cancer revealed by an integrated
sensitivity assay. Takahiro Tashiro, Hiroaki Okuyama, Hiroko
Endo, Kenji Kawada, Masayuki Ohue, Yoshiharu Sakai,
Masahiro Inoue.
3230 Human stem cell-based model of MYCN-driven
neuroblastoma. Miller Huang, Lauren K. McHenry, Matthew L. Miller,
Grace E. Kim, Branden S. Moriarity, Yuichiro Miyaoka, Marianne E.
Bronner, David A. Largaespada, Bruce R. Conklin, Hanlee P. Ji, John
M. Maris, Katherine K. Matthay, William A. Weiss.
3231 An orthotopic xenograft model of sarcoma
metastasis demonstrates essential role of tumor
microenvironment for metastasis. Seth D. Goldstein,
Masanori Hayashi, Catherine M. Albert, Kyle W. Jackson,
David M. Loeb.
3232 CEP-37440, a highly selective and potent dual
inhibitor of ALK and FAK1 inhibits the proliferation of
inflammatory breast cancer cells. Israa Salem, Lucy Aburto,
Sankar Addya, Inna Chervoneva, Zhaomei Mu, Bruce Ruggeri,
Massimo Cristofanilli, Sandra V. Fernandez.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
456
Abstract
Number
Poster
Board
15.
17.
18.
20.
21.
22.
23.
24.
25.
27.
28.
29.
30.
Abstract
Number
3233 Contribution of cell types and genetic alterations
in breast cancer progression. Divya Bhagirath, Xiangshan
Zhao, William W. West, Hamid Band, Vimla Band.
3235 Validation of anti-human PD1 and PD-L1
antibodies in MiXeno mouse models. Juan Zhang, Meng
Qiao, Lan Zhang, Qian Shi.
3236 Clonal heterogeneity in patient-derived
xenografts: The SCLC model LG0904F1496M23 contains
stable clones with epithelial or mesenchymal
characteristics and differential drug sensitivities. Michael
Mullendore, Luke H. Stockwin, Carrie Bonomi, Kelly
Dougherty, Howard Stotler, Adrienne Kimmel, Biswajit Das,
Vivekananda Datta, Jason Lih, Mickie Williams, James
Doroshow, Melinda Hollingshead, Dianne L. Newton.
3238 Taiwanin A targets against nonsteroidal antiinflammatory drug-activated gene-1 in human lung
carcinoma. Hong-Meng Chuang, Horng-Jyh Harn.
3239 Time-resolved functional perfusion-based analysis of
peptide vs. antibody tumor penetration by photoacoustics.
Christopher Bull, Gavin Bennet, Athena Fletcha, Hellen
Harrison, Leonardo Baldassare, Bruce Hamilton.
3240 Understanding clonal complexity of a tumor
xenograft model via cellular barcoding technology. Justina
X. Caushi, Hyo-eun C. Bhang, Jie Li, Iris Kao, Viveksagar
Krishnamurthy Radhakrishna, Vesselina G. Cooke, Joshua M.
Korn, David A. Ruddy, Shailaja Kasibhatla, Frank Stegmeier.
3241 Tumor-targeting Salmonella typhimurium A1-R
inhibits peritoneal dissemination of ovarian cancer and
prolongs survival of the tumor-bearing nude mice.
Yasunori Matsumoto, Shinji Miwa, Ming Zhao, Yong Zhang,
Shuya Yano, Fuminari Uehara, Mako Yamamoto, Yukihiko
Hiroshima, Makoto Toneri, Michael Bouvet, Hisahiro
Matsubara, Robert Hoffmann.
3242 Xenograft dose-response from intra-mouse dose
escalation. Andrew Chen, Christopher J. Zopf, Jing-Tao Wu,
Wen Chyi Shyu, Arijit Chakravarty.
3243 Notch inhibitors and chemoradiation in an
orthotopic glioblastoma model. Sanaz Yahyanejad, Patrick
Granton, Stefan van Hoof, Lydie Barbeau, Jan Theys, Frank
Verhaegen, Marc Vooijs.
3245 Targeted inhibition of Hedgehog (HH) signal
transduction in rhabdomyosarcoma (RMS) reduces cell
survival in vitro and tumor growth in vivo. Joon Won Yoon,
Christopher Chandler, Marilyn Lamm, King-Fu Leong,
Stephen Iannaccone, Gregory Taborn, Philip Iannaccone,
David Walterhouse.
3246 Novel luciferase labelling technique to improve
imaging of orthotopic prostate and pancreatic cancer
models. Jenni Bernoulli, Johanna Tuomela, Matthias Bozza,
Katja M. Fagerlund, Mari I. Suominen, George Morris, Jussi M.
Halleen, Richard Harbottle.
3247 Primary tumor cell lines generated from patientderived-xenograft models are useful tools for study tumor
biology, drug efficacy. Gang Hu, Yong Huang, Fubo Xie,
Xuzhen Tang, Xueyan Yang, Kunyan Liu, Yixin Zhang,
Weikang Tao, He Zhou.
3248 Establishment and characterization of primary
penile carcinoma cell culture versus xenograft by using
transcriptome analysis. Juan J. Muñoz, Sandra A. Drigo,
Tiago Goss, Hellen Kuasne, Fabio Marchi, Gustavo Guimaraes,
Ademar Lopes, Cristovam S. Neto, Silvia R. Rogatto.
POSTER SESSION
Tumor Biology
Metastasis-Suppressing Genes
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
3249 Recurrent 3p21 deletion in head and neck
squamous cell carcinoma identifies SEMA3F as an antilymphangiogenic metastasis suppressor gene. Colleen L.
Doçi, Constantinos M. Mikelis, Michail S. Lionakis, Alfredo A.
Molinolo, J. S. Gutkind.
2.
3250 Prostaglandin E2 receptor EP1 suppresses breast
cancer metastasis. Jocelyn C. Reader, Xinrong Ma, Namita
Kundu, Olga Goloubeva, Amy Fulton.
3.
3251 Regulation of TNBC kinome by the metastasis
suppressor Raf kinase inhibitory protein (RKIP). Ali E.
Yesilkanal, Casey Frankenberger, Daniel Rabe, Gary L.
Johnson, Marsha R. Rosner.
4.
3252 LGR5 suppresses colon cancer metastasis. Xiaolin
Zhou, Jing J. Wang.
5.
3253 Metastasis suppression by non-KP54 kisspeptins.
Kelsey R. Hampton, Keke M. Pounds, Andrew P. Tremblath,
Danny R. Welch.
6.
3254 Promotion of colon cancer invasion and
metastasis via activation of Notch-Dab1-Abl-RhoGEF
protein Trio. Mark Taketo.
7.
3255 The role of Hdj2 protein in metastatic progression
of experimental intracranial glioma. Darya A. Meshalkina,
Maxim A. Shevtsov, Boris A. Margulis, Irina V. Guzhova.
8.
3256 Glypican-3 (GPC3) inhibits the metastasis
development in a murine breast cancer model through the
activation of p38MAPK signaling pathway. Rocio S. Tascon,
Lilian Castillo, Elisa Bal de Kier Joffé, María G. Peters.
9.
3257 NME1 mediates a switch in expression of beta
integrin subunits that correlates with prolonged patient
survival. M. Kathryn Leonard, Marian Novak, Xiuwei Yang,
Alexey Belkin, David Kaetzel.
Poster
Board
Abstract
Number
10.
3258 Breast Metastasis Suppressor 1 (BRMS1)
phosphorylation appears necessary for metastasis
suppressor activity. Lellys M. Contreras, Boris Sarcevic, Keke
M. Pounds, Danny R. Welch.
11.
3259 Giant obscurins: Novel tumor and metastasis
suppressors in breast cancer. Aikaterini KontrogianniKonstantopoulos, Marey Shriver, Nicole Perry, Kimberly
Stroka, Michele Vitole, David Huso, Stuart Martin,
Konstantinos Konstantopoulos.
12.
3260 Identification of a novel signaling axis that leads
to co-induction of two major actin-regulatory proteins
with anti-migratory properties in breast cancer cells.
Marion Joy, Partha Roy.
13.
3261 Cytochrome p450 3a5 manipulates the
progression of hepatocellular carcinoma via selectively
targeting ros/mtorc2/p-akt (s473) signaling. lei chen,
hongyang Wang.
14.
3262 Mitochondrial haplotype effects on tumor
formation and metastasis are both cell autonomous and
non-cell autonomous. Amanda E. Brinker, Carolyn J. Vivian,
Kyle P. Feeley, Scott W. Ballinger, Danny R. Welch.
15.
3263 Investigating TIP60’s role in regulating cancer
metastasis. Yanzhou Zhang.
16.
3264 Genome-wide shRNA screen identifies ITIH5 gene
as a metastasis suppressor of pancreatic ductal
adenocarcinoma (PDAC). Ken Sasaki, Hiroshi Kurahara, S
Natsugoe, Tomoo Iwakuma, Danny R. Welch.
17.
3265 Thrombopoietin and megakaryocytes in breast
cancer metastasis to bone. Walter Jackson, Andrea M.
Mastro, Donna M. Sosnoski.
16
16
457
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
17
17
Pediatric Cancer: Basic Science 2
Poster
Board
1.
2.
3.
3266 Inhibition of Rho-associated kinase 2 suppresses
MYCN expression and induces differentiation of
neuroblastoma. Cecilia Dyberg, David Forsberg, Susanne
Fransson, Jessika Lännerholm Palm, Bjorn Helge Haug,
Baldur Sveinbjornsson, Tommy Martinsson, Per Kogner, John
Inge Johnsen, Malin Wickstrom.
3267 Novel combination treatment with 13-cis-retinoic acid and
tolfenamic acid induces anti-proliferative response in high-risk
neuroblastoma cells. Sagar Shelake, Don Eslin, Robert Sutphin, Anmol
Wadhwani, Laura E. Kenyon, W. Paul Bowman, Riyaz Basha.
3268 Gene expression associated to relapsing disease in Wilms
tumor indicates a more differentiated phenotype unveiling a distinct
transformation process for patients with a higher risk of relapse.
Antonio Fiorino, Loris De Cecco, Beatrice Gamba, Edoardo Marchesi, Paola
Collini, Andrea Pession, Marilina Nantron, Maurizio Bianchi, Filippo
Spreafico, Silvana Canevari, Paolo Radice, Daniela Perotti.
4.
Ezrin binds to DEAD-box RNA helicase DDX3 and regulates
its function and protein level. Haydar Celik, Kamal P. Sajwan, Amrita V.
Pai, Ben J. Marsh, Yasemin Saygideger Kont, Said Rahim, Jenny Han, Tsion
Minas, Jeffrey A. Toretsky, Aykut Uren.
5.
3270
6.
7.
3269
Distinct and heterogeneous response of Ewing sarcoma cells
to canonical Wnt signaling. Elisabeth A. Pedersen, Rajasree Menon,
Dafydd Thomas, Eric Fearon, Elizabeth Lawlor.
3271 Novel orthotopic pediatric high grade glioma xenografts
evaluated with magnetic resonance imaging mimic human disease.
Jessica K. Boult, Kathryn R. Taylor, Maria Vinci, Sergey Popov, Alexa Jury,
Valeria Molinari, Marta M. Alonso, Wendy Ingram, Angel M. Caraboso,
Michelle Monje, Suzanne A. Eccles, Chris Jones, Simon P. Robinson.
3272 Targeting LIN28 and the RAS/MAP kinase pathway in
atypical teratoid rhabdoid tumors. Jeffrey Rubens, Melanie Weingart,
Antoinette Price, Marianne Hutt-Cabezas, Isabella Taylor, Sariah Allen,
Brent Orr, Charles Eberhart, Eric Raabe.
Poster
Board
Abstract
Number
16.
3281 Oklahoma Nitrone-007: A novel compound for treating
pediatric glioblastoma. Samantha Mallory, Rene McNall-Knapp, Patricia
Coutinho deSouza, Kar-Ming Fung, Debra Saunders, Nataliya Smith,
Shanna Smartwood, Rheal Towner.
17.
3282 Induction and characterization of cyclopamine resistance in
SK-N-DZ neuroblastoma and DAOY medulloblastoma cell lines. Javier
de la Rosa, Amaia Paredes, Javier Asensio-Salazar, Xing Fan, Bárbara
Meléndez, Juan A. Rey, Javier S. Castresana.
18.
3283 The role of formyl peptide receptor 1 (FPR1) in
neuroblastoma tumorigenesis. Igor Snapkov, Carl Otto Öqvist, Yngve
Anton Figenschau, Per Kogner, John Inge Johnsen, Baldur Sveinbjørnsson.
19.
3284 Unfavorable outcomes of EWS-FLI1 expression in different
tissues of a transgenic mouse model. Tsion Z. Minas, Jenny Han, SungHyeok Hong, Tahereh Javaheri, Michaela Schlederer, Lukas Kenner,
Richard Moriggl, Jeffrey Toretsky, Aykut Uren.
20.
3285 Importance of Ras signaling in EphB2-mediated
ependymoma development. Robert A. Johnson, Phylip Chen, Robert
Lyons, Samuel Priddy.
21.
3286 A tissue engineered model of Ewing’s sarcoma. Joseph A.
Ludwig, Salah Lamhamedi Cherradi, Brian Menegaz, Marco Santoro,
Antonios Mikos.
22.
3287 Targeting GSK-3: a new approach for the treatment of
neuroblastoma. Oleksii Dubrovskyi, Andrey Ugolkov, Irina Gaisina,
Gennadiy Bondarenko, Luigi Strizzi, Naira Margaryan, Thomas O’Halloran,
Alan Kozikowski, Mary Hendrix, Andrew Mazar.
23.
3288 The KCNA5 promoter is hypermethylated in Ewing sarcoma
and silencing contributes to cell proliferation. Katherine Ryland, Allegra
Hawkins, Daniel J. Weisenberger, Scott Borinstein, Peter W. Laird, Jeffrey
R. Martens, Elizabeth R. Lawlor.
24.
3289 Skeletal consequences of bone resorption inhibitors
(zoledronic acid and RANKL blocking antibody) injections during
growth: mouse strain disparities and synergic effect. Frederic P. Lezot,
Benjamin Navet, YongWon Choi, Hideo Yagita, Ariane Berdal, Christopher
G. Mueller, Francoise Redini, Dominique Heymann.
8.
3273 PAX3-FOXO1 is essential for initiation but not for recurrence
during rhabdomyosarcoma tumorigenesis. Puspa R. Pandey, Stephen M.
Hewitt, Markku M. Miettinen, Frederic G. Barr.
9.
3274 Neuroblastoma express a novel EGFR extracellular mutation,
EGFR⌬768, which possesses distinct biological and biochemical
properties. James Keller, Kristen A. VanHeyst, Anjaruwee S. Nimnual,
Mathew Varghese, Michael J. Hayman, Edward L. Chan.
25.
3290 Limited intra-tumor versus inter-tumor heterogeneity as
assessed by proteomic profiling of high-risk neuroblastoma. Raquel
Castellanos, Katherine Heaton-Johnson, Jonathan Chung, Edward Nieves,
Michael Fremed, Stephen R. Master, Daniel Weiser.
10.
3275 A novel approach to treat medulloblastoma: The omega-3
fatty acids DHA and EPA reduce medulloblastoma tumor growth in
vitro and in vivo. Linda M. Ljungblad, John-Inge Johnsen, Malin
Wickström, Per Kogner, Helena Gleissman.
26.
3291 Prenatal stress increases neuroblastoma tumorigenesis in
TH-MYCN mice model. Sung-Hyeok Hong, David Christian, Emily Trinh,
Susana Galli, Meredith Horton, Yichien Lee, Christopher Albanese, Olga
Rodriguez, Jason U. Tilan, Joanna Kitlinska.
11.
3276 Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft
models of acute lymphoblastic leukemia by the pediatric preclinical
testing program. Santi Suryani, Kathryn Evans, Jennifer Richmond, Alissa
Robbins, Lauryn Bracken, Raushan Kurmasheva, Peter J. Houghton,
Malcolm A. Smith, Richard B. Lock.
27.
3292 Therapeutic targeting of INI1 deficiency in pediatric ATRT: a
preclinical study utilizing patient-derived orthotopic xenograft (PDOX)
models. Holly B. Lindsay, Mari Kogiso, Lin Qi, Jeffrey C. Murray, Laszlo
Perlaky, Jack M. Su, Patricia Baxter, Adekunle Adesina, Donald W. Parsons,
Murali Chintagumpala, Xiao-Nan Li.
12.
3277 Optimized treatment schedule with the new generation
CD22-targeting immunotoxin LMB11 induces near MRD-negativity in an
ALL mouse model. Fabian Mueller, XiuFen Liu, Alan Wayne, Ira Pastan.
28.
13.
3278 Distinct methylation profiles characterize fusion-positive
and fusion-negative rhabdomyosarcoma. Wenyue Sun, Bishwanath
Chatterjee, Yonghong Wang, Holly S. Stevenson, Daniel C. Edelman, Paul
S. Meltzer, Frederic G. Barr.
3293 Molecular evidence for a parent of origin effect in pediatric
insulinomas. Arupa Ganguly, Tricia Bhatti, Karthik Ganapathy, Laura
Conlin, Courtney MacMullen, Susan Becker, Eduardo Ruchelli, Charles
Stanley.
29.
3279 Expression of chemerin and chemerin receptors in
neuroblastoma: implications in tumorigenesis. Conny Tuemmler, Igor
Snapkov, Ugo L. Moens, Per Kogner, John Inge Johnsen, Baldur
Sveinbjørnsson.
3294 Clonal evolution and integral analysis of hepatoblastoma.
Noriko Hoshino, Masafumi Seki, Motohiro Kato, Kenichi Yoshida, Yusuke
Sato, Atsuko Nakazawa, Satoru Miyano, Akira Oka, Tadashi Iwanaka,
Yasuhide Hayashi, Seishi Ogawa, Junko Takita.
30.
3295 A novel patient-derived xenograft model for evaluating the
role of TSLP in CRLF2 B-ALL. Olivia L. Francis, Parveen Shiraz, Terry-Ann
Milford, Ineavely Baez, Jacqueline S. Coats, Karina Mayagoitia, Elizabeth
Ginelli, Katherine R. Salcedo-Concepcion, Shannalee Martinez, Xiaobing
Zhang, Valeri Filippov, Ruijun J. Su, Ross Fisher, Christopher L. Morris,
Sinisa Dovat, Kimberly J. Payne.
14.
15.
458
Abstract
Number
3280 Sequencing approaches define the mutation and fusion
landscape of choroid plexus carcinomas. Diana M. Merino, Yongjin Li,
Xiaotu Ma, Jinghui Zhang, David Malkin, Richard J. Gilbertson.
POSTER SESSION
Tumor Biology
Radiation Biology 1: DNA Damage and Repair, Molecular Modulators of Radiation
Response, and Resistance
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Abstract
Number
3296 Tumor treatment fields slow cell proliferation and
enhance radiosensitivity in a model of non-small cell lung
cancer. Kalayarasan Srinivasan, Brock Sishc, Debabrata Saha,
Michael D. Story.
3297 Cell phone use and cytokines expression in saliva
of the parotid glands. Fabrício T. de Souza, Carolina C.
Gomes, Luiz Armando De Marco, Elisa C. Siqueira, Samuel M.
Costa, Jeane F. Correia-Silva, Ricardo S. Gomez.
3298 ABL1 is required for Tie2-mediated DNA repair in
brain tumor stem cells. Mohammad B. Hossain, Rehnuma
Shifat, David G. Johnson, Mark T. Bedford, Mien-Chie Hung,
Nahir Cortes-Santiago, Konrad Gabrusiewicz, Joy Gumin,
Ravesanker Ezhilarasan, Erik P. Sulman, Frederick Lang,
Raymond Sawaya, W.K. Alfred Yung, Juan Fueyo, Candelaria
Gomez-Manzano.
3299 The role of H3K9 acetylation and tri-methylation
in stem cell radiosensitivity. Barbara Meyer, Keith M.
Jacobs, Suyash Raj, Cheri L. Zobel, Dennis E. Hallahan,
Girdhar G. Sharma.
3300 Concerted epigenetic and signaling mechanisms
regulate normal stem cell radiosensitivity. Keith M. Jacobs,
Sandeep Misri, Barbara Meyer, Suyash Raj, Cheri L. Zobel,
Barry P. Sleckman, Dennis E. Hallahan, Girdhar G. Sharma.
3301 Uncovering novel radiation sensitivity syndromes
through exome sequencing. Deborah I. Ritter, Andrea K.
Petersen, Katherine M. Haines, Ryan C. Zabriskie, David A.
Wheeler, Sharon E. Plon.
3302 Subtype-specific radiation response in a mouse
model of human breast cancer. Chen-Ting Lee, Yingchun
Zhou, Sharareh Siamakpour-Reihani, Kingshuk R. Choudhury,
Mark W. Dewhirst, Janet K. Horton.
3303 Radioresistance in glioma stem cells driven by
Rad51 dependent homologous recombination repair.
Henry King, Helen Payne, Tim Brend, Anjana Patel, Alex
Wright, Teklu Englu, Lucy Stead, Heiko Wurdak, Susan C.
Short.
3304 Role of Vascular Endothelial Growth Factor C in
promoting radioresistance of prostate cancer. Steffi
Haberlau, Pia Hönscheid, Rafael E. Jimenez, Gustavo B.
Baretton, Donald J. Tindall, Mechthild Krause, Kaustubh
Datta, Michael H. Muders.
3305 The role of mTOR in mediating nicotine induced
alpha-7 nicotinic acetylcholine receptor activation and the
regulation of radiotherapeutic response. Samantha L.
Sobus, Sundaravadivel Balasubramanian, Michelle A.
Romano, Graham W. Warren.
3306 The RNA-binding protein HuR radiosensitizes
human TNBC cells by modulating the cellular response to
DNA damage and oxidative stress. Meghna Mehta, James
Griffith, Kanthesh Basalingappa, Anish Babu, Narsireddy
Amreddy, Ranganayaki Muralidharan, Myriam Gorospe,
Terence Herman, Wei-Qun Ding, Rajagopal Ramesh,
Anupama Munshi.
3307 Chemopotentiation by low dose fractionated
radiation therapy in colon cancer cells. Teresa Smith, Palak
R. Parekh, Elizabeth T. Chang, Michael Chuong, France
Carrier.
3308 Enhanced expression of galectin-3 isassociated
with the alternative activation of macrophages and
development oflung fibrosis following radiation. Weiling
Zhao, Jing-Hua Zhang, Ingrid J. Lopes.
Poster
Board
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
Abstract
Number
Poster
:LJ[PVU
18
18
3309 Co-inhibition of ALK and EGFR and/or c-MET on
cell growth and response to radiation in ALK-positive
NSCLC cells. Chunrong Li, Shyhmin Huang, Fang Ma, Eric A.
Armstrong, David Francis, Lauryn Werner, Paul M. Harari.
3310 Targeting MUC1-mediated metabolism sensitizes
pancreatic cancer cells to radiation therapy. Venugopal
Gunda, Jaime Abrego, Surendra K. Shukla, Nina V. Chaika,
Fang Yu, Tadayoshi Bessho, Chi Lin, Pankaj K. Singh.
3311 Molecular targeted photoimmunotherapy as a
treatment for bladder cancer. Reema Railkar, Quentin Li,
Srinivas Vourganti, Sam J. Brancato, Peter L. Choyke,
Hisataka Kobayashi, Piyush K. Agarwal.
3312 Growth inhibition of cancer cells by 5aminolevulinic acid. Toshikatsu Horiuchi, Yusuke Serizawa,
Syoichiro Tateishi, Keiichi Iwaya, Junichi Watanabe, Shinichi
Kobayashi, Ken Sato, Fumihiko Kimura, Nariyoshi Shinomiya,
Yuji Morimoto.
3313 Evaluation of silicon phthalocyanine 4
photodynamic therapy in human cervical cancer cells. Jill
A. Gadzinski, Brian Philips, Per Basse, Jianxia Guo, Anirban
Sen Gupta, Lisa Bailey, John T. Comerci, Julie L. Eiseman.
3314 DNA methylome analysis identifies epigenetic
silencing of FHIT as a determining factor for
radiosensitivity in oral cancer and its implication in
treatment and outcome prediction. Hon-Yi Lin, Shih-Kai
Hung, Moon-Sing Lee, Wen-Yen Chiou, Tze-Ta Huang, ChihEn Tseng, Liang-Yu Shih, Ru-Inn Lin, Jora Lin, Yi-Hui Lai,
Chia-Bin Chang, Feng-Chun Hsu, Liang-Cheng Chen, ShiangJiun Tsai, Yu-Chieh Su, Szu-Chi Li, Hung-Chih Lai, Wen-Lin
Hsu, Dai-Wei Liu, Chien-Kuo Tai, Shu-Fen Wu, Michael W.
Chan.
3315 Functional genomic profiling of lung
adenocarcinoma identifies BRAF mutations as novel
therapeutic targets. Mohamed Abazeed, Brian Yard, Drew
Adams, Pablo Tamayo, Jason Hearn, Eui Kyu Chie, Stuart
Schreiber, Matthew Meyerson, Craig Peacock, Peter
Hammerman.
3316 The role of high mobility group box 1 in the
combination therapy of gemcitabine and radiation in
muscle invasive bladder cancer. Jose J. Mansure, Wael S.
Almajed, Sanhita Shrivastava, Fabio Cury, Gerardo Ferbeyre,
Marija Popovic, Jan Seuntjens, Wassim Kassouf.
3317 Radiation induced multinucleated giant cells: A
novel therapeutic target to prevent survival and relapse of
glioblastoma. Ekjot Kaur, Jacinth Rajendra, Sanket Shah,
Jyothi Nair, Ankit Khushwaha, Aliasgar Moiyadi, Shilpee Dutt.
3318 Phosphoproteomic profiling of glioblastoma stem
cells to uncover mechanisms of radiation resistance. Emily
Bassett, Kamalakannan Palanichamy, Arnab Chakravarti.
3319 Identification of cervical cancer stem cells by
using an imaging system for proteasome activity. Keisuke
Tamari, Hideshi Ishii, Kazuhiko Hayashi, Masamitsu Konno,
Koichi Kawamoto, Naohiro Nishida, Jun Kozeki, Takahito
Fukusumi, Yuichiro Doki, Masaki Mori, Kazuhiko Ogawa.
3320 Identification of potential molecular targets
related to radioresistance in human oral cancers. Tanuja R.
Teni, Mohd Yasser, Sagar Pawar.
3321 Effects of glioma presence during radiotherapy
on tissue damage. Janice A. Zawaski, Omaima M. Sabek,
Kelvin Wong, M. Waleed Gaber.
3322 Adding pericyte inhibition to combined antiangiogenesis and irradiation slows tumor growth but
increases metastasis in mice model. Lei Deng, Jiazhuo He,
Jianxin Xue, Jie Lan, Lin Zhou, Yongmei Liu, You Lu.
459
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
19
19
Radiation Biology 2: Modifiers and Signal Transduction, Sensitivity, Resistance, and
Therapy
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
460
Abstract
Number
3323 Radiation-induced ER stress contributes to
survival in glioblastoma cell lines. David Dadey, Vaishali
Kapoor, Arpine Khudanyan, Dinesh Thotala, Dennis Hallahan.
3324 A novel role for PAK4 in the regulation of EMT and
stemness in glioblastoma. Divya Kesanakurti, Jihong Xu,
Rao S. Jasti, Vinay K. Puduvalli.
3325 A protein phosphatase 2A-ATM complex
regulates the DNA damage response and pro-survival
signaling. Amrita D. Sule, Mary Tokarz, Mostafa Ahmed, Glen
E. Kellogg, Kristoffer C. Valerie.
3326 Targeting lysophosphatidic acid receptor 1
(LPAR1) radiosensitizes poor prognosis cancers. Arpine
Khudanyan, David Dadey, Rowan Karvas, Rama Kotipatruni,
Dennis Hallahan, Dinesh Thotala.
3327 Metabolomics: Potential molecular mechanisms
of radiotherapy (RT)-related normal tissue toxicities in
breast cancer. Jennifer J. Hu, Eunkyung Lee, Cristiane Takita,
Jean L. Wright, Omar L. Nelson.
3328 Mitigating long-term cardiac adverse effects of
radiation exposure: Emerging opportunities in protein
oxidation and autophagy modulation. Elliot T. Rosen,
Dmitry Kryndushkin, Yanira Gonzalez, Baikuntha Aryal, Leena
Chehab, Jennifer Dickey, Ashutosh Rao.
3329 Ionizing radiation modifies the molecular
composition of exosomes derived from breast cancer cells.
Julie M. Diamond, Jessica R. Chapman, Beatrix M.
Ueberheide, Sandra Demaria.
3330 Genomic profiling of breast cancers in women
with protracted exposure to low doses of radiation from
the 1986 Chernobyl nuclear accident. Jamie Guenthoer,
Lynn Onstad, Xiaoyu Chai, Nikolai B. Rivkind, Irina V.
Kurnasova, Vladislav P. Troshin, Margarita Makarova, Elena A.
Korchagina, Valeriy F. Stepanenko, Irina Beluhka, Sergei M.
Kulikov, Nikita E. Shklovsky-Kordi, Li Hsu, Paul Voillequé,
Kenneth J. Kopecky, Scott Davis, Peggy L. Porter.
3331 Gene expression profiling after radiation in
human breast cancer specimens and breast cancer cell
lines. Sharareh Siamakpour-Reihani, Wei Chen, Chen-Ting
Lee, Yingchun Zhou, Kouros Owzar, Jen-Tsan Chi, Janet K.
Horton.
3332 Radiation-induced translational control of gene
expression in glioblastoma stem-like cells. Amy Wahba,
Barbara H. Rath, Kevin Camphausen, Philip J. Tofilon.
3333 The expression of FKTN gene in gastric cancer
related to radiation exposure: research on atomic bomb
survivors. Trang T. Pham.
3334 Microarray analysis of radioresistant mouse
squamous cell carcinoma: comparison of x-ray resistance
and carbon-ion beam resistance. Sungjae Baek, Hideshi
Ishii, Katsutoshi Sato, Naohiro Nishida, Keisuke Tamari,
Kazuhiko Hayashi, Yuji Seo, Koichi Kawamoto, Jun Koseki,
Masamitsu Konno, Yuichiro Doki, Masaki Mori, Kazuhiko
Ogawa.
3335 Targeting Egr1 selectively radioprotects normal
tissues while killing cancer cells. Diana Yi Zhao, Keith M.
Jacobs, Dennis E. Hallahan, Dinesh Thotala.
3336 NF-␬B inhibition by DMAPT radiosensitizes nonsmall cell lung carcinoma by impairing DNA double strand
break repair. Colin O’Leary, Peter Deraska, Christopher
Sweeney, Alan D’Andrea, David Kozono.
Poster
Board
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
Abstract
Number
3337 Titanium peroxide nanoparticles enhance
antitumor efficacy through reactive oxygen species in
pancreatic cancer radiation therapy. Masao Nakayama,
Ryohei Sasaki, Toru Mukohara, Chiaki Ogino, Kenta Morita,
Mitsuo Umetsu, Satoshi Ohara, Kazuyoshi Sato, Chiya
Numako, Seiichi Takami, Akihiko Kondo.
3338 Pharmacological inhibition of MRK/ZAK kinase for
the treatment of medulloblastoma. Rosamaria Ruggieri,
Daniel Markowitz, Caitlin Powell, Nhan Tran,
Magimairajanissai Vanan, Mingzu He, Yousef Al-Abed, Marc
Symons.
3339 Silibinin improves radiotherapeutic efficacy in
prostate cancer by reducing IR-induced toxicity and EMT.
Dhanya K. Nambiar, Paulraj Rajamani, Anil Jain, Gagan Deep,
Rajesh Agarwal, Rana P. Singh.
3340 Intraoral administration of mitochondrial
targeted GS-nitroxide (JP4-039) radioprotects the oral
mucosa but not orthotopic tumors in Fancd2-/- mice.
Michael W. Epperly, Ashwin Shinde, Hebist Berhane, Byung
Han Rhieu, Ronny Kalash, Karen Xu, Darcy Franicola, Xichen
Zhang, Tracy Dixon, Donna Shields, Hong Wang, Peter Wipf,
Kalindi Parmar, Eva Guinan, Valerian Kagan, Yulia Tyurina,
Robert L. Ferris, Song Li, Joel S. Greenberger.
3341 TP508 sensitizes cancer stem cells to radiation
and delays brain cancer cell relapse in vitro. Stephanie M.
Moya, Carla Kantara, Laurie Sower, Darrell H. Carney.
3342 Combining Pemetrexed with methoxyamine to
enhance the radiosensitization of non-small-cell lung
cancer (NSCLC): Preclinical studies in vivo . Ravi Patel,
Rutul Patel, Tithi Biswas, Pingfu Fu, Mitchell Machtay, Nancy
Oleinick.
3343 Podophyllotoxin acetate (PA) enhancing ␥ionizing radiation-induced apoptosis via the ROS/p38/
caspase pathway. Jae Yeon Choi, Sang-Gu Hwang, HongDuck Um, Jong Kuk Park.
3344 Enhanced radioresponse in squamous cell
carcinoma of esophagus by recombinant human
endostatin. Hongcheng Zhu, Xi Yang, Qin Qin, Xiaolin Ge,
Jiayan Chen, Yuandong Cao, Xinchen Sun.
3345 Inhibition of STAT3 reduces radiation induced
changes in cellular plasticity and sensitizes breast cancer
cells to radiation. Kimberly M. Arnold, Lynn M. Opdenaker,
Daniel Flynn, Jennifer Sims-Mourtada.
3346 The ketone body ␤-hydroxybutyrate increases
radiosensitivity in glioma cell lines in vitro. Alex P. Rossi,
Eric C. Woolf, Kenneth S. Brooks, Marshall J. Fairres, Adrienne
C. Scheck.
3347 Radiation-induced gastrointestinal (GI)
syndrome as a function of age. Hongyan Li, Herman
Kucharavy, Carla Hajj, Guoqiang Hua, Ryan Glass, Zhaoshi
Zeng, Zvi Fuks, Philip B. Paty, Richard Kolesnick, Karen
Hubbard, Adriana Haimovitz-Friedman.
3348 Tumor irradiation induced a phenotype change of
monocytes to facilitate vascular regrowth. Lei Deng, Jason
Stafford, Sophia Chernikova, Shie-chau Liu, Jianguo Sun, J.
Martin Brown.
3349 Optimizing radioimmunotherapy techniques for
the alpha-emitter 225Actinium. Ricklie A. Julian, Chi Soo
Kang, Xiang Sun, Hyun A. Song, Ekaterina Revskaya, HyunSoon Chong, Ekaterina Dadachova.
POSTER SESSION
Tumor Biology
Stroma and Immune-Tumor Interactions
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
3350 Neutrophils in human colorectal cancer. Valeria
Governa, Valentina Mele, Christian Hirt, Raoul Droeser, Luca
Quagliata, Luigi Terracciano, Giandomenica Iezzi, Nina Kanna,
Giulio Spagnoli, Elisabetta Padovan.
3351 NF-␬B signaling between stromal macrophages
and breast cancer cells. Jennifer W. Bradford.
3352 Identification of factors that recruit tumorassociated neutrophils to head and neck squamous cell
cancer. Hanan A. Niaz.
3353 Prostate cancer microenvironment modulates
macrophage phagocytosis. Evita G. Weagel, Nicholas B.
Anderson, Wei Meng, Josh Davis, Richard A. Robison, Kim L.
O’Neill.
3354 Cancer-associated or cirrhosis fibroblasts
recovered from hepatocellular carcinoma promote
macrophages and cancer cells to progressive phenotype.
Yohei Mano, Tatsuya Kanto, Hirotaka Shoji, Schiyo Yoshio,
Masaya Sugiyama, Yosuke Osawa, Kiminori Kimura, Ken
Shirabe, Yoshihiko Maehara, Masashi Mizokami.
3355 Are cancer cells redefining macrophages’
aggressiveness. Elias Inga Jaco, Evita G. Weagel, Nicholas B.
Anderson, Wei Meng, Joshua J. Davis, Richard A. Robinson,
Kim L. O’Neill.
3356 Diversity of CD8+ and rgulatory T cells is inversely
correlated in follicular lymphoma: A potential predictive
biomarker. Justin P. Kline, Xiao Liu, Girish Venkataraman,
Jiaying Lin, Kazuma Kiyotani, Sonali M. Smith, Magdeline
Montoya, Yusuke Nakamura.
3357 Breast cancer-associated a2 isoform vacuolar
ATPase regulates neutrophils: potential association for
tumor invasion. Safaa A. Ibrahim, Magdy Amin, Arpita
Kulshrestha, Sahithi Pamarthy, Kenneth D. Beaman.
3358 SOCS3 deficiency in myeloid cells promotes
tumor development: Involvement of STAT3 activation and
myeloid-derived suppressor cells. Hao Yu, Hongwei Qin,
Etty (Tika) Benveniste.
3359 PEDF modulatory action on macrophages: A new
way to curb prostate cancer development. Dalia MartinezMarin, Thomas Nelius, Olga Volpert, Stephanie Filleur.
3360 Macrophages promote resistance to pegylated
arginine deiminase in malignant pleural mesothelioma.
Melissa M. Phillips, Ramsay Khadeir, Laura Tookman, Fiona
McCarthy, Jeremy Steele, John Bomalaski, Essam Ghazaly,
Peter W. Szlosarek.
3361 CD73 expression on tumor-infiltrating breast
cancer leukocytes. Laurence Buisseret, Soizic Garaud,
Bertrand Allard, Isabelle Cousineau, Guillaume Chouinard,
Christos Sotiriou, Karen Willard-Gallo, John Stagg.
3362 Systematic evaluation of immune checkpoint
inhibitors. Sheri Barnes, Paula Miliani de Marval, Jacob
Hauser, Tracy Brainard, Daniel Small, Aidan J. Synnott,
Robert J. Mullin.
3363 RAGE/S100A7/Stat3-axis enhances breast cancer
growth and metastasis via modulating tumor
microenvironment. Mohd W. Nasser, Nissar A. Wani, Janani
Ravi, Grace A. Amponsah, Dinesh K. Ahirwar, Catherine A.
Powell, Mohamad Elbaz, Helong Zhao, Konstantin Shilo,
Ramesh K. Ganju.
3364 Epithelial-mesenchymal transition is associated
with a profound inflammatory tumor microenvironment in
lung adenocarcinoma. Yanyan Lou, Lixia Diao, Parra Cuentas
Edwin Roger, Warren L. Denning, Limo Chen, Youhong Fan,
Jaime Rodriguez, Lauren Byers, Jing Wang, Vassiliki
Papadimitrakopoulou, Behrens Carmen, Ignacio I. Wistuba,
Patrick Hwu, John V. Heymach, Don L. Gibbons.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
3365 High infiltration of mast cells predicts worse
outcome following resection of colorectal liver
metastases. Shinsuke Suzuki, Yasushi Ichikawa, Kazuya
Nakagawa, Takafumi Kumamoto, Ryutaro Mori, Ryusei
Matsuyama, Kazuhisa Takeda, Mitsuyoshi Ota, Kuniya Tanaka,
Itaru Endo.
3366 The mechanical microenvironment and ␤1/FAK
signaling control fibroblast accumulation in lung cancer.
Jordi Alcaraz, Marta Gabasa, Óscar Busnadiego, Fernando
Rodríguez-Pascual, Pere Gascón, Noemí Reguart.
3367 BMP-6 regulates expression of androgen receptor
via NF-␬B signaling pathway and activated macrophages.
Emma Wilcox, Seok Joo Kwon, Geun Taek Lee, Isaac Y. Kim.
3368 Sustained adrenergic signaling activates proinflammatory prostaglandin network in ovarian
carcinoma. Archana S. Nagaraja, Piotr Dorniak, Nouara
Sadaoui, Guillermo Armaiz-Pena, Behrouz Zand, Sherry Y.
Wu, Julie K. Allen, Rajesha Rupaimoole, Cristian RodriguezAguayo, Sunila Pradeep, Lin Tan, Rebecca A. Previs, Jean M.
Hansen, Peiying Yang, Garbiel Lopez-Berestein, Susan K.
Lutgendorf, Steve Cole, Anil K. Sood.
3369 Nuclear hormone receptor profiling of skin
cancer-associated fibroblasts for targeted
pharmacological modulation of skin squamous cell
carcinoma. Jeremy S. Chan, Ming Keat Sng, Zi Qiang Teo,
Nguan Soon Tan.
3370 Incorporation of mesenchymal stem cells into
areas of lung metastasis in an osteosarcoma model.
Luciana M. Gutierrez, Mariana A. Amoros, Gustavo Sevlever,
Osvaldo Podahjcer, Graciela Cremaschi, Eugenie S.
Kleinerman, Marcela F. Bolontrade.
3371 Periostin secreted by breast cancer cells inhibits
macrophage phagocytosis and adhesion to fibronectin.
Michelle M. Coleman, Rachel S. Helms, Didier Dreau.
3372 Molecular characteristics of cancer-associated
adipocytes in breast cancer. Hyeong-Gon Moon, Jiwoo Lee,
Han-Byoel Lee, Han Suk Ryu, Wonshik Han, Dong-Young
Noh.
3373 Identification of inflammation-related genes that
regulate tumor-associated stemness using highthroughput siRNA screening. Junling Xie, Huiwen He, Chong
Chen, Lipeng Bai, Wei Wang, Yan Liu, Jian Guo, Peng Wu,
Rong Xiang, Yunping Luo.
3374 Prostate cancer bone metastases acquire
resistance to androgen deprivation via WNT5A-mediated
BMP6 induction. Geun Taek Lee, Seok Joo Kwon, Isaac Y.
Kim.
3375 Can prostate cancer derived neuromodulators
regulate intratumoral axonogenesis. Dmitriy W. Gutkin,
Galina V. Shurin, Michael R. Shurin, Anton A. Keskinov.
3376 Ras activation in aberrant crypt foci is associated
with decreased expression of cell cycle regulators and
disruption of stromal homeostasis. Allen Mo, Nicole A.
Horelik, Stephen Jackson, Thomas J. Devers, Daniel W.
Rosenberg.
3377 Co-spheroid analysis reveals attenuating effect of
HS27A stroma cells on DLD1 colon carcinoma susceptibility
to MEK kinase inhibitor trametinib. Claudia Hoffmann,
Daniel Feger, Oliver Siedentopf, Holger Weber, Sarah Umber,
Jan E. Ehlert.
3378 Discoidin domain receptor 2 differentially
controls HT-1080 cell proliferation in young-adult and old
type I collagen 3D matrices. Charles Saby, Roselyne
Garnotel, Hassan El Btaouri, Laurence Van Gulick, Pierre
Jeannesson, Hamid Morjani.
3379 HSF1: Essential for myeloma cell survival and a
promising therapeutic target. Jacqueline H. Fok, Somaieh
Hedayat, Lei Zhang, Lauren I. Aronson, Fabio Mirabella,
Suzanne A. Eccles, Faith E. Davies.
20
20
461
POSTER SESSION
Clinical Research
Poster
:LJ[PVU
21
21
Development of Prognostic and Predictive Biomarker Assays
Poster
Board
Poster
Board
Abstract
Number
1.
3380 Loss of immunorecognition of selected molecules
during long-term storage of paraffin blocks. Dennis Otali,
Victoria R. Maston, Denise K. Oelschlager, William E. Grizzle.
12.
3391 Companion diagnostic strategies specific to
antibody therapies. Joseph S. Krueger, David Young, Holger
Lange, Steve Potts.
2.
3381 Standardizing the analysis of Ki-67
immunohistochemical assays. Tian Yu Liu, Trillium Chang,
Adewunmi Adeoye, Willa Shi, Sheng-Ben Liang, Dianne
Chadwick, Michael H. Roehrl, Naomi Miller, Fei-Fei Liu, Susan
J. Done.
13.
3.
3382 Exosomes analysis in non-small cell lung cancer:
looking for a clinical application. Christian D. Rolfo, Marta
Castiglia, Marco Giallombardo, Jorge Chacartegui, Nele Van
Der Steen, Inge Mertens, Marc Peeters, Antonio Russo,
Patrick Pauwels.
3392 Ex vivo analysis of RAD51 foci induction in fresh
tumor tissue: a promising new tool for the identification of
homologous recombination-deficient tumors. Maaike
Vreeswijk, M. Meijers, K.A.T. Naipal, N.S. Verkaik, R. Kanaar,
J.H.J. Hoeijmakers, A. Jager, D.C. van Gent, K.N.
Gaarenstroom, V.T.H.B.M. Smit, H. Vrieling.
14.
3393 Using protein microarray technology to screen
anti-PD-1 monoclonal antibodies for specificity and
applications in anatomic pathology. Caiwei Chen, Yanlin
Tang, Haitao Wei, Kehu Yuan, Guiyin Wu, Jian Chen, Boyang
Chu, Guangli Wang, Youmin Shu, Wei-Wu He, Donghui Ma.
15.
3394 Controls to detect limit of detection for BRAF
V600E as an actionable mutation of interest by NextGen
Sequencing and qPCR. Cristine L. Chisholm, Russell Garlick,
Bharathi Anekella.
16.
3395 Clinical Survey of 19 actionable proteins in
multiple indications using multiplex mass spectrometry.
Fabiola Cecchi, Adele Blackler, Heather Jordan, Marlene
Darfler, Todd Hembrough, Michael Stocum, Jon Burrows.
17.
3396 Optimization of an assay for the detection of PDL1 by immunohistochemistry in formalin-fixed, paraffinembedded human tissue and cell lines. Lisa M. Dauffenbach,
Gela C. Sia, Patricia A. Cash, Sherif K. Girees, Jianping Zheng,
Ryan S. Lim, Eric P. Olsen, Christopher A. Kerfoot.
18.
3397 A novel clinical tool that provides quantitative
and accurate measurement of Met protein. Fabiola Cecchi,
Wei-Li Liao, Sheeno Thyparambil, Marlene Darfler, David
Krizman, Todd Hembrough, Jon Burrows, Don Bottaro, Daniel
V. Catenacci.
19.
3398 Development of a mass spectrometry based
antibody-drug conjugate biomarker panel. Adele Blackler,
Wei-Li Liao, Sheeno Thyparambil, Eunkyung An, Fabiola
Cecchi, Marlene Darfler, Todd Hembrough, Jon Burrows.
20.
3399 Using protein chips to develop a highly specific
HER2 antibody for HER2 amplification testing. Lixin Zhou,
Kehu Yuan, Fangfang Ren, Lili Qi, Zhongwu Li, Guiyin Wu,
Xiaozheng Huang, Yi Shen, Min Zhao, Wei Fu, Huibo Liu,
Boyang Chu, Guangli Wang, Youmin Shu, Donghui Ma, WeiWu He, Jian Chen.
21.
3400 Mitochondrial profiling in AML patients treated
with an Alvocidib containing regimen reveals MCL1
dependency in responder bone marrow. Elisha J. Dettman,
Steven L. Warner, Camille Doykan, Melissa Arn, Noel Blake,
David J. Bearss, Michael Cardone, Bruce D. Smith.
4.
3383 Correlation of mutations detected in liquid and
tissue biopsies. Douglas H. White, Douglas Horejsh, Molly
Accola, William Rehrauer, Marjeta Urh.
5.
3384 Cancer Core 125 Panel for quantitative expression
and mutation profiling. Alex Chenchik, Mikhail Makhanov,
Gregory Dolganov, Stefanie Jeffrey.
6.
3385 Cancerous tissue can be identified by the
presence of oxMIF, the oxidized form of macrophage
migration inhibitory factor. Nicolas Sabarth, Dirk Völkel,
Michael Thiele, Alexander Schinagl, Patrice Douillard,
Friedrich Scheiflinger, Randolf Kerschbaumer.
7.
3386 The development of a highly specific monoclonal
antibody against Ki67 useful for immunohistochemistry.
Caiwei Chen, Kehu Yuan, Boyang Chu, Youmin Shu, Jian
Chen, Joe Stafford, Wei Fu, Wei-Wu He, Ross Chambers,
Donghui Ma.
8.
3387 A complete workflow for high throughput
isolation of serum microRNAs and downstream analysis by
qRT-PCR: application to cancer biomarker discovery. Emily
M. Zeringer, Alex J. Rai, Joel DeCastro, Luming Qu, Marie
Gonzalez, Laura Chapman, Alexander V. Vlassov, Susan M.
Magdaleno, Chunmei Liu, Fangqi Hu, Shoulian Dong, Linda
Wong.
9.
10.
11.
462
Abstract
Number
3388 Analytical validation and clinical verification of
phosphoprotein biomarker modulation using a novel
preservation system-based flow cytometry assay in
multiple myeloma clinical trials. Anil Pahuja, Shyam
Sarikonda, Benjamin Lee, Armin Graber, Shabnam Tangri,
Naveen Dakappagari.
3389 A multiplexed immunohistochemistry test to
screen for protein overexpression of ROS1, TrkA, TrkB and
TrkC in multiple tumor tissue types. Aaron Boomer, Diane
Fernandez, Danielle Murphy, Jason Christiansen, Jennifer
Lamoureux.
3390 Validating the RNAscope for molecular profiling
of key biomarkers associated with gemcitabine resistance.
Essam A. Ghazaly, Chathunissa Gnanaranjan, Bill Greenhalf,
Sarah P. Blagden, Peter Mullen, David Harrison, John G.
Gribben.
POSTER SESSION
Clinical Research
Prognostic Biomarkers 1: Gastrointestinal Cancers
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Abstract
Number
3401 MicroRNA-503 promotes tumor progression and
acts as a novel biomarker for prognosis in esophageal
cancer. Koichiro Mori, Yuji Toiyama, Shozo Ide, Tomofumi
Noguchi, Hiroki Imaoka, Hiromi Yasuda, Susumu Saigusa,
Masaki Ohi, Yasuhiro Inoue, Koji Tanaka, Yasuhiko Mohri,
Tsutomu Nobori, Masato Kusunoki.
3402 Activin signal promotes cancer progression and is
involved in cachexia in a subset of pancreatic cancer.
Yosuke Togashi, Akihiro Kogita, Hiroki Sakamoto, Hidetoshi
Hayashi, Masato Terashima, Marco A. de Velasco, Kazuko
Sakai, Yoshihiko Fujita, Shuta Tomida, Masayuki Kitano,
Masatoshi Kudo, Kazuto Nishio.
3403 SIAH and SIAH-interacting proteins as potential
prognostic and predictive biomarkers in pancreatic
adenocarcinoma. Elizaevta Svyatova.
3404 NDRG2 suppresses growth and invasion of
gallbladder carcinoma via regulation of matrix
metalloproteinase 19/slug interaction. Nayoung Kim,
Jeong-Ki Min, Jin-Man Kim, Hyo Jin Lee.
3405 Impact of VEGF and VEGFR polymorphisms on
neuroendocrine tumors of the gastro-entero-pancreatic
system (GEP-NETs) outcome. Rossana Berardi, Mariangela
Torniai, Silvia Pagliaretta, Silvia Rinaldi, Francesca Morgese,
Stefano Partelli, Miriam Caramanti, Azzurra Onofri, Vanessa
Polenta, Sonia Pasquini, Massimo Falconi, Stefano Cascinu.
3406 Enhancer of zeste homolog 2 (EZH2) expression
and proliferation index (Ki-67) in neuroendocrine tumors
of the gastrointestinal tract and pancreas. Jia Qin, Raag
Agrawal, Miguel G. Echevarria, LAura A. Martello, M.A
Haseeb, Raavi Gupta.
3407 FGFR4 Arg388 polymorphism is a poor prognostic
factor for resected stage III colon cancer. Sang-Hee Cho,
Min-Ho Shin, Sun-Seog Kweon, Hee-Nam Kim, Hyun-Jeong
Shim, Jun-Eul Hwang, Woo-Kyun Bae, Ik-Joo Chung.
3408 Nedd4-1 is an exceptional prognostic biomarker
for gastric cardia adenocarcinoma and functionally
associated with metastasis. Aiqin Sun, Guanzhen Yu,
Xiaoyan Dou, Xiaowei Yan, Wannian Yang, Qiong Lin.
3409 Clinicopathological significance of AOS2
expression in human gastric cancer. Chia-Siu Wang, ChungYing Tsai, Liang-Mou Kuo, Kwang-Huei Lin.
3410 Onodera’s prognostic nutritional Index predicts
survival in patients with unresectable advanced or
recurrent colorectal cancer. Tetsuro Ikeya.
3411 MicroRNA-503 promotes tumor progression and
acts as a novel biomarkers for early recurrence and poor
prognosis in human colorectal cancer. Yuji Toiyama,
Takahito Kitajima, Hiroki Imaoka, Mikio Kawamura, Hiroyuki
Fujikawa, Junichiro Hiro, Susumu Saigusa, Minako Kobayashi,
Toshimitsu Araki, Masaki Ohi, Koji Tanaka, Yasuhiro Inoue,
Yasuhiko Mohri, Masato Kusunoki.
3412 Virus-guided fluorescence imaging of
intraperitoneal free gastric cancer cells: a preliminary
clinical study as a potential clinical biomarker. Megumi
Watanabe, Shunsuke Kagawa, Kazuya Kuwata, Michihiro
Ishida, Yuuri Hashimoto, Naoto Hori, Satoru Kikuchi, Shinji
Kuroda, Hiroyuki Kishimoto, Masahiko Nishizaki, Hiroshi
Tazawa, Yasuo Urata, Toshiyoshi Fujiwara.
3413 Assessment of recurrence risk stratification
markers after curative resection of stage II or III gastric
cancer and potential clinical applications. Takashi Oshima,
Kentaro Sakamaki, Yohei Miyagi, Manabu Shiozawa, Chikara
Kunisaki, Takaki Yoshikawa, Yasushi Rino, Toshio Imada,
Munetaka Masuda.
Poster
Board
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
Abstract
Number
3414 Development and validation of 6-gene recurrence
risk score for gastric cancer. Keun-Wook Lee, Sung Sook
Lee, Sang Bae Kim, Hyun-Sung Lee, Ju-Seog Lee.
3415 PAICS is the prognostic marker in colorectal
cancer patients with stage III. Yusuke Kobayashi, Kensuke
Kumamoto, Yoshiko Matsumoto, Motonobu Saito, Tatsuo
Shimura, Seiichi Takenoshita.
3416 IHC assessment of PBRM1 loss in colon and lung
carcinomas. Aihua Li, Yongfu Gao, Yuekai Zhang, Hongyang
Pan, Jackie K. Chan, Ximing J. Yang, Taiying Chen.
3417 Snail and serpinA1 promote tumor progression
and predict prognosis in colorectal cancer. Chae Hwa
Kwon, Hye Ji Park, Ja Rang Lee, Hye Kyung Kim, Do Youn
Park.
3418 Impact of the preoperative Controlling Nutritional
Status (CONUT) score on the clinical outcome after
curative surgery for colorectal cancer. Yasuhito Iseki,
Masatsune Shibutani, Kiyoshi Maeda, Hisashi Nagahara,
Hiroshi Ohtani, Tetsuro Ikeya, Kenji Sugano, Sadaaki
Yamazoe, Katsinobu Sakurai, Kenjiro Kimura, Takahiro
Toyokawa, Ryosuke Amano, Naoshi Kubo, Hiroaki Tanaka,
Kazuya Muguruma, Masaichi Ohira, Kosei Hirakawa.
3419 VEGFA and SLC2A1 are prognostic biomarkers for
patients with resectable colorectal cancer liver
metastases. Jeroen A. Goos, Erienne M. de Cuba, Veerle M.
Coupe, Begona Diosdado, Pien M. Delis-van Diemen, Cemile
Karga, Jeroen A. Belien, C. Willemien Menke - Van der
Houven van Oordt, Albert A. Geldof, Gerrit A. Meijer, Otto S.
Hoekstra, Remond J. Fijneman, on behalf of the DeCoDe PET
group.
3420 Expression and significance of proliferation
markers phosphohistone H3, Ki-67/MIB-1, and survivin in
gastrointestinal stromal tumors. Ming Wang, Benedict
Grissmann, Alexander Marx, Cleo-Aron Weiss, Maria
Deligianni, Djeda Belharazem, Hui Cao, Peter Hohenberger.
3421 Comparing gene expression of matched FFPE
colorectal cancer samples measured by Nanostring
nCounter® platform and Affymetrix GeneChip® Human
Transcriptome Array platform. Jing Zhu, Natasha G. Deane,
Keeli B. Lewis, Mary K. Washington, Xi Chen, Robert D.
Beauchamp.
3422 Alteration of aldo-keto reductase family 1,
member B10 (AKR1B10) expression among tumor and
background non-tumorous tissue of curatively resected
hepatocellular carcinoma is associated with worse
prognosis. Shuji Nomoto, Fuminori Sonohara, Yoshikuni
Inokawa, Mitsuro Kanda, Tsutomu Fujii, Hiroyuki Sugimoto,
Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera.
3423 Expression level of inflammasomes compornents
NLRP3, NLRC4, and CASP1 in background non tumorous
tissue were associated with worse prognosis for curatively
resected hepatocellular carcinoma. Fuminori Sonohara,
Shuji Nomoto, Yoshikuni Inokawa, Mitsuro Kanda, Suguru
Yamada, Tsutomu Fujii, Masahiko Koike, Hiroyuki Sugimoto,
Michitaka Fujiwara, Yasuhiro Kodera.
3424 The efficacy of Gasdermin gene family for tumor
marker in colorectal cancer. Hajime Orita, Shigekazu
Tanaka, Shunsuke Watanabe, Hirokazu Matsuzawa, Konomi
Mizuguchi, Tomoaki Ito, Koji Senuma, Tomoyuki Kushida,
Mutsumi Sakurada, Hiroshi Maekawa, Ryo Wada, Koichi Sato.
3425 Overexpression of TRIM44 contributes to
malignant outcome in upper GI tract cancer. Tsutomu
Kawaguchi.
Poster
:LJ[PVU
22
22
463
POSTER SESSION
Clinical Research
Poster
:LJ[PVU
23
23
Special Populations, Supportive Care, and Survivorship Research / Radiation
Oncology
Poster
Board
1.
3426 Occult and clinical pancreatic cancers in elderly
patients. Yoko Matsuda, Akemi Suzuki, Yuri Hamashima,
Hideki Hamayasu, Hisashi Yoshimura, Toshiyuki Ishiwata,
Tomio Arai.
2.
3427 Split-dose R-CHOP: A novel approach to
administer cytotoxic chemotherapy to geriatric patients
with DLBCL. Nirav Shah, Nandita Mitra, Joshua Brikman,
Sunita Nasta, Daniel Landsburg, Anthony Mato, Dan Vogl,
Noelle Frey, Stephen Schuster, Jakub Svoboda.
3.
3428 Aging, telomere and TP53: a potential biological
insight into the mechanistic origin of acute lymphoblastic
leukemia (ALL) in the elderly. Ghada Zakout, Lena Rai,
Adele K. Fielding.
4.
3429 Patient awareness of staging in cancer diagnosis:
Helpful or hurtful. Ariel Schaap, Rashi Aggarwal, Jason
Domogauer.
5.
3430 Toxicity and long-term outcomes of elderly
patients with refractory or relapsed diffuse large B cell
lymphoma undergoing autologous stem cell
transplantation. Scott F. Huntington, Boyu Hu, Daniel J.
Landsburg, Anthony R. Mato, Sunita D. Nasta, Stephen J.
Schuster, Edward A. Stadtmauer, Jakub Svoboda.
Poster
Board
Abstract
Number
13.
3438 Whole pelvis versus prostate-only radiotherapy
with or without short course androgen deprivation therapy
and mortality risk. Lior Z. Braunstein, Ming-Hui Chen, Daniel
E. Dosoretz, Sharon Salenius, Michael Katin, Akash Nanda,
Anthony V. D’Amico.
15.
3440 High-dose-rate brachytherapy as monotherapy
for favorable-risk adenocarcinoma of the prostate
delivered in a single 19 Gy fraction: Preliminary results of a
prospective pilot study. Scott Dahlbeck, Chase C. Hansen,
Werner deRiese, A. Robert Kagan, Carlos Torres, Maurizio
Chiriva-Internati, Everardo Cobos, Jose A. Figueroa, Diane
Nguyen, Lukman Tijani, Jaden D. Evans.
16.
3441 Proteomic profiling identifies PTK2/FAK as a
targetable marker of radioresistance in head and neck
cancer. Heath D. Skinner, Uma Giri, John S. Yordy, Michael D.
Story, Jing Wang, Lauren A. Byers, Michelle D. Williams, Adel
K. El-Naggar, Sang H. Woo, Liang P. Yang, You Fan, Curtis R.
Pickering, Jeffrey N. Myers,, John V. Heymach.
17.
3442 Ganetespib sensitizes colorectal cancer in vitro
and in vivo to a clinically relevant regimen of radiation and
chemotherapy. Ganji P. Nagaraju, Kirtesh Patel, Jing Wen,
Roberto Diaz, El-Rayes F. Bassel.
18.
3443 A new medical tool to discriminate on a
radiotherapy concomitant treatment for non-small cell
lung cancer patients. Maria I. Ibáñez-de-Cáceres, Olga
Pernía, Cristobal Belda-Iniesta, Olga Vera, Julia Jimenez,
Carlos Rodriguez, Javier Soto, Javier de Castro, Teresa
Macias, Federico Rojo, Joan Albanell, Rosario Perona.
6.
3431 What are the greatest challenges of rectal cancer
survivors? Results of a population-based survey. Robert S.
Krouse, Joanna E. Bulkley, Andrea Altschuler, Christopher S.
Wendel, Marcia Grant, Mark C. Hornbrook, Virginia Sun,
Carmit K. McMullen.
7.
3432 Dietary modifications of rectal cancer survivors to
improve bowel function symptoms. Robert S. Krouse,
Christopher S. Wendel, Wendy Demark-Wahnefried, Joanna
E. Bulkley, Carmit K. McMullen, Marcia Grant, Mark C.
Hornbrook, Andrea Altschuler, Virginia Sun, Lisa J. Herrinton.
19.
3433 Identification of potential salivary response
biomarkers in subjects practicing yogic breathing.
Sundaravadivel Balasubramanian, Michael G. Janech, Graham
W. Warren.
3444 Identification of a miRNAs signature of
radioresistance in a prostate cancer model. Niamh
McDermott, Armelle Meunier, Christopher Hernandez, Karen
J. Bowman, George D. Jones, Laure Marignol.
20.
3445 Diacylglycerol kinase alpha as a novel
epigenetically regulated risk marker for radiotherapyinduced fibrosis. Christoph Weigel, Marlon R. Veldwijk,
Christopher C. Oakes, Petra Seibold, Alla Slynko, David B.
Liesenfeld, Carsten Herskind, Elena Sperk, Axel Benner,
Christoph Plass, Frederik Wenz, Jenny Chang-Claude, Peter
Schmezer, Odilia Popanda.
22.
3447 Radium-223 dichloride exhibits dual mode-ofaction inhibiting both tumor and tumor-induced bone
growth in two osteoblastic prostate cancer models. Mari I.
Suominen, Katja M. Fagerlund, Jukka P. Rissanen, Yvonne
Konkol, Jukka Morko, Zhiqi Peng, Esa Alhoniemi, Dominik
Mumberg, Karl Ziegelbauer, Sanna-Maria Käkönen, Jussi M.
Halleen, Robert L. Vessella, Arne Scholz.
8.
9.
10.
464
Abstract
Number
3434 An evaluation of laboratory data at admission for
predicting mortality among critically ill patients with
cancer. Lee Cheng, Yvette DeJesus, Alma M. Rodriguez.
3435 Notch signaling and inflammation in a murine
model of sarcoma-associated cachexia. Kurt R. Weiss,
Xiaodong Mu, Rashmi Agarwal.
11.
3436 A topical botanical product improves recovery
from chemotherapy alopecia and persistent hair issues in
cancer survivors. Tadafumi Shiiba, Reiko Kondo, Saad Harti,
Angelo Mello, Geert Cauwenbergh, Jiawei Liu.
12.
3437 Visceral abdominal fat is associated with
incisional hernia occurrence after colorectal cancer surgery
- the ColoCare Study. Jürgen Böhm, Johanna Nattenmüller,
Frank Pianka, Biljana Gigic, Yesilda Balavarca, Nina Stüttgen,
Petra Schrotz-King, Dominique Scherer, Alexis Ulrich, Markus
K. Diener, Hans-Ulrich Kauczor, Cornelia M. Ulrich.
POSTER SESSION
Endocrinology
Hormonal Regulation of Tumor Growth and Metastasis
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
12.
13.
14.
15.
Abstract
Number
3448 Overexpression of the steroid inactivating UGT2B28
enzyme is associated with high circulating androgens, tumor
aggressiveness and adverse prostate cancer outcome. Anaïs
Belledant, Hélène Hovington, Hervé Brisson, Bernard Têtu, Yves
Fradet, Louis Lacombe, Patrick Caron, Chantal Guillemette, Eric
Lévesque.
3449 Risk for death from prostate cancer predicted from
complete family history of lethal prostate cancer. Frederick S.
Albright, Neeraj Agarwal, William T. Lowrance, Robert A.
Stephenson, Lisa A. Cannon-Albright.
3450 Resistance to P450c17 inhibitors in castration-resistant
prostate cancer may result from the DHEA-S depot that remains
and can be used by AKR1C3 for intratumoral androgen
biosynthesis. Daniel Tamae, Elahe Mostaghel, Bruce Montgomery,
Peter S. Nelson, Steven P. Balk, Philip W. Kantoff, Mary-Ellen Taplin,
Trevor M. Penning.
3451 Distinct nuclear translocation mechanism of androgen
receptor variant ARv7. Seaho Kim, Luigi Portella, Paraskevi
Giannakakou.
3452 Conversion of abiraterone to D4A drives antitumor
activity in castration-resistant prostate cancer. Zhenfei Li, Nima
Sharifi.
3453 Effect of a histone DNA demethylase on castration
resistant prostate cancer cell lines, a potential therapeutic
application. Thenappan Chandrasekar, Joy C. Yang, Min Xie, Sheng
Ding, Michael G. Rosenfeld, Christopher P. Evans.
3454 High expression of fibroblast growth factor 13 (FGF13)
in prostate cancer is associated with a shortened time to
biochemical recurrence after radical prostatectomy. Lan Yu, Miikka
Tuomala, Mervi Toriseva, Teresa Elo, Johanna Tuomela, Heikki
Seikkula, Martti Nurmi, Peter Boström, Tuomas Mirtti, Kalle Alanen,
Markku Kallajoki, Pirkko Härkönen.
3455 Functional imaging tests vs. computed tomography
scan: detection of new metastases and clinical usefulness in
digestive neuroendocrine neoplasms follow-up. Elettra Merola,
Francesco Panzuto, Gabriele Capurso, Patrizia Kump, Rainer Lipp,
Noemi Cicchese, Elsa Iannicelli, Daniela Prosperi, Patrizia Pizzichini,
Maria Rinzivillo, Stefano Partelli, Anja Rinke, Massimo Falconi,
Gianfranco Delle Fave.
3456 MUC16/CA125, TNF␣ and IFN␥ are co-expressed in
malignant gynecologic neoplasms. Micaela Morgado, Margie N.
Sutton, Mary Simmons, Jinsong Liu, Zhen Lu, Pamela E.
Papadopoulos, Robert C. Bast, Daniel D. Carson.
3457 Evaluating estrogen receptor ␤ agonists for the treatment of
breast cancer. Cathy Samayoa, Naveen Krishnegowda Krishnegowda, Ratna
Vadlamudi, Rajeshwar Tekmal.
3459 A new promising drug through abating endoplasmic reticulum
stress response in treating endometrial cancer. Chao Wang, Wei Guo,
Gordon B. Mills, Yiling Lu.
3460 Fetal alcohol exposure increases susceptibility to
carcinogenesis in the pituitary. Shaima Jabbar, George
Maglakelidze, Dipak K. Sarkar.
3461 RSK2 is a driver of estrogen receptor positive breast
cancer. Katarzyna Ludwik, Deborah Lannigan.
3462 Proteomic profiling reveals novel targets for
combination treatment with lanreotide in neuroendocrine tumors.
Omid Fotouhi, Hanna Kjellin, Jamileh Hashemi, Ming Lu, Christofer
Juhlin, Anders Höög, Jan Zedenius, Catharina Larsson, Janne Lehtiö,
Magnus Kjellman.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
26.
27.
28.
29.
30.
Abstract
Number
3463 Targeting Hedgehog pathway and EGFR signaling to
overcome endocrine resistance. Mark A. Rudolph, Stephen
Sizemore, Yuanzhi Lu, Kun-yu Teng, Alec Gonos, Bhuvaneswari
Ramaswamy, Sarmila Majumder.
3464 Prognostic value of DICER1 expression in adrenocortical
cancer patients. Gabriela R. Sousa, Tamaya C. Ribeiro, André M.
Faria, Beatriz M. Mariani, Antonio M. Lerario, Ibere C. Soares, Maria
Claudia N. Zerbini, Alda Wakamatsu, Venancio A. Alves, Berenice B.
Mendonca, Maria Candida B. Fragoso, Ana Claudia Latronico, Madson
Almeida.
3465 p53 status as a determinant of estrogen receptor beta
function in breast cancer. Gokul M. Das, Utpal K. Mukhopadhyay,
Sanjay Bansal, Nadi Wickramasekera, Rajesh Medisetty, Wendy M.
Swetzig, Austin Miller, Jianmin Wang, Chetan Oturkar, Alka
Mukhopadhyay, Santhi Konduri.
3466 Regulation of iodine uptake by SENP2 in thyroid cancer.
Eun Kyung Lee, Min Ji Park, You Jin Lee.
3467 Androgen receptor expression reduces post-hepatectomy
surgery recurrence risks of hepatocellular carcinoma. Wen-Lung Ma, PeiYin Liao, Chun-Chieh Yeh, Long-Bin Jeng, Hsueh-Chou Lai, Shang-Feng
Huang, Fu-Ju Lei.
3468 Impact of histology on serum thyroglobulin as a
biomarker for nonmedullary thyroid cancer recurrence. Logesh
Raki, Rehena Ganguly, Joanne Ngeow.
3469 Measuring antitumor effect of c-Myc-Max
heterodimerization inhibitor 100258-F4 on ovarian cancer cells
using cellometer image cytometry. Leo L. Chan, Jiandong Wang,
Xiaoli Ma, Fang Song, Weiyuan Zhang, Hannah M. Jones, Victoria L.
Bae-Jump, Chunxiao Zhou.
3470 Atypical protein kinase C inhibition in prostate cancer cells: A
study of ICA-1 and ACPD. Andre H. Apostolatos, Christopher Apostolatos,
Mildred Acevedo-Duncan.
3471 Comparative assessment of in vitro activity and
aactivated progesterone receptor (APR) biomarker predictivity for
multiple antiprogestins. Alexander Zukiwski, Erard Gilles, Guillaume
Serin, Jacques Bosq, Charline Alleaume.
3473 Sub-classification of prostate cancer circulating tumor
cells (CTCs) by nuclear size reveals very-small nuclear CTCs in
patients with visceral metastases. Jie-Fu Chen, Hao Ho, Jake
Lichterman, Yi-Tsung Lu, Yang Zhang, Mitch A. Garcia, Shang-Fu
Chen, An-Jou Liang, Haiyen E. Zhau, Shuang Hou, Rafi S. Ahmed,
Daniel J. Luthringer, Jiaoti Huang, Ker-Chau Li, Leland W. Chung,
Zunfu Ke, Hsian-Rong Tseng, Edwin M. Posadas.
3474 The effect of forced expression of k-ras mutation on
gastrointestinal cancer cells and IGF-IR targeting therapy. Yasushi
Adachi, Yasutaka Matsunaga, Yasushi Sasaki, Katsuhiko Nosho,
Hiroyuki Yamamoto, Yoshiaki Arimura, Takao Endo, Yasuo Kato,
Takashi Tokino, David P. Carbone, Yasuhisa Shinomura.
3475 Diurnal suppression of EGFR signaling by glucocorticoids:
implications for tumor progression and treatment. Mattia Lauriola,
Yehoshua Enuka, Amit Zeisel, Gabriele D’Uva, Lee Roth, Silvia Carvalho,
Rossella Solmi, Eytan Domany, Yosef Yarden.
3476 Intermittent anti-androgen monotherapy: a possible
treatment for androgen receptor-overexpressing prostate cancer.
Tim Oliver, Dan Berney, Greg Shaw.
3477 3D morphological hallmarks of breast carcinogenesis:
Diagnosis of non-invasive and invasive breast cancer with
Lightsheet microscopy. Octavian Bucur, Humayun Irshad, Laleh
Montaser-Kouhsari, Nicholas W. Knoblauch, Eun-Yeong Oh, Jonathan
Nowak, Andrew H. Beck.
Poster
:LJ[PVU
26
26
465
POSTER SESSION
Experimental and Molecular Therapeutics
Poster
:LJ[PVU
27
27
Combination Chemotherapy 2
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
466
Abstract
Number
3478 A multi-orthogonal strategy for targeting
EGFRvIII expressing glioblastomas. Ying Shen, Jie Li, Frank
B. Furnari, Arshad Desai, Hong-Zhuan Chen, Clark Chen.
3479 CPX-351 (cytarabine:daunorubicin liposome for
injection) anti-leukemia activity is potentiated by Chk1
inhibition. Nicole D. Vincelette, Larry M. Karnitz, Judith E.
Karp, Douglas B. Smith, Allan D. Hess, Lawrence D. Mayer,
Scott H. Kaufmann.
3480 Combinatorial apoptotic activity of capsaicin and
camptothecin in human small cell lung cancer. Haley E.
Perry, Kathleen C. Brown, Cathryn D. Stevenson, William D.
Rollyson, Cody A. Stover, Piyali Dasgupta.
3481 Sigma-2 ligands sensitize triple negative breast
cancer cells to PARP inhibitor treatment. Chenbo Zeng,
Julia Mankoff, Robert H. Mach.
3482 Combination of bexarotene and the retinoid
CD1530 reduces murine oral-cavity carcinogenesis
induced by the carcinogen 4-nitroquinoline 1-oxide. XiaoHan Tang, Lorraine J. Gudas.
3483 Synergistic combination therapy with molecular
targeted drugs in glioma stem-like cells. Takashi Shingu,
Lindsay Holmes, Verlene Henry, Khatri Latha, Anupama E.
Gururaj, Laura A. Gibson, Tiffany Doucette, Frederick F. Lang,
Ganesh Rao, Liang Yuan, Erik P. Sulman, Nicholas P. Farrell,
Waldemar Priebe, Kenneth R. Hess, Yaoqi A. Wang, Jian Hu,
Oliver Bogler.
3484 Synergism from combination of targeted therapy
with tumor active phytochemicals in ovarian tumor
models and changes in protein expression. Fazlul Huq.
3485 Uncertainty envelope to evaluate drug
interactivity with statistical analysis. Liang Zhao, Jessie L.
Au, M. Guill Wientjes.
3486 Synergistic effect of quinacrine in combination
with decitabine for the treatment of acute myeloid
leukemia cells in vitro: implication for treatment of AML in
the elderly. Wenge Wang, David T. Dicker, David F. Claxton,
Hong-Gang Wang, Wafik S. El-Deiry.
3487 A novel role of transient receptor potential
vanilloid type 2 (TRPV2) for augmentation of
chemotherapeutic drug efficacy in triple-negative breast
cancer. Mohamad M. Elbaz, Mohd W. Nasser, Helong Zhao,
Ramesh K. Ganju.
3488 BPM 31510 has broad utility as both a single
agent and in combination with standard-of-care
chemotherapy in triple-negative breast cancer. Niven R.
Narain, Anne R. Diers, Arleide Lee, Rakibou Ouro-Djobo,
Vivek K. Vishnudas, Ely Benaim, Joaquin J. Jimenez,
Rangaprasad Sarangarajan.
3489 Novel translational pharmacology approaches on
dose reduction and alternative scheduling for the
combination of JAK inhibitor, ruxolitinib, PIM inhibitor,
LGH447, and CDK4/6 inhibitor, LEE011 in a preclinical
model of myeloproliferative neoplasia. Maria Pinzon-Ortiz,
Xianhui Rong, Gary Vanasse, Z. A. Cao.
3490 Topotecan synergizes with CHEK1 inhibitor to
induce apoptosis in ovarian cancer cells. Marianne K. Kim,
Jana James, Christina Annunziata.
3491 Enhancing nab-paclitaxel antitumor activity
through addition of BMS-754807, a small-molecule
inhibitor of IGF-1R/IR, in experimental pancreatic cancer.
Niranjan Awasthi, Margaret A. Schwarz, Roderich E. Schwarz.
3492 Metformin inhibits salivary gland tumor growth
through cell cycle arrest and apoptosis. Yuqi Guo.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
3493 Disulfiram a dual mgmt and aldehyde
dehydrogenase inhibitor sensitizes pancreatic cancer to
gemcitabine and abraxane. George C. Bobustuc, Alisher
Holmuhamedov, Kalkunte S. Srivenugopal, Jacob C. Frick,
JAMES L. WEESE, Santhi D. Konduri.
3494 Combined MEK1/2 and PI3K inhibition induces
synergistic caspase-dependent apoptosis in
neuroblastoma. Lori S. Hart, Lucy Chen, Vandana Batra,
Matthew Tsang, Pichai Raman, Giordano Caponigro, Shiva
Krupa, Markus Boehm, Malte Peters, John M. Maris.
3495 Tumor growth arrest induced by a proprietary
inhibitor of JAK2 on TNBC patient-derived xenografts.
Daniel Davila-Gonzalez, Sergio Granados, Roberto Rosato,
Jenny C. Chang.
3496 Improvement of response to chemotherapy in
breast cancer cells by the use of the non-oncologic drug
minocycline. Christof Bernemann, Ludwig Kiesel.
3497 Mechanism-based scheduling of triple therapy
gemcitabine/CHK1i/WEE1i in pancreatic cancer at
submaximal yet synergistic concentrations. Siang-Boon Koh,
Frances M. Richards, Esther Rodriguez, Scott K. Lyons, Duncan I.
Jodrell.
3498 Synergistic cytotoxicity of everolimus in
combination with crizotinib in ALK-positive anaplastic large
cell lymphoma cells. Ji-Won Kim, Wendan Xu, Sung-Soo Yoon.
3499 Improving therapeutic efficacy of Docetaxel in
breast cancer. Jeronay King, Hina Mir, Neeraj Kapur, Shailesh
Singh.
3500 Combinations of ARQ087 with chemotherapeutic
agents are safe and show a striking antitumor activity in
different xenograft models. Rosaria Chilà, Federica Guffanti,
Terence Hall, Francesca Ricci, Massimo Broggini, Giovanna
Damia.
3501 EGFR tyrosine kinase inhibitors combined with
cytotoxic drugs for treatment of NSCLC with EGFR gene
mutations: Efficacy and mechanisms. Ryohei Yoshida,
Synsuke Okumura, Takaaki Sasaki, Yoshinobu Ohsaki.
3502 Selective targeting of CTNBB1-, KRAS- or MYCdriven cell growth by combinations of existing drugs. Joost
C. Uitdehaag, Jeroen A. de Roos, Antoon M. van Doornmalen,
Martine B. Prinsen, Jill A. Spijkers - Hagelstein, Judith R. de
Vetter, Jos de Man, Rogier C. Buijsman, Guido J. Zaman.
3503 Gilenya and Alimta interact to kill breast cancer
cells. Jane L. Roberts, Seyedmehrad Tavallai, Andrew
Poklepovic, Laurence Booth, Paul Dent.
3504 Synergism from combinations of monofunctional
platinums with phytochemicals in human ovarian cancer
cell lines. Laila Arzuman, Fazlul Huq, Jun Q. Yu, Philip Beale.
3505 Inhibition of PARP activity by BGB-290
potentiates efficacy of temozolomide in patient derived
xenografts of glioblastoma multiforme. Shiv K. Gupta, Brett
L. Carlson, Mark A. Schroeder, Katrina K. Bakken, Ann C.
Tuma, Jann N. Sarkaria.
3506 Targeting breast cancer stem cells and non-stem
breast cancer cells through combination therapies. LingWei Hii, Felicia F. Chung, Boon-Shing Tan, Yang Mooi Lim,
Soon-Keng Cheong, Chee-Onn Leong.
3507 APR-246 reactivates mutant p53 in non-small cell
lung cancer cell lines and sensitizes cells for CDDP
treatment under normoxic and hypoxic conditions.
Christophe Deben, Vanessa Deschoolmeester, An Wouters,
Jolien Van den Bossche, Julie Jacobs, Filip Lardon, Christian
Rolfo, Patrick Pauwels.
POSTER SESSION
Epigenetic Targets and BET Inhibitors
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
Abstract
Number
3508 Inhibition of EZH2 overcomes resistance to
sunitinib in clear cell renal cell carcinoma models. Remi M.
Adelaiye-Ogala, Sreenivasulu Chintala, Li Shen, Ashley
Orillion, Eric Ciamporcero, May Elbanna, Kiersten Marie Miles,
Bryan Gillard, Michael Buck, Roberto Pili.
3509 Novel dual inhibitors of LSD1-HDAC for treatment
of cancer. Dhanalakshmi Sivanandhan, Sridharan
Rajagopalan, Sreekala Nair, Purushottam Dewang, Durga
Prasanna Kumar, Chandrika Mulakala, Lavanya Mahadevan,
Neema Skariah, Venkata Giri Kavuru, Damodara Kuntrapaku,
Suchitra Sajja, Mohammad Zainuddin, Krishnakumar V, Ritu
Singh, Swarnakumari V, Ramachandraiah Gosu, Jayashree
Aiyar, Pravin Iyer, Sriram Rajagopal.
3510 Novel lysine demethylase LSD1 inhibitors
promote differentiation and apoptosis of glioma stem
cells. Gangadhara R. Sareddy, Takayoshi Suzuki, Andrew J.
Brenner, Ratna K. Vadlamdui.
3511 Targeted epigenetic reprogramming reverts
tumor progression in triple-negative breast cancer models
by the activation of retinoic acid receptor alpha. Nidhi
Bansal, Almudena Bosch, Boris A. Leibovitch, Keely
Pierzchalski, Zhou Ming-Ming, Maureen Kane, Samuel
Waxman, Eduardo Farias.
3512 Measuring intracellular target engagement and
drug residence time with nanoBRET. Matthew B. Robers,
Melanie Dart, Chad Zimprich, Thomas Kirkland, Sergiy Levin,
Thomas Machleidt, Jim Hartnett, Kris Zimmerman, Rachel
Ohana, Danette Daniels, Mei Cong, Frank Fan, Keith Wood.
3513 Inhibition of LSD1 for the treatment of cancer.
Kimberly Smitheman, Monica Cusan, Yan Liu, Michael
Butticello, Melissa Pappalardi, James Foley, Kelly Federowicz,
Glenn Van Aller, Jiri Kasparec, Xinrong Tian, Dominic Suarez,
Jess Schneck, Jeff Carson, Patrick McDevitt, Thau Ho, Charles
McHugh, William Miller, Scott Armstrong, Christine Hann, Neil
Johnson, Ryan G. Kruger, Helai P. Mohammad, Shekhar
Kamat.
3514 A novel inhibitor of IDH1 abrogates 2-HG
production and reverses aberrant epigenetic alterations in
IDH1 mutant cells. Cynthia Rominger, Chad Quinn, Enoch
Gao, Beth Pietrak, Alan Rendina, Angela Smallwood, Arthur
Groy, Susan Korenchuk, Charles McHugh, Ken Wiggall,
Alexander Reif, Stanley Schmidt, Hongwei Qi, Huizhen Zhao,
Nestor Concha, Christopher Carpenter, Juan Luengo, Ryan
Kruger, Benjamin Schwartz, Nicholas Adams, Michael T.
McCabe.
3515 RRx-001: A double action systemically non-toxic
epigenetic agent for cancer therapy. Hongjuan Zhao,
Shoucheng Ning, Jan Scicinski, Bryan Oronsky, Susan Knox,
Donna M. Peehl.
3516 EZH2 overexpression in myeloma patients
shortens survival and in-vitro data supports a potential
new targeted treatment strategy. Charlotte Pawlyn, Martin
F. Kaiser, Caleb K. Stein, Christopher P. Wardell, Veronica
Macleod, Rick Edmondson, Bart Barlogie, Brian Walker,
Gareth J. Morgan, Faith E. Davies.
3517 Honokiol inhibits bladder tumor growth by
suppressing EZH2/miR-143 axis. Jun Yan, Qing Zhang, Wei
Zhao, Changxiao Ye, Cunjie Chang, Xiaojing Huang, Junlong
Zhuang, Jiannan Song, Yangyan Cui, Isaac Eliaz, Bing Shen,
Ruimin Huang, Hao Ying, Hongqian Guo.
3518 Growth inhibition of SCLC cell lines by treatment
with LSD1 inhibitors is associated with modulation of
neuroendocrine pathways. Thomas A. Paul, Shikhar Sharma,
Jill Hallin, Tao Xie, Timothy Nichols, Mike Greig, James
Hardwick, Martin Wythes, Dominique Verhelle.
Poster
Board
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
Abstract
Number
3519 A phenotypic screen to discover novel epigenetic
anticancer drugs from natural compounds. Hanghang Zhang, Noël
Raynal, Takahiro Sato, Yasuyuki Okamoto, Ryan Henry, Andrew J.
Andrews, George Morton, Wayne Childers, Marlene A. Jacobson,
Magid Abou-Gharbia, Jean-Pierre J. Issa.
3520 Small molecule inhibitors of ring1B-Bmi1 E3
ligase target polycomb repressive complex 1 activity and
regulate cell proliferation. Shirish Shukla, Qingjie Zhao, Weijang
Ying, Felicia Gray, Kelly Vandenberg, George Lund, Bohdan Boytsov,
Shihan He, Jolanta Grembecka, Tomasz Cierpicki.
3521 Combined targeting of DNA and histone
methylation improves the efficacy and specificity of
epigenetic therapy. Takahiro Sato, Matteo Cesaroni, Jaroslav
Jelinek, Jean-Pierre Issa.
3522 BET and BRAF inhibitors act synergistically
against BRAF mutant melanoma. Luca Paoluzzi, Douglas
Hanniford, Elena Sokolova, Iman Osman, Farbod Darvishian,
Jinhua Wang, James E. Bradner, Eva Hernando.
3523 Discovery of a novel BET inhibitor INCB054329.
Phillip C. Liu, Xuesong M. Liu, Matthew C. Stubbs, Thomas
Maduskuie, Richard Sparks, Nina Zolotarjova, Jun Li,
Xiaoming Wen, Margaret Favata, Patricia Feldman, Alla
Volgina, Darlise DiMatteo, Robert Collins, Nikoo
Falahatpisheh, Padmaja Polam, Yu Li, Maryanne Covington,
Sharon Diamond-Fosbenner, Richard Wynn, Timothy Burn,
Kris Vaddi, Swamy Yeleswaram, Andrew P. Combs, Wenqing
Yao, Reid Huber, Peggy Scherle, Gregory Hollis.
3524 BAY 1238097, a novel BET inhibitor with strong
efficacy in hematological tumor models. Pascale Lejeune,
Tatsuo Sugawara, Kathy A. Gelato, Heidrun Ellinger-Ziegelbauer,
Amaury E. Fernandez-Montalvan, Norbert Schmees, Stephan Siegel,
Hilmar Weinmann, Volker Gekeler, Annette O. Walter, Matthias
Ocker, Stuart Ince, Bernard Haendler.
3525 The BET inhibitor INCB054329 is efficacious as a
single agent or in combination with targeted agents in
colorectal cancer models. Xuesong Liu, Jun Li, Xin He, Matthew
Stubbs, Margaret Favata, Xiaoming Wen, Hong Chang, Beth R.
Rumberger, Yanlong Li, Thomas Maduskuie, Richard Sparks, Nikoo
Falahatpisheh, Padmaja Polam, Andrew P. Combs, Reid Huber,
Gregory Hollis, Peggy Scherle, Phillip C. Liu.
3526 OTX015 effects in triple-negative breast cancer
(TNBC) models are independent of hypoxia conditions and
synergistic with other anticancer agents. Ramiro Vázquez,
Lucile Astorgues-Xerri, María E. Riveiro, Luca Beltrame, Sergio
Marchini, Francesco Bertoni, Ivo Kwee, Mohamed Mohamed,
Esteban Cvitkovic, Roberta Frapolli, Maurizio D’Incalci.
3527 OTX015, a novel BET-bromodomain (BET-BRD)
inhibitor, displays antitumoral effects in orthotopic and
heterotopic models of human glioblastoma. Lucile
Astorgues-xerri, Caroline Berenger, Mylène Cayol, Mohamed
Bekradda, Elodie Odore, Keyvan Rezai, Esteban Cvitkovic,
Maria E. Riveiro, L’Houcine Ouafik.
3528 The SMARCA2/4 catalytic activity, but not the
bromodomain, is a drug target in SWI/SNF mutant
cancers. Bhavatarini Vangamudi, Thomas Paul, Parantu K. Shah,
Maria K. Alimova, Lisa Nottebaum, Xi Shi, Yanai Zhan, Elisabetta Leo,
Harshad S. Mahadeshwar, Alexei Protopopov, Andrew Futreal, Trang
N. Tieu, Mike Peoples, Alessia Petrocchi, Joseph R. Marszalek, Carlo
Toniatti, Timothy P. Heffernan, Dominique Verhelle, Giulio Draetta,
Dafydd Owen, Philip Jones, Wylie Palmer, Shikhar Sharma, Jannik N.
Andersen.
3529 BET bromodomain proteins regulate the
canonical WNT signaling and drug resistance in colorectal
cancer. Lihong Wang, Yufang Ma, Ethan Lee, Jialiang Wang.
3530 Gene expression profile of OTX015, a BET
bromodomain inhibitor, in preclinical models of nonsmall-cell lung cancer (NSCLC) and small-cell lung cancer
(SCLC) models. Maria E. Riveiro, Ivo Kwee, Lucile AstorguesXerri, Mohamed Bekradda, Ramiro Vazquez, Andrea Rinaldi,
Esteban Cvitkovic, Francesco Bertoni.
28
28
467
POSTER SESSION
Poster
:LJ[PVU
29
29
Gene- and Vector-Based Therapy
Poster
Board
1.
2.
3.
468
Abstract
Number
3531 Companion diagnostics-based telomerasespecific oncolytic virotherapy: preclinical evaluation in
human colorectal cancer cell lines differentially affected in
the RAS/RAF/MEK signaling pathway. Shuta Tamura,
Hiroshi Tazawa, Naoto Hori, Takeshi Koujima, Satoru Kikuchi,
Shinji Kuroda, Hiroyuki Kishimoto, Takeshi Nagasaka,
Masahiko Nishizaki, Yasuo Urata, Shunsuke Kagawa,
Toshiyoshi Fujiwara.
3532 Selective eradication of colorectal cancer cells by
adenovirus-based delivery of toxins. Shiran Shapira, Assaf
Shapira, Dina Kazanov, Ilana Nabiochtchikov, Nadir Arber,
Sarah R. Kraus.
3533 Systemic delivery of CTNNB1 Dicer-substrate
siRNAs (DsiRNAs) leads to efficient oncogene silencing in
diverse tumor types of extra hepatic origin. Shanthi
Ganesh, Bo Ying, Martin Koser, Wendy Cyr, Girish Chopda,
Hank Dudek, Cheng Lai, Weimin Wang, Bob Brown, Marc T.
Abrams.
4.
3534 Development of the novel AAV-based vectors
with selective tropism to human cancer cells. Rana Sayroo,
Zifei Yin, Diego Nolasco, Munjal Pandya, Chen Ling, George
Aslanidi.
5.
3535 A novel tumor-specific oncolytic biological
therapy against invasive pancreatic cancer. Takeshi
Koujima, Hiroshi Tazawa, Naoto Hori, Shuta Tamura, Shinji
Kuroda, Hiroyuki Kishimoto, Masahiko Nishizaki, Yasuo Urata,
Shunsuke Kagawa, Toshiyoshi Fujiwara.
6.
3536 Targeting ␤-catenin with a Dicer-substrate siRNA
(DsiRNA) in a sleeping beauty transposon-driven murine
hepatoblastoma model. Marc T. Abrams, Junyan Tao,
Shanthi Ganesh, Wendy Cyr, Bo Ying, Martin Koser, Rokhand
Arvan, Girish Chopda, Hank Dudek, Cheng Lai, Weimin Wang,
Bob Brown, Satdarshan Monga.
7.
3537 Stem-cell based selective delivery of alpha keto
reductases for therapeutic targeting of residual androgens
in prostate cancer. Manish Ranjan, Zakaria Abd Elmageed,
Hogyoung Kim, Amrita Datta, Nobel Bhasin, Steven E. Braun,
Debasis Mondal, Asim B. Abdel-Mageed.
8.
3538 Quorum-sensing Salmonella selectively trigger
protein expression within tumors. Charles A. Swofford, Nele
Van Dessel, Neil S. Forbes.
Poster
Board
Abstract
Number
9.
3539 Modifications of adenoviral structure and genome
improves transduction efficiency and transgene
expression. Paulo R. Del Valle, Daniela B. Zanatta, Bryan E.
Strauss.
10.
3540 Novel targeted combinational therapies for
melanoma. Robert Suriano, Neha Y. Tuli, Jan Geliebter, Raj K.
Tiwari, Marc Wallack.
11.
3541 Therapeutic effect of CD133-targeted oncolytic
adenovirus in colon cancer. Mizuho Sato, Yoshiaki Miura,
Masato Yamamoto.
12.
3542 Inhibition of HuR effectively suppresses ovarian
tumor growth in mice. Janet A. Sawicki, Yu-Hung Huang,
Jonathan R. Brody, Robert C. Getts, Kelly Rhodes, Jackie
Gerhart.
13.
3543 Ligand-directed and transcription-based
molecular imaging and treatment of cancer. Andrey S.
Dobroff, Bedrich L. Eckhardt, Carolina C. Salmeron, Daniel F.
Cimino, Wadih Arap, Renata Pasqualini.
14.
3544 Clinical applicable human adipose tissue-derived
mesenchymal stem cells delivering therapeutic genes to
brainstem glioma. Seung Ah Choi, Young Eun Lee, Phil Ae
Kwak, Youn Joo Moon, Ji Hoon Phi, Kyu-Chang Wang, Sung
Su Kim, Kyu-Chang Wang, Kyeung Min Joo, Seung-Ki Kim.
15.
3545 Stromal selective targeting by uPAR retargeted
oncolytic measles virus inhibits breast cancer progression.
Yuqi Jing, Marcela Toro Bejarano, Krisztina Kovacs, Jaime
Merchan.
16.
3546 Arming a tumor targeted oncolytic herpes
simplex sirus type 1 with matrix metalloproteinase 9 for
enhanced vector distribution and killing activity. Aofei Li,
Marco Marzulli, Mingdi Zhang, William Goins, Balveen Kaur,
Chelsea Bolyard, Nduka Amankulor, Daniela Leronni, Paola
Sette, Justus Cohen, Joseph Glorioso, Paola Grandi.
17.
3547 Systemically delivered human telomerase reverse
transcriptase (hTERT)-targeting p53-laden adenovirus
shows strong antitumor effects in intrahepatic Hep3B
xenograft mouse model. Won Sup Lee, Hye Lim Kang,
Arulkumar Nagappan, Jeong Won Yun, GonSup Kim, Soon
Chan Hong, Sang-Jin Lee, In-Hoo Kim.
18.
3548 Oncolytic adenovirus Ad5dlE1b replication
efficiency is dependent on p53 mutation type in cancer
cells. Moemen Abdalla, Basma M. Abbas, Yousef Haj-Ahmad.
POSTER SESSION
Molecular Targets
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
14.
15.
16.
Abstract
Number
3549 Special characteristics of betel-nuts related head
and neck squamous cell carcinoma (HNSCC) in Taiwan.
Jo-Pai Chen, Ling-Yu Chen, Sung-Hsin Kuo, Ruey-Long Hong.
3550 Expression of Oct-2, OCA-B, BCL6, PU.1 and IRF8
predicts prognosis in Diffuse Large B Cell Lymphoma
patients. Erica A. Rojas Bilbao, Elisa D. Bal de Kier Joffe,
Marta E. Zerga, Lydia I. Puricelli, Stella Maris N. Ranuncolo.
3551 A microRNA-1280/JAG2 network comprises a
novel biological target in high-risk medulloblastoma.
Fengfei Wang, Marc Remke, Kruttika Bhat, Eric Wong,
Shuang Zhou, Vijay Ramaswamy, Adrian Dubuc, Ekokobe
Fonkem, Saeed Salem, Hongbing Zhang, Tze-chen Hsieh,
Stephen O’Rourke, Lizi Wu, David Li, Cynthia Hawkins, Isaac
Kohane, Joseph Wu, Min Wu, Michael Taylor, Erxi Wu.
3552 Metabolite profiling reveals the glutathione
biosynthetic pathway as a therapeutic target in triple
negative breast cancers. Alexander Beatty.
3553 xCT is a new cancer stem cell immunotherapeutic
target for breast cancer. Marco Macagno, Stefania Lanzardo,
Laura Conti, Roberto Ruiu, Raffaele A. Calogero, Federica
Cavallo.
3554 A short ASPM splicing variant but not the full
length variant as a molecular target in hepatocellular
carcinoma. Hung-Wei Pan, Yu-Chia Chen.
3555 Akt kinase-interacting protein1 as a potential
therapeutics target in CREB1 signaling in malignant
pleural mesothelioma. Tadaaki Yamada, Joseph M. Amann,
Konstantin Shilo, Naoya Fujita, Seiji Yano, David P. Carbone.
3556 Fibroblast growth factor receptor 2 is associated
with poor overall survival in clear cell carcinoma of the
ovary and may be a novel therapeutic approach. Hiroaki
Itamochi, Nao Oumi, Tetsuro Oishi, Fuminori Taniguchi,
Tadahiro Shoji, Hiroyuki Fujiwara, Toru Sugiyama, Mitsuaki
Suzuki, Junzo Kigawa, Tasuku Harada.
3557 Cancerous inhibitor of PP2A is a novel molecular
target and resistance factor of Lapatinib. Ming Zhao,
Amanda Blackwelder, Harry Lee, Xiaohe Yang.
3558 uPAR mediated endothelial targeting by oncolytic
measles virus. Marcela M. Toro Bejarano, Yuqi Jing, Krisztina
Kovacs, Jaime Merchan.
3559 Ubiquitin C-terminal hydrolase L1 (UCHL1)
modulates uterine papillary serous cancer progression
through interaction with cyclin B1. Suet Ying Kwan, Samuel
C. Mok, Kwong-Kwok Wong, Rosemarie E. Schmandt, Karen
H. Lu.
3560 IFITM1 overexpression enhances the aggressive
phenotype of inflammatory breast cancer in a STAT2dependent manner. Joshua W. Ogony, Joan Lewis-Wambi.
3562 Protein palmitoylation in breast cancer: DHHC5
palmitoyltransferase as a potential therapeutic target. Hui
Tian, Xiaoxia Qi, Kenneth Huffman, John Minna, Sandra L.
Hofmann.
3563 Unlocking the potential of CD70 as a therapeutic
target in non-small cell lung cancer. Julie Jacobs, Patrick
Pauwels, Christian Rolfo, Filip Lardon, Vanessa
Deschoolmeester, Christophe Deben, Jolien Van den Bossche,
Karen Zwaenepoel, Christophe Hermans, Karen Silence, Alain
Thibault.
3564 PlGF/VEGFR-1-dependent activation of the Dll4Notch4/Ephrin B2 cascade contributes to liver vessel
anomalies in hepatocellular carcinoma. Annemilai TijerasRaballand, Jean-Olivier Contreres, Patricia Hainaud-Hakim, Carole Le
Hénaff, Marc Pocard, Evelyne Dupuy, Armand de Gramont.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Abstract
Number
3565 Gli2 induces melanoma tumor growth and
progression: A critical role of c-Myc. Neel M. Fofaria, Sanjay
K. Srivastava.
3566 Targeting CD99 in T-cell neoplasms. Montreh Tavakkoli*,
Dong H. Lee, Stephen S. Chung, Christopher Y. Park.
3567 Identification of potential biomarkers and novel
therapeutic candidates for neuroendocrine cancer. Angela Carter,
Karine Pozo, Chun-Feng Tan, Fiemu Nwariaku, James Bibb.
3568 CYP3A4 epoxygenase activity mediates ER+
mammary tumor growth and angiogenesis, in part,
through EET biosynthesis and is inhibited by biguanides.
Zhijun Guo, Irina F. Sevrioukova, Eric Hanse, Ilia Denisov, Xia
Zhang, Ting-Lan Chiu, Daniel Swedien, Justin Stamschror,
Juan Alvarez, William M. Ortiz, Monique Morgan, Michael
Maher, Kathryn J. Chavez, Dafydd Thomas, Young K. Bae,
Jonathan Henriksen, Beverly Norris, Robert J. Schumacher,
Henry Wang, Robin Bliss, Haitao Chu, Rebecca Cuellar,
Thomas L. Poulos, Stephen G. Sligar, William Atkins, Stephen
Schmechel, Jorge Capdevila, John Falck, Ian Blair, Jeffrey P.
Jones, Gunda Georg, Kalpna Gupta, Ameeta Kelekar,
Elizabeth Amin, David A. Potter.
3569 Inhibition of the TRPM7 kinase domain inhibits
breast cancer cell migration and invasion and tumor
metastasis. Tamer S. Kaoud, Xuemei Xie, Jihyun Park, Clint D.
Tavares, Shreya Mitra, Micael Cano, Rachel M. Sammons, Mohamed
F. Radwan, Chandra Bartholomeusz, Kevin N. Dalby.
3570 Identification of the DEAD box RNA helicase DDX3
as a therapeutic target in colorectal cancer. Marise R.
Heerma van Voss, Farhad Vesuna, Kari Trumpi, Justin
Brilliant, Liudmila L. Kodach, Folkert H. Morsink, G. Johan A.
Offerhaus, Horst Buerger, Elsken van der Wall, Paul J. van
Diest, Venu Raman.
3571 Furin activity: A driver of rhabdomyosarcoma
progression. Patricia A. Jaaks, Gianmarco Meier, Beat W.
Schäfer, Michele Bernasconi.
3572 Metformin inhibits the oncogenic potential and
invasiveness of pancreatic cancer cells targeting CCN1CXCR4 axis : A new perspective for an old antidiabetic
drug. Amlan Das, Archana De, Inamul Haque, Gargi Maity,
Sushanta Banerjee, Snigdha Banerjee.
3573 Novel G protein-coupled receptor targets in
HER2+ breast cancer. Raksha Bhat, Puja Yadav, Pavel
Christiny, Rachel Schiff, Meghana V. Trivedi.
3574 Novel roles of an axon-guidance molecule,
semaphorin 3E, in pancreatic cancer. Lin-Kin Yong, Dali Li,
Ethan Poteet, Zhengdong Liang, William Fisher, Changyi
Chen, Qizhi C. Yao.
3575 Novel targets and monoclonal antibodies for
antibody-drug conjugate therapy. Matteo Parri, Susanna
Campagnoli, Alberto Grandi, Elisa De Camilli, Paolo
Sarmientos, Boquan Jin, Guido Grandi, Giuseppe Viale, Luigi
Terracciano, Piero Pileri, Renata Maria Grifantini.
3576 Rictor alterations elicit non-canonical signaling
mechanisms contributing to tumorigenicity and
therapeutic resistance in non-small cell lung cancer
(NSCLC). Dennis Ruder, Vassiliki Papadimitrakopoulou,
Kazuhiko Shien, Neda Kalhor, J. Jack Lee, Waun K. Hong,
Ximing Tang, Luc Girard, John D. Minna, Lixia Diao, Jing
Wang, Nana E. Hanson, James Sun, Vincent Miller, Garrett
Frampton, Roy S. Herbst, Ignacio I. Wistuba, Julie G. Izzo.
3577 Targeting localization and function of the RNA
helicase DDX5/p68 with 1-(3,5-dimethoxyphenyl)-4-[(6fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl]
piperazine (RX-5902). Judit Remenyi, Mi Young Yang,
Young Bok Lee, Deog Joong Kim, Frances V. Fuller-Pace.
30
30
469
POSTER SESSION
Poster
:LJ[PVU
31
31
Resistance to Pathway-Targeted Therapeutics 2
Poster
Board
1.
3578 Dual mTOR kinase inhibitor overcomes rapamycin resistance
in vitro. Yao Dai, Li Zhao, Dietmar Siemann.
2.
3579 Identification of biomarkers of AXL-mediated drug
resistance in head and neck squamous cell carcinoma. Kavitha Balaji,
Robert Cardnell, Lixia Diao, Pan Tong, Milena Mak, You H. Fan, Fatemeh
Masrorpour, Steven L. Warner, David J. Bearss, Ignacio Wistuba, Gordon B.
Mills, John Heymach, Khandan Keyomarsi, Jing Wang, Lauren A. Byers.
3.
3580 Downregulated miR-30a promotes acquisition of
chemoresistance by targeting endothelin A receptor in ovarian
carcinoma. Rosanna Sestito, Roberta Cianfrocca, Laura Rosanò, Elisa
Semprucci, Piera Tocci, Valeriana Di Castro, Gabriella Ferrandina, Anna
Bagnato.
4.
3581
Rapid conversion to resistance, of a colon PDX with retfusion, by ponatinib treatment could potentially be attributed to the
introduction of the gate keeper mutation V804M. Mengmeng Yang, Jie
Cai, Sheng Guo, Jean-Pierre Wery, Henry Q. Li.
5.
3582 Epidermal growth factor receptor and anaplastic lymphoma
kinase bypass signaling in oral squamous cell carcinoma in vivo. Cara B.
Gonzales, Heping Chen, Jorge J. De La Chapa, Nameer B. Kirma.
6.
3583 Drug-resistant NPM/ALK mutants show different sensitivity
to second generation tyrosine kinase inhibitors. Luca Mologni, Monica
Ceccon, Diletta Fontana, Alessandra Pirola, Rocco Piazza, Carlo
Gambacorti-Passerini.
7.
8.
9.
3584 Lysine specific demethylase 1 inhibition attenuates
enzalutamide resistant androgen receptor V7 splice variant activation.
Sergio Regufe da Mota, Sarah Bailey, Rosemary A. Strivens, Annette L.
Hayden, Graham Packham, Simon J. Crabb.
3585 HER3 and IGF1R are major mediators of both acquired and
intrinsic cetuximab resistance in head and neck squamous cell
carcinomas. Ida Kjaer, Trine Lindsted, Camilla Fröhlich, Ivan D. Horak,
Michael Kragh, Jesper V. Olsen, Mikkel W. Pedersen.
3586 The use of kinome profiling to determine potential
resistance pathways in pancreatic cancer cells treated with PIM kinase
inhibitors. Vandana Singh, Brittany Nixon, T.S. Karim Gilbert, Steve
Warner, David Bearss, Lee M. Graves, Antonio T. Baines.
10.
Developing targeted therapy for the treatment of drugresistant ovarian cancer. Kelly M. Kreitzburg, Zacchary Dobbins, Ashwini
Katre, Tooba Anwer, Ronald Alvarez, Charles N. Landen, Karina J. Yoon.
11.
3588 Emergence of multiple EGFR extracellular mutations during
cetuximab treatment in colorectal cancer. Luca Lazzari, Sabrina Arena,
Beatriz Bellosillo, Giulia Siravegna, Alejandro Martínez, Israel Cañadas,
Noelia Ferruz, Mariangela Russo, Sandra Misale, Iria González, Mar Iglesias,
Elena Gavilan, Giorgio Corti, Sebastijan Hobor, Giovanni Crisafulli, Marta
Salido, Juan Sánchez, Alba Dalmases, Joaquim Bellmunt, Gianni De
Fabritiis, Ana Rovira, Federica Di Nicolantonio, Joan Albanell, Alberto
Bardelli, Clara Montagut.
12.
470
Abstract
Number
Poster
Board
16.
3593 Raptor upregulation contributes to maintenance of 4EBP1
phosphorylation and TORC kinase resistance in renal cancer cells. Philip
Earwaker, Frances Willenbrock, Andrew Protheroe, Valentine Macaulay.
17.
3594 P-glycoprotein attenuates Src activation and DNA repair
activity via increased C-terminal Src kinase-binding protein, a negative
regulator of Src, in multidrug-resistant cells. Li-Fang Lin, Ming-Hsi Wu,
Tsann-Long Su, Te-Chang Lee.
18.
3595 In vivo acquired resistance to the mutant EGFR inhibitor
Rociletinib (CO-1686) is associated with activation of the c-MET
pathway. Henry J. Haringsma, Andrew Allen, Thomas C. Harding, Andrew
D. Simmons.
19.
3596 A biomarker study of lapatinib in the neoadjuvant treatment
of HER2 over expressing esophago-gastric adenocarcinoma (EGA).
Nadeera K. De Silva, Laura Schulz, Anna Paterson, Tara Nuckcheddy-Grant,
Wendi Qain, Edmund Godfrey, Heok Cheow, Maria O’Donovon, Minesh
Jobanputra, Daniel Hochhauser, Rebecca C. Fitzgerald, Hugo Ford.
20.
3597 EZH2 D1 domain mutants confer acquired resistance to
EZH2-targeted inhibitors and reprogram B-cell transcription. Francois
Gonzalvez, Theresa Baker, Justin Pritchard, Victor M. Rivera, Andrew
Garner.
21.
3598 Selective internal radiation (SIRT) is most effective when
comparing local treatment to control progressive liver metastases of
gastro-intestinal stromal tumors beyond treatment with tyrosine
kinase inhibitors. Peter Hohenberger, Nils Rathmann, Franka Menge,
Maliha Sadick, Stefan Schönberg, Steffen Diehl.
22.
3599 Resistance mechanisms to HER2-targeting treatment in
HER2-positive gastric cancer. Kyo Hwa Kang, Ah-Rong Nam, Ji Eun Park,
Ju-Hee Bang, Jin Ling, Mei Hua Jin, Tae Yong Kim, Sae-Won Han, SangHyun Song, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang.
23.
3600 Impaired taxane binding to MTs in intrinsically taxane
resistant gastric cancer cells without ␤-tubulin mutation. Katsuhiro
Kita, Giuseppe Galletti, Kyle Cleveland, Prashant V. Thakkar, Ada Gjyezi,
Chao Zhang, Isabel Barasoain, J. Fernando Díaz, Doron Betel, Manish A.
Shah, Paraskevi Giannakakou.
24.
3601 Antibody-drug conjugates (ADCs) with tubulysin and PBD
warheads, maintain potent in vitro cytotoxicity against multidrugresistant tumor cells expressing P-glycoprotein (P-gp). Shenlan Mao,
Ryan Fleming, Binyam Bezabeh, Nazzareno Dimasi, Dorin Toader, Thais
Cailleau, Philip Howard, Changshou Gao, Bob Hollingsworth, Adeela
Kamal, Jay Harper.
25.
3602 Cross-resistance to 1st, 2nd, and 3rd generation EGFR
tyrosine kinase inhibitors in vitro is characterized by MET amplification
and PTEN loss. Sarah M. Paul, Dorothee Nickles, Xioafen Ye, Robert L.
Yauch, David S. Shames.
26.
3603 Molecular targeting of cetuximab resistant head and neck
cancer. Adam D. Swick, Dana Gunderson, Molly Smith, Grace Blitzer,
Andrew Stein, Kwangok P. Nickel, Randall J. Kimple.
27.
3604 Targeting the PIM kinases in combination with BTK inhibition
is synergistic in preclinical models of B-cell malignancies. Jeremiah J.
Bearss, Brigham L. Bahr, Katie K. Soh, Peter W. Peterson, Clifford J.
Whatcott, Adam Siddiqui-Jain, David J. Bearss, Steven L. Warner.
28.
3605 Combined inhibition of IL-1, CXCR1/2, and TGF␤ signaling
pathways modulates in vivo acquired resistance to anti-VEGF
treatment. Carmine Carbone, Anna Tamburrino, Geny Piro, Marco
Zanotto, Maria Mihaela Mina, Silvia Zanini, Federico Boschi, Aldo Scarpa,
Giampaolo Tortora, Davide Melisi.
29.
3606 Increase of MET gene copy number confers resistance to a
monovalent MET antibody and establishes drug dependence. Valentina
Martin, Simona Corso, Paolo M. Comoglio, Silvia Giordano.
30.
3607 Loss-of-function screens using haploid KBM7 and HAP1 cells
to identify mechanisms of anti-cancer drug resistance. Nora M.
Gerhards, Charlotte Guyader, Vincent A. Blomen, Aslı Küçükosmanoğlu,
Olaf van Tellingen, Daniel J. Vis, Lodewyk F. Wessels, Thijn R.
Brummelkamp, Piet Borst, Sven Rottenberg.
3587
3589 Validation of the role of circulating tumor DNA (ctDNA) in
tracking mechanisms of resistance to anti-EGFR monoclonal antibodies
(AE-mABs): preliminary results of the PROSPECT-C prospective trial.
Khurum Khan, George Vlachogianis, David Cunningham, Jens Hahne,
Mahnaz Darvish-Damavandi, Sarah Barton, Francesco Trevisani, Giulia
Mentrast, Clare Peckitt, Andrea Lampis, Chiara Braconi, Nasir Khan,
Ruwaida Begum, Naureen Starling, Sheela Rao, David Watkins, Annette
Bryant, Ian Chau, Nicola Valeri.
13.
3590 Resistance mechanisms to ALK inhibitors. Ryohei Katayama,
Noriko Yanagitani, Sumie Koike, Takuya Sakashita, Satoru Kitazono,
Makoto Nishio, Yasushi Okuno, Jeffrey A. Engelman, Alice T. Shaw, Naoya
Fujita.
14.
3591
Inhibition of heme oxygenase 1 decreases proliferation and
resensitizes TKI-resistant Flt3-ITD-positive AML cells. Mary E. Irwin,
Joya Chandra.
15.
3592
Androgens interfere with enzalutamide agonism of mutant
F876L androgen receptor. Daniel Coleman, Katy Van Hook, Robert Lisac,
Carly King, Nicholas Wang, Jacob Schwartzman, Martin Gleave, Lina Gao,
Joshua Urrutia, Laura Heiser, Joshi J. Alumkal.
Abstract
Number
POSTER SESSION
Targeting Cell Death and DNA Repair
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
3608 Prostaglandin E-2 promotes resistance to
oxaliplatin in colorectal cancer cells. Huakang Huang,
Daniel W. Rosenberg.
3609 In vitro comparison of conventional hyperthermia
and electro-hyperthemia. Kwan-Hwa Chi, Yu-Shan S. Wang,
Cheng-Chung Huang, Chao-Chun Chang, Mau-Shin Chi, KaiLin Yang, Yuk-Wah Tsang, Gabor Andocs.
3610 DMH4, A VEGFR2 inhibitor effectively suppresses
proliferation and migration of lung cancer cells. Hao Li,
Chay Bae, Nicky Gazy, Jijun Hao, Li Zhong.
3611 An investigation of thermal dose as a parameter
to model the thermal effects of high intensity focused
ultrasound in cancer therapy. Petros Mouratidis, Gail ter
Haar.
3612 Study of the functional importance of PPAR␥ in
honokiol-induced apoptosis of hepatoma cells. Chin-Wen
Chi, Hui-Tzu Hsu, Jia-Dong Hou, Chih-Chun Lee, Ying-Ju Kuo,
Hsin-Chen Lee, Cheng-Yuan Hsia.
3613 P300 inhibition enhances cytotoxic effect of
Gemcitabine through E2F1 activation in pancreatic cancer.
Hiroaki Ono, Marc D. Basson, Hiromichi Ito.
3614 The anti-tumor effect of antimalarial chloroquine
on endometrial cancer cells is dependent on autophagy
inhibition. Tomohiko Fukuda, Katsutoshi Oda, Osamu WadaHiraike, Kenbun Sone, Kanako Inaba, Yuji Ikeda, Tomoko
Kashiyama, Aki Miyasaka, Chinami Makii, Reiko Kurikawa,
Takahide Arimoto, Tetsu Yano, Kei Kawana, Noboru
Mizushima, Yutaka Osuga, Tomoyuki Fujii.
3615 Autophagy as a drug target to prevent tumor
progression in head and neck squamous cell carcinoma:
Validation using a physiologically relevant mouse model.
Erin E. Mowers, Mark Lingen, Ezra E. Cohen, Kay Macleod.
3616 Development of a Sox2 targeting therapy for the
treatment of lung squamous cell carcinoma. Naomasa
Ishida, Takuya Fukazawa, Munenori Takaoka, Tomoki
Yamatsuji, Ichiro Morita, Minoru Haisa, Nagio Takaoka, Yoshio
Naomoto.
3617 Inhibition of KLF4 expression in resistant B-NHL
cell lines inhibited cell growth and sensitized the cells to
drug-induced apoptosis. Mayra R. Montecillo-Aguado,
Gabriel G. Vega, Hector Mayani, Sara Huerta-Yepez, Rogelio
Hernández-Pando, Otoniel Martinez-Maza, Benjamin
Bonavida, Mario I. Vega.
3618 SGKs survival signal via inhibition of proapoptotic Mixed Lineage Kinase 3 (MAP3K11) in cancer
cells. Gautam V. Sondarva, Velusamy Rangasamy, Navin
Viswakarma, Subhasis Das, Rakesh S. Nair, Basabi Rana, Ajay
Rana.
3619 Arsenic trioxide downregulates NPM-ALK and
inhibits the proliferation of ALK-positive anaplastic large
cell lymphoma. Wenying Piao, David HW Chau, Kevin LM
Yue, Yok Lam Kwong, Eric WC Tse.
3620 An oral procaspase activating drug, PAC-1, shows
preclinical promise for glioblastoma therapy. Avadhut D.
Joshi, Rachel C. Botham, Howard S. Roth, Timothy M. Fan,
Theodore M. Tarasow, Paul J. Hergenrother, Gregory J.
Riggins.
3621 Deubiquitination of AXIN1 by USP9X promotes
apoptosis in melanoma in response to BRAF or MEK
inhibition. Harish Potu, Luke F. Peterson, Malathi Kandarpa,
Eric Fearon, Moshe Talpaz, Nicholas J. Donato.
3622 Novel SMAC-mimetic birinapant demonstrates
antitumor activity in human head and neck cancer models
exhibiting alterations in cell death pathways. Sophie
Carlson, Danielle Eytan, Grace Snow, Stephen Schiltz, Suresh
Mohan, Anthony Saleh, Shaleeka Cornelius, Jamie Coupar,
Carter Van Waes, Zhong Chen.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
3623 Neoadjuvant chemotherapy is associated with
increased expression of DNA repair proteins and epithelial
to mesenchymal transition (EMT) in patients with nonsmall cell lung cancer (NSCLC). Daniel R. Gomez, Lixia Diao,
Jing Wang, Ignacio I. Wistuba, Cesar Moran, Neda Kalhor,
Milind B. Suraokar, Stephen G. Swisher, Carmen Behrens,
Youhong Fan, John V. Heymach, Lauren A. Byers.
3624 A novel, selective DNA-PK inhibitor sensitizes
poor prognosis chronic lymphocytic leukemia (CLL) cells
to mitoxantrone. Gesa Junge.
3625 Expression of CRBN binding protein AGO2 plays
important roles for myeloma cell growth. Qinqin Xu,
Yuexian Hou, Paul Langlais, Patrick Erickson, James Zhu,
Changxin Shi, Moulun Luo, Yuanxiao Zhu, Lawrence
Mandarino, Keith Stewart, Xiu-Bao Chang.
3626 Expression of BARD1 splice variant impairs
homologous recombination and can predict PARP1
inhibitor therapy in colorectal cancer. Ozkan Ozden, Faraz
Bishehsari, Jessica Bauer, Seung Hyua Baik, Barbara Jung.
3627 Generation and characterization of phosphospecific antibodies against human O6-methylguanine-DNA
methyltransferase (MGMT) DNA repair protein. Amit
Rawat, Upendra Gumaste, Mohammed A. Yusuf, Suryakant K.
Niture, Kalkunte S. Srivenugopal.
3628 Tyrosyl-DNA phosphodiesterase I as a therapeutic
target: lessons from yeast functional studies. Selma M.
Cuya, Ashley C. Conoway, Robert C. van Waardenburg.
3629 Balance shift between error-free and error prone
DNA double-strand break repair as a novel mechanism of
radiosensitization by nucleoside analogs. George Iliakis,
Simon Magin.
3630 Inhibition of PARP by hyperthermia or
pharmacological inhibitors synergize with cisplatin and
doxorubicin but not with 5-FU or paclitaxel. Lea Schaaf,
Christoph Ulmer, Wolfgang Steurer, Thomas E. Mürdter,
Walter E. Aulitzky, Heiko van der Kuip.
3631 A novel combination of Hedgehog inhibitors with
carboplatin exhibits synergy in ovarian cancer treatment
by altered regulation of DNA repair networks. Sebastian M.
Spencer, Kaushlendra Tripathi, Erhong Meng, Jennifer Scalici,
Rodney P. Rocconi, Komaraiah Palle.
3632 Synergistic interaction of auranofin with PARP
inhibitors in ATM-proficient mantle cell lymphoma.
Siddhartha Ganguly, Trisha Home, Sumedha Gunewardena,
Scott Weir, Joseph McGuirk, Rekha M. Rao.
3633 Combination of PARP inhibitor ABT-888 with NOdonor SNAP sensitizes BRCA1 positive cancer cell lines to
ionizing radiation. Aaron Wilson, Vasily A. Yakovlev.
3634 A gain-of-function mutation in tyrosine
phosphatase SHP-2 enhances breast carcinoma malignant
phenotypes. Zhongqian Hu, Haoshu Fang, Siying Wang.
3635 Histone demethylase NDY1/KDM2B as a driver of
survival and proliferation of normal and neoplastic mast
cells. Parthena Foltopoulou, Raymond Pfau, Monica
Betancur-Boissel, Manar AbdelMageed, Philip N. Tsichlis,
Elizabeth A. McNiel.
3636 Targeting the MLL complex in castration resistant
prostate cancer. Rohit Malik, Amjad P. Khan, Irfan A.
Asangani, Marcin Cieślik, John R. Prensner, Xiaoju Wang,
Matthew K. Iyer, Xia Jiang, Dmitry Borkin, June Escara-Wilke,
Rachell Stender, Yi-Mi Wu, Xuhong Cao, Felix Y. Feng, Jolanta
Grembecka, Tomasz Cierpicki, Arul M. Chinnaiyan.
3637 Delivery of an epigenetic agent using a
microparticle drug delivery system. Duc P. Do, Keane O.
Soluade.
32
32
471
POSTER SESSION
Chemistry
Poster
:LJ[PVU
34
34
Drug Discovery: Kinases, Nuclear Hormone Receptors, and Novel Targets
Poster
Board
Poster
Board
Abstract
Number
2.
3639 Design and development of a novel series of orally
active, selective PI3K-p110␤/␦ inhibitors for the treatment of
solid and hematological cancers. Stephen J. Shuttleworth.
15.
3652 Development of novel chemical inhibitors targeting the
N-terminal domain (NTD) of androgen receptor variants as antiprostate cancer agents. Jian Hui Wu.
3.
3640 Discovery of quinazolinones as fibroblast growth factor
receptor (FGFR1-4) kinase inhibitors. Olivier Querolle, Patrick
Angibaud, Hélène Colombel, Virginie Caron, Isabelle Pilatte, Virginie
Poncelet, Norbert Esser, Ron Gilissen, Peter King, Lieven Meerpoel,
Tinne Verhulst, Berthold Wroblowski, Jorge Vialard, Chris W. Murray,
David C. Rees, Anita Reningovolo, Gordon Saxty.
16.
3653 Structure-based study to overcome cross-reactivity of
novel androgen receptor inhibitors. Huifang Li, Nada Lallous, Kush
Dalal, Eric Leblanc, Fuqiang Ban, Fabrice Ciesielski, Paul S. Rennie,
Artem Cherkasov.
17.
3654 Targeting binding function-3 site on the androgen
receptor to treat Enzalutamide-resistant prostate cancer. Ravi
Shashi Nayana Munuganti, Mohamed D. Hassona, Eric Leblanc, Emma
T. Guns, Paul S. Rennie, Artem Cherkasov.
18.
3655 Discovery of SC10914: a highly potent, selective and
orally active PARP inhibitor for the treatment of BRCA1/2 deficient
cancer. Daxin Gao, Heping Yang, Yajun Yu, Norman Kong.
19.
3656 PARG inhibition: development of novel compounds and
a biomarker strategy to determine cell line sensitivity in breast
cancer. Ian D. Waddell, Dominic James, Kate Smith, Sarah Holt, Ben
Acton, Emma Fairweather, Niall Hamilton, Nicola Hamilton, James
Hitchen, Colin Huttom, Allan Jordan, Alison McGonagle, Helen Small,
Alex Stowell, Bohdan Waszkowycz, Donald Ogilvie.
20.
3657 Preclinical evaluation of water-soluble pyrrolo[3,2d]pyrimidines as single agents with tubulin and multiple receptor
tyrosine kinase inhibition and as antitumor agents. Khushbu Shah,
Aleem Gangjee, Roheeth Pavana, Dybdal-Hargreaves F. Nicholas,
Susuan Mooberry.
21.
3658 Structure-guided de novo design of selective Mcl-1
Inhibitors: Synthesis, structural and biochemical characterization.
Lei Miao, Ahmed Mady, Andrej Perdih, Chenzhong Liao, Naval Bajwa,
Jeanne Stuckey, Zaneta Nikolovska-Coleska.
22.
3659 Target validation and structural optimization of
selective small molecule survivin inhibitors as potential anticancer agents. Jin Wang, Min Xiao, Duane D. Miller, Wei Li.
23.
3660 Discovery of a small molecule TUBB3/␤III-tubulin
modulator in lung cancer. Felicity Chao Lin Kao, Tim Failes, Greg M.
Arndt, Murray Norris, Maria Kavallaris.
24.
3661 Development of novel small-molecule inhibitors of ETS
oncoproteins as anti-prostate cancer agents. Xiaohong Tian.
25.
3662 Design and development of a novel series of HDAC6selective inhibitors for the treatment of hematological and solid
tumors. Stephen J. Shuttleworth.
26.
3663 Discovery of sulfonamide-piperidinones as potent
inhibitors of the MDM2-p53 protein-protein interaction . Zhihong
Li, Jiasheng Fu, Yosup Rew, Michael W. Gribble, Jude Canon, Ada
Chen, John Eksterowicz, Xin Huang, Lixia Jin, Mei-Chu Lo, Lawrence
R. McGee, Tao Osgood, Anne Y. Saiki, Paul Shaffer, Daqing Sun, Sarah
Wortman, Qiuping Ye, Dongyin Yu, Xiaoning Zhao, Jing Zhou,
Jonathan D. Oliner, Steve H. Olson, Julio C. Medina.
27.
3664 Hybrid anticancer drugs: Synthesis of a combretastatinpiperlongumine analog with mutant p53 reactivation and
antimicrotubule properties. Surendra R. Punganuru,
Hanumantharao Madala, Kalkunte S. Srivenugopal.
28.
3665 Reconstructing the itraconazole scaffold towards
improved specificity for hedeghog signaling inhibition. Albert M.
DeBerardinis, M. Kyle Hadden.
29.
3666 Synthesis and evaluation of itraconazole analogues for
hedgehog pathway inhibition. Jennifer Pace, M. Kyle Hadden.
30.
3667 Synthesis and biological evaluation of vitamin D3
analogues as selective Hedgehog pathway inhibitors. Chad A.
Maschinot, Kyle Hadden.
4.
3641 Identification of naphthyridines as potent inhibitors of
fibroblast growth factor receptor kinase family. Patrick R.
Angibaud, Michel Obringer, Julien Marin, Matthieu Jeanty, Norbert
Esser, Ron Gilissen, Peter King, Lieven Meerpoel, Olivier Querolle,
David C. Rees, Bruno Roux, Gordon Saxty, Tinne Verhulst, Berthold
Wroblowski, Christopher C. Murray, Jorge Vialard.
5.
Structure enabled design of inhibitors of the mitotic
kinase MPS1. Paolo Innocenti, Hannah Woodward, Kwai_Ming
J. Cheung, Sébastien Naud, Savade Solanki, Isaac M. Westwood, Amir
Faisal, Angela Hayes, Jessica Schmitt, Ross Baker, Berry Matijssen,
Rosemary Burke, Suzanne A. Eccles, Florence I. Raynaud, Spiros
Linardopoulos, Julian Blagg, Rob L. van Montfort, Swen Hoelder.
6.
3643
3642
Targeting the acetyl-lysine binding site of BRD4 with
dual nanomolar BET-JAK2 inhibitors: A new anticancer
therapeutic strategy. Steven Gunawan, Ayaz Muhammad, Stuart W.
Ember, Jin-Yi Zhu, Rebecca A. Jacobsen, Norbert Berndt, Que T.
Lambert, Gary W. Reuther, Harshani R. Lawrence, Ernst Schonbrunn,
Nicholas J. Lawrence.
7.
3644 Identification of existing targeted agents that inhibit
NTRK and ROS1 in lung cancer. Curtis Chong, Dalia Ercan, Magda
Bahcall, Marzia Capelletti, Nathanael Gray, Pasi Janne.
8.
A non-ATP competitive IKK␤ inhibitor for cancer
therapy. Sandeep Rana, Elizabeth Blowers, Amarnath Natarajan.
9.
3646 Novel IRAK-4 inhibitors exhibit highly potent antiproliferative activity in DLBCL cell lines with activating MYD88
L265P mutation. Wesley Roy Balasubramanian, Venkateshwar Rao
Gummadi, Ravi Krishna Babu D, Sivapriya Marappan, Bhavesh
Choudhary, Sreevalsam Gopinath, Kavitha Nellore, Shekar Chelur,
Girish Daginakatte, Murali Ramachandra.
3645
10.
Targeting cancer-induced anemia with hepcidin
lowering ALK2 inhibitors. Peter W. Peterson.
11.
3648 A high-throughput fluorescence anisotropy screening
for discovery of inhibitors that target the D-recruitment site of
ERK in vitro and in cells. Rachel M. Sammons, Tamer S. Kaoud,
Ashwini K. Devkota, Eun J. Cho, Kevin N. Dalby.
12.
3649 Broad profiling reveals opportunities for selective
inhibition of disease-associated mutant kinases. Krisna C. DuongLy, Karthik Devarajan, Shuguang Liang, Kurumi Horiuchi, Yuren
Wang, Haiching Ma, Jeffrey R. Peterson.
13.
14.
472
Abstract
Number
3647
3650 Discovery of the clinical candidate AZD9496: a potent
and orally bioavailable selective estrogen receptor downregulator
and antagonist. Chris De Savi, Robert H. Bradbury, Alfred A. Rabow,
Richard A. Norman, David Buttar, Gordon S. Currie, Hazel Weir, Craig
Donald, David Andrews, Phil MacFaul, Peter Ballard, Jon Curwen,
Zena Wilson, Graham Richmond, Celina D’Cruz, Steve Powell, Graeme
Walker, Michael Hulse, Michael Tonge.
3651
The development of anti-estrogens targeting the
activation function 2 site of estrogen receptor alpha for treatment
of Tamoxifen resistant breast cancer. Kriti Singh, Ravi Shashi
Nayana Munuganti, Eric Leblanc, Artem Cherkasov, Paul S. Rennie.
POSTER SESSION
Chemistry
Nanotechnology, Imaging, Screening, and Informatics
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Abstract
Number
3668 Multistage delivery of RNA interfering
nanotherapeutics targeting the PI3K/Akt/mTOR pathway.
Elvin Blanco, Suhong Wu, Francisca Cara, Victor SeguraIbarra, Funda Meric-Bernstam, Mauro Ferrari.
3669 Engineering the biointerface of synthetic high
density lipoprotein nanoparticles enables efficient nucleic
acid loading, delivery, and target gene regulation in
cancer cells. Kaylin M. McMahon, Don Vander Griend, Olga
Volpert, C. Shad Thaxton.
3670 NanoPARPi inhibitors for ovarian and prostate
cancer therapy. Shifalika Tangutoori, Paige Bladwin, Anders
Ohman, Houari Korideck, Robert Cormack, Daniela Dinulescu,
Mike Makrigiorgos, Srinivas Sridhar.
3671 Loading and molecular labeling of cell-specific
exosomes by HDL-like AuNPs. Nicholas L. Angeloni, Kaylin
M. McMahon, C. Shad Thaxton.
3672 Expression patterns of scavenger receptor B-1
(SR-B1) to guide biomimetic HDL gold nanoparticle
therapy. Young Kwang Chae, Alan Pan, Denise Scholtens,
Shuo Yang, Jonathan Rink, Colby S. Thaxton, Leo Gordon.
3673 High-density lipoprotein-like nanoparticles
target SR-B1 and inhibit the cellular uptake of melanomacell derived exosomes. Michael P. Plebanek, Alexandre
Matov, Kannan Mautharasan, Jesse Gatlin, C. Shad Thaxton.
3674 Pentarins: Improved tumor targeting through
nanoparticle encapsulation of miniaturized biologic drug
conjugates. Mark T. Bilodeau, Rajesh Shinde, Brian White,
Patrick Bazinet, Kerry Whalen, Michelle Dupont, Kristina
Kriksciukaite, Jamie Quinn, Beata Sweryda-Krawiec, Rossitza
Alargova, Adam Brockman, Patrick Lim Soo, Kristan Meetze,
Benoit Moreau, Haley Oller, Mike Ramstack, Danielle
Rockwood, Sukhjeet Singh, Tsun Au Yeung, Sudha Kadiyala,
Craig Dunbar, Richard Wooster.
3675 Double receptor targeting multifunctional iron
oxide nanoparticles drug delivery system for the
treatment and imaging of prostate cancer. Md Shakir U.
Ahmed, Mohamed O. Abdalla, Clayton Yates, Jesse Jaynes,
Timothy Turner.
3676 Attenuation of pancreatic cancer stemness and
growth by a novel magnetic nanoparticle formulation.
Sheema Khan, Murali M. Yallapu, Sonam Kumari, Aditya
Ganju, Swathi Balakrishna, Stephen W. Behrman, Nadeem
Zafar, Meena Jaggi, Subhash C. Chauhan.
3677 Enhanced targeted delivery of paclitaxel to tumor
cells of epithelial and neuroectodermal origin using
chlorotoxin-chitosan nanodelivery system. Rana Falahat,
Eva Williams, Marzenna Wiranowska, Ryan Toomey, Norma
Alcantar.
3678 Imaging AZD1152HQPA Accurin™ nanoparticle
accumulation in preclinical tumors. Richard Goodwin, John
Swales, Anna Nilsson, Per Andren, Nicola Strittmatter, Zoltan
Takats, Colin Howes, Paula Taylor, Susan Ashton, Philip
Jewsbury, Simon T. Barry.
3679 Nanotechnology delivery and mechanism of
action of telomere oligonucleotides in melanoma. Luke
Wojdyla, Neelu Puri.
3680 Albumin-chitosan hybrid onconase nanocarriers
for mesothelioma therapy. Rakesh K. Tekade, Susanne R.
Youngren-Ortiz, Haining Yang, Rahul Haware, Mahavir B.
Chougule.
Poster
Board
14.
15.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
3681 Facile fabrication of MRI-capable and NIRresonant core-satellite nanomediators for photothermal
therapy. Hongwei Chen, Xiaoqing Ren, Hayley Paholak,
Joseph Burnett, Feng Ni, Duxin Sun.
3682 Characterization of PolyDots, a novel nanomicelle
drug delivery system, for targeted therapy of neurological
malignancies. Jihong Xu, Alessandra Welker, Brandon Miller, Mark
Calhoun, Jose Otero, Catherine Czeisler, J. Brad Elder, Christine E.
Beattie, Metin N. Gurcan, Jessica O. Winter, Vinay K. Puduvalli.
3684 Nanoparticle-encapsulated piperine and
piperlongumine inhibit breast cancer cell growth and
metastatic activity. Javad Ghassemi-Rad, David W. Hoskin.
3685 Managing cervical cancer using multifunctional
gold nanorods. Sheetal Parida, Mahitosh Mandal.
3686 Engineering nanoparticles of polymalic acid for
controlled delivery of anticancer drugs. José A. PortillaArias, Alberto Lanz-Landazuri, Montserrat Garcia-Alvarez,
Antxon Martinez de Ilarduia, Rameshwar Patil, Eggehard
Holler, Julia Ljubimova, Sebastian Muñoz-Guerra.
3687 A novel computational platform technology
(VOLVOX™) for designing anticancer supramolecular
therapeutics. Prithvi Raj Pandey, Shiladitya Sengupta, Sudip Roy.
3688 Target identification for anticancer molecules
using a Big Data approach. Neel S. Madhukar, Linda Huang,
Kaitlyn Gayvert, David Rickman, Olivier Elemento.
3689 Comparative oncology drug discovery for
Osteosarcoma in dogs and humans. Joy M. Fulbright,
Kathleen Neville, Melinda Broward, Tyce A. Bruns, Anuradha
Roy, Peter McDonald, Megan Ottomeyer, Douglas H. Thamm,
Tomoo Iwakuma.
3690 Ligand- and structure-based virtual screening to
discover dual EGFR and BRD4 inhibitors. Bryce Allen,
Saurabh Mehta, Nagi Ayad, Stephan Schürer.
3691 A chemical therapeutic screen identifies new targets
for wt/wt melanoma. Daniel Verduzco, Keiran Smalley.
3692 Development and validation of high content
screening assay for identification of compounds based on
cytotoxicity and cell cycle analysis using FUCCI probe.
Pawel Znojek, Sona Gurska, Petr Dzubak, Marian Hajduch.
3693 Quantitative fluorescent microscopy to measure
permeability in brain adjacent to tumor. Chris E. Adkins,
Rajendar K. Mittapalli, Paul Lockman.
3694 Molecular modeling studies of novel receptor
targeted peptides in the treatment of prostate cancer.
Mohamed O. Abdalla, Ahmad Bin Salam, Vincent Hembrick,
Manikanthan Bhavaraju, Clayton Yates, Jesse Jaynes,
Timothy Turner.
3695 Discovery of probes to evaluate the disruption of
the protein-protein interactions mediated by RPA70N.
Alex G. Waterson, Phillip Kennedy, James D. Patrone,
Nicholas F. Pelz, Andreas O. Frank, Bhavatarini Vangamudi,
DeMarco V. Camper, Elaine M. Souza-Fagundes, Michael D.
Feldkamp, Edward T. Olejniczak, Olivia W. Rossanese, Walter
J. Chazin, Stephen W. Fesik.
3696 Molecular dynamics simulations of C7/C7’-linked
pyrrolobenzodiazepine (PBD) dimers. Paul J. Jackson,
Khondaker M. Rahman, David E. Thurston.
3697 Development of a focused non-hydrolyzable
phosphopeptide library based on a high affinity SHP2
substrate. Harshani R. Lawrence, Yunting Luo, Steven
Gunawan, Andreas Becker, Yuan Ren, Ernst Schonbrunn, Jie
Wu, Nicholas J. Lawrence.
Poster
:LJ[PVU
35
35
473
POSTER SESSION
Epidemiology
Poster
:LJ[PVU
37
37
Descriptive Epidemiology, Health Disparities, and Survivorship
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
474
Abstract
Number
3698 The landscape of published cancer
meta-analyses: a descriptive look from 2008-2013. Ximena
V. Qadir, Mindy Clyne, Tram K. Lam, Muin J. Khoury, Sheri D.
Schully.
3699 Estrogen receptor status and the future burden of
invasive and in-situ breast cancers in the United States.
Philip S. Rosenberg, Kimberly A. Barker, William F. Anderson.
3700 Incidence trends of breast, endometrial, and
ovarian cancer among US women in relation to changing
patterns of menopausal hormone therapy. Hannah P. Yang,
William F. Anderson, Britton Trabert, Philip S. Rosenberg,
Gretchen L. Gierach, Clara Bodelon, Nicolas Wentzensen,
Kathleen A. Cronin, Mark E. Sherman.
3701 Health disparity characteristics on growth
patterns of breast cancer mortality trends among the US
Counties, 1989-2010. Wonsuk Yoo, George Rust, Shun
Zhang, James Lillard.
3702 Cumulative incidence rates of breast cancer for
Filipinos and Chamorros in Guam and the United States.
Grazyna Badowski, Rachael Leon Guerrero, Brayan Simsiman,
Rachel Novotny, Lynne Wilkens.
3703 A prospective study of racial/ethnic disparities in
pain experience among breast cancer patients undergoing
radiotherapy. Eunkyung Lee, Cristiane Takita, Jean L.
Wright, Isildinha M. Reis, Wei Zhao, Jennifer J. Hu.
3704 Demographics of colorectal cancer patients vary
by aspirin use. Jennifer S. Davis, Shailesh Advani, Emilyn
Banfield, Michael Overman, Zhi-Qin Jiang, Shanequa Manuel,
Carrie Daniel, Shine Chang, Scott Kopetz.
3705 Variable incidence of gastric cancer in Morocco.
Brittney Smith, Mouna Khouchani, Mehdi Karkouri, Audrey
Lazenby, Katherine Watkins, Ali Tahri, Abdel-Latif Benider,
Shireen Rajaram, Amr Soliman.
3706 Risk of bladder and kidney cancers in end-stage
renal disease patients: a nationwide, population-based
study in Taiwan. Wei-Tang Kao, Cheng-Huang Shen, KeeThai Kiu, Hsin-An Chen, Chia-Chang Wu, Yuan-Hung Wang.
3707 Baseline quality of life and genetic determinants
and the impact on five-year lung cancer survival. Jeanne A.
Pierzynski, Michelle A. Hildebrandt, Yuanqing Ye, Jack A.
Roth, Xifeng Wu.
3708 Filling the void of Canadian T-cell lymphoma
epidemiology: Data from the canadian institute for health
information discharge abstract database. Etienne R. Mahe,
Princess Margaret Cancer Centre Advanced
MolecularDiagnostics Laboratory, Trevor Pugh, Tracy
Stockley, Suzanne Kamel-Reid.
3709 Second cancers following Waldenström
macroglobulinemia/lymphoplasmacytic lymphoma in the
United States: analysis of Surveillance, Epidemiology and
End Results (SEER) registry data, 1992 - 2011. Mary L.
McMaster, Lynn R. Goldin, Neil E. Caporaso.
3710 The gap in cancer mortality between Western and
Eastern Europe. Marta Manczuk, Urszula Sulkowska, Dana
Hashim, Paolo Boffetta.
3711 The decrease in global cancer mortality. Paolo
Boffetta.
3712 Incidence trend of NPC using age-period-cohort
analysis from1987 to 2011 in Sihui County, southern China.
Qing Liu, Sumei Cao, Qihong Huang, Lifang Zhang, Yanhua Li,
Shanghang Xie.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
3713 Second malignant neoplasms after non-CNS
embryonal tumors in North America. Xuchen Zong, Jason D.
Pole, Paul Grundy, Salaheddin M. Mahmud, Louise Parker,
Rayjean J. Hung.
3714 Detroit African Americans (AA) are
overrepresented among patients with large high-grade
dysplastic (HGD) adenomas (LHiGDA) versus those with
small HGD adenomas (ShiGDA). Martin Tobi, Fadi Antaki,
MaryAnn Rambus, Paula Sochacki, Edi Levi.
3715 Survival of patients with mucinous ovarian
carcinoma and ovarian metastases: A population-based
cancer registry study. Michiel Simons, Nicole Ezendam,
Johan Bulten, Iris Nagtegaal, Leon Massuger.
3716 The origin of metastatic ovarian tumors: A
national population-based analysis. Michiel Simons, Jolien
Bruls, Lucy Overbeek, Johan Bulten, Leon Massuger, Iris
Nagtegaal.
3717 One year mortality following pancreatectomy for
pancreatic cancer: analysis of the SEER-Medicare data.
Preethy Nayar, Chandrakanth Are, Fang Yu, Aastha N.
Chandak, Niodita Gupta.
3718 Trends in tobacco use and prostate cancer
mortality in four US states, 1999-2010. Miranda R. Jones,
Corinne E. Joshu, Norma F. Kanarek, Ana Navas-Acien, Kelly
A. Richardson, Elizabeth A. Platz.
3719 Snus use, smoking and prostate cancer survival.
Kathryn M. Wilson, Fang Fang, Caroline Nordenvall, Weimen
Ye, Hans-Olov Adami, Olof Nyrén, Lorelei Mucci.
3720 Diabetes and prostate cancer (CaP): Clinical
characteristics and disparity in outcomes. Elaine Spangler,
Charnita Zeigler-Johnson, Jonathan Mitchell, Timothy
Rebbeck.
3721 Rapid widening of age and race health disparities
in prostate cancer outcomes within the United States,
1973-2014. Richard J. Lawrence, Damien Urban, Talia Golan,
Akram Saad, Raanan Berger, Raya Leibowitz-Amit, Jair Bar,
Robert Den, Jeffrey Goldstein, Zvi Symon.
3722 Modification of obesity effects on prostate cancer
outcomes by age and education. Charnita M. ZeiglerJohnson, Knashawn Morales, Jonathan Mitchell, Elaine
Spangler, Karen Glanz, Timothy Rebbeck.
3723 The use of complementary health approaches
among US cancer survivors. Tainya C. Clarke.
3724 Race/ethnicity, genetic ancestry, and breast
cancer-related lymphedema. Marilyn L. Kwan, Valerie S.
Lee, Janise M. Roh, Isaac J. Ergas, Yali Zhang, Susan E.
Kutner, Charles P. Quesenberry, Christine B. Ambrosone,
Lawrence H. Kushi, Song Yao.
3725 Subsequent gastrointestinal cancer risks of
childhood and early adulthood cancer survivors. Jason J.
Liu, Lindsay M. Morton, Amy Berrington de González, Peter D.
Inskip, Rochelle E. Curtis.
3726 Race-based disparities in loss of functional
independence after uterine cancer. Lorraine Dean, Xiaochen
Zhang, Nawar Latif, Ashley Haggerty, Robert Giuntoli, Sarah
Kim, David Shalowitz, Caitlin Stashwick, Mark Morgan, Emily
Ko, Kathryn Schmitz.
3727 Influence of patient, physician, and hospital
characteristics on the receipt of guideline-concordant care
for inflammatory breast cancer. Ryan A. Denu, John M.
Hampton, Adam Currey, Roger T. Anderson, Rosemary D.
Cress, Steven T. Fleming, Joseph Lipscomb, Susan A.
Sabatino, Xiao-Cheng Wu, J F. Wilson, Amy Trentham-Dietz.
POSTER SESSION
Prevention Research
Novel Developments Spanning Primary to Tertiary Prevention to Reduce the
Burden of Cancer
Poster
Board
Abstract
Number
1.
3728 Rapid deployment of statewide tobacco cessation
program for cancer patients. Jane Severson, Hilary Baca,
Karen Brown, Jamie Lindsay, Sarah Mott, Laura Petersen,
Anna Schulze, Graham Warren.
2.
3729 Inhibition of non small-cell lung cancer by stress
reduction. Jheelam Banerjee, Arokya M. Papu John,
Hildegard M. Schuller.
3.
3730 Feasibility of office hysteroscopy for evaluation
of women with postmenopausal bleeding and association
with improved pathological diagnosis. Jacquelyn M. Shaw,
Sukrant Mehta, Scott Chudnoff, Mark Levie, Mark H. Einstein,
Gary L. Goldberg, Nicole S. Nevadunsky.
4.
3731 The course of fatigue and its correlates in
colorectal cancer survivors: A prospective cohort study of
the PROFILES registry. Olga Husson, Floortje Mols, Lonneke
van de Poll-Franse, Melissa Thong.
5.
3732 Detecting germline PTEN mutations among atrisk cancer patients: An age and gender-specific cost
effectiveness analysis. Joanne Ngeow, Chang Liu, Ke Zhou,
Kevin Frick, David B. Matchar, Charis Eng.
6.
3733 Mobile phone multimedia messaging intervention
for breast cancer screening. Hee Y. Lee, Chap Le, Rahel
Ghebre, Douglas Yee.
7.
3734 Modified dietary inflammatory index and
increased number of colonic aberrant crypt foci. Helen
Swede, Masteneh Sharafi, Rong Wu, Valerie B. Duffy, Daniel
W. Rosenberg, David A. Drew, Thomas Devers, Richard G.
Stevens.
8.
3735 Dietary sugar induces tumorigenesis in mammary
gland partially through 12 lipoxygenase pathway. Yan
Jiang, Yong Pan, Patrea R. Rhea, Lin Tan, Mihai GageaIurascu, Lorenzo Cohen, Peiying Yang.
Poster
Board
Abstract
Number
9.
3736 Assessment of tobacco use within 30 days
increases referral for cessation support. Samuel L. Cooper,
Katherine Hoover, Elizabeth Garrett-Mayer, Kenneth M.
Cummings, Matthew J. Carpenter, Kelly Crowley, David T.
Marshall, Graham W. Warren.
10.
3737 Severe obesity and colorectal cancer patient
survival. Carrie R. Daniel, Xiang Shu, Yuanqing Ye, Jian Gu,
G. S. Raju, Scott Kopetz, Xifeng Wu.
11.
3738 Body mass, weight, and body size and uterine
leiomyoma in the Korea Nurses’ Health Study. Jung Eun
Lee, Ji Eun Lee, Eunyoung Cho, Hee Jung Jang, Heeja Jung,
Hea-Young Lee, Su Kim, Ok Soo Kim.
12.
3739 Are young adults with colorectal cancer doing
enough to stay healthy. Y. Nancy You, Eduardo Vilar,
Amanda Cuddy, Caiqian Wu, Patrick M. Lynch, Cathy Eng,
Miguel Rodriguez-Bigas, George Chang.
13.
3740 Exergame development for cancer prevention
and intervention. Blessing Ahabue, Paula Pullen, Afebuameh
Ogbesor, William S. Seffens, James W. Lillard.
14.
3741 Selection of BRCA1/2 negative cases using data
mining analytical approach for hereditary breast cancer
prediction in high risk breast cancer patients. Seda Kilic,
Ozge Sukruoglu, Demet Akdeniz, Mukaddes Avsar, Bugra
Tuncer, Şimal Aysever, Suzan Güreli, Fadime ÜneyYüksektepe, Tulin Aktin, Hulya Yazici.
15.
3742 The influence of masculinity, racism, and social
support on colorectal cancer screening uptake among
African American men: A systematic review. Charles R.
Rogers, Jamie A. Mitchell, Gabriel J. Franta, Margaret J.
Foster, Deirde Shires.
Poster
:LJ[PVU
38
38
475
LATE-BREAKING AND CLINICAL TRIALS POSTER SESSIONS
Tuesday, 8:00 a.m.-12:00 p.m.
Halls B-E, Pennsylvania Convention Center
Abstracts will be available online and in the Proceedings Part 2.
Section 24
Section 39
Section 40
Section 41
476
Phase I Clinical Trials
Late-Breaking Research: Molecular and Cellular Biology 3
Late-Breaking Research: Epidemiology
Late-Breaking Research: Tumor Biology 2
PLENARY SESSION
Tuesday, 8:15 a.m.-10:15 a.m.
Hall A (200 Level), Pennsylvania Convention Center
Drug Resistance
Chairperson: Bert Vogelstein, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
Drug resistance is the primary challenge faced by all practicing oncologists. The advent of targeted
therapies has provided exciting opportunities not only to understand the mechanisms through which
resistance occurs, but also to design approaches that overcome this resistance. The presentations in
this session will describe the latest developments in this area of research, from the perspectives of
genetics, drug development, clinical application, and cell biology.
8:15 a.m.
Drug resistance: A genetic perspective
Bert Vogelstein, Johns Hopkins Kimmel Comprehensive Cancer Center,
Baltimore, MD
8:45 a.m. Genetic screens to understand drug resistance
Alan Ashworth, UCSF Helen Diller Family Comprehensive Cancer Center,
San Francisco, CA
9:15 a.m.
Drug resistance: Translating discoveries into the clinic
Alice T. Shaw, Massachusetts General Hospital Cancer Center,
Boston, MA
9:45 a.m. Drug resistance: A cell biologist’s perspective
Joan S. Brugge, Harvard Medical School, Boston, MA
477
PROFESSIONAL ADVANCEMENT SESSION (not eligible for CME credit)
Tuesday, 8:30 a.m.-2:00 p.m.
Hall G, Pennsylvania Convention Center
Special Program for High School Students: The Conquest of
Cancer and the Next Generation of Cancer Researchers
Chairperson: Kathleen W. Scotto, Rutgers, The State University of New Jersey, New Brunswick, NJ
This free day of learning includes distinguished scientists discussing topics such as understanding
cancer, cancer control and prevention, and cancer career opportunities. In addition, students listen to
an inspiring presentation from a young cancer survivor, visit state-of-the-art exhibit booths to learn
about the latest equipment for laboratory and clinical research, and get an introduction to scientific
posters describing the most current research on the causes, diagnosis, treatment, and prevention
of cancer.
During a complimentary networking lunch, students meet one-on-one with leading scientists, present
posters of their school or lab research projects, and learn about summer internship opportunities.
AACR members volunteer as mentors for this program, and we thank them for supporting the next
generation of cancer researchers.
8:30 a.m.
Registration and Refreshments
9:00 a.m.
Welcome
Kathleen W. Scotto, Rutgers, The State University of New Jersey, New Brunswick, NJ
9:10 a.m.
Controlling Cancer Through Research
Donald S. Coffey, Johns Hopkins University School of Medicine, Baltimore, MD
9:30 a.m.
Message from a Cancer Survivor
Melanie A. Nix, Breast Cancer Comfort Site, Hyattsville, MD
9:45 a.m.
Why Cancer Research Needs You
Oliver Bögler, The University of Texas MD Anderson Cancer Center, Houston, TX
10:05 a.m.
Introduction of Mentors
10:15 a.m.
Tour of Exhibits and Posters
12:30 p.m.
Networking Luncheon
1:15 p.m.
Student Poster Presentations and Awards
1:50 p.m.
Evaluation and Departure
478
MEET AND GREET (not eligible for CME credit)
Tuesday, 9:00 a.m.-10:00 a.m.
Booth #1827 (Publications Booth), Halls B-E
Meet the Editor-in-Chief of Molecular Cancer Therapeutics
Napoleone Ferrara, MD, FAACR
Senior Deputy Director for Basic Sciences
UC San Diego Moores Cancer Center
Join us at Booth #1827 at AACR Annual Meeting 2015 to meet the editors of the AACR Publications. The
Editors-in-Chief will explain the mission and scope of their journal, recent submission trends, and other
topics of interest for researchers looking to publish their work in the highly esteemed AACR journals.
Learn what Editors look for in manuscripts and participate in a unique Q&A session.
Molecular Cancer Therapeutics strives to be the top choice for publishing the best science in the
discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of
approved therapeutics, mechanisms of drug action, mechanism of drug resistance, biomarkers of drug
response, novel models and technologies, and occasional drug toxicity mechanisms. While the journal's
main focus is on small molecule and protein drugs, other molecular entities may be considered.
479
CAREER CONVERSATIONS (not eligible for CME credit)
Tuesday, 10:30 a.m.-11:30 a.m.
AACRcentral, Associate Member Resource and Career Center, Halls B-E, Booth #725
A Day at the FDA: Careers at the U.S. Food and Drug Administration
Organized by the Associate Member Council (AMC)
Career Conversations, organized by the Associate Member Council, are informal networking and
discussion sessions designed to allow early-career scientists the opportunity to interact with junior
faculty and recently transitioned peers from various employment sectors. The topics change year to
year to offer a broad array of information that could be relevant to the diverse Annual Meeting earlycareer attendees. This peer-to-peer session will introduce participants to scientific careers and
avenues for professional development within the FDA, including the development of clinical trials. The
FDA structure and areas of focus will be briefly introduced and speakers will focus on how they
decided to pursue a government position, describe their role and typical day, and provide an overview
of the skills needed for different roles within the administration. The hiring process and insights on
how to successfully make the transition into a government career will also be addressed.
Designed to provide advice that can help attendees figure out their career path and potential future
career opportunities, Career Conversations are open to all graduate students, medical students,
residents, and clinical and postdoctoral fellows. All Career Conversations will take place in
AACRcentral and limited seating will be available on a first-come, first-served basis. #AACRcentral
Speakers:
Julia A. Beaver, U.S. Food and Drug Administration and The Johns Hopkins University School of
Medicine, Silver Spring, MD
Emily M. Fox, U.S. Food and Drug Administration, Silver Spring, MD
480
NCI/NIH-SPONSORED SESSION (not eligible for CME credit)
Tuesday, 10:30 a.m.-12:00 p.m.
Funding Opportunities for Cancer Research at
Multiple NIH Institutes and Centers with NIH Experts
Chairperson: Phuong Kim Pham, National Institutes of Health, Bethesda, MD
Did you know that your cancer research could be funded by many other NIH Institutes and Centers in
addition to the National Cancer Institute? Would you like to maximize your chance of getting NIH
funding from NIH experts? Then come to our workshop to explore all possibilities with the insiders.
We will provide you with an overview of the NIH grant process and tips on how to work with the
system and staffs to increase your chance. A summary of cancer funding sources and contacts at
multiple NIH Institutes and Centers including Center for Scientific Review (CSR), National Cancer
Institute (NCI), National Institute of General Medical Sciences (NIGMS), National Institute of Allergy
and Infectious Diseases (NIAID), National Institute on Alcohol Abuse and Alcoholism (NIAAA),
National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and
Health Disparities (NIMHD), as well as National Institute of Dental and Craniofacial Research (NIDCR),
and National Institute of Mental Health (NIMH) will be provided.
Slides for the NIAID and NIEHS presentation were provided by Drs. Helen Quill and Kimberly
McAllister, respectively.
Speakers:
Rajeev K. Agarwal, National Cancer Institute, Bethesda, MD
Julia T. Arnold, National Cancer Institute, Bethesda, MD
Philip J. Brooks, NIAAA, Bethesda, MD
Rina Das, NCI-CRCHD, Rockville, MD
Pamela Anne Marino, NIH-NIGMS, Bethesda, MD
Phuong Kim Pham, National Institutes of Health, Bethesda, MD
Syed Musaddaq Quadri, Center for Scientific Review, Bethesda, MD
Sundar Venkatachalam, NIH-NIDCR, Bethesda, MD
Mukesh Verma, NCI-DCCPS, Bethesda, MD
481
CLINICAL TRIALS PLENARY SESSION
Tuesday, 10:30 a.m.-12:40 p.m.
Clinical Trials Using PARP Inhibitors
Chairperson: Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA
Additional chairperson to be announced
10:30 a.m.
CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a
phase II trial of olaparib in metastatic castration resistant prostate cancer
Joaquin Mateo, The Institute of Cancer Research and The Royal Marsden NHS Trust,
London, United Kingdom
10:50 a.m.
Discussant to be announced
11:00 a.m.
CT323: Accelerated phase I trial of two schedules of the combination of the PARP
inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose
escalation design in advanced cancer pts
Vasiliki Michalarea, Royal Marsden Hospital and The Institute of Cancer Research,
London, United Kingdom
11:20 a.m.
CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous
ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus
olaparib cohort
Ursula A. Matulonis, Dana-Farber Cancer Institute, Boston, MA
11:40 a.m.
Discussant to be announced
11:50 a.m.
CT325: Combination of the PARP inhibitor veliparib (ABT888) with irinotecan
(CPT-11) in patients with triple negative breast cancer: Preliminary activity
and signature of response
Patricia M. LoRusso, Yale Cancer Center, New Haven, CT
12:10 p.m.
CT326: Pharmacokinetic/pharmacodynamic study of sequence specificity of the PARP
inhibitor, olaparib and carboplatin in recurrent women’s cancers (NCT01237067)
Victoria L. Chiou, National Cancer Institute-CCR, Bethesda, MD
12:30 p.m.
Discussant
Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD
Please refer to the online Itinerary Planner or Annual Meeting App for program updates.
482
MAJOR SYMPOSIA
Tuesday, 10:30 a.m.-12:30 p.m.
Cellular Reprogramming in Carcinogenesis:
Implications for Tumor Heterogeneity,
Prognosis, and Therapy
Chairperson: Peter B. Dirks, University of Toronto Hospital
for Sick Children, Toronto, ON, Canada
Cancers, both solid and liquid, consist of phenotypically
heterogeneous cell types that make up the full cellular
complement of disease. Deep sequencing of bulk cancers
also frequently reveals a genetic intratumoral
heterogeneity that reflects clonal evolution in space and in
time and under the influence of treatment. How the
distinct phenotypic and genotypic cells contribute to
individual cancer growth and progression is incompletely
understood. In this symposium, we will discuss issues of
cancer heterogeneity and effects on growth and treatment
resistance, with emphasis on cancer cell functional
properties and influences of the microenvironment,
interclonal genomic heterogeneity, and lineage
relationships between cancer cells with stem cell and
differentiated properties. Understanding these complex
cellular relationships within cancers will have critical
implications for devising more effective treatments.
10:30 a.m.
Introduction
10:40 a.m.
Origins, evolution, and selection in
childhood leukemia
Tariq Enver, Cancer Research UK, London,
United Kingdom
11:00 a.m.
Discussion
11:05 a.m.
Cytokine-controlled stem cell plasticity in
intestinal tumorigenesis
Florian Greten, Georg-Speyer-Haus,
Frankfurt, Germany
11:25 a.m.
Discussion
11:30 a.m.
Intratumoral heterogeneity in human serous
ovarian carcinoma [SY23-03]*
John P. Stingl, Cancer Research UK
Cambridge Research Institute, Cambridge,
United Kingdom
11:50 a.m.
Discussion
11:55 a.m.
Functional and genomic heterogeneity in
brain tumors
Peter B. Dirks, University of Toronto Hospital
for Sick Children, Toronto, Ontario, Canada
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
Challenges in Mutation Detection
Chairperson: Gad Getz, Massachusetts General Hospital
Cancer Center, Charlestown, MA
Massively parallel sequencing is continuing to revolutionize
our ability to detect various types of mutations in tumors
and dramatically enhance our understanding of cancer.
Detecting somatic variants is still a challenge and many
new tools are being developed around the world. Recently,
different benchmarking exercises were held and results will
be described in this session. In addition, new types of
variants and new challenges will also be discussed.
10:30 a.m.
Introduction
10:40 a.m.
Mutation detection and validation using
massively parallel sequencing data
Gad Getz, Massachusetts General Hospital
Cancer Center, Charlestown, MA
11:00 a.m.
Discussion
11:05 a.m.
The ICGC-TCGA DREAM somatic mutation
calling challenge
Paul C. Boutros, Ontario Institute for Cancer
Research, Toronto, ON, Canada
11:25 a.m.
Discussion
11:30 a.m.
Is somatic mutation calling a solved
problem? Experience of the ICGC somatic
mutation calling benchmark
Ivo Gut, Centre Nacional d’Anàlisi Genòmica,
Barcelona, Spain
11:50 a.m.
Discussion
11:55 a.m.
Challenges and approaches for mutation
discovery and validation in pan-cancer
projects
Li Ding, Washington University School of
Medicine, St. Louis, MO
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
483
MAJOR SYMPOSIA
Tuesday, 10:30 a.m.-12:30 p.m.
Convention Center
12:00 p.m.
Illuminating the druggable genome: Target
prioritization for cancer drug discovery and
repurposing
Tudor Oprea, University of New Mexico,
Albuquerque, NM
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
Dharma Master Jiantai Symposium in
Biomarkers: Computational Approaches to
Cancer Target and Drug Discovery
Chairperson: Bissan Al-Lazikani, The Institute of Cancer
Research, London, United Kingdom
Great advances in patient profiling technology have
revolutionized our understanding of tumorigenic
mechanisms and pathways. Yet, this technological
revolution has highlighted the need for innovative
computational approaches to turn the massive data
generated into tangible benefits in cancer biomarker and
drug discovery, and ultimately patient benefit. In this
session we will explore how the application of
computational approaches has driven in the discovery of
drivers of cancer tumorigenesis and drug resistance, the
identification of new generations of cancer drug targets,
and tackling resistance through effective cancer drug
combinations. We will also highlight innovative tools
developed along the way to manage, analyze, and
integrate multidisciplinary cancer data and make it
available for public benefit.
10:30 a.m.
Introduction
10:40 a.m.
Selecting future cancer drug targets
Bissan Al-Lazikani, The Institute of Cancer
Research, London, United Kingdom
10:55 a.m.
Discussion
11:00 a.m.
Calling both simple and complex mutations
in cancer genome
David Haussler, Howard Hughes Medical
Institute, Santa Cruz, CA
11:15 a.m.
Discussion
11:20 a.m.
Perturbation biology of cancer cells for the
discovery of targeted combination therapy
Chris Sander, Memorial Sloan Kettering
Cancer Center, New York, NY
11:35 a.m.
Discussion
11:40 a.m.
Exploring the cancer genome atlas for
cancer subtypes and targetable alterations
Nikolaus Schultz, Memorial Sloan Kettering
11:55 a.m.
Discussion
Grand Ballroom (300 Level), Pennsylvania
Convention Center
Dharma Master Jiantai Symposium in
Targeted Therapy: How to Combine
Targeted Therapy with Immunotherapy
Chairperson: Antoni Ribas, UCLA Medical Center,
Los Angeles, CA
Small molecule inhibitors of driver oncogenes give high
response rates, but responses are usually limited by
frequent development of acquired resistance. Cancer
immunotherapy tends to have lower response rates, but
most responses are long lasting. There has been a lot of
interest to rationally combine both treatment strategies.
Key to these combinations are the potential effects of the
targeted therapies on immune effector cells, which can
change their function and may result in toxicities. In
addition, small molecule inhibitors can be used to improve
the tumor microenvironment by blocking oncogenic
signaling leading to immune suppressive factor production
by cancer cells, or directly inhibiting or depleting immunesuppressive tumor microenvironment cells. Multiple
combinations of targeted therapies and immunotherapy for
cancer are being tested in the clinic, in what is becoming an
area of high interest for future cancer therapy.
10:30 a.m.
Introduction
10:40 a.m.
Immune cells as targets for pathway
inhibition
Nicholas P. Restifo, National Cancer Institute,
Bethesda, MD
11:00 a.m.
Discussion
11:05 a.m.
Complex immune effects of inhibiting
BRAF [SY26-02]*
Antoni Ribas, UCLA Medical Center,
Los Angeles, CA
484
11:25 a.m.
Discussion
the onset of drug resistance.
11:30 a.m.
Immune effects of targeted therapy and
implications for combination
strategies [SY26-03]*
Jennifer A. Wargo, The University of Texas
MD Anderson Cancer Center, Houston, TX
10:30 a.m.
Introduction
10:40 a.m.
Resistance to tyrosine kinase inhibitors:
Heterogeneity and therapeutic strategies
Jeffrey A. Engelman, Massachusetts General
Hospital, Boston, MA
10:55 a.m.
Discussion
11:00 a.m.
Clinical acquired resistance to RAF inhibitor
combinations in BRAF mutant colorectal
cancer through MAPK pathway alterations
**Ryan B. Corcoran, Massachusetts General
Hospital Cancer Cetner, Boston, MA
11:15 a.m.
Discussion
11:20 a.m.
Tumor heterogeneity and therapy resistance
in melanoma [SY27-02]*
Claudia Wellbrock, University of Manchester,
Manchester, United Kingdom
11:35 a.m.
Discussion
11:40 a.m.
Breast cancer stem cell state transitions
mediate therapeutic resistance [SY27-03]*
Max S. Wicha, University of Michigan
Comprehensive Cancer Center, Ann Arbor, MI
11:55 a.m.
Discussion
12:00 a.m.
Induction of cancer stemness and drug
resistance by EGFR blockade [SY27-04]*
David A. Cheresh, UCSD Moores Cancer
Center, La Jolla, CA
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
11:50 a.m.
Discussion
11:55 a.m.
Concurrent BRAF and CTLA-4 inhibition: An
update
Jedd D. Wolchok, Memorial Sloan Kettering
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
Convention Center
Mechanisms of Resistance: From Signaling
Pathways to Stem Cells
Chairperson: David A. Cheresh, UCSD Moores Cancer
Center, La Jolla, CA
Even the most effective cancer therapies are limited due to
the development of one or more resistance mechanisms.
Acquired resistance to targeted therapies can, in some
cases, be attributed to the selective propagation of a small
population of intrinsically resistant cells. However, there is
also evidence that cancer drugs themselves can drive
resistance by triggering the biochemical- or geneticreprogramming of cells within the tumor or its
microenvironment. Therefore, understanding drug
resistance at the molecular and biological levels may
enable the selection of specific drug combinations to
counteract these adaptive responses. This symposium will
explore some of the recent advances addressing the
molecular basis of cancer cell drug resistance. We will
address how tumor cell signaling pathways become
rewired to facilitate tumor cell survival in the face of some
of our most promising cancer drugs. Another topic to be
discussed involves how drugs select for or induce the
reprogramming of tumor cells toward a stem-like, drugresistant fate. By targeting the molecular driver(s) of
rewired signaling pathways and/or cancer stemness it may
be possible to select drug combinations that prevent the
reprogramming of tumors and thereby delay or eliminate
**NextGen Star, selected to give a talk by the AACR President and Annual Meeting Program Chairperson through a competitive application process designed
to bring more visibility to early-career scientists. Abstract can be found in the Invited Abstracts: NextGen Stars section of the Proceedings.
485
MAJOR SYMPOSIA
Tuesday, 10:30 a.m.-12:30 p.m.
Metabolism and Aging
MICR Scientific Symposium: Emerging
Methodology and Tools for Understanding
the Genetics of Cancer Disparities
Chairperson: Leonard P. Guarente, Massachusetts Institute
of Technology, Cambridge, MA
Over the past 20 years, several metabolic pathways have
been identified that control the rate of aging in
experimental animals – sirtuins, IGF signaling, AMPK, and
mTOR. Interestingly, these pathways all play important
roles in cancer metabolism. This session will feature talks
on sirtuins and NAD, PI3K/PTEN of the IGF pathway, and
mTOR as they relate to metabolism, aging, and cancer. The
sirtuin SIRT1 and its cosubstrate for deacetylation, NAD,
will be related to circadian control and aging, and shown to
decline functionally with aging with deleterious
consequences. SIRT6 will be discussed as a tumor
suppressor via its repression of the Warburg effect. mTOR
will be discussed as a sensor of amino acids to set the rate
of protein synthesis, cell growth, and aging. Finally,
PI3K/PTEN, a major pathway in cancer, will be related to
aging and disease. All told, these key metabolic pathways
can be seen in a biological context affecting not only
cancer, but aging and diseases as well.
10:30 a.m.
Introduction
10:40 a.m.
Sirtuins and NAD link metabolism and health
Leonard P. Guarente, Massachusetts Institute
of Technology, Cambridge, MA
11:00 a.m.
Discussion
11:05 a.m.
The histone deacetylase SIRT6: At the
crossroad between epigenetics,
metabolism, and cancer
Raul Mostoslavsky, Massachusetts General
Hospital, Boston, MA
11:25 a.m.
Discussion
11:30 a.m.
Control of growth and metabolism
David M. Sabatini, MIT Whitehead Institute
for Biomedical Research, Cambridge, MA
11:50 a.m.
Discussion
11:55 a.m.
The PTEN/PI3K pathway beyond cancer: Its
impact on metabolic syndrome and aging
Manuel Serrano, Spanish National Cancer
Center (CNIO), Madrid, Spain
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
Organized by the Minorities in Cancer Research
(MICR) Council
Co-Chairpersons: Rick A. Kittles, University of Arizona
Cancer Center, Tucson, AZ; Lisa A. Newman, University of
Michigan Comprehensive Cancer Center, Ann Arbor, MI
This session will provide an update on the current state of
knowledge regarding genetic ancestral background and its
association with specific patterns of cancer. This session
will also explore novel biobanking and tissue acquisition
methods for genomic studies in disparate populations.
Presenters will discuss the impact of the emerging
methodology on cancer incidence and outcome disparities.
10:30 a.m.
Introduction
10:40 a.m.
Triple-negative breast cancer and West
African ancestry in African American women
Julie R. Palmer, Boston University, Boston, MA
11:05 a.m.
The use of innovative prostate biopsy tissue
print techniques for molecular genomic,
epigenomic, and gene expression
studies [SY29-02]*
Sandra M. Gaston, Tufts Medical Center, New
England Baptist Hospital, Boston, MA
11:30 a.m.
Novel genomic approaches to
understanding colorectal cancer disparities
Xavier Llor, Yale University School of
Medicine, New Haven, CT
11:55 a.m.
Panel Discussion
486
Convention Center
The Tumor Proteome as a Guide for
Precision Medicine
Chairperson: Kojo Elenitoba-Johnson, University of
Michigan, Ann Arbor, MI
Recent advances in proteomics have begun to unveil novel
aspects of tumor biology and opportunities for translation.
This program features nationally recognized speakers who
will discuss cutting-edge research spanning the gamut
from basic research using innovative tools to study histone
modifications in specific cancer settings, to the large-scale
exploration of ligands or inhibitor compounds that interact
with proteins. This session will also offer novel insights on
the promising prospects for identification of selective
proteins as biomarkers and therapeutic targets in specific
human cancers, as well as the investigation of proteins that
result from genetic aberrations in cancers by leveraging
multi-institutional consortia.
10:30 a.m.
Introduction
10:40 a.m.
Discovery of biomarkers and therapeutic
targets by functional glycoproteomics
Kojo Elenitoba-Johnson, University of
11:00 a.m.
Discussion
11:05 a.m.
Understanding the proteome through the
chaperome: From mechanisms to
diagnostics and drugs [SY30-02]*
Gabriela Chiosis, Memorial Sloan Kettering
11:25 a.m.
Discussion
11:30 a.m.
CPTAC breast cancer proteomics analysis
Matthew J. Ellis, Baylor College of Medicine
11:50 a.m.
Discussion
11:55 a.m.
Can protein discovery with complete
molecular specificity increase return on
investment for cancer biomarkers?
[SY30-04]*
Neil Kelleher, Northwestern University,
Evanston, IL
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
487
Tuesday, 10:30 a.m.-12:30 p.m.
Grand Ballroom Salons A-B (Level 5), Philadelphia Marriott Downtown
Effective Communication with Peers and the Public
Effective communication is a skill critical for the success of early-career scientists, whether it is
between scientists during oral or poster presentations, with the general public, or with media,
politicians, and patient advocates. This Professional Advancement Session offers the opportunity to
learn the basic components of effective and concise “scientific” communication and “science”
communication. The Associate Member Council organizes several Professional Advancement Sessions
aimed specifically toward the professional needs of graduate students, medical students and
residents, and clinical and postdoctoral fellows. Each year the topics change to cover a broad range of
interests relevant to early-career scientists.
For AACR members, all 2015 Professional Advancement Sessions are free with your Annual Meeting
registration (except for $45 for the Grant Writing Workshop) and are an added benefit of your
membership. For nonmembers, there is an additional fee of $50 ($95 for the Grant Writing Workshop)
for attendance at each session. If you are not an AACR member, we strongly encourage you to join
and take advantage of the many benefits of membership, which include attendance at these sessions.
Participation is on a first-come, first-served basis, and space is limited. Nonmembers are required to
pay onsite. #AACRcareer
Scientific communication: Engaging in dialogue with fellow scientists
Thomas A. Sellers, Moffitt Cancer Center, Tampa, FL
Presenting your work to your colleagues
V. Craig Jordan, The University of Texas MD Anderson Cancer Center, Houston, TX
Engage and excite: Communicating your science to a broad audience
Kathleen Heppner Goss, University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL
488
RECENT ADVANCES IN DIAGNOSTICS AND THERAPEUTICS RESEARCH
Tuesday, 10:30 a.m.-12:30 p.m.
Clinical Applications of Liquid Biopsy:
Current Status and Future Developments
Curative Ablation of Oligometastases
During Systemic Therapy: Patient Selection
and Molecular Predictors
Chairperson: Caroline Dive, Paterson Institute for Cancer
Research, Manchester, United Kingdom
The implementation of minimally invasive “liquid biopsies”
to monitor tumor evolution and to optimize stratified
medicine is increasingly attractive in oncology where serial
tumor biopsy remains challenging. Strides forward in
analysis of circulating tumor DNA (ctDNA) have
culminated in increased sensitivity and regulatory approval
of a ctDNA based companion diagnostic of EGFR mutation
status. This session showcases the power of ctDNA as a
routine clinical management tool and notably, to chart
emergence of resistance mechanisms to targeted
treatments. Although the technical challenges are greater,
the molecular analysis of circulating tumor cells (CTCs)
offers additional scope as a “liquid biopsy,” where cell-tocell heterogeneity can be explored and where evaluation of
single CTC DNA, RNA, and proteins can be undertaken.
With development of marker independent CTC
technologies, the technical challenges are being met and
clinical CTC based biomarkers are continually emerging.
Recent progress also now includes the culture of viable
CTCs both in vitro and in vivo offering exciting new
avenues for translational cancer research.
10:30 a.m.
The versatility of CTCs in lung cancer:
Biomarkers, biology, mouse models, and
drug development
Caroline Dive, Paterson Institute for Cancer
Research, Manchester, United Kingdom
Chairperson: Robert G. Bristow, University Health Network
Princess Margaret Hospital, Toronto, ON, Canada
The presence of a potential oligometastatic disease in
which limited nonprimary anatomic sites are involved
without widespread synchronous metastases can be a
staging and therapeutic dilemma. If the disease is truly
limited to definable sites, then patients may be cured of
their disease by combining treatment of the primary with
the ablation of macrometastases (using surgery or
stereotactic ablative radiotherapy (SABR)) and adjuvant
systemic treatment. But defining exactly which patients and
which diseases will benefit from such aggressive treatment
remains elusive. In this session, we will review the clinical
evidence for oligometastases and the response to SABR
and surgery across different tumor types. It will also
describe technical issues pertaining to such ablation. The
session will also discuss potential molecular signatures that
can predict the presence or absence of oligometastatic
disease using DNA and RNA and miRNA indices. The
session will end with a panel discussion regarding future
research and opportunities for clinical trials to drive
precision cancer medicine in oligometastatic patients.
10:30 a.m.
Clinical radiobiology metastases
Paul Okunieff, University of Florida Shands
Cancer Center, Gainesville, FL
10:50 a.m.
Discussion
10:55 a.m.
Molecular signatures for oligometastases in
prostate cancer: A default approach
Robert G. Bristow, University Health Network
Princess Margaret Hospital, Toronto, ON,
Canada
10:50 a.m.
Discussion
10:55 a.m.
Resistance to therapy in colorectal cancers:
Clonal evolution and liquid biopsies
Alberto Bardelli, IRCC - University of Turin,
Medical School, Candiolo, Italy
11:15 a.m.
Discussion
11:15 a.m.
Discussion
11:20 a.m.
11:20 a.m.
Defining the role of ctDNA in clinical and
investigative oncology
Luis A. Diaz, Johns Hopkins Kimmel
Comprehensive Cancer Center, Baltimore, MD
Cellular and molecular pathways in
oligometastasis
Ralph R. Weichselbaum, University of
Chicago Medicine, Chicago, IL
11:40 a.m.
Discussion
11:40 a.m.
Discussion
11:45 a.m.
11:45 a.m.
Monitoring the cancer genome in plasma
using ctDNA
Nitzan Rosenfeld, Cancer Research UK
Cambridge Research Institute, Cambridge,
United Kingdom
Stereotactic radiotherapy versus surgery
for oligometastases: Uncertainties and
clinical trials
Alexander Louie, London Health Sciences
Centre, London, ON, Canada
12:05 p.m.
Discussion
12:05 p.m.
Discussion
12:10 p.m.
Panel Discussion
12:10 p.m.
Panel Discussion
489
Tuesday, 10:30 a.m.-12:30 p.m.
New Strategies in Theranostics
Chairperson: Zaver M. Bhujwalla, Johns Hopkins University
School of Medicine, Baltimore, MD
Theranostic imaging is a rapidly expanding field located at
the interface of diagnosis and therapy that is creating
exciting new possibilities for personalized precision
medicine in cancer. The field can be broadly categorized
based on different imaging modalities and the different
aspects of cancer being targeted. The session will cover
several aspects of the latest advances in cancer
theranostics, including development of novel plasmonic
noble metal-based nanotheranostics, radioimmunotherapy
and ultrasound-based theranostic strategies, and
theranostics of the tumor microenvironment. The session
will provide insights into the capabilities and applications
of this exciting new field in cancer treatment. In this era of
personalized molecular medicine, the effective
implementation of theranostic agents may achieve cancer
cures, a goal that remains elusive for many cancers despite
the technological advances available in the 21st century.
10:30 a.m.
Theranostic imaging of the tumor
microenvironment
Zaver M. Bhujwalla, Johns Hopkins University
10:50 a.m.
Discussion
10:55 a.m.
Ultrasonic imaging and therapy in small
animal cancer models
Charles F. Caskey, Vanderbilt University,
Nashville, TN
11:15 a.m.
Discussion
11:20 a.m.
Plasmonic noble metal-based
nanotheranostics
Xiaoyuan Chen, National Institutes of Health,
Bethesda, MD
11:40 a.m.
Discussion
11:45 a.m.
Theranostic pretargeted
radioimmunotherapy with anti-DOTAhapten bispecific antibodies
Sarah Marie Cheal, Memorial Sloan Kettering
12:05 p.m.
Discussion
12:10 p.m.
Panel Discussion
490
RECENT ADVANCES IN EPIDEMIOLOGY AND PREVENTION RESEARCH
Tuesday, 10:30 a.m.-12:30 p.m.
Breast Cancer Around the World: Is It the Same Disease?
Chairperson: Timothy R. Rebbeck, University of Pennsylvania School of Medicine, Philadelphia, PA
Differences in biomarkers, risk factors, clinical features, and outcomes across groups can inform cancer
etiology. Extreme differences, such as those seen among widely divergent populations, may be
particularly informative if they capture the maximal variation that may exist. Knowledge gained from
these population differences may be translated into precision prevention or treatment that can target
specific subpopulations of individuals. This session will review the features of breast cancer across
populations to identify features that may hallmark common markers of risk or outcome that may be
universal to all breast cancer. The session will also identify population-specific features that may
inform prevention and treatment in specific groups of women.
10:30 a.m.
Global cancer research: What can we learn from differences across populations?
Timothy R. Rebbeck, University of Pennsylvania School of Medicine, Philadelphia, PA
10:50 a.m.
Discussion
10:55 a.m.
Prevalence and clinical utility of breast cancer subtypes
Laura J. Van ‘t Veer, UCSF Helen Diller Family Comprehensive Cancer Center,
San Francisco, CA
11:15 a.m.
Discussion
11:20 a.m.
Mutations in context: Genotype phenotype correlations in diverse populations
Olufunmilayo I. Olopade, University of Chicago Medical Center, Chicago, IL
11:40 a.m.
Discussion
11:45 a.m.
Breast cancer in Asian women: What is different and what have learned from
recent studies?
Wei Zheng, Vanderbilt University Medical Center, Nashville, TN
12:05 p.m.
Discussion
12:10 p.m.
Panel Discussion
491
RECENT ADVANCES IN ORGAN SITE RESEARCH
Tuesday, 10:30 a.m.-12:30 p.m.
Elucidating Mechanisms that Underlie the
Development of Pediatric Brain Cancers
The Expanding Prostate Cancer Imaging
Armamentarium: New Tools for Tackling
a Heterogeneous Disease
Chairperson: Suzanne J. Baker, St. Jude Children’s
Research Hospital, Memphis, TN
Tumors of the nervous system in children are associated
with significant morbidity and mortality, and comprise a
heterogeneous spectrum of disease. Despite similarities
with adult disease in some histopathological and clinical
features, genome-wide sequencing studies have revealed
striking differences in the mutation spectrum of pediatric
brain cancer, illuminating a critical connection between
developmental context and the selective pressures driving
tumorigenesis at different ages. This session will focus on
the latest advances in understanding the mechanisms
underlying several different types of brain tumors in
children, including discussions of molecular classification,
the contribution of cellular and developmental context, and
the therapeutic implications of these findings for this
devastating collection of pediatric cancers.
10:30 a.m.
Genetic and epigenetic drivers of pediatric
high-grade glioma
Suzanne J. Baker, St. Jude Children’s
Research Hospital, Memphis, TN
10:50 a.m.
Discussion
10:55 a.m.
Humanized models for pediatric brain tumors
William A. Weiss, University of California,
San Francisco, CA
11:15 a.m.
Discussion
11:20 a.m.
The molecular and cellular mechanisms
underlying the formation of childhood
ependymomas
Michael D. Taylor, University of Toronto
Hospital for Sick Children, Toronto, ON,
Canada
Chairperson: Hedvig Hricak, Memorial Sloan Kettering
The imaging armamentarium for prostate cancer has
expanded beyond anatomical imaging. Multiparametric
MRI is gaining acceptance; PET tracers, such as C-11
choline, F-18 choline, and PSMA-targeting ligands are
emerging; and new modalities, such as MR/PET and
hyperpolarized MR, are entering the clinical arena. These
tools have great potential for addressing the most
stubborn diagnostic challenges that affect prostate cancer
management, such as distinguishing insignificant from lifethreatening disease, detecting a recurrent tumor early, and
distinguishing local recurrence from metastasis. These
tools should help us better understand the mechanisms of
prostate cancer progression, enable the development of
new, minimally invasive treatments, targeted therapies and
theranostics, and ultimately improve patient outcome.
However, standards for applying even widely used imaging
methods have yet to be established, and many
fundamental issues remain to be addressed. This session
will review exciting advances in prostate cancer imaging
and image-guided therapy while also discussing important
knowledge and practice gaps.
10:30 a.m.
Multimodality imaging of primary and
metastatic prostate cancer: Advances, gaps,
and limitations
Hedvig Hricak, Memorial Sloan Kettering
10:50 a.m.
Discussion
10:55 a.m.
Advances in MRI diagnostics
Masoom A. Haider, University of Toronto,
Toronto, ON, Canada
11:15 a.m.
Discussion
11:40 a.m.
Discussion
11:20 a.m.
11:45 a.m.
Drivers and drugs for medulloblastoma
Robert J. Wechsler-Reya, Sanford-Burnham
Medical Research Institute, La Jolla, CA
Molecular imaging in biochemical recurrence
Peter Choyke, National Cancer Institute,
Bethesda, MD
11:40 a.m.
Discussion
12:05 p.m.
Discussion
11:45 a.m.
12:10 p.m.
Panel Discussion
PSMA ligands for diagnosis and therapy of
prostate cancer
Uwe Haberkorn, German Cancer Research
Center, Heidelberg, Germany
12:05 p.m.
Discussion
12:10 p.m.
Panel Discussion
492
MicroRNAs and Long Noncoding RNAs
in the Pathogenesis of Liver Cancer:
From Function to Therapeutics
Chairperson: Sakari Kauppinen, Aalborg University
Hospital, Copenhagen, Denmark
Recent data imply that over 70% of the human genome is
transcribed to produce thousands of noncoding RNA
(ncRNA) transcripts. MicroRNAs (miRNAs) are a class of
small ncRNAs that function as important posttranscriptional regulators of gene expression in most, if not
all, biological processes. Furthermore, many miRNAs play
key roles in the pathogenesis of cancer and have been
implicated either as oncogenes or tumor suppressors in a
wide range of malignancies. These findings underscore the
potential of miRNAs as a new class of targets for cancer
therapeutics. Long ncRNAs (lncRNAs) comprise a highly
diverse group of ncRNAs greater than 200 nucleotides in
length, with emerging roles in cancer biology. This session
will focus on the functions of miRNAs and lncRNAs in the
pathogenesis of liver cancer and describe recent progress
in the discovery and development of ncRNA-based cancer
therapeutics.
10:30 a.m.
Long noncoding RNA in liver cancers
Tushar Patel, Mayo Clinic Cancer Center
Jacksonville, Jacksonville, FL
10:50 a.m.
Discussion
10:55 a.m.
Role of microRNA-122 in liver homeostasis
and hepatocellular carcinoma
Kalpana Ghoshal, The Ohio State University,
Columbus, OH
11:15 a.m.
Discussion
11:20 a.m.
Approaches for therapeutic modulation of
microRNA activity
Sakari Kauppinen, Aalborg University
Hospital, Copenhagen, Denmark
11:40 a.m.
Discussion
11:45 a.m.
Preclinical and clinical development of
microRNA-34 mimic, MRX34, for treatment
of liver cancer
David S. Hong, The University of Texas MD
Anderson Cancer Center, Houston, TX
12:05 p.m.
Discussion
12:10 p.m.
Panel Discussion
493
SPECIAL SESSIONS (not eligible for CME credit)
Tuesday, 10:30 a.m.-12:30 p.m.
Commonwealth Hall (Second Floor), Loews Philadelphia Hotel
2014 Pancreatic Cancer Action NetworkAACR Research Grants
Poster and Presentation Session
Chairperson: Steven D. Leach, Memorial Sloan Kettering
This session aims to stimulate opportunities for
collaboration between Pancreatic Cancer Action NetworkAACR grantees and others in the pancreatic cancer research
field. Senior investigators will deliver presentations on their
funded research, followed by a moderated Q&A session.
Mentored and early-career investigators will present posters
highlighting progress on their research projects. The
Pancreatic Cancer Action Network has adopted a goal of
doubling survival from pancreatic cancer by the year 2020
and is building a robust Community for Progress comprised
of researchers working together to accelerate scientific and
medical advances. The grants portfolio includes funding
mechanisms that support researchers throughout their
career trajectory, beginning in postdoctoral/clinical research
through independence as a junior and senior investigator.
Funding is provided for basic, translational and clinical
research. Beyond providing financial support for research,
Pancreatic Cancer Action Network-AACR grantees have
ongoing opportunities for information exchange and
mentorship. Come meet the grantees, learn about their
funded projects and participate in the discussion.
Moderator: Christine A. Iacobuzio-Donahue, Memorial
Sloan Kettering Cancer Center, New York, NY
Pancreatic Cancer Action Network-AACR Innovative
Grant: PDA development: Heads or tails?
Dafna Bar-Sagi, New York University Langone Medical
Center, New York, NY
Grant: Genomic drivers of therapeutic responses in
metastatic disease
Michael T. Barrett, Mayo Clinic, Scottsdale, AZ
Grant: Mesenchymal stem cells in pancreatic cancer
biology and therapeutic development
Diane M. Simeone, University of Michigan, Ann Arbor, MI
494
Moderator: Steven D. Leach, Memorial Sloan Kettering
Pancreatic Cancer Action Network Clinical Continuation
Research Grant: Exploiting an NQO1 “Kiss of Death” for
pancreatic cancer therapy
David A. Boothman, UT Southwestern Medical Center,
Dallas, TX
Pancreatic Cancer Action Network-AACR Research
Acceleration Network Grant, in memory of Skip Viragh:
Developing a novel oxidative phosphorylation inhibitor in
pancreatic cancer
Giulio F. Draetta, The University of Texas MD Anderson
Moderator: Robert H. Vonderheide. Abramson Cancer
Center of the University of Pennsylvania, Philadelphia, PA
Grant, supported by Celgene Corporation: Regulation of
pancreatic tumorigenesis by necroptosis
George Miller, New York University School of Medicine,
New York, NY
Pancreatic Cancer Action Network-AACR Research
Acceleration Network Grant, supported
by the Fredman Family Foundation: GVAX + CRS-207
heterologous prime boost vaccination with PD-1 blockade
Dung Le, Johns Hopkins Kimmel Comp. Cancer Center,
Baltimore, MD
Poster Presentations
Pancreatic Cancer Action Network-AACR Career
Development Award: Targeting IL-17 signaling axis in
pancreatic ductal adenocarcinoma
Florencia McAllister, The University of Texas MD Anderson
Development Award, in memory of Skip Viragh: Changes
in mass transport as a biomarker of response in
pancreatic cancer
Eugene J. Koay, The University of Texas MD Anderson
Pancreatic Cancer Action Network Translational
Continuation Research Grant: Circulating tumor cells to
assess pancreatic cancer disease status
David T. Ting, Massachusetts General Hospital Cancer
Center, Charlestown, MA
Development Award: Functionalizing metabolic pathway
driver aberrations in pancreatic cancer
Kenneth L. Scott, Baylor College of Medicine, Houston, TX
Development Award: Understanding metabolic control of
the pancreatic cancer epigenome
Kathryn E. Wellen, University of Pennsylvania School of
Medicine, Philadelphia, PA
Pancreatic Cancer Action Network-AACR Pathway to
Leadership Grant: Therapeutic targeting of NRF2regulated metabolism in pancreatic cancer
Gina M. DeNicola, Joan and Sanford I. Weill Medical College
of Cornell University, New York, NY
Pancreatic Cancer Action Network-AACR Fellowship, in
memory of Samuel Stroum: Multiplexed in vivo drug
screening: Inhibitors of metastatic seeding
Barbara M. Gruener, Stanford University School of
Medicine, Stanford, CA
Fourth Annual AACR-PCWG Special
Scientific Session: Optimizing Targeted
Therapy Avenues for Pediatric Cancers
Moderator: Lee J. Helman, National Cancer Institute,
Bethesda, MD
All meeting attendees are invited to attend this special
Pediatric Cancer Working Group-sponsored event
showcasing cutting-edge pediatric cancer-based research.
10:30 a.m.
New agent development in pediatric
oncology: Hitting the target
Brenda J. Weigel, University of Minnesota,
Minneapolis, MN
11:00 a.m.
Novel oncogenic drivers in T cell acute
lymphoblastic leukemia
David M. Langenau, Massachusetts General
Hospital/Harvard Medical School,
Charlestown, MA
11:30 a.m.
Advancing CAR T cell immunotherapy in
pediatric oncology
Michael C. Jensen, Seattle Children’s
Hospital, Seattle, WA
12:00 p.m.
Nanoparticle drug delivery in a mouse
model of neuroblastoma
Garrett M. Brodeur, Children’s Hospital of
Philadelphia, Philadelphia, PA
495
Tuesday, 12:00 p.m.-1:00 p.m.
Booth #1827 (Publications Booth), Halls B-E
Meet the Editor-in-Chief of Cancer Immunology Research
Glenn Dranoff, MD
Founding Editor-in-Chief, Cancer Immunology Research
Global Head of Exploratory Immuno-Oncology
Novartis Institutes for BioMedical Research
Join us at Booth #1827 at AACR Annual Meeting 2015 to meet the editors of the AACR Publications.
The Editors-in-Chief will explain the mission and scope of their journal, recent submission trends, and
other topics of interest for researchers looking to publish their work in the highly esteemed AACR
journals. Learn what Editors look for in manuscripts and participate in a unique Q&A session.
Cancer Immunology Research publishes outstanding original articles reporting major advances in
cancer immunology that span the discipline from basic investigations in host-tumor interactions to
developmental therapeutics in model systems, early translational studies in patients, and late-stage
clinical trials. The journal disseminates knowledge of immunology to the cancer research community,
catalyzing cross-disciplinary work that yields a deeper understanding of the host-tumor relationship,
more potent cancer treatments, and improved clinical outcomes.
Tuesday, 12:00 p.m.-1:30 p.m.
Technology Transfer and Intellectual Property: Financial and Career
Opportunities for Researchers
Chairperson: Phuong Kim Pham, National Institutes of Health, Bethesda, MD
Technology Transfer (TT) is the licensing or sale of intellectual property (IP), including patents, patent
applications, know-how, and trade secrets, from one party to another in exchange for financial
compensation and further development of the technology.
What do scientists need to know about IP/TT? What kind of financial consideration as well as career
opportunities can scientists receive from getting involved in TT as an inventor or with a career in TT?
Come and join representatives from Thompson Coburn Law Firms, Johns Hopkins University, and the
National Institutes of Health for a lively discussion on their IP/TT experiences and career paths, and
discover new opportunities for you.
Speakers:
Joseph G. Contrera, Johns Hopkins Technology Ventures, Baltimore, MD
Jason V. Cristofaro, National Cancer Institute-DHHS, Bethesda, MD
Thomas J. Siepmann, Thompson Coburn LLP, Washington, DC
Laurie Whitney, National Cancer Institute, Bethesda, MD
Phuong Kim Pham, National Institutes of Health, Bethesda, MD
496
AACR-ELION AWARD LECTURE
Tuesday, 12:30 p.m.-1:00 p.m.
Eleventh Annual AACR Gertrude B. Elion Cancer Research Award Lecture
The Role of Serine Metabolism in Melanoma
Matthew G. Vander Heiden, MD, PhD
MIT Koch Institute for Integrated Cancer Research, Cambridge, MA
The AACR Gertrude B. Elion Cancer Research Award
provides a one-year grant to foster meritorious basic,
translational, or clinical cancer research by a tenure-track
scientist at the level of Assistant Professor. This award
honors the late Dr. Gertrude B. Elion, Scientist Emeritus at
Glaxo Wellcome Co. (now GlaxoSmithKline). Her seminal
research at the company revolutionized cancer
therapeutics and her prolific contributions to biomedical
science earned her the Nobel Prize in Physiology or
Medicine in 1988. The AACR is extremely pleased to
sponsor this award in the name of Dr. Elion, a distinguished
Past President and Honorary Member of the AACR.
This year we honor Dr. Matthew G. Vander Heiden, who is
studying how serine metabolism contributes to melanoma
initiation and progression. Altered metabolism is a poorly
understood feature of many cancers that holds great
promise for improved therapy. However, to successfully
target metabolism requires an understanding of how
metabolic regulation provides an advantage for tumor cells.
Most knowledge of cancer metabolism is based on studies
from cultured cells where conditions are different from
those experienced by tumor cells in vivo. Thus, better
models to study cancer metabolism in vivo have been a
limitation for the field. Recently, several studies have
converged on serine production from glucose as an
important metabolic pathway for cancers. Increased serine
synthesis is critical for cancer cell proliferation, and many
cancer signaling pathways influence serine metabolism.
However, increased production of serine is necessary for
cancer cells even when serine is abundant, and why
increased serine synthesis is still important is not
understood. The gene encoding the first enzyme of the
serine biosynthesis pathway, PHGDH, is amplified in human
melanoma and allows cancer cells to increase serine
production from glucose. Because PHGDH enzyme levels
regulate serine synthesis, these studies generated a mouse
model to control PHGDH expression and study the impact
of this pathway on melanoma progression and metabolism.
Using transgenic mice with tissue specific, doxycyclineinducible PHGDH expression, Dr. Vander Heiden’s lab found
that increased PHGDH expression alone appears insufficient
to cause cancer, but does result in inappropriate melanin
accumulation in the skin of these mice. When crossed to a
mouse melanoma model based on mutant BrafV600E
expression and Pten loss that is relevant to human
melanomas, they find that PHGDH expression can
accelerate tumor growth. In addition, while expression of
mutant BrafV600E results in nevi that do not progress to
invasive melanoma, PHGDH-expression can cooperate with
BrafV600E to cause invasive melanoma. These data argue
that PHGDH expression and increased serine biosynthesis
can promote the initiation and progression of melanomas
and provide the foundation for studies into how altered
serine metabolism affects tumor biology.
Dr. Vander Heiden is the Eisen and Chang Associate
Professor of Biology at the Koch Institute at MIT, and is also
an Instructor of Medicine at the Dana-Farber Cancer
Institute and Harvard Medical School. Dr. Vander Heiden
received his MD and PhD from the University of Chicago.
He also completed clinical training in Internal Medicine and
Medical Oncology at the Brigham and Women’s
Hospital/Dana-Farber Cancer Institute and is a practicing
medical oncologist.
497
Dedicated to the Memory of Eddie Reed
Tuesday, 12:30 p.m.-3:00 p.m.
12:30 p.m.
Remembering Dr. Eddie Reed
Bruce A. Chabner, Massachusetts General Hospital Cancer Center, Boston, MA
12:45 p.m.
Special Presentation from the MICR Council and the AACR 2015-2016 President Elect
Chanita Hughes-Halbert, Medical University of SC Hollings Cancer Center, Charleston, SC, and
Nancy E. Davidson, University of Pittsburgh Cancer Institute, Pittsburgh, PA
This Recent Advances in Diagnostics and Therapeutics Research Session is
dedicated to the memory of Dr. Eddie Reed, clinical director of the National
Institute on Minority Health and Health Disparities (NIMHD) of the National
Institutes of Health (NIH) in Bethesda, Maryland, who passed away on May 28,
2014, at the age of 60. Dr. Reed, a world-renowned cancer expert, was an AACR
member for 27 years (since 1987) and served on numerous boards and
committees, including the board of directors and served as chair of the Minorities
in Cancer Research (MICR) Council. Dr. Reed was known internationally in the
cancer research field for his two interests, cancer drug development and cancer
care for the underserved. His clinical research primarily focused on DNA damage
and repair in cancer cells. Dr. Reed was recognized as an authority on the actions
and use of the anticancer agents paclitaxel and cisplatin, and collaborated on
many public health cancer prevention, screening, and control programs.
Prior to his recruitment to the NIMHD in 2012, which was established in an effort
to improve minority health and eliminate health disparities, Dr. Reed was a
professor of oncologic sciences and the Abraham Mitchell distinguished
investigator at the University of South Alabama Mitchell Cancer Institute in
Mobile. He had served as chief of the pharmacology branch and chief of the
Ovarian Cancer and Metastatic Prostate Cancer Clinic in the Division of Clinical
Science at the NCI; he was the first African American branch chief to serve at the
institute. He had also served as director of the Mary Babb Randolph Cancer
Center at West Virginia University in Morgantown, and director of the Division of
Cancer Prevention and Control at the Centers for Disease Control and Prevention
in Atlanta.
Dr. Reed was a very active AACR member; in addition to his election to the board
of directors and MICR Council chair, he also served on the MICR-Jane Cooke
Wright Lectureship Award Committee and the Research Grant Review
Committee. Additionally, he served on the Cancer Prevention Research and
Molecular Cancer Therapeutics editorial boards, and was a member of several
other committees, including the Annual Meeting 2011 Program Committee and
the Award for Lifetime Achievement in Cancer Research Committee.
Dr. Reed had also served on the National Advisory Council on Minority Health and
Health Disparities and on the Institute of Medicine’s National Cancer Policy Forum.
He twice received the United States Public Health Service Commendation Medal.
498
DNA Repair Pathways in Cancer: Basic Biology and Clinical Utility
Chairperson: Andrea L. Richardson, Brigham and Women’s Hospital, Boston, MA
This Recent Advances in Diagnostics and Therapeutics Research session honors the late Dr. Eddie
Reed (1953-2014), who was a pioneer and leader both in the research of DNA repair and as a mentor
and role model for minority scientists. This session will present state of the art findings in the genomic
features and mutational patterns that characterize cancers with defects in DNA repair. Findings in
breast and lung cancer will be highlighted. The talks will describe novel gene expression and DNA
based assays for predicting the presence of a DNA repair defect in a tumor and the potential utility of
such assays in optimizing therapy choice for patients.
1:00 p.m.
DNA repair pathway choice in cancer therapy
Junjie Chen, The University of Texas MD Anderson Cancer Center, Houston, TX
1:15 p.m.
Discussion
1:20 p.m.
Chromatin accessibility underlies the tumor-suppression role of BAF (mSWI/SNF)
complexes in many malignancies
**Courtney Hodges, Stanford University School of Medicine, Stanford, CA
1:35 p.m.
Discussion
1:40 p.m.
RPS: A DNA repair pathway gene expression score that provides prognostic
information and predicts sensitivity to treatment
Phillip P. Connell, University of Chicago, Chicago, IL
1:55 p.m.
Discussion
2:00 p.m.
Genomic signatures of DNA repair defects and prediction of therapy
response in cancer
Andrea L. Richardson, Brigham and Women's Hospital, Boston, MA
2:15 p.m.
Discussion
2:20 p.m.
Whole-genome sequencing readouts of deficiences in DNA repair pathways
Serena Nik-Zainal, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
499
CAREER CONVERSATIONS (not eligible for CME credit)
Tuesday, 1:00 p.m.-2:00 p.m.
AACRcentral, Associate Member Resource and Career Center, Halls B-E, Booth #725
Calling All Physician-Scientists: Pursuing a Career in Both
Science and Medicine
Career Conversations, organized by the Associate Member Council, are informal networking and
discussion sessions designed to allow early-career scientists the opportunity to interact with junior
faculty and recently transitioned peers from various employment sectors. The topics change year to
year to offer a broad array of information that could be relevant to the diverse Annual Meeting earlycareer attendees. This peer-to-peer session will allow attendees to hear about the unique challenge
physician-scientists face in balancing both a research and clinical practice. Participants will explore
how to effectively consider the decision-making process, obtain an overview of typical work-week
time management strategies, and discuss how to set and attain career goals related to clinical
practice, research, or permutations of the two. Program leaders will provide lessons they have learned
when overcoming challenges with starting and maintaining their clinical practices and research
programs. Designed to provide advice that can help attendees figure out their career path and
potential future career opportunities, Career Conversations are open to all graduate students, medical
students, residents, and clinical and postdoctoral fellows. All Career Conversations will take place in
AACRcentral and limited seating will be available on a first-come, first-served basis. #AACRcentral
Speakers:
Kimberly Stegmaier, Harvard Medical School, Dana-Farber Cancer Institute, Boston Children’s Hospital,
and the Broad Institute, Boston, MA
David T. Ting, Harvard Medical School and Massachusetts General Hospital Cancer Center, Boston, MA
500
MAJOR SYMPOSIA
Tuesday, 1:00 p.m.-3:00 p.m.
Grand Ballroom (300 Level), Pennsylvania
Convention Center
Convention Center
Adoptive T Cell Therapy
Aging and Senescence
Chairperson: Carl H. June, Abramson Cancer Center of the
University of Pennsylvania, Philadelphia, PA
Chairperson: Jan M. Van Deursen, Mayo Clinic,
Rochester, MN
Adoptive cell therapy has emerged as an important
modality in the treatment of cancer. Over the past several
years several centers have demonstrated long lasting
effects in patients with advanced cancer. The modalities
primarily consist of infusions of autologous tumor
infiltrating lymphocytes or redirected T cells that have
been engineered to have new specificities using various
forms of gene transfer. For the first time the biotechnology
and pharmaceutical industries have significant investments
in this field. Late stage trials are underway that could lead
to widespread commercial approval for various forms of B
cell leukemia and lymphoma. This session will elaborate on
the progress being made in laboratory and clinical studies
to take these therapies to the next level. This includes talks
on next-generation chimeric antigen receptor designs,
therapy with enhanced T cell receptors and strategies to
overcome checkpoint inhibition following adoptive transfer.
Cellular senescence has historically been viewed as an
irreversible cell-cycle arrest mechanism that acts to protect
against cancer, but recent discoveries have expanded its role
into complex biological processes such as development,
tissue repair, aging, and age-related disorders. Furthermore,
it is becoming increasingly clear that senescence may not
represent a static state but instead a series of progressive
and phenotypically diverse cellular states acquired after the
initial cell-cycle arrest. The symposium on senescence and
aging will focus on new insights into the molecular
mechanisms underlying the multistep progression of
senescence, the compositions of senescence-associated
secretomes and their autocrine and paracrine effects, the
tumor promoting properties of senescent cells, and the
development of anti-senescent cell therapeutics for
treatment of age-related disorders and diseases.
1:00 p.m.
Introduction
1:00 p.m.
Introduction
1:10 p.m.
1:10 p.m.
TCR-engineered T cells: Can they catch CARs?
Carl H. June, Abramson Cancer Center of the
University of Pennsylvania, Philadelphia, PA
Cell autonomous and non-cell autonomous
programs of senescence
Scott W. Lowe, Memorial Sloan Kettering
1:30 p.m.
Discussion
1:30 p.m.
Discussion
1:35 p.m.
CARs: From assembly to distribution
Michel Sadelain, Memorial Sloan Kettering
1:35 p.m.
The yin and yang of cellular senescence
Judith Campisi, Buck Institute for Age
Research, Novato, CA
1:55 p.m.
Discussion
1:55 p.m.
Discussion
2:00 p.m.
Employing TCRs in engineered T cells to
develop therapeutic reagents for effectively
targeting malignancies [SY31-03]*
Philip D. Greenberg, Fred Hutchinson Cancer
Research Center and University of
Washington, Seattle, WA
2:00 p.m.
Role of senescent cells in cancer and aging
Jan M. Van Deursen, Mayo Clinic,
Rochester, MN
2:20 p.m.
Discussion
2:25 p.m.
Activation of retrotransposable elements in
cellular senescence
John M. Sedivy, Brown University,
Barrington, RI
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
2:20 p.m.
Discussion
2:25 p.m.
Engineering virus-specific T cells to redirect
them to cancer
Malcolm K. Brenner, Baylor College of
Medicine, Houston, TX
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
501
MAJOR SYMPOSIA
Tuesday, 1:00 p.m.-3:00 p.m.
2:30 p.m.
Systems analysis of drug-induced Met
receptor tyrosine kinase reprogramming
Morag Park, Goodman Cancer Research
Centre, McGill University, Montréal, QC, Canada
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
Applying Systems Biology in
the Oncology Clinic
Chairperson: Morag Park, Goodman Cancer Research
Centre, McGill University, Montréal, QC, Canada
An important challenge facing the field is how better to
translate in vitro discoveries to the clinic. Computational
systems biology approaches that use multiple omic based
data to predict biology along with novel experimental
systems that better represent human in vivo biology are
proving useful in bridging this gap. This session will integrate
a variety of omic-based approaches to model tumor
complexity and predict response to inhibitors in the clinic.
These include large scale integration of genomic data with
phosphoproteomic data to identify metabolism proteome
signatures in lung cancer, development of mechanisms of
resistance and the integration of mathematical modeling to
predict disease response. The potential application of
systems biology and the future evolution of the field will
significantly affect understanding of cancer disease
mechanisms and the ability to devise effective therapeutics.
1:00 p.m.
Introduction
1:10 p.m.
Evolutionary mathematical modeling allows
identification of optimum treatment
schedules in lung and brain cancer
Franziska Michor, Dana-Farber Cancer
Institute, Boston, MA
1:25 p.m.
Discussion
1:30 p.m.
Integrated omic analysis of lung cancer
reveals metabolism-proteome signatures
with prognostic impact
Michael F. Moran, Hospital for Sick Children,
Toronto, ON, Canada
Chronic Infections Driving Cancer
Chairperson: Cynthia L. Sears, Johns Hopkins University
Microbes are increasingly believed to serve as critical
drivers of cell biologic and mutational changes that initiate
or promote diverse cancers. In this session, the most recent
estimates of the fraction of cancers attributable to
infection worldwide will be presented, highlighting the
wide variations existing between geographical areas for
specific infections related cancer sites. The contributions of
Helicobacter pylori, hepatitis B and C viruses, and human
papillomaviruses will be discussed along with our rapidly
evolving understanding of how the microbiome or specific
bacteria may contribute to colon cancer. The potential for a
public health victory through cure of hepatitis C infection
that markedly reduces the risk of hepatocellular carcinoma
will be discussed.
1:00 p.m.
Introduction
1:10 p.m.
Infection causing cancer: An update on the
global burden [SY34-01]*
Catherine de Martel, International Agency for
Research on Cancer, Lyon, France
1:30 p.m.
Discussion
HPV as a cause of cancer
Maura L. Gillison, The Ohio State University
Comprehensive Cancer Center, Columbus, OH
1:45 p.m.
Discussion
1:35 p.m.
1:50 p.m.
Role of JAK-STAT pathway activation in MPN
pathogenesis and therapeutic response
Ross L. Levine, Memorial Sloan Kettering
1:55 p.m.
Discussion
2:00 p.m.
Colon cancer: Alpha-bugs or community as
disease drivers [SY34-03]*
Cynthia L. Sears, Johns Hopkins University
2:20 p.m.
Other
2:25 p.m.
Hepatitis C: Curing of an infectious cause
of cancer
David Thomas, Johns Hopkins University,
Frederick, MD
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
2:05 p.m.
Discussion
2:10 p.m.
The Trojan Horse Strategy: Packaging
chemotherapeutics can help alleviate toxicity
**Surojit Sur, Ludwig Center at the Johns
Hopkins Kimmel Cancer Center, Baltimore, MD
2:25 p.m.
Discussion
502
Empowering Antibodies to Fight Cancer:
ADCs and Immunoconjugates
Intraoperative Imaging
Chairperson: Jonathan G. Drachman, Seattle Genetics, Inc.,
Bothell, WA
With the recent approvals of brentuximab vedotin
(ADCETRIS®) and trastuzumab emtansine (Kadcyla®), there
has been great interest in the next wave of ADCs entering
clinic. In this symposium, we will focus on recent clinical and
preclinical advances that have occurred in the field.
Jonathan Drachman will focus on efforts to evaluate ADCs
in novel clinical trials as well as technological improvements
designed to enhance linker stability, pharmacokinetic
properties, and payloads. Paul Polakis will highlight clinical
and preclinical experiences with ADCs that underscore the
complexities associated with their development. Anna Wu
will discuss advances in radiolabeling of antibodies and
antibody fragments for preclinical and clinical evaluation of
novel targets. Dario Neri will discuss immunocytokine fusion
molecules, focusing on preclinical and early clinical results
as a method of targeting immune activation to the tumor.
Chairperson: Samuel Achilefu, Washington University
School of Medicine, St. Louis, MO
The use of optical imaging methods in the operating room
for real-time image-guided surgery has received
tremendous interest because of the ease of image
acquisition, real-time image projection, detection of cancer
with high accuracy, and relatively low-cost devices that do
not disrupt surgical workflow. To improve imaging depth
and minimize interference by tissue autofluorescence, these
methods typically utilize near-infrared (NIR) fluorescent
light, which is invisible to human eyes. This symposium will
highlight advances in fluorescence imaging devices and
emerging tumor-avid molecular probes for intraoperative
tumor detection, resection, and real-time surgical margin
assessment. Discussion will include practical considerations,
challenges to clinical translation of molecular probes to
clinics, and strategies to overcome them.
1:00 p.m.
Introduction
1:10 p.m.
Fluorescence image-guided cancer
resection: From bench to bedside
Samuel Achilefu, Washington University
School of Medicine, St. Louis, MO
1:00 p.m.
Introduction
1:10 p.m.
The next generation of ADCs [SY35-01]*
Jonathan G. Drachman, Seattle Genetics, Inc.,
Bothell, WA
1:30 p.m.
Discussion
1:30 p.m.
Discussion
1:35 p.m.
1:35 p.m.
Lessons learned from ADCs
Paul G. Polakis, Genentech, Inc., South
San Francisco, CA
1:55 p.m.
Discussion
Visualizing cancer: Surgical navigation
using targeted fluorescent imaging
agents [SY36-02]*
Eben L. Rosenthal, University of Alabama at
Birmingham, Birmingham, AL
2:00 p.m.
Radioimmunoconjugates for molecular
imaging of cancer
Anna M. Wu, David Geffen School of
Medicine at UCLA, Los Angeles, CA
1:55 p.m.
Discussion
2:00 p.m.
Intraoperative molecular imaging with
protease-activated fluorescent imaging
agents [SY36-03]*
David G. Kirsch, Duke University Medical
Center, Durham, NC
2:20 p.m.
Discussion
2:25 p.m.
Seeing cancer in a new light: Interventional
targeted fluorescence imaging goes clinical
Vasilis Ntziachristos, German Research
Center for Environmental Health,
Neuherberg, Germany
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
2:20 p.m.
Discussion
2:25 p.m.
Arming tumor-targeting antibodies with
cytokine payloads: Emerging clinical
results [SY35-04]*
Dario Neri, Swiss Federal Institute of
Technology (ETH Zürich), Zürich, Switzerland
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
503
MAJOR SYMPOSIA
Tuesday, 1:00 p.m.-3:00 p.m.
Convention Center
Convention Center
Liquid Biopsy Approaches for Detecting,
Monitoring, and Characterizing Human Cancer
Targeting Myc to Treat Cancer
Chairperson: Victor E. Velculescu, Johns Hopkins Kimmel
Chairperson: Gerard I. Evan, University of Cambridge,
Cambridge, United Kingdom
Analyses of cancer genomes have revealed mechanisms
underlying tumorigenesis and new avenues for
personalized therapeutic intervention. Nevertheless, there
is great complexity in the alterations of individual tumors
and a realization that these can change during disease
progression. This session will focus on new technologies
that have emerged to analyze molecular alterations in the
circulation of cancer patients, including as circulating
tumor cells, cell-free tumor DNA, and exosomal nucleic
acids. These approaches have important implications for
noninvasive detection and monitoring of human cancer,
therapeutic stratification, and identification of mechanisms
of resistance to targeted therapies.
The importance of Myc to human cancer is incontestable.
The great majority of adult human cancers of all types
exhibit demonstrable Myc elevation or deregulation,
implicating aberrant Myc expression as pivotal, potentially
obligate, in the genesis and evolution of neoplasia.
Whether this makes Myc a suitable candidate for
pharmacological targeting, however, remains uncertain: we
still have no clear understanding of what Myc contributes
to cancers – whether this contribution is essential for
tumor evolution and/or tumor maintenance, or how bad
might be the side effects caused by systemic Myc
inhibition. This session explores a variety of innovative
genetic, pharmacological, and biochemical strategies to
answer these questions.
1:00 p.m.
Introduction
1:00 p.m.
Introduction
1:10 p.m.
Characterization of circulating tumor cells
Daniel A. Haber, Massachusetts General
Hospital, Charlestown, MA
1:10 p.m.
1:30 p.m.
Discussion
Using switchable genetic mouse models to
validate Myc as a therapeutic target
Gerard I. Evan, University of Cambridge,
Cambridge, United Kingdom
1:35 p.m.
Monitoring tumor evolution by wholegenome plasma sequencing [SY37-02]*
Michael R. Speicher, Medical University of
Graz, Graz, Austria
1:30 p.m.
Discussion
1:35 p.m.
Targeting post-translational activation of
MYC for the treatment of cancer [SY38-03]*
Rosalie C. Sears, Oregon Health and Science
University, Portland, OR
1:55 p.m.
Discussion
2:00 p.m.
Targeting MYCN in childhood
neuroblastoma
Marie Arsenian-Henriksson, Karolinska
Institute, Stockholm, Sweden
2:20 p.m.
Discussion
2:25 p.m.
Therapeutic approaches to MYC inhibition
James E. Bradner, Dana-Farber Cancer
1:55 p.m.
Discussion
2:00 p.m.
Exosomes: Next-generation diagnostics
Johan Skog, Exosome Diagnostics, Inc.,
Cambridge, MA
2:20 p.m.
Discussion
2:25 p.m.
Liquid biopsy approaches for characterizing
cancer genomes
Victor E. Velculescu, Johns Hopkins Kimmel
2:45 p.m.
Discussion
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
2:50 p.m.
General Discussion
504
Tuesday, 1:00 p.m.-3:00 p.m.
Grand Ballroom Salons A-B (Level 5), Philadelphia Marriott Downtown
Science Reproducibility: Proper Management and Publication of Data
Improper management of data, poorly written lab notebooks, and irreproducibility are major road
blocks for scientific progress and can be detrimental to one’s career. In this Professional Advancement
Session, attendees will be introduced to open science focusing on how it can provide greater
transparency and collaboration by allowing the sharing of negative data and large data sets. Journal
editors will discuss the do’s and don’ts of data publishing and provide an in depth look at a case study.
The Associate Member Council organizes several Professional Advancement Sessions aimed
specifically toward the professional needs of graduate students, medical students and residents, and
clinical and postdoctoral fellows. Each year the topics change to cover a broad range of interests
relevant to early-career scientists.
For AACR members, all 2015 Professional Advancement Sessions are free with your Annual Meeting
registration (except for $45 for the Grant Writing Workshop) and are an added benefit of your
membership. For nonmembers, there is an additional fee of $50 ($95 for the Grant Writing Workshop)
for attendance at each session. If you are not an AACR member, we strongly encourage you to join
and take advantage of the many benefits of membership, which include attendance at these sessions.
Participation is on a first-come, first-served basis, and space is limited. Nonmembers are required to
pay on site. #AACRcareer
Accurate reporting of data in journals
Yves A. DeClerck, USC/Children’s Hospital Los Angeles, Los Angeles, CA
Transparency and data sharing
Jean C. Zenklusen, National Cancer Institute, Bethesda, MD
Possible pitfalls: When good science goes bad
Lee M. Ellis, The University of Texas MD Anderson Cancer Center, Houston, TX
505
Tuesday, 1:00 p.m.-3:00 p.m.
Metabolism and Adaptive Immune Responses
Chairperson: Douglas R. Green, St. Jude Children’s Research Hospital, Memphis, TN
As in cancer, the metabolic reprogramming of T lymphocytes following activation dictates their
proliferation, differentiation, and function. Understanding this reprogramming gives insights into cell
metabolism in general, and provides opportunities for the manipulation of T cell function in immune
therapies. In this session several aspects of T cell metabolism will be explored. Steven Bensinger will
discuss how the mechanisms underlying how cholesterol and fatty acid metabolic pathways control
immune cell function and host immunity. Shao-Cong Sun will explore how T cell receptor signaling,
coupled with the function of a glutamine transporter, influences TORC1 activation and function during
T cell activation. Douglas R. Green will describe the process of asymmetric T cell division, and how
metabolic events, TORC1, and c-Myc interact asymmetrically to maintain and direct T cell function and
differentiation. Finally, Jonathan Powell will consider the influence of the tumor microenvironment on
T cell metabolism, and how this can be manipulated to promote antitumor immunity.
1:00 p.m.
Regulating host immunity through reprogramming of sterol metabolism
Steven Bensinger, University of California, Los Angeles, CA
1:20 p.m.
Discussion
1:25 p.m.
New insights into mTORC1 signaling in T cells
Shao-Cong Sun, The University of Texas MD Anderson Cancer Center, Houston, TX
1:45 p.m.
Discussion
1:50 p.m.
Metabolic maintenance of asymetric divisiion of T cells
Douglas R. Green, St. Jude Children’s Research Hospital, Memphis, TN
2:10 p.m.
Discussion
2:15 p.m.
Targeting immunometabolism as a means of enhancing immunotherapy
Jonathan D. Powell, Johns Hopkins Kimmel Comprehensive Cancer Center,
Baltimore, MD
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
506
RECENT ADVANCES IN EPIDEMIOLOGY AND PREVENTION RESEARCH
Tuesday, 1:00 p.m.-3:00 p.m.
Cancer Risk Factors and Targeted Screening
Chairperson: Graham A. Colditz, Washington University, St. Louis, MO
This session brings together new insights to risk factors for breast cancer such as mammographic
density and the use of computational pathology to refine risk assessment in benign breast disease.
How we approach new risk factors from a quantitative perspective is important, as we strive to
integrate scientific advances into models and improve their performance. Ideally models will allow us
to stratify cancer risk more precisely and refine population subgroups where risk-benefit tradeoffs are
maximized in favor of benefits. Examples of breast cancer incidence models and their translation to
clinical use will be presented as a basis for considering the refinement of risk and potential population
health impact of scientific advances.
1:00 p.m.
Translating models of breast cancer incidence to clinical, stratifying screening for
population health
Graham A. Colditz, Washington University,
St. Louis, MO
1:20 p.m.
Discussion
1:25 p.m.
New insight into mammographic measures and breast cancer risk
Celine M. Vachon, Mayo Clinic, Rochester, MN
1:45 p.m.
Discussion
1:50 p.m.
New approaches in computational pathology for risk assessment in
benign breast diseases
Andrew H. Beck, Beth Israel Deaconess Medical Center, Boston, MA
2:10 p.m.
Discussion
2:15 p.m.
Practical assessment of novel risk factors
Michael W. Kattan, The Cleveland Clinic, Cleveland, OH
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
507
RECENT ADVANCES IN ORGAN SITE RESEARCH
Tuesday, 1:00 p.m.-3:00 p.m.
Modeling Human Sarcomas
Pancreatic Cancer: The Promise and Pitfalls
of Targeting the Stroma
Chairperson: Mario R. Capecchi, University of Utah,
Salt Lake City, UT
Soft tissue sarcomas are a major cause of morbidity and
mortality among children, adolescents, and young adults
with cancer, and not insignificant among older adults.
Advances in genomics, patient-derived xenograft (PDX)
techniques, and conditional mouse modeling are shedding
light on not only the biology of this spectrum of cancers,
but also the potential therapeutic options. Unlike epithelial
cancers, sarcomas may be a prime example where cell of
origin and the state of differentiation explain the genomic
aberrations as well as the options for epigenetic
therapeutic interventions. Increased attention to the basic
science of tumor initiation and progression (via genetically
engineered mouse models), as well as diversifying the
range of human PDX models, may inform and improve
clinical trial design which has hereunto been largely
empirically based and for which few targeted therapies
have resulted in long-term survival benefit.
Chairperson: Ben Z. Stanger, Abramson Cancer Center of
the University of Pennsylvania, Philadelphia, PA
In addition to cancer calls, tumors contain non-mutant
stromal cells – fibroblasts, leukocytes, and endothelial cells
– that influence tumor behavior. In pancreatic cancer, the
stromal compartment makes up a large percentage of
tumor bulk, comprising more than 70-80% of total tumor
mass and leading to what is histologically termed a
“desmoplastic” stroma. Many functional properties have
been attributed to the pancreatic tumor stroma, including
the notion that fibroblasts act as a barrier to the delivery of
chemotherapy and the idea that the tumor builds an
immunosuppressive microenvironment early in tumor
progression. In this session, our speakers will discuss their
own findings and evolving work in the field, providing
insight into the promise, and risk, of targeting the tumor
stroma in this disease.
1:00 p.m.
Pro-inflammatory cytokines in pancreatic
cancer pathogenesis
Steven D. Leach, Memorial Sloan Kettering
Discussion
1:20 p.m.
Discussion
1:25 p.m.
Lineage of origin informs pharmacological
response
Charles Keller, Children’s Cancer Therapy
Development Institute, Fort Collins, CO
1:25 p.m.
Oncogenic Kras and the pancreatic cancer
microenvironment
Marina Pasca Di Magliano, University of
1:45 p.m.
Discussion
1:45 p.m.
Discussion
1:50 p.m.
Advances in basic, translational, and clinical
sarcoma research: Year in review
Torsten O. Nielsen, University of British
Columbia, Vancouver, BC, Canada
1:50 p.m.
Pancreatic tumor stroma as a therapeutic
target [RAOS15-03]*
Ronald M. Evans, Salk Institute for Biological
Studies, La Jolla, CA
2:10 p.m.
Discussion
2:10 p.m.
Discussion
2:15 p.m.
Modeling translocation sarcomas using
CRISPR/Cas technology and use of
functional genomic screens to identify
potential novel drug targets
Marc Ladanyi, Memorial Sloan Kettering
2:15 p.m.
Complex cellular interactions in the
pancreatic cancer microenvironment
Ben Z. Stanger, Abramson Cancer Center of
the University of Pennsylvania, Philadelphia, PA
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
1:00 p.m.
Modeling alveolar soft parts sarcoma
Mario R. Capecchi, University of Utah,
Salt Lake City, UT
1:20 p.m.
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
508
What Does Stem Cell Reprogramming
Teach Us About Hematologic Malignancies?
Chairperson: Ash A. Alizadeh, Stanford University,
Stanford, CA
This session focuses on emerging knowledge of the
reprogramming of stem cells and progenitor populations
and their relevance to hematological malignancies
including lymphomas, leukemias, and myelodysplastic
syndromes. Dr. Ash Alizadeh will discuss recent advances
implicating hit-and-run reprogramming by the Bcl6
oncogene, within models where Bcl6 is sufficient for
oncogenic function and induction of mature B-cell
lymphomas. Dr. Eftychia Apostolou will discuss somatic cell
reprogramming as a system to study imprinting
deregulation. Dr. Jose Polo will discuss his group’s work on
use of reprogramming to model leukemia. Dr. Eirini
Papapetrou will discuss work on modeling myelodysplastic
syndromes with patient-derived isogenic iPSCs. Based on
the speakers and topics to be discussed, this session
promises to be both exciting and highly informative.
1:00 p.m.
Hit-and-run lymphomagenic
reprogramming by the Bcl6 oncogene
Ash A. Alizadeh, Stanford University,
Stanford, CA
1:20 p.m.
Discussion
1:25 p.m.
Somatic cell reprogramming as a system to
study imprinting deregulation
Eftychia Apostolou, Weill Cornell Medical
College, New York, NY
1:45 p.m.
Discussion
1:50 p.m.
Using reprogramming to model leukemia
Jose Polo, Monash University, Clayton,
Australia
2:10 p.m.
Discussion
2:15 p.m.
Modeling myelodysplastic syndromes with
patient-derived isogenic iPSCs
Eirini Papapetrou, Mount Sinai Hospital,
New York, NY
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
509
REGULATORY SCIENCE AND POLICY SESSION
Tuesday, 1:00 p.m.-3:00 p.m.
Incorporating Next-Generation Sequencing (NGS) into Oncology
Diagnostics, Therapeutics, and Treatment
Chairperson: Laura J. van ‘t Veer, UCSF Helen Diller Family Comprehensive Cancer Center,
San Francisco, CA
Advances in next-generation sequencing (NGS) technology are enabling rapid, low cost, highthroughput, molecular profiling and biomarker identification. Large-scale, tumor-profiling efforts have
revealed similarities in mutation prevalence across different cancer types, potentially indicating
similarities in tumor development pathways and/or mutations of significance in tumor growth. These
findings could inform and optimize use of targeted therapies in multiple indications and disease
settings. NGS technologies are also being utilized in the clinical setting as screening tools for large,
multi-arm, investigational studies, as well as companion diagnostics to choose from multiple targeted
therapies. The transition of NGS from the research setting into the clinical setting to direct treatment
of patients raises exciting new possibilities while simultaneously raising translational, regulatory, and
reimbursement concerns. While NGS technologies hold much promise for the realization of precision
medicine in the clinic, there are uncertainties with regards to evidence development for analytical
validity, clinical validity, and clinical utility of these tests. This session, will discuss strategies to
optimize evaluating the clinical validity and utility of NGS based tests, the U.S. Food and Drug
Administration’s current thinking on regulation of NGS-based tests as well as payer perspectives on
coverage and reimbursement of tests.
A panel discussion will be moderated by Laura J. van 't Veer, UCSF Helen Diller Family Comprehensive
Cancer Center, and audience Q and A will follow the presentations.
Speakers:
Laura J. van ‘t Veer, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Mia A. Levy, Vanderbilt University, Nashville, TN
Barbara A. Conley, National Cancer Institute, Rockville, MD
Elizabeth Mansfield, U.S. Food and Drug Administration, Rockville, MD
Dane Dickson, Palmetto GBA, Columbia, SC
510
POSTER SESSION
Poster Section 1 • Tuesday, 1:00 PM-5:00 PM
Cancer Systems Biology
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
8.
9.
10.
Abstract
Number
3744 Single-cell analysis of adaptive resistance and
fractional responses of melanoma cells to RAF/MEK
inhibition. Mohammad Fallahi-Sichani, Nathan J. Moerke,
Mario Niepel, Tnghu Zhang, Nathanael S. Gray, Peter K.
Sorger.
3745 Comprehensive integrative characterization of
hepatocellular carcinoma: The TCGA HCC project. Lewis R.
Roberts, David A. Wheeler.
3746 Novel therapeutic possibilities for
chemorefractory ovarian cancer patients identified by
functional ex vivo drug sensitivity testing of primary cells
from ascites. Astrid Murumägi, Akira Hirasawa, Mariliina
Arjama, Katja Välimäki, Bhagwan Yadav, Jing Tang,
Agnieszka Szwajda, Laura Turunen, John Patrick Mpindi, Teijo
Pellinen, Krister Wennerberg, Ralf Bützow, Tero Aittokallio,
Olli Kallioniemi.
3747 Identification of NSCLC biomarkers underlying
quantifiable drug-induced clonal fitness. Katherine L.
Jameson, Peter L. Frick, Darren R. Tyson, Thomas E.
Yankeelov, Vito Quaranta.
3748 Transcriptome landscape of brain tumor
progression at single-cell resolution. Kyu-Tae Kim, Jin-Ku
Lee, Dong-Hyun Park, Do-Hyun Nam, Hae-Ock Lee, WoongYang Park.
3749 Uses and update for CellMiner, a tool for access to
and comparison of molecular data and pharmacological
response for the NCI-60. William C. Reinhold, Margot
Sunshine, Sudir Varma, Vinodh Rajapakse, James Doroshow,
Joel Morris, Yves Pmmier.
3751 Defining the temporal effects of TGF␤ inhibition
on the cellular heterogeneity of the bone metastatic
prostate cancer microenvironment. Leah M. Cook, Arturo
Araujo, David Basanta, Conor C. Lynch.
3752 Integrating proteomics and metabolomics
characterizes active pathways and potential drug targets
in small cell lung cancer. Paul A. Stewart, Jiannong Li, Kate
J. Fisher, Suraj Dhungana, Delisha Stewart, Susan Sumner,
Eric Gardner, John Poirier, Charles M. Rudin, Eric A. Welsh,
Steven Eschrich, Ann Chen, Eric B. Haura.
3753 An integrated approach to identify functional
signaling modules in retinoblastoma cancer progression.
Nilanjan Guha, Deepak SA, Syed Lateef, Seetaraman
Gundimeda, Arunkumar Padmanabhan, Carolina B Livi, Nigel
Skinner, Arkasubhra Ghosh, Ashwin Mallipatna, Vishnu
Suresh Babu, Arun Sreekumar.
Poster
Board
Abstract
Number
11.
3754 Predicting cancer phenotypes with mechanismdriven multi-omics data integration. Luigi Marchionni,
Donald Geman.
13.
3756 Identification of prognostic gene signatures of
glioblastoma: a study based on TCGA data analysis. YongWan Kim.
14.
3757 The network behavior of microRNA, genes, and
pathways as a biomarker for patient stratification. Rotem
Ben-Hamo, Alona Zilberberg, Sol Efroni.
15.
3758 A combined machine learning and bioinformatic
analysis approach identifies biological pathways that
predict clinical stage and survival outcome in
neuroblastoma patients. Alex Carlisle, Ivan Caceres, Sonali
Mehta, Jay Schindler, Jonathan Sharma.
16.
3759 Xenograft rebound kinetics are consistent with
the founder effect. Andrew Chen, Christopher J. Zopf, JingTao Wu, Wen Chyi Shyu, Arijit Chakravarty.
17.
3760 Modeling spatial tumor growth as seen in clinical
and radiological observations. Louise Viger, Clément
Draghi, Fabrice Denis, Christophe Letellier.
18.
3761 Distinct transcriptional programs drive
phenotypic heterogeneity in small cell lung cancer.
Akshata R. Udyavar, Megan Hoeksema, David J. Wooten,
Mukesh Bansal, Andrea Califano, Lourdes Estrada, Jonathan
Irish, Pierre Massion, Vito Quaranta.
19.
3762 The landscape of therapeutic targetable fusions.
Kosuke Yoshihara, Qianghu Wang, Wandaliz Torres-Garcia,
Siyuan Zheng, Rahulsimham Vegesna, Hoon Kim, Roel G.
Verhaak.
20.
3763 How stochastic single-cell fate decisions drive
population dynamics in oncogene-addicted cancer. Erin M.
Shockley, Leonard A. Harris, Carlos F. Lopez.
21.
3764 Modeling tumors in their environment. Juan
Delgado, James Yates.
22.
3765 Population pharmacodynamics: Mechanismbased modeling of receptor tyrosine kinase networks in
cancer. R. Joseph Bender, Feilim Mac Gabhann.
23.
3766 Identifying rational combination therapies with
rapamycin for the treatment of epithelial cancers. Moez
Dawood, Yiling Lu, Gordon Mills.
1
1
511
POSTER SESSION
Poster
:LJ[PVU
2
2
Cell Cycle Regulatory Pathways
Poster
Board
Poster
Board
Abstract
Number
1.
3767 Structural and functional characterization of
Skp2-containing complexes. Bailey C. Massa, Mathew P.
Martin, Martin E. Noble, Jane A. Endicott.
15.
3781 Effects of a novel microtubule inhibitor, AK301 on
Apc heterozygote colon cells. Avijeet Chopra, Amy
Anderson, Daniel Rosenberg, Charles Giardina.
2.
3768 Identification of new alternative lengthening of
telomeres (ALT)-positive cancer cell lines using the Ccircle assay. Andrei G. Malykh, Jonathan R. Doyle, Fang Tian,
Joyce H. Lee, Jeremy D. Henson, Roger R. Reddel.
16.
4.
3770 The spindle assembly checkpoint requires
phosphatase activity. Kristen Foss, Liguo Zhang, Alexander
C. Robeson, Sally Kornbluth.
3782 Extensive cancer cell proliferation despite
continuously shortening telomeres. Loretta M. Lau, Rebecca
A. Dagg, Hilda A. Pickett, Axel A. Neumann, Christine E.
Napier, Jeremy D. Henson, C. P. Reynolds, Jayne Murray,
Michelle Haber, Roger R. Reddel.
17.
3783 High resolution telomere FISH analysis of
testicular germ cell tumors reveals telomere anomalies
specific to cancer subtypes and demonstrates telomere
shortening as an early event in TGCT carcinogenesis.
Mohammed T. Shekhani, John Barber, Christopher M.
Heaphy, Leonardo Reis, Gunes Guner, Corinne Joshu, George
J. Netto, Alan K. Meeker.
18.
3784 Regulation of chromatin condensation by mitotic
checkpoint protein MAD2. Jayasha Shandilya, Stefan G.
Roberts.
19.
3785 Cdk1 coordinates telomere replication by
regulating the temporal recruitment of telomerase and the
CST complex. Veena Gopalakrishnan, Chang-Ching Liu, Lai
Fong Poon, Tingdong Yan, Shang Li.
21.
3786 Novel regulation of cyclin D1 stability and the
DNA damage response. Fadila Guessous, Jinho Heo, Naga
Vaddadi, Tarek Abbas.
5.
3771 Tank-binding kinase 1 associates with
centrosomes and regulates microtubule dynamics and
mitosis. Smitha R. Pillai, Jonathan Nguyen, Joseph Johnson,
Eric Haura, Domenico Coppola, Srikumar Chellappan.
6.
3772 Cyclin E as a prognostic marker and predictor of
response to neoadjuvant chemotherapy and adjuvant
hormonal therapy in patients with stage II-III breast
cancer. Cansu Karakas, Ashleigh Francis, Min Yi, Aysegul
Sahin, Khandan Keyomarsi, Kelly Hunt.
7.
3773 Plk1-mediated stabilization of 53BP1 suppresses
centrosome abnormal amplification. Hyungshin Yim, SangUk Woo, Sol-Bi Shin, Raymond L. Erikson.
8.
3774 Investigating the role of CDC25B in inhibition of
cellular proliferation. Caleb C. Lee, James Manfredi.
9.
3775 p53 is differentially regulated in proliferative and
invasive melanoma cells. Marie R. Webster, Subhasree Basu,
Amanpreet Kaur, Jessica Appleton, Maureen E. Murphy,
Ashani T. Weeraratna.
22.
3787 EphrinB1 is a novel microtubule associated
protein whose expression may predict sensitivity to
taxane. Paola D. Vermeer, Paul L. Colbert, Daniel W.
Vermeer, Bryant G. Wieking, John H. Lee.
10.
3776 HnRNP A1 regulates cell cycle and proliferation in
oral squamous cancer cells. Cheng Yu, Jihua Guo, Jun Jia,
Rong Jia, Mingwen Fan.
23.
11.
3777 In silico rendering of cell cycle progression of
erlotinib and gemcitabine treatment in pancreatic cancer
cells. Monica Lupi, Francesca Falcetta, Maurizio D’Incalci,
Paolo Ubezio.
3788 Contributions of novel nuclear nucleoside
transporters, HNP36 and HNP32, to DNA synthesis during
cell cycle. Natalia Grañe-Boladeras, W.J.Brad Hanna, Marçal
Pastor-Anglada, Imogen R. Coe.
24.
3789 BAL101553 (prodrug of BAL27862): the spindle
assembly checkpoint is required for anticancer activity.
Felix Bachmann, Karin Burger, Heidi Lane.
25.
3790 Defining the gain of function mutant PTEN. Jaimie
M. Gendron, Kristin Bredhold, Lindsey D. Mayo.
26.
3791 PGRMC1 expression is significantly up-regulated
in triple negative breast cancer in vivo with associated
activation of cyclin D1 target genes: Analysis of 1019
invasive breast cancers in the TCGA database. Elizabeth S.
McDonald, Chenbo Zeng, David A. Mankoff, Andrew
Kossenkov, Robert H. Mach.
26.
3792 SKP2 supports cell proliferation and is regulated
by Notch signaling in myoblasts and embryonal
rhabdomyosarcoma. Rossella Rota, Laura Adesso, Beatrice
Conti, Roberta Ciarapica, Lavinia Raimondi, Maria De Salvo,
Sonia Rodriguez, Nadia Carlesso, Lucio Miele, Franco
Locatelli.
12.
512
Abstract
Number
3778 Inhibition of NF-␬B translocation induces G0/G1
arrest and downregulates thymidylate synthase in
colorectal cancer. Ganji P. Nagaraju, Alese Olatunji, Sandhya
Gupta, Mamoru Shoji, Bassel F. El-Rayes.
13.
3779 Mutational analysis of MCPH1 C-terminal tandem
BRCT domain reveals residues essential for cell cycle
arrest. Volha A. Golubeva, Nicholas T. Woods, Alvaro N.
Monteiro.
14.
3780 Aven-mediated checkpoint kinase control
regulates proliferation and resistance to chemotherapy in
osteosarcoma cells. Zuzanna Baranski, Tijmen T. Booij,
Yvonne D. Jong, Jolieke V. Oosterwijk, Anne-Marie Cleton,
Leo Price, Bob V. Water, Judith V. Bovée, Pancras C.
Hogendoorn, Erik Danen.
POSTER SESSION
Cell Death Therapies 2
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
3793 Overexpression of A20 and activated-Src result in
TRAIL resistance in oral cancer cells. Satoshi Hino,
Tomohiro Hamakawa, Koh-ichi Nakashiro, Hiroyuki
Hamakawa.
2.
3794 Mechanistic studies on the anti-tumor effect of
jacaric acid on murine macrophage-like leukemia PU5-1.8
cells. Wai Nam Liu, Kwok Nam Leung.
3.
3795 Cardiac glycoside digitoxin and its
monosaccharide analogue MonoD inhibit NF␬B to induce
apoptotic cell death in ER+ MCF7 and triple-negative
MDAMB-468 breast cancer cells. Yogesh Kulkarni, Vivek
Kaushik, Raj Venkatadri, Clayton Wright, Juan Sebastian
Yakisich, George O’Doherty, Neelam Azad, Anand Iyer.
4.
3796 Synergistic effect of targeted combination
therapy in bladder cancer model using HSP90 inhibitors.
Raju Chelluri, Piyush K. Agarwal, Leonard M. Neckers, Armine
K. Smith.
3797 C6Ceramide as potential novel therapy for
pancreatic cancer. Apurva Limaye, Edith Mathiowitz, Wayne
D. Bowen, Harold Wanebo.
5.
6.
7.
8.
3798 KHF16, a new cycloartane triterpenoid isolated
from Cimicifuga foetida, suppresses triple-negative breast
cancer by inhibiting the NF-␬B signaling pathway. Yanjie
Kong, Ceshi Chen.
3799 Cordyceptin induces apoptosis through
repressing hTERT expression and inducing extranuclear
export of hTERT. Nam Deuk Kim, Gi-Young Kim, Yung Hyun
Choi.
3800 Targeting PI3K signaling pathway for therapeutic
enhancement of verteporfin-mediated photodynamic
therapy. Daniel E. Kraus, Pratheeba Palasuberniam, Bin
Chen.
Poster
Board
Abstract
Number
13.
3805 Effect of Imatinib mesylate in gastric cancer cell
progression. Jung Lim Kim, Bo Ram Kim, Yoo Jin Na, Seong
Hye Park, Yoon A Jeong, Sang Cheul Oh.
14.
3806 Inhibition of s-adenosylhomocysteine hydrolase
(SAHH) induces fas ligand gene expression and apoptotic
death in leukemic T lymphocytes. Harold B. Ghooray.
15.
3807 Capsazepine attenuates JAK/STAT3 signaling
pathway, proliferation, survival of prostate carcinoma
DU145 cells through induction of the protein tyrosine
phosphatase epsilon (PTP-epsilon). Jong Hyun Lee,
Chulwon Kim, Seok-Geun Lee, Junhee Lee, Jung-woo Lee,
Kwang Seok Ahn.
16.
3808 Targeting cholesterol for increased chemotherapy
efficacy. Ryuji Yamaguchi.
17.
3809 Synthesis of the novel prostamide, 15-deoxy⌬12,14 prostaglandin J2-ethanolamide, and
characterization of its anti-tumor activity. Daniel Ladin,
Colin Burns, Rukiyah T. Van Dross.
18.
3810 Leptomycin B sensitizes ovarian and endometrial
cancer cells to TRAIL-induced apoptosis. François Fabi,
France-Hélène Joncas, Sophie Parent, Valérie Leblanc, Eric
Asselin.
19.
3811 Arsenic trioxide induces cell cycle arrest,
apoptosis through interaction of DAXX and degradation of
MDM2 in acute leukemia cells. Sanjay Kumar, Paul B.
Tchounwou.
20.
3812 Induction of apoptosis by zeaxanthin in human
uveal melanoma cells. Sandeep Goswami, Arpna Srivastava,
Neelam Pushker, Mandeep S. Bajaj, Seema Kashyap, Jasbir
Kaur.
21.
3813 TRAIL and IAP inhibitor AZD5582 combination
treatment induces profound tumor cell death, which is
differentially dependent on the mitochondrial apoptotic
pathway. Radoslaw Polanski, John Vincent, Urszula
Polanska, Eric Tang.
9.
3801 Role of microRNAs in resveratrol induced breast
cancer cell death. Rajkumar Venkatadri, Clayton Wright,
Vivek Kaushik, Yogesh Kulkarni, Juan Sebastian Yakisich,
Anand Krishnan V. Iyer, Neelam Azad.
22.
10.
3802 Selective cytotoxicty and mechanism of
Myrothamnus flabellifolius, an edible medicinal plant, on
acute myeloid leukemia cells. Abeer Badiab, Jasjit Dhillon,
Fizal Nabbie, Bela Peethambaran.
3814 Metformin induces ER stress-dependent
apoptosis through miR-708-5p/NNAT pathway in prostate
cancer. Jian Yang, Juncheng Wei, Yushi Wu, Zhilin Wang,
Yuqi Guo, Xin Li.
23.
11.
3803 Transcriptome analysis of MCF7 breast cancer
cells with different expression profile of PAR-4 (prostate
apoptosis response-4) in the presence and absence of
docetaxel. Simone A. de Bessa Garcia, Ana C. Pavanelli,
Natalia C. Melo, Maria A. Nagai.
3815 Synergistic mechanisms of oncolytic reovirus with
bortezomib in overcoming therapy resistance of multiple
myeloma. Chandini M. Thirukkumaran, Zhong-Qiao Shi,
Joanne Luider, Karen Kopciuk, Paola Neri, Nizar Bahlis, Don
Morris.
24.
3816 The DNA methylation inhibitor induces telomere
dysfunction and apoptosis of leukemia cells that is
attenuated by telomerase over-expression. Bingnan Li,
Xiaolu Zhang, Nick D. Jonge, Magnus Björkholm, Dawei Xu.
25.
3817 Suicidal autophagy induced by immunotherapy
targeting folate receptor in ovarian cancer. Yun-Fei Wen,
Anil K. Sood.
12.
3804 Disruption of spindle microtubules by TTFields
result in abnormal chromosomes segregation and
subsequent caspase-dependent cell death. Tali Voloshin
Sela, Rosa S. Schneiderman, Moshe Giladi, Yaara Porat, Mijal
Munster, Roni Blat, Shay Sherbo, Zeev Bomzon, Noa Urman,
Eilon D. Kirson, Uri Weinberg, Yoram Palti.
3
3
513
POSTER SESSION
Poster
:LJ[PVU
4
4
Epigenetic Changes in Cancer 1
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
514
Abstract
Number
3818 Deregulated long non-coding RNAs in
hepatocellular carcinoma (HCC). Jing Shen, Abby B. Siegel,
Helen Remotti, Qiao Wang, Yueyue Shen, Regina M. Santella.
3819 A simple method for selectively isolating small
size circulating cell-free DNA. Milka A. Rodriguez, Amanda
Conroy, Wei wei Li.
3820 Ultrasensitive DNA methylation detection using
sputum and plasma for early detection of NSCLC. Chen
Chen, Alicia Hulbert, Alejandro Stark, Kristen Rodgers,
Beverly Lee, Malcolm Brock, James Herman.
3821 Understanding the functional role of retinoic acid
receptor beta2 in the development of oral cancer. Raghu
Radhakrishnan, Keith Hunter.
3822 SOX17 gene promoter methylation in high-grade
serous epithelial ovarian cancer. Lydia Giannopoulou, Issam
Chebouti, Kitty Pavlakis, Sabine Kasimir-Bauer, Evi S.
Lianidou.
3823 Dysregulation of bone morphogenetic protein 2
serves as a candidate molecular marker in human renal cell
carcinoma. Yozo Mitsui, Hiroshi Hirata, Naoko Arichi, Miho
Hiraki, Hiroaki Yasumono, Inik Chang, Shinichiro Fukuhara,
Soichiro Yamamura, Varahram Shahryari, Guoren Deng,
Sharanjot Saini, Shahana Majid, Yuichiro Tanaka, Rajvir
Dahiya, Hiroaki Shiina.
3824 Human pan-cancer variomes and their epigenetic
profiles: Extending beyond the coding region. John P.
Torcivia-Rodriguez, Raja Mazumder.
3825 Whole genome bisulfite sequencing from plasma
of patients with metastatic breast cancer identifies
putative biomarkers. Christophe Legendre, Gerald C.
Gooden, Kyle N. Johnson, Rae Anne Martinez, Bodour Salhia.
3826 A reversible DNA methylation signature precedes
sporadic mutations in the colorectal adenoma-dysplasiacancer development. Bela Molnar, Balint Peterfia, Alexandra
Kalmar, Barnabas Wichmann, Arpad V. Patai, Zsolt Tulassay.
3827 Histone methytransferase SMYD3 promotes
invasion in ovarian carcinoma spheroids. Tianjiao Lyu, Nan
Jia, Jieyu Wang, Robert C. Bast, Jan P. Baak, Keqin Hua,
Weiwei Feng.
3828 Genomic, transcriptome and epigenomic analysis
reveal new genetic pathways in penile carcinoma. Hellen
Kuasne, Fabio A. Marchi, Ariane F. Busso, Mateus C. BarrosFilho, Juan J. Muñoz, Hector Hernandez-Vargas, Cristovam
Scapulatempo-Neto, Eliney F. Faria, Ademar Lopes, Gustavo
C. Guimarães, Jose C. Trindade-Filho, Zdenko Herceg, Silvia
R. Rogatto.
3829 DNA methylation profile in papillary thyroid
cancer according to BRAF (V600E) mutation. Caroline M.
Beltrami, Mariana B. dos Reis, Mateus C. Barros-Filho, Fabio
A. Marchi, Hellen Kuasne, Srikant Ambatipudi, Zdenko
Herceg, Luiz P. Kowalski, Silvia R. Rogatto.
3830 Employing reduced representation bisulfite
sequencing for biomarker discovery in colorectal cancer.
Ryan E. Fecteau, Helen Moinova, Joseph E. Willis, Omar De la
Cruz, Thomas LaFramboise, Sanford D. Markowitz.
3831 Ash2L and p300 mediate histone H3 modifications
at EGFR during its developmental silencing and reexpression in gliomas. Parsa Erfani, Jessica Tome Garcia,
Peter Canoll, Nadejda Tsankova.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
Abstract
Number
3833 Detection of prostate cancer associated DNA
hypermethylation in diagnostic needle biopsies: Insight
into field effects and heterogeneity. Mia Moller, Siri H.
Strand, Christa Haldrup, Soren Hoyer, Michael Borre, Torben
Orntoft, Karina D. Sorensen.
3834 Validation of potential methylation biomarkers in
HPV-associated HNSCC. Kang Mei Chen, Josena K. Stephen,
George Divine, Dhananjay Chitale, Tamer Ghanem, Steven
Chang, Maria J. Worsham.
3835 DNA methylation levels in mononuclear DNA in
breast cancer from the New York site of the BCFR. HuiChen Wu, Qiao Wang, Regina M. Santella, Mary B. Terry.
3836 Identification of key survival-correlating
microRNAs and Piwi-interacting RNAs dysregulated in
head and neck squamous cell carcinoma. Jonjei Ku, Angela
E. Zou, Thomas K. Honda, Hao Zheng, Maarouf A. Saad, Vicky
Yu, Yinan Xuan, Pranav Singh, Mehran Rahimy, Selena Z. Kuo,
Weg M. Ongkeko, Jessica Wang-Rodriguez.
3837 Super-enhancers define breast cancer subclasses
and identify novel tumor cell vulnerabilities. Cindy Collins,
Mei Wei Chen, Matthew Eaton, David Orlando, Michael
McKeown, Christian Fritz, Eric Olson, Matthew Guenther.
3838 Functional crosstalk between histone deacetylase
5 (HDAC5) and lysine-specific demethylase 1 (LSD1) as a
novel therapeutic target in triple-negative breast cancer
cells. Chunyu Cao, Shauna Vasilatos, Steffi Oesterreich,
Nancy E. Davidson, Yi Huang.
3839 Investigation of epigenetic based inter-tumoral
heterogeneity identifies novel ZMIZ1 gene as a biomarker
of cancer patient survival in multiple tumor types.
Dimitrios Mathios, Taeyoung Hwang, Jillian Phallen, Chetan
Bettewgoda, Patrick Ha, Peter Burger, Henry Brem, Kerrie
McDonald, Chul-Kee Park, Michael Lim.
3840 A new prognostic marker: interferon regulatory
factor 6 in renal cell carcinoma. Chih-Yang Wei, Ying-Tzu
Chen, See-Tong Pang, Wen-Hui Weng.
3841 Effects of KEAP1 genetic and epigenetic silencing
in SCLC cell lines. Domenico Trombetta, Annamaria la Torre,
Angelo Sparaneo, Teresa Balsamo, Massimiliano Copetti,
Montse Sanchez-Cespedes, Evaristo Maiello, Paolo Graziano,
Vito M. Fazio, Lucia A. Muscarella.
3842 Expression analysis of SMYD5 in breast cancer
and normal tissues. João N. Matos Neto, Maíra D. Araujo,
Doralina D. Rabello, Andrea B. Motoyama, Diego M. Oliveira,
Fabio Pittella Silva.
3843 Nrf2-keap1 axis: uncovers molecular profile in
lung carcinoids. Angelo Sparaneo, Annamaria la Torre,
Domenico Trombetta, Leonarda Di Candia, Massimiliano
Copetti, Teresa Balsamo, Evaristo Maiello, Paolo Graziano,
Vito M. Fazio, Lucia A. Muscarella, Montse Sanchez-Cespedes.
3844 Targeting EZH2 in neuroendocrine prostate
cancer. Loredana Puca, Dong Gao, Myriam Kossai, Clarisse
Marotz, Juan Miguel Mosquera, Theresa Y. MacDonald, Kyung
Park, Rema Rao, Andrea Sboner, Yu Chen, Mark A. Rubin,
Himisha Beltran.
3845 Smarce1 facilitates survival of metastatic breast
cancer cells in circulation. Aarti Sethuraman, Meiyun Fan,
Martin M. Brown, Zhaohui Wu.
POSTER SESSION
Genomic Instability in Cancer Development and Treatment
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
12.
13.
14.
Abstract
Number
3846 DNA double-strand breaks in hypoxic but not in
normoxic conditions determine different radiosensitivity
of tumors. Kazuhiro Ogi, Mayumi Kawata, Takafumi
Nakagaki, Kousuke Takeda, Miyazaki Akihiro, Hiratsuka
Hiroyoshi.
3847 MSI status frequency, MSI-target genes mutation
profile and ancestry proportions in Brazilian colorectal
carcinoma patients. Gustavo N. Berardinelli, Cristovam
Scapulatempo-Neto, Ronilson Duraes, Denise PeixotoGuimaraes, Armando Melani, Rui Pereira, Rui Reis.
3848 Subtype-specific DNA damage dependent and
independent functions of damage repair proteins confer
chemo-resistance to leukemia. Sameer Salunkhe, Ekjot
Kaur, Ashwin Ramaswamy, Ketaki Patkar, Shilpee Dutt.
3849 Analysis of the mutation rate in T lymphoblastic
leukemia cell lines. David J. Araten, Erik Sherman, Aaron
Etra.
3850 Understanding PARP inhibitor sensitivity:
Analyses of the genetic interactions between specific
PARP inhibitor targets and DNA double-strand repair
pathways. Rajib Ghosh, Sanchita Roy, Francoise Dantzer,
Sonia Franco.
3851 Low educational level is associated with a
reduced DNA repair capacity and higher risk of breast
cancer. Luisa Morales, Manuel Bayona, Carmen Ortiz, Damian
Adams, Carolina Alvarez-Garriga, Jaime L. Matta.
3852 Prevalent loss of BRCA1 and BRCA2 expression in
African TNBC suggests their prominent role in sporadic
carcinogenesis. Evelyn M. Jiagge, Shukmei Wong, Gabriel
Lupu, Mu Qiao, Michele Dziubinski, Lisa A. Newman, John
Carpten, Max Wicha, Sofia D. Merajver.
3853 Unique pattern of copy number changes including
chromothripsis in pulmonary adenocarcinoma with EML4ALK fusion. Hironori Ninomiya, Motohiro Kato, Seishi Ogawa,
Noriko Motoi, Kengo Takeuchi, Tatsushi Kodama, Hiroshi
Sakamoto, Nobuya Ishii, Mutsunori Fujiwara, Yuichi Ishikawa.
3854 Inhibition of uracil DNA glycosylase (UDG)
sensitizes cancer cells to thymidylate synthase inhibitors.
Yan Yan, Allison Condie, Stanton Gerson.
3855 Clinical implications of FADD copy number gain/
amplification and high protein expression in areca-quidassociated oral cavity squamous cell carcinomas. ChiaJung Liao, Huei-Tzu Chien, Shiang-Fu Huang, I-How Chen,
Chun-Ta Liao, Hung-Ming Wang, Ling-Ling Hsieh.
3857 The polymorphisms of XRCC1 Arg194Trp and the
XRCC1Arg399Gln affect the clinical features and the
prognosis of MDS. Batchimeg Norjmaa, Takayuki Saitoh,
Tetsuhiro Kasamatsu, Yusuke Minato, Noriaki Sunaga,
Hirokazu Murakami.
3858 Genetic polymorphisms of DNA repair genes in
the origin and progression of chronic myeloid leukemia.
Manjula Gorre, Prajitha E. Mohandas, Sailaja Kagita, Anuradha
Cingeetham, Sugunakar Vuree, Sandhya Annamaneni,
Raghunadharao Digumarti, Vishnupriya Satti.
3859 Histone deacetylase inhibitors promote persistent
binding of PARP-1 to DNA double strand breaks in
chromatin, thus decreasing repair via non-homologous
end joining. Carine Robert, Pratik K. Nagaria, Ivana Gojo,
Feyruz Rassool.
Poster
Board
15.
16.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
Abstract
Number
3860 USP7 deubiquitinase promotes ubiquitindependent DNA damage signaling by stabilizing RNF168.
Qianzheng Zhu, Nidhi Sharma, Jingshan He, Gulzar Wani,
Altaf A. Wani.
3861 Prognostic impact of KRAS copy number
amplification in esophagogastric junction
adenocarcinoma. Kenichi Nakamura, Yu Imamura, Ryuma
Tokunaga, Mayuko Ohuchi, Yuki Kiyozumi, Keisuke Kosumi,
Daisuke Izumi, Kazuto Harada, Junji Kurashige, Ryuichi
Karashima, Yukiharu Hiyoshi, Shiro Iwagami, Yoshifumi Baba,
Yasuo Sakamoto, Yuji Miyamoto, Naoya Yoshida, Hiroshi
Saeki, Eiji Oki, Yoshihiko Maehara, Hideo Baba.
3863 Novel fusion transcripts in TLX1-deregulated
T-lineage acute lymphoblastic leukemia. Carmen Martinez.
3864 Aneuploidy predicts aggressiveness and poor
prognosis in endometrial cancer, and is reflected in a 9gene signature. Karen K. Mauland, Kanthida Kusonmano,
Elisabeth Wik, Mari K. Halle, Jone Trovik, Hans K. Haugland,
Anne M. Oyan, Helga B. Salvesen.
3865 Thymocyte selection-associated HMG box protein
(TOX) induces genomic instability in T-cell acute
lymphoblastic leukemia. Riadh Lobbardi, Jordan Pinder,
Barbara Martinez, Jessica Blackburn, Nouran Abdelfattah,
Debra Toiber, Manon De Waard, Esha Jain, Ruslan Sadreyev,
John Asara, Raul Mostoslavsky, Graham Dellaire, David M.
Langenau.
3866 Potential oncogenic function of Rad51C splice
variant in colorectal tumors. Arjun Kalvala, Li Gao, Kathleen
Dotts, Fernando Ochoa Cortes, Brittany Barnwell, Greg
Otterson, Miguel Villalona Calero, Wenrui Duan.
3867 DNA repair processes involved with the hypoxiaactivated prodrug TH-302: comparison to cisplatin and
temozolomide. Fanying Meng, Deepthi Bhupathi, Charles P.
Hart.
3868 Clinical significance of MRE11A/ATM/CHEK1 DNA
damage response genes in oral cavity squamous cell
carcinomas. Huei-Tzu Chien, Shiang-Fu Huang, I-How Chen,
Chun-Ta Liao, Hung-Ming Wang, Ling-Ling Hsieh.
3869 Exploration of mechanisms for chromothripsis by
irradiation. Maki Morishita, Tomoki Muramatsu, Shin Hayashi,
Momoki Hirai, Yumiko Suto, Teruaki Konishi, Keiji Moriyama,
Johji Inazawa.
3870 Telomeric non-coding RNA causes genome-wide
alteration of gene expression in cancer. Kyotaro Hirashima,
Hiroyuki Seimiya.
3871 Telomere length and cancer mortality and allcause mortality. Stig E. Bojesen, Børge G. Nordestgaard,
Line Rode.
3872 Genotoxicity of zinc oxid nanoparticles and the
activation of ATM-Chk2 DNA-damage-response pathway
are caused by zinc-ions. Julia Heim, Nawaz Muhammad
Tahir, Anke Kaltbeitzel, Volker Mailänder, Hartmut Lüddens,
Wolfgang Tremel, Jürgen Brieger.
3873 Improving the effectiveness of chemotherapy by
combining compounds that suppress drug-induced
microsatellite instability. Christina L. Chang, Li-Yan Huang,
Chang-Lin Wu, Jhih-Ying Chi.
Poster
:LJ[PVU
5
5
515
POSTER SESSION
Poster
:LJ[PVU
6
6
Genomics 2
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
516
Abstract
Number
3874 Mutational landscapes of oral tongue squamous cell carcinoma
reveal recurrent mutations in genes of therapeutic and prognostic relevance.
Andre L. Vettore, Kalpana Ramnarayanan, Choon Kiat Ong, Hui Sun Leong,
Weng Khong Lim, Ioana Cutcutache, John R. Mcpherson, Shenli Zhang,
Thankshayeni Skanthakumar, Daniel S. Tan, Bin Tean Teh, Steve Rozen, Patrick
Tan, N Gopalakrishna Iyer.
3875 Merkel cell carcinomas in Australia have distinct mutation
profiles reflecting viral etiology and UV-related DNA damage. Stephen Q.
Wong, Kelly Waldeck, Ismael A. Vergara, Jason Li, Richard Lupat, Timothy
Semple, Carleen Cullinane, Gisela Mir Arnau, Meredith Johnston, Annette Hogg,
Anthony T. Papenfuss, Stephen Fox, Grant McArthur, Anthony Gill, Rodney J.
Hicks, Richard W. Tothill.
3876 Actionable somatic mutations in head and neck cancer prognosis.
Omar L. Nelson, Evan S. Wu, Jong Y. Park, Joseph Zeitouni, Carmen R. Gomez,
Isildinha M. Reis, Wei Zhao, Eunkyung Lee, Hui-Yi Lin, Elizabeth J. Franzman,
Jason Savell, Thomas V. McCaffrey, W. Jarrard Goodwin, Jennifer J. Hu.
3877 The mutational burdens and evolutionary ages of early gastric
cancers are comparable to those of advanced gastric cancers. Seung-Hyun
Jung, Min Sung Kim, Youn Jin Choi, Shinn Young Kim, Sun Shin, Nam Jin Yoo,
Yeun-Jun Chung, Sug Hyung Lee.
3878 A model to assess clonal evolution of metastatic colorectal
cancer during chemotherapy utilizing patient derived xenografts. Julie G.
Grossman, Matthew Strand, Ha Dang, Brian White, Timothy Fleming, Peter
Goedegebuure, Albert Lockhart, Kian Lim, Timothy Ley, Richard Wilson, Elaine
Mardis, Christopher Maher, Ryan Fields.
3879 Patient preferences for disclosure of incidental genetic
information discovered through high-throughput sequencing. Melinda L.
Yushak, Sara Bouberhan, Gang Han, Lianne Epstein, Sarah Mougalian, Maysa
Abu-Khalaf, Gina Chung, Michael DiGiovanna, Tara Sanft, Lajos Pusztai, Erin
Hofstatter.
3880 Next generation sequencing for discovery of somatic mutations
and clonal relationships in platinum-resistant metastatic urothelial cancer.
Bishoy M. Faltas, Himisha Beltran, Kenneth Eng, Chantal Pauli, Brian Robinson,
Juan Miguel Mosquera, David Nanus, Scott T. Tagawa, Mark A. Rubin.
3881 In vivo and in vitro characterization of genomic diversity and
clonal evolution in glioblastoma. Ana C. deCarvalho, Hoon Kim, Laila Poisson,
Roel Verhaak, Tom Mikkelsen.
3882 Clinical exome and transcriptome sequencing for identification
of actionable cancer targets: A pilot study for children and young adults with
relapsed or refractory solid tumors. Wen-I Chang, Andrew S. Brohl, Rajesh
Patidar, Jack F. Shern, Jun S. Wei, Young K. Song, Hongling Liao, Jimmy Lin,
Sivasish Sindiri, Li Chen, Berkley Gryder, Marielle E. Yohe, Shile Zhang, Melinda
S. Merchant, Brigitte C. Widemann, Javed Khan.
3883 Clonal evolution of a lethal prostate cancer: Integrated whole
genome analysis case study. Heini M. Kallio, Matti Annala, Kati Kivinummi,
Gunilla Högnäs, Gunes Gundem, David C. Wedge, Peter Van Loo, Holger Heyn,
Michael R. Emmert-Buck, William B. Isaacs, Manel Esteller, Ultan McDermott,
Matti Nykter, Tapio Visakorpi, G. Steven Bova.
3884 Genome-wide analysis of somatic mutations shared by cooccurring ovarian high-grade serous carcinomas and serous tubal
intraepithelial carcinomas. Yan Song, Maude Ardin, Vincent Cahais, Christine
Carreira, Reetta Holmila, Stephanie Villar, Xavier Castells, Maxime Vallee,
Adriana Heguy, Pierre-Paul Bringuier, Qin Guo, Xun Zhang, Jiri Zavadil.
3885 Mutational landscape and copy number alterations of mucinous
breast carcinoma. Salvatore Piscuoglio, Charlotte Ng, Carey A. Eberle, Elena
Guerini-Rocco, Caterina Marchio, Odette Mariani, Anne Vincent-Salomon, Britta
Weigelt, Jorge S. Reis-Filho.
3886 Comparing the mutational landscape of African American and
Caucasian lung cancers. Joshua Campbell, Christopher Lathan, Lynette Sholl,
Matthew Ducar, Mikenah Vega, Ling Lin, Aaron Thorner, Nick Faris, Paul van
Hummelen, Raymond Osarogiagbon, Matthew Meyerson, Laura MacConaill.
3887 Genomic analysis identifies drug targetable pathways and
predicts immune infiltration in inflammatory breast cancer tumors. Diarmuid
Moran, Christopher A. Hamm, Kakuturu Rao, Patricia Bacon-Trusk, Karen Pry,
Victor Velculescu, Massimo Cristofanilli, Sarah S. Bacus.
3888 Molecular profiling of sequential biopsies in patients with
metastatic colorectal cancer identifies genomic alterations that evolve
during first-line therapy and could have therapeutic implications: A
prospective study to identify molecular mechanisms of clinical resistance
(QCROC-01: NCT00984048). Suzan McNamara, Ryan Morin, Mathilde Couëtoux
du Tertre, Rosemary McCloskey, Rebecca Johnston, Daniel Fornika, Benoit
Samson, Bernard Lespérance, Thierry Alcindor, Yoo-Joung Ko, Richard Dalfen,
Eve St-Hilaire, Lucas Sideris, Felix Couture, Hans Prenen, Sabine Tejpar, Ronald
Burkes, André Constantin, Errol Camlioglu, Adriana Aguilar, Adrian Gologan,
Benoit Têtu, Celia M. Greenwood, Cyrla Hoffert, Samia Qureshi, Zuanel Diaz,
Maud Marques, Micheal Witcher, Thérèse Gagnon-Kugler, Petr Kavan, Gerald
Batist.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
3889 Genetic heterogeneity and distinct driver mutations in
synchronous primary and metastatic breast cancers from therapy-naïve
patients. Charlotte K. Ng, Francois-Clement Bidard, Salvatore Piscuoglio,
Raymond S. Lim, Jean-Yves Pierga, Paul Cottu, Anne Vincent-Salomon, Agnes
Viale, Larry Norton, Brigitte Sigal, Britta Weigelt, Jorge S. Reis-Filho.
3890 Whole-genome mutational landscape of liver cancers displaying
biliary phenotype reveals hepatitis impact and molecular diversity. Hidewaki
Nakagawa, Akihiro Fujimoto, Mayuko Furuta, Kunihito Gotoh, Toru Nakamura,
Masakazu Yamamoto, Hiroki Yamaue, Kazuaki Chayama, Satoru Miyano,
Tatsuhiko Tsunoda.
3891 Tackling the obstacles facing the implementation of a molecular
screening program in an early drug development unit: The Jules Bordet
Institute Program for Molecular Profiling of Metastatic Lesions - feasibility
(Precision-f). Philippe G. Aftimos, Marion Maetens, Catherine Sibille, JeanFrançois Laes, Sylvain Brohée, Thierry Berghmans, Joseph Kerger, Alain
Hendlisz, Alexandre Irrthum, Olivier De Henau, Amélie Deleporte, Stylianos
Drisis, Denis Larsimont, Jalal Vakili, Christos Sotiriou, Martine Piccart, Ahmad
Awada.
3892 Somatic genetic profiling in pheochromocytomas and
paragangliomas. Lauren Fishbein, Sanika Khare, Bradley Wubbenhorst, Virginia
LiVolsi, Kathleen Montone, Douglas Fraker, Debbie L. Cohen, Katherine L.
Nathanson.
3893 Whole-exome sequencing analysis of primary central nervous
system lymphoma reveals recurrent MYD88 and PIM1 mutations. Motoo
Nagane, Kazutaka Fukumura, Toshihide Ueno, Jeunghun Lee, Yukiko ShishidoHara, Mitsuaki Shirahata, Kazuhiko Mishima, Koichi Ichimura, Akitake Mukasa,
Yoshitaka Narita, Ryo Nishikawa, Hiroyuki Mano.
3894 The importance of matched tumor and normal DNA for somatic
mutation discovery and clinical interpretation. Siân Jones, Mark Sausen,
Valsamo Anagnostou, Samuel V. Angiuoli, Bryan Chesnick, Kevin Galens, Maura
Kadan, Lisa Kann, Karli Lytle, Derek Murphy, Monica Nesselbush, Eniko Papp,
Sonya Parpart-Li, David Riley, Manish Shukla, Theresa Zhang, Luis A. Diaz, Victor
E. Velculescu.
3895 Genomic alterations modify ubiquitination pathways in
pulmonary carcinoid tumors. Michael K. Asiedu, Charles L. Thomas, Jie Dong,
Prasidda Khadka, Zhifu Sun, Farhad Kosari, Jin Jen, Julian Molina, George
Vasmatzis, Marie Christine Aubry, Ping Yang, Dennis Wigle.
3896 Recurrent TERT promoter mutations in primary central nervous
system lymphoma. Aurélie Bruno, Mailys Daniau, Karima Mokhtari, Amithys
Rahimian, Marc Polivka, Anne Jouvet, Clovis Adam, Dominique FigarellaBranger, Catherine Miquel, Sandrine Eimer, Caroline Houillier, Carole Soussain,
Agusti Alentorn, Khê Hoang-Xuan.
3897 High-throughput profiling of actionable mutations in salivary
duct carcinoma. Bo Mi Ku, Yeon-Hee Bae, Hyun Ae Jung, Jong-Mu Sun, Young
Hyeh Ko, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Keunchil Park,
Myung-Ju Ahn.
3898 Exome analysis of an exceptional responder uncovers an
activating GNAS mutation that may confer sensitivity to cytotoxic
chemotherapy. Jeff P. Bruce, Arnavaz Danesh, Neil Winegarden, Patrick Yau,
Carl Virtanen, Suzanne Kamel-Reid, Michael H. Roehrl, Anthony M. Joshua,
Jennifer Knox, Trevor J. Pugh.
3899 Integrating RNA/DNA analysis with a comprehensive cancer
panel to improve interpretations of stage four metastatic renal cell
carcinoma. Sean M. Boyle, Michael J. Clark, Elena Helman, Alexander S. Parker,
Thai Ho, Shujun Luo, Scott Kirk, Parin Sripakdeevong, Mirian Karbelashvili,
Deanna M. Church, Michael Snyder, John West, Rich Chen.
3900 Genomic landscape of human cancer reveals dysregulated TGF-␤
signaling with prognostic significance. Jian Chen, Jiun-Sheng Chen, Jianping
Zhang, Liem Phan, Nina M. Muñoz, Lior H Katz, YoungJin Gi, Vipin Kumar Menon,
Ji-Hyun Shin, Yun Seong Jeong, Wilma Jogunoori, Patrizia Farci, Kirti Shetty,
Xiaoping Su, Tej K Pandita, Jon White, Bibhuti Mishra, Fausto Zamboni, Xifeng
Wu, Asif Rashid, Shulin Li, Milind Javle, Mien-Chie Hung, Franklin Herlong, Marta
Davila, John Stroehlein, Kenna R Shaw, Xuemei Wang, Jeffrey S Morris, Rehan
Akbani, Lopa Mishra.
3901 Identification of novel tumor suppressor candidates and
characterizing their potential driver role in familial cholangiocarcinoma.
Stephanie Greer, Lincoln D. Nadauld, Billy Lau, Laura Miotke, Erik Hopmans,
Christina M. Wood, John M. Bell, Hanlee P. Ji.
3902 MSS HNPCC frequently contain CNVs in chromatin regulators.
WeiXiang Chen, Xia sheng, Jun Ding.
3903 Differential transcript expression in nasopharyngeal carcinoma
by cDNA microarray analysis. Timothy T.C. Yip, Dora L.W. Kwong, Roger K.C.
Ngan, Cadmon K.P. Lim, Wai-Wai Cheng, Victor W.S. Ma, Stephen C.K. Law,
Loretta Tse.
POSTER SESSION
Growth Factors and GTPases
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
3904 Rspondin-1 contributes to tumor cell
proliferation via Wnt signaling pathway. So Hyun Park, Sol
Kim, Min Yeong Choi, Jiwoon Park, Shinae Kang, Hak-Zoo
Kim.
2.
3905 DBNL is a pro-survival adaptor in ErbB2+ breast
cancer. Josephine F. Wixted, Matthew K. Robinson.
3.
3906 Annexin A1 overexpression preferentially
predicts poor prognosis of basal-like breast cancer
patients by activating m TOR-S6 signaling. Kazunoshin
Tachibana, Anjana Bhardwaj, Nivetha Ganesan, Kimal
Rajapakshe, Constance T. Albarracin, Preethi H. Gunaratn,
Cristian Coarfa, Isabelle Bedrosian.
Poster
Board
Abstract
Number
13.
3916 Oncogenic potential of FGF9 in lung cancer. Kota
Ishioka, Kenzo Sejima, Hiroyuki Yasuda, Junko Hamamoto,
Ahmed Hegab, Tetsuo Tani, Aoi Kuroda, Daisuke Arai, Keiko
Ohgino, Takashi Sato, Terai Hideki, Ichiro Kawada, Katsuhiko
Naoki, Yuichiro Hayashi, Tomoko Betsuyaku.
14.
3917 PDGF induces cell growth and glycolysis in colon
cancer. Romana Moench, Vinicius Kannen, Tanja Grimmig,
Christoph T. Germer, Martin Gasser, Ana Maria WaagaGasser.
15.
3918 Synergistic targeting of fibroblast growth factor
receptor and AKT pathways significantly inhibits prostate
cancer progression. Shu Feng, Michael Ittmann.
4.
3907 Differential effects of 1␣, 25-dihydroxyvitamin
D3 dose on keratinocyte proliferation and ⌬Np63␣
stabilization. Natasha T. Hill, Jin Zhang, Mary K. Leonard,
Miryoung Lee, Madhavi Kadakia.
16.
3919 Inhibition of HER2 and IGF2 in trastuzumabresistant HER2 positive JIMT1 cells decreases cell growth
and reduces activation of MAPK and AKT. Xousaen M. Helu,
Daisy DeLeon.
5.
3908 Periostin mediated TNF␣ and IL-17 induced
collagen deposition: Potential role in liver fibrosis.
Venkataswarup Tiriveedhi.
17.
3920 Identification of LASEP1 as a new serological and
prognostic biomarker and a therapeutic target for lung
cancer. Atsushi Takano, Yusuke Nakamura, Yataro Daigo.
6.
3909 Iron oxide nanoparticle-leptin receptor
antagonist: A novel targeted adjuvant therapy for triple
negative breast cancer. Tia L. Harmon, Adriana Harbuzariu,
Lily Yang, Ruben R. Gonzalez-Perez.
18.
3921 TGF␤ sensitizes hepatocellular carcinoma cells to
growth factors, preventing sorafenib-induced apoptosis.
Nathan Ungerleider, Chang Han, Tong Wu.
19.
7.
3910 Acetylation of ⌬Np63␣ by Tip60 affects its
stability. Andrew J. Stacy, Zachary J. Smith, Jin Zhang,
Madhavi Kadakia.
3922 Novel hepatocyte growth factor and macrophage
stimulating protein antagonists for the treatment of
castration-resistant prostate cancer. Brett Vanderwerff,
Kevin Church, Leen Kawas, Joseph Harding.
8.
3911 A positive feedback loop between TGF-␤ and SCF
mediates TGF-␤1 ligand overexpression in advanced
hepatocellular carcinoma. Pingyu Zhang, Andres Rojas,
Ying Wang, Nina M. Munoz, Lianchun Xiao, Jing Wang,
Gregory J. Gores, Mien-Chie Hung, Boris R. Blechacz.
20.
3923 A role for fibroblast growth factor receptors in
growth of atypical teratoid rhabdoid tumor cells and as
potential therapeutic targets. David O. Azorsa, Oliver B.
Pepper, Madhavi Chakravadhanula, David W. Lee, Justin J.
Montoya, Victor Ozols, Ratan Bhardwaj, Robert J. Arceci.
9.
3912 GDF2 promotes anoikis susceptibility in ovarian
and breast epithelia. Archana Varadaraj, Pratik Patel, Anne
Serrao, Tirthankar Bandyopadhyay, Nam Y. Lee, Amir Jazaeri,
Susan Murphy, Karthikeyan Mythreye.
21.
3924 A homogenous bioluminescent system for
measuring GTPase, GAP and GEF activities. Subhanjan
Mondal, Kevin Hsiao, Said A. Goueli.
22.
10.
3913 Fibroblast growth factor receptor 1 isoforms in
prostate cancer bone metastases. Estefania Labanca, Xinhai
Wan, Jun Yang, Matthew Iyer, Christopher Logothetis, Arul
Chinnaiyan, Nora Navone.
3925 Production and biochemical characterization of
farnesylated and methylated KRAS4b using engineered
baculovirus. Andrew G. Stephen, William K. Gillette, Carissa
Grose, Dominic Esposito.
23.
11.
3914 IGF-II causes translocation of estrogen receptor
beta to the mitochondria in triple negative breast cancer
cell lines. Chane’ O’Bannon-Joseph, Daisy D. DeLeon, Center
for Health Disparities and Molecular Medicine.
3926 RhoB expression is upregulated by androgen in
thyroid cancer cells. Anvita Gupta, Melanie Jones, Augustine
Moscatello, Edward Shin, Raj K. Tiwari, Jan Geliebter.
24.
3927 Structural and mechanistic insights into the roles
of RIAM in integrin signaling. Jinhua Wu.
25.
3928 Structural basis for the failure of the C1 domain of
RasGRP2 to bind phorbol ester. Agnes Czikora, Daniel J.
Lundberg, Nancy E. Lewin, Noemi Kedei, Peter M. Blumberg.
12.
3915 Inhibition of cdc2 is linked to PMA-induced cell
differentiation. Daria Vasilyeva, Pairat Dolinsky, Shashana
Fielder, Alice Nakasone, Gerhild Packert, Xiaotang Hu.
7
7
517
POSTER SESSION
Poster
:LJ[PVU
8
8
Identification of Genes and Pathways Involved in Cancer Pathogenesis
Poster
Board
1.
2.
3.
Abstract
Number
3929 Overexpression of ZNF703 may activate Akt1 in
NSCLC. NUR BUYRU, Burak Bakir, Onur Baykara, Kamil
Kaynak, Nejat Dalay.
3930 Targeted cancer gene sequencing identifies
potential causative novel candidate mutations among
Caucasian colon carcinogenesis. Hassan Ashktorab, Michael
Nickerson, Sudhir Varma, Pooneh Mokarram, fakhraddin
Naghibalhossaini, Lee Moore, Joseph Boland, Sara Bass,
Meredith Yeager, Wen-Yi Haung, Hassan Brim.
3931 Generation of tumorgraft models to characterize novel
tumor suppressor genes implicated in lung carcinogenesis. Carolina
Pereira, Pol Gimenez-Xavier, Gonzalo Gomez, Enric Condom, Alberto
Villanueva, David Pisano, Montse Sanchez Cespedes.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
518
3932 Using Sleeping Beauty transposon mutagenesis
to identify CRC driver genes. Zhubo Wei, Haruna Takeda,
Neal G. Copeland, Nancy A. Jenkins.
3933 The landscape and clonal architecture in lower
grade glioma. Hiromichi Suzuki, Kosuke Aoki, Kenichi Chiba,
Yusuke Sato, Yusuke Shiozawa, Yuichi Shiraishi, Atsushi
Niida, Teppei Shimamura, Masashi Sanada, Satoru Miyano,
Toshihiko Wakabayashi, Atsushi Natsume, Seishi Ogawa.
3934 Restoration of NOTCH signaling in head and neck
squamous cell carcinoma inhibits tumor growth and cell
migratory abilities. Shhyam Moorthy, Rami Saade, Curtis
Pickering, David Neskey, Noriaki Tanaka, Patrick ZweidlerMcKay, Mitchell Frederick, Jeffrey Myers.
3935 CDKN2A/p16 is inactivated by the combination of
inversion and translocation. Alexis L. Norris, Hirohiko
Kamiyama, Ralph H. Hruban, James R. Eshleman.
3936 Frequent gain-of-function CCR4 mutations in
adult T-cell leukemia/lymphoma (ATLL). Masao Nakagawa,
Roland Schmitz, Wenming Xiao, Carolyn K. Goldman,
Weihong Xu, Yandan Yang, Xin Yu, Thomas A. Waldmann,
Louis M. Staudt.
3937 Comparative genomic hybridization reveals
complex genomic changes in plasmacytoid urothelial
carcinoma. Sven Wach, Christina Ellmann, Robert Stoehr,
Katrin Weigelt, Peter J. Goebell, Frank Kunath, Helge
Taubert, Arndt Hartmann, Bernd Wullich, Bastian Keck.
3938 MafB and ETS2 potentiate Notch signaling in TALL. Kostandin Pajcini, Lanwei Xu, Curtis Lee, Sara Cherry,
Warren Pear.
3939 The genomic landscape of nasopharyngeal
carcinoma. DECHEN LIN, Xuan Meng, Masaharu Hazawa,
Yasunobu Nagata, Ana Maria Varela, Liang Xu, Yusuke Sato,
Li-Zhen Liu, Ling-Wen Ding, Arjun Sharma, Boon Cher Goh,
Soo Chin Lee, Bengt Fredrik Petersson, Feng Gang Yu, Paul
Macary, Min Zin Oo, Soh Ha Chan, Henry Yang, Seishi Ogawa,
H. Phillip Koeffler.
3940 Inactivation of the PARD3 gene is a recurrent
event in lung squamous cell carcinomas and affects STAT3
activity and tumor invasiveness. Ester Bonastre, Sara
Verdura, Ilse Zondervan, Federica Facchinetti, Sylvie
Lantuejoul, Maria Dolores Chiara, Juan Pablo Rodrigo, Julian
Carretero, David Sidransky, Alberto Villanueva, Enric
Condom, Agustin Vidal, Luca Roz, Elisabeth Brambilla, Suvi
Savola, Montse Sanchez-Cespedes.
3941 Recurrent IL4R mutations in primary mediastinal
large B cell lymphoma. Jay Gunawardana, Tessa Van Tol,
Katina Mak, David Twa, Elizabeth Chavez, Bruce Woolcock,
Robert Kridel, Anja Mottok, Shannon Healy, Adele Telenius,
Merrill Boyle, Susana Ben-Neriah, Stacy Hung, Christoffer
Hother, Randy Gascoyne, Christian Steidl.
3942 Oncogenic BRAF fusion induces MAPK-pathway
activation targeted by MEK inhibitor and
phosphatidylinositol 3-kinase inhibitor combination
treatment in mucosal melanoma. Han Sang Kim, Kang Won
Jang, Minkyu Jung, Soo Hee Kim, Tae-Min Kim, Byoung Chul
Cho.
Poster
Board
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
29.
30.
Abstract
Number
3943 Genetic abnormalites in hypoxia sensing regulators
cause human pheochromocytoma/paraganglioma and
plolycythemia syndrome. Chunzhang Yang, Herui Wang,
Karel Pacak, Zhengping Zhuang.
3944 High incidence of somatic BAP1 alterations in
sporadic malignant mesothelioma. Masaki Nasu, Sandra
Pastorino, Hugh Luk, Erin Flores, Francine Baumann, Amy
Powers, Shreya Kanodia, Giovanni Gaudino, Yu-an Zhang,
Adi Gazdar, Haining Yang, Harvey I. Pass, Mitsuru Emi,
Michele Carbone.
3945 PTEN loss is associated with aggressive behavior
and poor prognosis in Middle Eastern Triple Negative
Breast Cancer. Abdul K. Siraj, Shaham Beg, Sarita
Prabhakaran, Zeenath Jehan, Dahish Ajarim, Fouad Al-Dayel,
Asma Tulbah, Khawla Al-Kuraya.
3946 Secretory ANXA3 endows liver cancer cells with
tumorigenic and self-renewal abilities and promotes HCC
development. Man Tong, Stephanie Ma.
3947 BP1 protein, a transcription factor, is secreted by
breast cancer cells. Jinguen Rheey, Anna Yakovleva, KellieAnn Yamane, Patricia E. Berg.
3948 Identification of a new therapeutic target in
prostate cancer from siRNA screening in Docetaxelresistant cells. Marine Garrido, Nicolas J. Martin, Catherine
Gaudin, Elaine Del Nery, Jacques Camonis, Franck Perez,
Stéphanie Lerondel, Alain Le Pape, Karim Fizazi, Anne
Chauchereau.
3949 Whole exome sequencing of platinum-refractory
recurrent or metastatic squamous cell carcinoma of head
and neck (R/M-SCCHN) reveals a novel cisplatin
mutational signature and REV3L mutation as a molecular
predictor for dacomitinib, a pan-ErbB inhibitor. Byoung
Chul Cho, Han Sang Kim, Myung-Ju Ahn, Keon Uk Park, SeHoon Lee, Hwan Jung Yun, Huang Kie Kyon, Tae-Min Kim,
Patrick Tan.
3950 Impact of IDH1 mutation in the expression of lysyl
oxidase family members in astrocytomas. Roseli D. Silva,
Miyuki Uno, Suely K. Nagahashi Marie, Sueli M. Oba-Shinjo.
3951 Functional analysis of the 11q23.3 glioma
susceptibility locus. Rebekah Baskin, Nicholas Woods,
Gustavo Mendoza-Fandino, Peter Forsyth, Kathleen Egan,
Alvaro Monteiro.
3952 BRE: a genetic interactor of BRCA2. Kajal Biswas,
Suhwan Chang, Subha Philip, Shyam K. Sharan.
3953 HORMAD1 plays an important role in the HNSCC
carcinogenesis. Viviane Carlin, Dorival M. Rodrigues-Junior,
Thais P. Biassi, Bruno H. Nozima, Marcus V. Buri, Andre L.
Vettore.
3954 lincRNA-UFC1 facilitates cell proliferation and
tumor growth in hepatocellular carcinoma by upregulating
HuR/␤-catenin expression. LI LIU, Dehua Wu, Chuanhui
Cao.
3955 A primary cell-based assay to identify initiating
oncogenic events in neuroblastoma. Rachelle Olsen, Joel
Otero, Zhirong Yin, Jesus Garcia-Lopez, Kevin Freeman.
3957 Integrated molecular characterization of mast cell
leukemia reveals recurrent inactivation of the SETD2
tumor suppressor gene. Simona Soverini, Caterina De
Benedittis, Michela Rondoni, Manuela Mancini, Cristina
Papayannidis, Luca Zazzeroni, Viviana Guadagnuolo, Elisa
Zago, Francesca Griggio, Alberto Ferrarini, Marianna Garonzi,
Massimo Delledonne, Giorgina Specchia, Roberta Zanotti,
Omar Perbellini, Livio Pagano, Michele Cavo, Peter Valent,
Giovanni Martinelli.
3958 The phenotypic and signaling consequences of a
novel aberrantly spliced transcript of fibroblast growth
factor receptor 3 in hepatocellular carcinoma. Weihua Qiu,
Weiping Yang, Xiaoqian Jing, Bingrui Wang, Xinyu Liu, Ding
Ma, Helen Lin.
POSTER SESSION
MicroRNA Cancer Diagnostics and Therapeutics
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
3959 microRNA as a potential biomarker for hepatitis C
virus mediated end-stage liver disease progression. Ratna B.
Ray.
3960 The role and therapeutic potential of miRNAs in
colorectal liver metastasis. Smiti Snigdha Sahu, Sarah Nabinger,
Jiang Guanglong, Allison Bates, Sangbin Lee, Tanaka Hiromi,
Yunlong Liu, Janaiah Kota.
3961 Utility of mir-21 detection by rapid chromogenic
in-situ hybridization in the diagnosis of well and moderately
differentiated hepatocellular carcinoma. Ravindra Kolhe, Amyn
Rojiani, Ashis Mondal, Abhishek A. Mangaonkar.
3962 Preclinical evaluation of miR-195 as a therapeutic
agent in NSCLC. Xiaojie Yu, Zhenze Zhao, Xiuye Ma, Liqin Du,
Alexander Pertsemlidis.
3963 Antisense agents and RNA mimics for miR-17-5p
guide strand and miR-17-3p passenger strand differentiate
the strength of guide and passenger strand targets in PDCD4
and PTEN mRNA 3’UTRs in MDA-MB-231 triple negative breast
cancer cells. Yuan-Yuan Jin, Nicole L. Simone, Eric Wickstrom.
3964 How to fish a good micro-marker out from a
worthless lake: The case of cell-free miR-181a-5p and breast
cancer. Manuela Ferracin, Laura Lupini, Irene Salamon, Elena
Saccenti, Barabara Zagatti, Alessandra Mangolini, Maria Vittoria
Zanzi, Paolo Carcoforo, Andrea Rocchi, Giorgio Cavallesco,
Antonio Frassoldati, Alan B. Hollingsworth, Massimo Negrini.
3965 MicroRNA markers for the diagnosis of pancreatic
cancer. Motohiro Kojima, Hiroko Sudo, Junpei Kawauchi, Satoko
Takizawa, Satoshi Kondou, Hitoshi Nobumasa, Atsushi Ochiai.
3966 Platelets possess prostate cancer specific miRNAs:
Implications for a novel source of biomarkers. Brady Miller,
Mackenzie Adams, Harene Venghatakrishnan, Maria Giraldez,
Muneesh Tewari, Ganesh Palapattu, Alexander Zaslavsky.
3967 miRNA reference samples for interlaboratory study.
P. Scott Pine, Lynn R. Sorbara, Sudhir Srivastava, Marc Salit.
3968 Identification of microRNAs markers in patients with
oral squamous cell carcinomas for the presence of lymph
nodes metastasis. Fernando T. Zamunér, André L. Carvalho, Luiz
P. Kowalski, André L. Vettore.
3969 Hepatic microRNA as biomarker for detection of
hepatocellular carcinoma in high-risk chronic Hepatitis B
patients. Amit Ghosh, Alip Ghosh, Somenath Datta, Debanjali
Dasgupta, Soumyajit Das, Sukanta Ray, Subash Gupta, Simanti
Datta, Abhijit Chowdhury, Saroj K. Mohapatra, Soma Banerjee.
3970 Development of novel form of mimic microRNA for
lung cancer therapy. Shinichiro Ohno, Karen Itano, Yuichirou
Harada, Koutaro Asada, Keiki Oikawa, Mikie Kashiwazako,
Masakatsu Takanashi, Katsuko Sudo, Norihiko Ikeda, Masahiko
Kuroda.
3971 Genome-wide tissue-based microRNA signature in
healthy women predicting breast cancer risk. Cenny Taslim,
Daniel Y. Weng, Theodore M. Brasky, Ramona G. Dumitrescu, Kun
Huang, Bhaskar V. Kallakury, Shiva Krishnan, Adana A. Llanos,
Catalin Marian, Sallie S. Schneider, Scott L. Spear, Melissa A.
Troester, Jo L. Freudenheim, Susan Geyer, Peter G. Shields.
3972 MicroRNAs as potential therapeutic agents for AML:
Targeting the AML1-ETO Oncogene by pre-miR-520 and -373.
Patricia A. Toniolo, Patrick M. Pilarski, Christian Bach, James D.
Griffin, Sophia Adamia.
3973 Comparison of different highly sensitive miRNA
array platforms for the investigation of circulating cell-free
microRNAs in blood. Melanie Maierthaler, Eric Mennesson,
Katarina Cuk, Dharanija Madhavan, Manuela Zucknick, Isabelle
Fixe, Alexandra Foucher, Markus Wallwiener, Andreas
Schneeweiss, Nadia Normand, Barbara Burwinkel.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Abstract
Number
3974 A preclinical study for miR181b as therapeutic in
Eu-TCL1FL-tg mouse model for CLL. Antonella Bresin, Elisa
Callegari, Lucilla D’Abundo, Caterina Cattani, Cristian Bassi,
Barbara Zagatti, Maria Grazia Narducci, Elisabetta Caprini, Yuri
Pekarsky, Carlo Maria Croce, Silvia Sabbioni, Massimo Negrini,
Giandomenico Russo.
3975 Pharmacologic inhibition of the ⌬Np63/DGCR8 axis
as a novel therapeutic strategy for p53-deficient and mutant
tumors. Marco Napoli, Avinashnarayan Venkatanarayan, Payal
Raulji, Hussein A. Abbas, William Norton, Anil K. Sood, Gabriel
Lopez-Berestein, Kenneth Y. Tsai, Cristian Coarfa, Preethi H.
Gunaratne, Elsa R. Flores.
3976 Targeted delivery of a synthetic microRNA-based
mimic as an approach to cancer therapy. Glen Reid, Marissa
Williams, Michaela B. Kirschner, Nancy Mugridge, Jocelyn Weiss,
Himanshu Brahmbhatt, Jennifer MacDiarmid, Nico van Zandwijk.
3977 Evaluation of miR10b and miR9 expression in breast
cancer and correlations with distant metastases development.
Raffaela Barbano, Barbara Pasculli, Massimiliano Copetti, Andrea
Fontana, Michelina Coco, Lorenzo Vitulano, Maria Luana Poeta,
Francesca Picardo, Gianfranco Marangi, Roberto Murgo, Luigi
Ciuffreda, Vanna Maria Valori, Vanna Maria Valori, Maria Morritti,
Evaristo Maiello, Vito Michele Fazio, Paola Parrella.
3978 MicroRNA-378 exerts anti-fibrotic role by regulating
hedgehog signaling in murine liver fibrosis. Jeongeun Hyun,
Youngmi Jung.
3979 Urinary cell-free microRNAs as potential biomarkers
of urothelial carcinoma of the urinary bladder. Jaroslav
Juráček, Hana Mlčochová, Michal Staník, Barbora Peltanová,
Robert Iliev, Táňa Macháčková, Jitka Mlčochová, Renata Héžová,
Jan Doležel, Ondřej Slabý.
3980 Recurrence prediction model using microRNA
expression in hormone receptor positive and tamoxifen
treated breast cancer. Aeree Kim, Chungyeul Kim.
3981 Tamoxifen inhibited cell migration and increased
chemosensitivity by reversal of EMT in ER-negative breast
cancer cells. Xiujuan Qu, Qian Wang, Yan Wang, Ye Zhang, Yuee
Teng, Yunpeng Liu.
3982 Targeting of miRNA networks for prevention of
basal-like breast cancers. Anjana Bhardwaj, Kazunoshin
Tachibana, Nivetha Ganesan, Yinghong Pan, Kimal Rajapakshi,
Cristian Coarfa, Preethi H. Gunaratne, Isabelle Bedrosian.
3983 MicroRNAs and other small RNA molecules expressed
in metastatic and non-metastatic oral squamous cell
carcinoma. Patricia Severino, Liliane S. Oliveira, Flavia M.
Andreghetto, Natalia Torres, Otavio Curioni, Patricia M. Cury,
Tatiana N. Toporcov, Alexandre R. Paschoal, Alan M. Durham.
3984 Increasing microRNA-378 to enhance sensitivity of
EGFR inhibitor in colorectal cancer. Shih-Chun Bian, Wai-Hung
Leung, Yeu-Jye Pang, Yu-Wen Wu, Jing-Jung Chen, Wen-Hui
Weng.
3985 Characterization of plasma-derived exosomes in CLL
reveals a distinct microRNA signature and the BCR regulation
in exosome secretion. Yuh-Ying Yeh, Hatice G. Ozer, Amy M.
Lehman, Lianbo Yu, Amy J. Johnson, John C. Byrd.
3986 Introduction of PTEN pseudogene in murine breast
cancer upregulates PTEN, p53 and activating protein 2 gamma
and delays tumor growth. Synnøve Yndestad, Eilin Austreid, Kai
Ove Skaftnesmo, Per Eystein Lønning, Hans Petter Eikesdal.
3987 Exosomal microRNA in cell-free urine samples as a
source for liquid prostate cancer biopsy. Thorarinn Blondal,
Anni R. Thomsen, Jörg Krummheuer, Michael Borre, Jacob
Fredsøe, Christa Haldrup, Ditte Andreasen, Maria W. Teilum, Niels
Tolstrup, Karina D. Sørensen, Torben F. Ørntoft, Peter Mouritzen.
9
9
519
POSTER SESSION
Poster
:LJ[PVU
10
10
MicroRNA Profiling and Cancer
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
520
Abstract
Number
3988 MicroRNA expression associated with response
grade in gastric cancer patients’ tumors. Michelle M.
Barcelos Baldoni, Cláudia M. Coutinho Camillo, Renato D.
Puga, Maria Dirlei F. Begnami.
3989 MicroRNA-16 and microRNA-193b as serological
predictors for chemoradiation response in esophageal
squamous cell carcinoma patients. Nikki P. Lee, Kenneth K.
Lai, Kin Tak Chan, Daniel K. Tong, Simon Law.
3990 Identification of microRNAs from exosomes of
bulk and stem cells from prostate cancer by next
generation sequencing. Catherine A. Sanchez, Eliana
Andahur, Rodrigo Valenzuela, Enrique Castellon, Christian
Ramos, Juan Carlos Triviño.
3991 Standardization and optimization of circulating
microRNA serum profiling in patients with cancer. Dennis
Poel, Johannes Voortman, Rosanne van den Oord, Helen Gall,
Henk M. Verheul.
3992 Value of miRNA profiling in urine to predict
significant prostate cancer. Hans Krause, Hannes Cash, Liam
Stelzer, Kurt Miller, Carsten Kempkensteffen.
3993 MicroRNA analysis of aromatase inhibitorresistant breast cancer cells reveals upregulation of a
unique miRNA cluster on chromosome 14. Erin L. Hayes,
Jennifer Knapp, Joan Lewis-Wambi.
3994 Herpes virus microRNA expression and
significance in serous ovarian cancer. Deep Pandya, Marisa
Mariani, Mark McHugh, Mirko Andreoli, Steven Sieber,
Shiquan He, Candice Dowell-Martino, Paul Fiedler, Giovanni
Scambia, Cristiano Ferlini.
3995 Breast cancer molecular subtypes are reflected in
circulating microRNA profiles. Dezheng Huo, Wendy M.
Clayton, Toshio F. Yoshimatsu, Jianjun Chen, Olufunmilayo I.
Olopade.
3996 Integrated analysis of miRNA profiling and
bioinformatics reveals the potential key miRNAs in gastric
cancer. Xiaojing Zhang, Xianling Feng, Yin Peng, Mengting
Yang, Yong Huang, Xinmin Fan, Stephen J. Meltzer, Zhe Jin.
3997 Expression profiling of a panel of apoptosisassociated microRNAs in acute myeloid leukemia identifies
differentially expressed microRNAs that target epigenetic
modifiers. Eleftheria Hatzimichael, Aggeliki Dasoula, Maria
Igglezou, Andreas Katsenos, Ioannis Sainis, Isidore Rigoutsos,
Evangelos Briasoulis.
3998 miRNA associated with distal metastasis and local
recurrence after post-operative radiotherapy in high-risk
head and neck cancer. Lianghao Ding, Narasimha Kumar
Karanam, John S. Yordy, Uma Giri, Michael D. Story.
3999 MicroRNA expression links obesity and recurrence
in renal cell carcinoma. Xiang Shu, Michelle A. Hildebrandt,
Jian Gu, Nizar M. Tannir, Surena Matin, Jose A. Karam.
4000 The increase of oncogenic miRNA expression in
tongue carcinogenesis of a mouse model. YUYU KAO, ShuChun Lin, Kuo-Wei Chang.
4001 Array profiling identified upregulated miRNAs
and target genes and pathways in laryngeal squamous cell
carcinoma. Meng Lian, Xiaoqin Liu, Demin Han, Jugao Fang,
Zhong Chen.
4002 Alternations in microRNA expression profiles
during the pancreatic multistep carcinogenesis. Takahiro
Kishikawa, Motoyuki Otsuka, Takeshi Yoshikawa, Motoko
Ohno, Kazuhiko Koike.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
Abstract
Number
4003 Serum miRNAs associated with prostate cancer:
correlation to deregulated signaling pathways. Nicholas H.
Farina, Jon E. Ramsey, Areg Zingiryan, Steven Ades, Mark K.
Plante, Gary S. Stein, Janet L. Stein, Jane B. Lian, Scott D.
Perrapato.
4004 Prognostic value of miRNAs in breast cancer
varies with patient race and molecular subtype.
Balananda-Dhurjati K. Putcha, Trafina Jadhav, Michael P.
Behring, Sejong Bae, Andra R. Frost, Isam-Eldin Eltoum, Li
Chen, Heidi L. Weiss, William E. Grizzle, Upender Manne.
4005 microRNA profiles in metastatic versus nonmetastatic salivary mucoepidermoid carcinoma. Cláudia M.
Coutinho-Camillo, Renato D. Puga, Cibele P. Nagano, Yukie
Sato-Kuwabara, Felipe D. Costa, Clóvis A. Lopes Pinto, Luiz P.
Kowalski, Fernando A. Soares, Silvia V. Lourenço.
4006 MiRNA profiling in esophageal precancerous for
malignancy progression risk assessment. Josef Srovnal,
Ondrej Slaby, Jiri Ehrmann, Jan Gregar, Lenka Radova,
Katerina Staffova, Marian Hajduch.
4007 Integrative analysis of miRNAs classify two
distinct stages of epithelial cell differentiation in head and
neck squamous cell carcinoma (HNSCC). Yoon Ho Ko, Vonn
Walter, Michael Catalano, Xiaoying Yin, Patrick Kimes,
Xiaobei Xiao Xiao, David N. Hayes.
4008 MiRNA expression profiling reveals a prognostic
signature in malignant pleural mesothelioma. Anna Truini,
Simona Coco, Ernest Nadal, Carlo Genova, Maria Giovanna
Dal Bello, Irene Vanni, Angela Alama, David G. Beer,
Francesco Grossi.
4009 Comparative microRNA profiling of prostate
carcinomas with increasing tumor stage by deepsequencing. Elke Nolte, Martin Hart, Sven Wach, Jaroslaw
Szczyrba, Helge Taubert, Tilman Rau, Arndt Hartmann,
Friedrich A. Grässer, Bernd Wullich.
4010 Prognostic role of miRNAs in resectable nonsmall cell lung cancer. Sandra Gallach, Eloisa JantusLewintre, Silvia Calabuig-Fariariñas, Ana Blasco, Ricardo
Guijarro, Miguel Martorell, Carlos Camps.
4011 Tumor evolution inferred by patterns of miRNA
expression through the course of disease, therapy and
recurrence in breast cancer. Maya Dadiani, Noa Bossel,
Shani Paluch-Shimon, Gili Peri, Anya Pavlovski, Smadar
Kahana-Edwin, Nora Balint, Adi Yosepovich, Adi Zundelevich,
Einav Gal-Yam, Raanan Berger, Iris Barshack, Eytan Domany,
Bella Kaufman.
4012 miRNA profiling in breast carcinoma associated
fibroblasts. Patricia B. Rozenchan, Cristina V. de Carvalho,
Tatiana Bonetti, Manoel J. Girão, Ismael D. da Silva, M Mitzi
Brentani.
4013 A 5-microRNA signature for prediction of
prognosis and response to treatment in breast cancer.
Jing-Ye Hu, Jun Tang, Wei Yi, Rong Deng, Mei-Yin Zhang,
Guo-Liang Huang, Hui-Zhong Zhang, Jie-Hua He, X.F. S.
Zheng, Yibing Kang, Hui-Yun Wang.
4014 Whole-genome microRNA profiling identifies
prognostic serum biomarkers of esophageal
adenocarcinoma. Yongyue Wei, Li Su, David C. Christiani.
4015 miR-221 ans miR-222 expression in salivary gland
tumors. Renata Carolina F. Ianez, Cláudia Coutinho-Camillo,
Clóvis Pinto, Fernando Soares, Silvia Lourenço.
POSTER SESSION
Tumor Cell-Stromal and Cell-Cell Interactions
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
4016 c-MET associated with osteogenesis in multiple myeloma
patients by induction of MMP9 expression by HGF in BMSCs. Hyejoo
Park, Jeong In Oh, Kwang-Sung Ahn, Youngil Koh, Sung-Soo Yoon.
2.
4017 Matrix manipulation affects attachment and growth of
breast cancer cells in a bone-like microenvironment in vitro. Shelby J.
Foster, Donna M. Sosnoski, Andrea M. Mastro.
3.
4018
The role of c-MET/HGF signaling as a critical mediator of an
invasive and resistant phenotype in colorectal cancer. Conor A. Bradley,
Philip Dunne, Darragh McArt, Ken Arthur, Stephen McQuaid, Manuel SaltoTellez, Patrick Johnston, Sandra Van Schaeybroeck.
4.
4019 Examining mechanisms by which macrophages enhance
intravasation in breast cancer. Serena Chiang, Zhenni Zhou, Jeffrey E.
Segall.
5.
4020 Identifying the role of CRYBB2 in breast cancer tumor-tumor
and tumor-stromal interactions. Lynnelle Thorpe, Jasmine Young,
Melissa A. Troester, Jodie M. Fleming.
6.
4021 Cyclooxygenase-2 downregulation reduces activated
fibroblasts and modifies the extracellular matrix in MDA-MB-231 breast
cancer xenograft. Balaji Krishnamachary, Ioannis Stassinopoulos, Samata
M. Kakkad, Marie-France Penet, Desmond Jacob, Flonne Wildes, Yelena
Mironchik, Arvind Pathak, Meiyappan Solaiyappan, Zaver M. Bhujwalla.
Poster
Board
Abstract
Number
17.
4032 Functional analysis of exosomes derived from human
esophageal squamous cell carcinoma. Yasunori Matsumoto, Masayuki
Kano, Yasunori Akutsu, Takanori Nishimori, Naoyuki Hanari, Isamu
Hoshino, Kentaro Murakami, Takeshi Toyozumi, Hiroshi Suito, Masahiko
Takahashi, Nobufumi Sekino, Yoshihiro Nabeya, Hisahiro Matsubara.
18.
4033 Suppressive role of normal epithelium in pre-malignant to
malignant progression of Barrett’s esophagus. Laimonas Kelbauskas, Jia
Zeng, Aida Rezaie, Kristen Lee, Benjamin Ueberroth, Weimin Gao, Dmitry
Derkach, Colleen Ziegler, Thai Tran, Kimberly J. Bussey, Dean Smith, Roger
H. Johnson, Deirdre R. Meldrum.
19.
4034 Macrophage-dependent activation of a non-canonical
NOTCH-RhoA signaling pathway regulates tumor cell intravasation.
Jose Javier Bravo Cordero, Minna Roh-Johnson, Jeanine Pignatelli, Maja
Oktay, Louis Hodgson, John Condeelis.
20.
4035 Extracellular secreted Ref-1 triggers triple negative breast
cancer cells apoptosis. Yu Ran Lee, Ki Mo Kim, Hee Kyoung Joo, Byeong
Hwa Jeon, Sunga Choi.
21.
4036 Palmitoylated Ras-driven MAPK signaling, transformation
and tumorigenesis, but not tumor progression, are spatially regulated
by plasma membrane microdomains. James Michael, Jeremy G. Wurtzel,
Lawrence E. Goldfinger.
22.
4037 The pattern of extracellular vesicles secretion and their role
in head and neck squamous cell carcinoma. Fernanda S. Giudice, Bruna
R. Rodrigues, Tonielli C. Lacerda, Rodrigo T. Cartaxo, Antuani R.
Baptistella, Marcos V. S. Dias, Luiz P. Kowalski, Vilma R. Martins.
7.
4022 Fibroblast-derived PEDF inhibits tumor growth and
angiogenesis and is suppressed by TGF-␤ and PDGF. Nkechiyere G.
Nwani.
8.
4023 Notch3 signal activation promotes tumorigenesis in a mouse
model of peritoneal epithelial ovarian cancer. Jessica Price, Nathaniel
Jones, Jan Kitajewski.
23.
4024 Understanding the role of mitochondria in the progression
from normal fibroblasts to DCIS associated fibroblasts. Ying-Hui Ko,
Zhao Lin, Ubaldo E. Martinez Outschoorn.
4038 Role of the Rho-GTPase CDC42 in glioma migration. Hidehiro
Okura, Brian J. Golbourn, Amanda J. Luck, Christian A. Smith, James T.
Rutka.
24.
4039 Inhibition of Pak4 blocks growth of breast cancer cells.
Chetan K. Rane, William Senapedis, Erkan Baloglu, Sharon Shacham,
Audrey G. Minden.
25.
4026 Growth of monoclonal gammopathy of undetermined
significance (MGUS) in a 3-dimensional co-culture in vitro model. Brea
C. Lipe, Omar Aljitawi, Tara Lin, Joseph Fontes.
4040 Transcription factor Snail mediates EMT by altering vesicular
trafficking protein Rab25. Shreya Mitra, Lorenzo Federico, Tapashree
Roysarkar, Sendurai Mani, Gordon B. Mills.
26.
4027 Aggressive breast cancer associated fibroblasts
communicate with cancer cells via microRNAs and promote an
aggressive breast cancer phenotype. Sanket Shah, Zheng Ao, Philip
Miller, Ram Dattar, Marc Lippman, Dorraya El-Ashry.
4041 IQGAP1 in human acutae myelogenous leukemia. Deepak M.
Sahasrabudhe, Jeremy Bechelli, Fred P. Hagen, Mark Paris, Marlene Balys,
Mohammad Minhajuddin, Jane Liesveld.
27.
13.
4028 ARHI plays a critical role in ovarian cancer tumor dormancy
by inhibition of angiogenesis switch. Zhen Lu, Weiqun Mao, Yan Wang,
Douglas A. Levine, Robert C. Bast.
4042 Kruppel-like factor 5 promotes breast cancer proliferation,
migration and invasion partially through upregulating the transcription
of TNF␣-induced protein 2. Lin Jia, Rong Liu, Ceshi Chen.
28.
14.
4029 Accumulation of arachidonic acid-containing
phosphatidylinositol at the margin of colorectal cancer revealed by
imaging mass spectrometry. Takanori Hiraide, Takanori Sakaguchi, Koji
Ikegami, Yoshifumi Morita, Noritaka Masaki, Michihiko Waki, Eiji Sugiyama, Satoru
Shinriki, Makoto Takeda, Yasushi Shibasaki, Shinichiro Miyazaki, Atsushi Suzuki,
Hirotoshi Kikuchi, Mitsutoshi Setou, Hiroyuki Konno.
4043 A novel CXCR4 pathway is required for migration of
metastatic breast cancer cells. Jacqueline Freed, Corena V. Shaffer,
Catherine C. Moore.
29.
4044 R-ketorolac targets Cdc42 and Rac1 GTPases and alters
ovarian tumor cell behaviors critical for invasion and metastasis. Yuna
Guo, S. Ray Kenney, Larry A. Sklar, Tione Buranda, Tudor I. Oprea, Oleg
Ursu, Sarah F. Adams, Teresa Rutledge, Carolyn Muller, Lesley Lomo,
Laurie G. Hudson, Angela Wandinger-Ness.
30.
4045 MRAS and SHOC2 interact with SCRIB and coordinate ERK
pathway activation with polarity and tumorigenic growth. Lucy C.
Young, Nicole Hartig, Marta Munoz-Alegre, Juan A. Oses-Prieto, Sevi
Durdu, Sabine Bender, Vineetha Vijakumar, Matteo Vietri Rudan, Christina
Gewinner, Amit P. Jathoul, Rupinder Ghatrora, Mark L. Lythgoe, Alma L.
Burlingame, Pablo Rodriguez-Viciana.
9.
10.
11.
12.
4025
Exogenous HGF bypasses ErbB inhibition on tumor cell
viability in medulloblastoma cell lines. Walderik W. Zomerman, Sabine L.
Plasschaert, Sander H. Diks, Harm-Jan Lourens, Tiny Meeuwsen-de Boer,
Eelco W. Hoving, Wilfred F. den Dunnen, Eveline S. de Bont.
15.
4030 Interactions between co-cultured myoblasts and prostate
cancer cells kill myoblasts but promote cancer cell proliferation and
fusion: implications for cachexia and metastasis to skeletal muscle.
Berna Uygur, Evgenia Leikina, Leonid V. Chernomordik.
16.
4031 CDK4/6 inhibition amplifies IMiD killing of myeloma cells by
accelerating CRL4CRBN-dependent degradation of IKZF1 and IKZF3 in
opposition to MEIS2. Xiangao Huang, David Jayabalan, Maurizio Di
Liberto, Tomer M. Mark, Zhengming Chen, Adriana Rossi, Anna C. Schinzel,
William C. Hahn, Mohamad A. Hussein, Rubin Niesvizky, Selina ChenKiang.
11
11
521
POSTER SESSION
Immunology
Poster
:LJ[PVU
13
13
522
Adaptive Immunity and Immune Tolerance
Poster
Board
Abstract
Number
1.
4046 Interleukin-10 and programmed death-1
cooperate to regulate tumor antigen-specific CD8+ T cells
in melanoma patients. Zhaojun Sun, Julien Fourcade,
Ornella Pagliano, Joe-Marc Chauvin, Cindy Sander, John M.
Kirkwood, Hassane M. Zarour.
2.
4047 CD8+T cell-mediated tumor-specific induction of
the NKG2D ligands to trigger NKG2D-dependent tumor
cell death in vivo. Jiemiao Hu, Xueqing Xia, Eugenie S.
Kleinerman, Shulin Li.
3.
4048 HPV16 immunity induced by immune responses
to mutations in E6 and E7 proteins. Maria Agarwal, Ashley
Saint-Fleur, Jie Fu, Hyam Levitsky, Cornelia L. Trimble.
4.
4049 Neutrophil elastase induces post-transcriptional
increase of surface MHC class I expression on lung cancer
cells. Haley L. Peters, Satyendra C. Tripathi, Hiro Katayama,
Celine Kerros, Alex Perakis, Lisa S. St. John, Gheath AlAtrash, Samir Hanash, Jeffrey J. Molldrem.
5.
4050 Association of long term NK cell culture and
TIMP3 over-expression with NK cell reduced susceptibility
to leukemia and epithelial cancer cell induced damage.
Giuseppe Sconocchia, Roberto Arriga, Sara Caratelli, Giulia
Lanzilli, Andrea Coppola, Giulio C. Spagnoli, Adriano Venditti,
Sergio Amadori, Davide Lauro, Maria I. Del Principe, Luca
Maurillo, Francesco Buccisano, Barbara Capuani, Xinhui
Wang, Soldano Ferrone.
6.
4051 Protection from CTL mediated killing by iNOS
expression in a mouse model of melanoma. Douglas M.
Marvel, Dmitry Gabrilovich.
7.
4052 Location of oncogene expression within a
stratified squamous epithelium drives distinct B and CD4 T
cell crosstalk to dictate the tumor immune response.
Michael A. Podolsky, Carrie J. Oakes, Andrew Gunderson,
Kyle Breech, Adam B. Glick.
Poster
Board
Abstract
Number
10.
4055 Immune checkpoint protein expression is upregulated in tumor-bearing elderly mice. So Jung Lim,
Jeong Min Kim, Won Suk Lee, Woo Sun Kwon, Tae Soo Kim,
Kyu Hyun Park, Hyen Cheol Chung, Sun Young Rha.
11.
4056 Recognition of tumor cells by Dectin-1
orchestrates innate immune cells for anti-tumor
responses. Hiroaki IKUSHIMA, Tadatsugu TANIGUCHI.
12.
4057 Gender and the immune system in lung and liver
colonization of murine melanoma in a B16 metastatic
model. Janet L. Markman, Daiko Wakita, Timothy R. Crother,
Moshe Arditi.
13.
4058 Hypoxia-induced soluble CD137 in malignant cells
blocks CD137L-costimulation as an immune escape
mechanism. Sara Labiano, Asís Palazón, José I. Quetglas,
Elixabet Bolaños, Arantza Azpilicueta, Aizea MoralesKastresana, Alfonso Rodriguez, Maria Rodriguez-Ruiz,
Alfonso Gurpide, M A. Aznar, Maria Jure-Kunkel, Ignacio
Melero.
14.
4059 Crosstalk between CD8+ T and NK cells: finetuning of antitumor immune response. Roman V.
Uzhachenko, J S. Goodwin, Lino Costa, Alexander Terekhov,
Menaka C. Thounaojam, William H. Hofmeister, Anil Shanker.
15.
4060 Promoter methylation regulates interferon-␥
induced indoleamine 2,3-dioxygenase expression in breast
cancer. Satish Kumar R. Noonepalle, Eun Joon Lee, Maria
Ouzounova, Jaejik Kim, Jeong-Hyeon Choi, Austin Shull,
Lirong Pei, Ravindra Kolhe, Pei-Yin Hsu, Nagireddy Putluri,
Tim Hui-Ming Huang, Arun Sreekumar, Hasan Korkaya, David
Munn, Huidong Shi.
17.
4062 Role of CD137 signaling in immune evasion of
Hodgkin and Reed-Sternberg cells. Sakthi Rajendran,
Herbert Schwarz.
8.
4053 Misregulation of dicer miRNA processing
correlates with antigen presentation and survival in
colorectal cancer. Lena Sokol, Viktor H. Koelzer, Eva
Karamitopoulou, Alessandro Lugli, Inti Zlobec.
18.
4063 The oncogenic cell cycle-related kinase promotes
tumor immune escape via modulation of myeloid-derived
suppressor cells in hepatocellular carcinoma. Jingying
Zhou, Alfred S. Cheng, Zhiwei Chen.
9.
4054 Mast cells contribute to T cell tolerance against
prostate cancer- associated antigens favoring tumor
growth. Elena Jachetti, Alice Rigoni, Lucia Bongiovanni,
Claudio Tripodo, Mario P. Colombo.
19.
4064 Targeting the anti-tumor function of B cells in
non-small cell lung cancer patient tumors. Tullia C. Bruno,
Brandon L. Moore, Daniel J. Munson, Peggy Ebner, Jeffrey
Kern, Jill E. Slansky.
POSTER SESSION
Tumor Biology
Cancer Stem Cells 2
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
4065 Delineating the role of epithelial-mesenchymal
transition in the generation and maintenance of prostate
cancer stem cells. Anurag N. Paranjape, Rama
Soundararajan, Steven J. Werden, Robiya Joseph, Joseph H.
Taube, Neeraja Bhangre, Hui Liu, Jaime Rodriguez-Canales,
Ignacio I. Wistuba, Jeffrey T. Chang, Dean G. Tang, Nupam
Mahajan, Kiran Mahajan, Naoyuki Miura, Sendurai A. Mani.
3.
4067 Pluronic micelle-encapsulated Disulfiram targets
cancer stem-like cells and reverses pan-resistance in
acquired resistant breast cancer cell lines. EREBI P.
TAWARI, Peng Liu, Zhipeng Wang, Vinodh Kannappan,
Christopher Mcconville, Angel Armesilla, John Darling, Juan
Irache, Krassimira Yoncheva, Weiguang Wang, Petar Petrov.
4.
4068 In vivo analysis of the residual disease uncovers
early and late response of cytarabine-resistant cells in
human acute myeloid leukemia. Jean-Emmanuel Sarry.
5.
4069 Abolish cancer progenitor cells in a mouse model
of diabetes associated hepatocellular carcinoma. Yan Li,
Harshul Pandit, Xuanyi Li, Suping Li, Jingwen Zhang,
Guozhen Cui, Robert C. Martin.
6.
4070 Prolonged silencing of diacylglycerol
acyltransferase-1 induces a dedifferentiated phenotype in
human liver cells. Soyoung Chang, Pil Soo Sung, Jungsul
Lee, Junseong Park, Eui-Cheol Shin, Chulhee Choi.
7.
4071 Cancer stem cell-induced vascularization of skin
cancer tumors. Dan Grun, Gautam Adhikary, Richard Eckert.
8.
4072 Embryonic rest hypothesis of cancer
development revisited: functional gonadotropic hormone
receptors are expressed by normal and malignant
hematopoietic cells and functional erythropoietin receptor
is expressed by germline-derived tumors. Malwina
Suszynska, Katarzyna Mierzejewska, Agata PoniewierskaBaran, Ahmed Abdelbasit Ismail, Gabriela Schneider, Pranesh
Gunjal, Janina Ratajczak, Sham S. Kakar, Magda Kucia,
Mariusz Z. Ratajczak.
Poster
Board
9.
Abstract
Number
4073 Efficient conditional reprogramming of
differentiated prostate cancer cells back to a stem cell-like
state with increased aggressive properties. Josselin
Caradec, Amy A. Lubik, Mannan Nouri, Na Li, Manuel
Altimarano-Dimas, Jennifer Bishop, Mani Moniri, Down
Cochrane, Martin Gleave, Ralph Buttyan.
10.
4074 Cancer stem cells in tobacco-induced
carcinogenesis and subsequent effect of ATRA-based
chemoprevention. Subin Surendran, Christina Mimikos,
Amritha Suresh, Wesley L. Hicks, Mukund Seshadri, Moni A.
Kuriakose.
11.
4075 Proportion of breast cancer stem cells in fine
needle aspirates co-relates with the marker of metastatic
outcome TMEM. Maja H. Oktay, Eli Grunblatt, Sweta Roy,
Nathan Agi, Esther Adler, Joan G. Jones, John S. Condeelis,
Sumanta Goswami.
12.
4076 Combination of docetaxel with sulforaphane
synergistically inhibits triple negative breast cancer and
cancer stem cells. Joseph P. Burnett, Ronack B. Shah, Hayley
J. Paholak, Sean P. McDermott, Yasuhiro Tsume, Max W.
Wicha, Duxin Sun.
13.
4077 Adipose-derived stem cells after Paclitaxel
treatment demonstrate decreased function and
suppression of breast cancer cell viability. William M.
Harris, Michael Plastini, Telisha Ortiz, Nikolas Kappy,
Jefferson Benites, Shaohua Chang, A. L. Fahey, Martha S.
Matthews, Alexandre Hageboutros, Jeffrey P. Carpenter,
Spencer Brown, Ping Zhang.
14.
4078 Investigating chemoresistance mechanisms in
colorectal cancer stem cells. Stacey J. Butler, Lisa
Richardson, Nathan Farias, Brenda L. Coomber.
15.
4079 Role of HPVE6 oncoprotein in the maintenance of
cervical cancer stem cells. Bhudev C. Das, Abhishek Tyagi,
Kanchan Vishnoi, Sutapa Mahata, Gaurav Verma, Alok C.
Bharti.
15
15
523
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
16
16
Cancer Stem Cells and Epithelial-Mesenchymal Transition
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
10.
11.
12.
13.
14.
15.
524
Abstract
Number
4080 Role of nuclear PKM2 in transcriptional regulation
leading to EMT. Masamitsu Konno, Naohiro Nishida, Koichi
Kawamoto, Jun Koseki, Yuichiro Doki, Masaki Mori, Hideshi Ishii.
4081 Lung metastasis of ovarian cancer in a transplantable
MUC1.Tg mouse model is accompanied by upregulation of
MUC1 expression and epithelial to mesenchymal transition.
Lixin Zhang, Tianzhou Ma, Joan Brozick, Kathlene Babalola,
Raluca Budiu, George Tseng, Anda Vlad.
4082 PDLIM2 : A cytoskeleton to nuclear courier protein
for the IGF-1, Wnt and TGF beta signalling pathways in
Epithelial to Mesenchymal Transition. Milan Bustamante
Garrido, Orla T. Cox, Ciara O’Flanagan, Deirdre A. Buckley, Patrick
A. Kiely, Rosemary O’Connor.
4083 Deletion of the BMP receptor BMPR1a results in EMT
and impairs mammary gland tumor formation and metastasis.
Laura D. Hover, Michael W. Pickup, Agnieszka E. Gorska, Anna Chytil,
Yan Guo, Sergey V. Novitskiy, Harold L. Moses, Philip Owens.
4084 Transient SNAIL1 expression is necessary for metastatic
competence in breast cancer. Hung D. Tran, Michael Kim, Krishna
Luitel, Kun Zhang, Gregory Longmore, David D. Tran.
4085 Depletion of Runx1 promotes epithelial to
mesenchymal transition in breast cancer. Deli Hong, Jane Lian,
Janet Stein, Gary Stein.
4086 HMG Box Domain Containing 3 (HMGXB3), a novel
TGF␤-induced cancer gene that influences cancer stem cells
and metastasis in triple negative breast cancer. Sergio
Granados-Principal, Yi Liu, Cristian Rodriguez-Aguayo, Anil K.
Sood, Jenny C. Chang.
4087 Epithelial to mesenchymal transition in the
metastatic progression of gastroenteropancreatic
neuroendocrine tumors. Stephanie Mok, Zia A. Khan, Douglas
Quan, Christopher J. Howlett.
4089 CADM1 is a TWIST1 regulated suppressor of
melanoma invasion. Edward J. Hartsough, Michele B. Weiss,
Curtis H. Kugel, Sheera R. Rosenbaum, Andrew E. Aplin.
4090 Programmed cell death 4 (Pdcd4), a tumor
suppressor, inhibits Slug translation to regulate E-cadherin
expression. Qing Wang, Jiang Zhu, Shilong Han, Yan Zhang,
Hsin-Sheng Yang.
4091 Investigations on the role of epithelial-mesenchymal
transition and cancer stem cells in the response to therapy in
patient-derived ovarian carcinoma xenografts. Francesca Ricci,
Federica Guffanti, Maddalena Fratelli, Broggini Massimo,
Giovanna Damia.
4092 PDGFR␣ and ␤ play critical roles in mediating
Foxq1-driven breast cancer stemness and chemoresistance.
Fanyan Meng, Cecilia Speyer, Bin Zhang, Yongzhong Zhao, Wei
Chen, David Gorski, Fred R. Miller, Guojun Wu.
4093 Cadherin “switch” and ovarian cancer: Studies using
in vitro models and patient samples. Marina Rosso, Blanca
Majem, Laura Devis, Lara Lapyckyj, Marta Llauradó, Lucía Lanau,
María F. Abascal, María L. Matos, María J. Besso, Josep Castellví,
Jose L. Sanchez-Iglesias, Asunción Pérez-Benavente, Antonio
Gil-Moreno, Jaume Reventós, Marina Rigau, Mónica VazquezLevin.
4094 Neutralizing anti-TGF-␤ antibodies elicit
heterogeneous therapeutic responses in a panel of murine
metastatic breast cancer models. Yu-an Yang, Kathleen C.
Flanders, Binwu Tang, Miriam R. Anver, Anand Merchant, Howard
Yang, Maxwell Lee, Scott Lonning, John M. McPherson, Lalage M.
Wakefield.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
4095 Protein kinase C alpha (PKC␣) is a novel regulator of
FOXC2 and p120-catenin in triple negative and endocrine
resistant breast cancer. Thao N. Pham, Bethany Perez-White,
Debra A. Tonetti.
4096 Identification of EMT inhibitors using novel zebrafish
reporter lines. Laura Jimenez, Jindong Wang, Cicely Jette,
Steven L. Warner, David Bearss, Rodney Stewart.
4097 Small molecule mediated transcriptional
derepression of E-cadherin and inhibition of epithelial to
mesenchymal transition. Hanbing An, Natasha Deane, Sydney
Stoops, Jing Zhu, Alex Waterson, Andries Zijlstra, Craig Lindsley,
Robert D. Beauchamp.
4098 Musashi-2 (MSI2) activates TGF-␤ signaling and
inhibits CLDN7 to promote non-small cell lung cancer (NSCLC)
metastasis. Alexander Kudinov, Alexander Deneka Deneka,
Anna Nikonova, Young-Ho Ahn, Xin Liu Liu, Ilya Serebriiskii,
Andrey Efimov, Dong-Hua Yang, Mark Andrake Andrake,
Emmanuelle Nicolas, Brian Egleston, Hossein Borghaei, Don
Gibbons, Jonathan Kurie, Erica Golemis, Yanis Boumber.
4099 IGF1R signaling connects DNp73-mediated EMT with
the acquisition of cancer stem cell properties. Claudia Meier,
Marc Steder, Philip Hardtstock, Vijay Alla, Brigitte M. Pützer.
4100 Epithelial-mesenchymal transition and tumor
vascular remodeling in eribulin chemotherapy for breast
cancer. Kashiwagi Shinichiro, Yuka Asano, Yukie Tauchi,
Tokumoto Mao, Tamami Morisaki, Satoru Noda, Hidemi Kawajiri,
Tsutomu Takashima, Naoyoshi Onoda, Kosei Hirakawa.
4101 Clinical significance of ZEB1 mRNA levels in
peritoneal washing for gastric cancer. Norimitsu Yabusaki,
Suguru Yamada, Toshifumi Murai, Mitsuro Kanda, Daisuke
Kobayashi, Chie Tanaka, Tsutomu Fujii, Goro Nakayama, Hiroyuki
Sugimoto, Masahiko Koike, Shuji Nomoto, Michitaka Fujiwara,
Yasuhiro Kodera.
4102 The involvement of EMT in heparanase promoted
bone-metastasis in multiple myeloma. Qianying Pan, Juan Li,
Patrick D. Rowan, Timothy N. Trotter, Yang Yang.
4103 Knockdown of Notch1 inhibits tumor cell
proliferation, migration, and invasion and reverses epithelialmesenchymal transition (EMT) in nasopharyngeal carcinoma.
Huajiao Guo, Yi Lu, Chaonan Qian, Jian Zhang.
4104 LIX1L, an EMT-correlated gene that behaves as if it
inhibits the EMT. Mihoko Yamade, Yves Pommier, Kurt W. Kohn.
4105 Cathepsin L inhibition reverts epithelial
mesenchymal transition in prostate and breast cancer cells.
Liza J. Burton, Bethany Smith, Manu Platt, Valerie Marah.
4106 Lyn kinase promotes metastasis through EMT in
cancers. Daksh Thaper, Sepideh Vahid, Ka Mun Nip, Kirsi Ketola,
Jennifer Bishop, Amina Zoubeidi.
4107 CCR9/CCL25 mediates epithelial-mesenchymal
transition in prostate cancer. Patrick P. Carriere, Hina Mir,
Neeraj Kapur, Rajesh Singh, Guru Sonpavde, James W. Lillard,
Shailesh Singh.
4108 NKX6.1 suppresses cancer invasion and epithelialmesenchymal transition in cervical cancer. Hsin-Jung Li, PeiNing Yu, Yu-Lueng Shih, Ya-Wen Lin.
4109 Clonal evolution of metastatic colorectal cancer. Ha
X. Dang, Julie Grossman, Brian S. White, Matthew Strand, David
E. Larson, Jason Walker, Elizabeth Pittman, Timothy Fleming,
Peter S. Goedegebuure, Robert S. Fulton, Christopher A. Miller,
Malachi Griffith, Kian H. Lim, Timothy J. Ley, Richard K. Wilson,
Elaine R. Mardis, A.Craig Lockhart, Ryan C. Fields, Christopher A.
Maher.
POSTER SESSION
Tumor Biology
Clonal Evolution and Antimetastatic Therapies
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
4110 Inhibition of angiopoietin 1/2 and c-MET impairs
metastatic potential in a patient derived xenograft of renal
carcinoma. Ashley Orillion, Remi Adelaiye-Ogala, Li Shen,
Eric Ciamporcero, Sheng Yu Ku, Swathi Ramakrishnan, May
Elbanna, Sreenivasulu Chintala, Roberto Pili.
4111 The salt inducible kinase 2 (SIK2) links lipid
metabolism to survival of ovarian cancer metastasis.
Fabrizio Miranda, Shujuan Liu, Sandra Herrero-Gonzalez,
David Mannion, Stefan Knapp, Ahmed A. Ahmed.
4112 Mechanisms of transendothelial migration by
invasive breast carcinoma cells from patients. Jeanine
Pignatelli, Joan Jones, Xiaoming Chen, Bryan Smith, Daniel
Flynn, John Condeelis, Maja Oktay.
4113 Characterization of a novel TIMP-2 deficient
mouse model of experimental lung metastasis. Sarvesh
Kumar.
4114 Chemopreventive and chemotherapeutic effect of
Withaferin-A on in vivo models of prostate cancer. Suman
Suman, Trinath P. Das, Murali K. Ankem, Chendil Damodaran.
4115 BNC420 is a novel VEGFR3 selective inhibitor,
which unlike the pan-VEGFR inhibitor Sunitinib,
suppresses lymphatic metastasis in a model of metastatic
melanoma. Annabell Leske, Tina Lavranos, Donna
Beaumont, Chloe Brown, Darham Paul, Daniel Inglis, Michaela
Scherer, Andrew Harvey, Gabriel Kremmidiotis.
4116 A small-molecule antagonist of CX3CR1 impairs
homing and colonization of breast cancer cells in the
skeleton. Fei Shen, Yun Zhang, Danielle Jernigan, Jie Yan,
Fernando Garcia, Olimpia Meucci, Joseph Salvino, Alessandro
Fatatis.
4117 Syk is a candidate kinase target for the treatment
of advanced prostate cancer. Erik Danen.
4118 Near infrared photoimmunotherapy for lung
metastases. Kazuhide Sato, Tadanobu Nagaya, Peter L.
Choyke, Hisataka Kobayashi.
4119 Tyrosine phosphorylation of MACC1 is essential
and druggable for colorectal cancer metastasis restriction.
Dennis Kobelt, Gunnar Dittmar, Claudia Fleuter, Janice Smith,
Mathias Dahlmann, Rebekka Migotti, Peter M. Schlag, Ulrike
S. Stein.
4120 Tasquinimod inhibits local invasion and
metastases in two preclinical models of renal cell
carcinoma. Li Shen, Valerie Pierron, Anne-Laure Bauchet,
Jessica Nakhle, Ashley Orillion, Remi Adelaiye, Eric
Ciamporcero, Florence Meyer-Losic, Helena Eriksson, Nathalie
Lassau, Ingrid Leguerney, Fabien Schmidlin, Anders Olsson,
Roberto Pili.
4121 Autophagy influences the development of the
pre-metastatic niche. Rebecca A. Barnard, Daniel Regan,
Ryan J. Hansen, Paola Maycotte, Andrew Thorburn, Daniel L.
Gustafson.
4122 C-Met inhibition sensitivity in vitro: Autocrine vs.
paracrine activation of the c-Met pathway. Veronica
Hughes, Dietmar W. Siemann.
4123 Simvastatin prevents triple-negative breast
cancer metastasis though regulation of FoxO3a. Adam R.
Wolfe, Bisrat Debeb, Lara Landry, Xuelin Huang, Wendy
Woodward, Francois Bertucci.
4124 Potent anti-tumor and metastatic breast cancer
efficacy of bevacizumab with CRLX101, an investigational
chemotherapy nanoparticle-drug conjugate that
secondarily suppresses HIF-1␣. Elizabeth Pham, Christina
R. Lee, Ping Xu, Shan Man, Melissa Yin, F. Stuart Foster,
Christian G. Peters, Douglas Lazarus, Scott Eliasof, Robert S.
Kerbel.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
4125 SSA, a novel sulindac derivative, inhibits breast
cancer cell invasion and migration. Bin Yi, Xingling Feng,
Ruixia Ma, Xiaoguo Zhang, Hong Chang, Hongyou Zhao,
Ziping Liang, Xi Chen, Xiuhua Hu, Gary Piazza, Yaguang Xi.
4126 CSF-1R inhibition blocks rhabdomyoscarcoma
metastasis by polarizing macrophage differentiation.
Justin Evans, Amber Giles, Caitlin Reid, Rosandra Kaplan.
4127 Bolus high-dose neoadjuvant sunitinib treatment
overcomes potential for rebound growth during presurgical treatment breaks. Michalis Mastri, Amanda Tracz, Li
Shen, Roberto Pili, John M. Ebos.
4128 Extensive morphological heterogeneity of
circulating and selected high metastatic variants and
differential chemosensitivity of human prostate cancer in
mouse models. Lei Zhang, Chengyu Wu, Robert. M Hoffman.
4129 Chloroquine and romidepsin: combination
therapy for treatment of breast cancer metastases. Dong
Soon Choi, Jenny C. Chang.
4130 Dual targeting of VEGF and endoglin inhibits
tumor angiogenesis and metastatic spread. Madelon
Paauwe, Renier C. Heijkants, Lotte H. Oudt, Gabi W. van Pelt,
Cornelis F. Sier, Charles P. Theuer, Lukas J. Hawinkels.
4131 MEK inhibitor diminishes nasopharyngeal
carcinoma (NPC) cell growth and NPC-induced
osteoclastogenesis via modulating CCL2 and CXCL16
expression. Yu Zhu, Qiong Song, Yi Lu.
4132 Anti-tumor and anti-metastatic effect of sunitinib
in a patient derived metastatic clear cell renal cell
carcinoma xenograft model. Remi M. Adelaiye-Ogala, Li
Shen, Sreenivasulu Chintala, Eric Ciamporcero, Ashley
Orillion, May Elbanna, Shengyu Ku, Kiersten Marie Miles,
Bryan Gillard, Michael Buck, Roberto Pili.
4133 ODM-203, a novel, selective and balanced FGFR
and VEGFR inhibitor with strong activity on primary and
metastatic tumor growth in FGFR-dependent and
angiogenic cancer models. Tim Holmström, Anu Moilanen,
Mari Björkman, Tero Linnanen, Gerd Wohlfahrt, Stefan
Karlsson, Riikka Oksala, Timo Korjamo, Susanta Samajdar,
Srinivasan Rajagopalan, Shekar Chelur, Kishore Narayan,
Raghuveer Ramachandra, Thomas Anthony, Samiulla DS,
Murali Ramachandra, Pekka Kallio.
4134 MM-302 is more effective than PEGylated
liposomal doxorubicin (PLD) at reducing pulmonary
metastatic burden in breast cancer models expressing
intermediate levels of HER2. Nancy Dumont, Elena Geretti,
Shannon Curtis Leonard, Christopher Espelin, Daniel Gaddy,
Bart Hendriks, Ulrik Nielsen, Thomas Wickham.
4135 A polyclonal origin for pancreatic cancer
metastases. Ravikanth Maddipati, Ben Z. Stanger.
4136 Mutational analysis of paired primary and relapse
diffuse large B-cell lymphoma. Darius Juskevicius, Valeria
Perrina, Luca Quagliatta, Christian Ruiz, Stephan Dirnhofer,
Alexandar Tzankov.
4137 Clonal evolution defines the natural history of
metastatic pancreatic cancer. Alvin P. Makohon-Moore,
Ming Zhang, Johannes G. Reiter, Ivana Bozic, Fay Wong,
Yuchen Jiao, Krishnendu Chatterjee, Martin Nowak, Nickolas
Papadopoulos, Bert Vogelstein, Kenneth W. Kinzler, Christine
A. Iacobuzio-Donahue.
4138 Integrating SNPs, epigenetics and transcriptomics
to better understand the inherited predisposition to breast
cancer metastasis. Anjali Shukla, Ling Bai, Howard Yang,
Anthony Doran, Ying Hu, Thomas Geiger, Maxwell Lee,
Thomas Keane, Kent W. Hunter.
4139 Role of Akt2 in cell survival and metastasis of
colorectal cancer (CRC) cells. Ekta Agarwal.
17
17
525
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
18
18
Extrinsic Modulators of Motility and Invasion
Poster
Board
1.
4140 Role of nitric oxide in invasiveness of tumor cells
irradiated with carbon-ion beams. Mayumi Fujita, Kaori
Imadome, Yoshimi Shoji, Robert Cheng, Aparna H.
Kesarwala, David A. Wink, Takashi Imai.
2.
4141 Hypoxia-induced transition from collective to
amoeboid single cell dissemination in epithelial cancer
cells. Steffi Lehmann, Veronika A. te Boekhorst, Julia
Odenthal, Liying Jiang, Sjoerd van Helvert, Peter Friedl.
3.
4.
526
Abstract
Number
4142 A role for apolipoprotein E in invasion in oral
squamous cell carcinoma. Sangeeta K. Jayakar, Olivier D.
Loudig, Margaret Brandwein-Gensler, Ryung Kim, Thomas J.
Ow, Michael B. Prystowsky, Geoffrey Childs, Jeffrey E. Segall,
Thomas J. Belbin.
4143 Discrete clones cooperate to promote tumor
progression through a non-cell-autonomous mechanism in
intestinal cancers. Alyssa A. Leystra, Amanda M. Wisinger,
Christopher D. Zahm, Kristina A. Matkowskyj, Chelsie K.
Sievers, Alex Schwartz, Dawn M. Albrecht, Linda Clipson,
Dustin A. Deming, Michael A. Newton, Richard B. Halberg.
5.
4144 Extracellular nucleotides and purinergic signaling
as novel, underappreciated, pro-metastatic factors for
human lung cancer cells. Gabriela Schneider, Talita Glaser,
Ahmed Abdelbaset Ismail, Henning Ulrich, Mariusz Z.
Ratajczak.
6.
4145 Brain-derived endothelial cells stimulate
migration of different human, mouse, and rat glioma cell
lines in vivo and in vitro. Viveka N. Yadav, Gregory J. Baker,
Samanthi Narayanan, Maria G. Castro, Pedro R. Lowenstein.
7.
4146 Overexpression of C5a receptor becomes risk
factor in gastric cancer. Takayoshi Kaida, Hidetoshi Nitta,
Kota Arima, Hideaki Takeyama, Takaaki Higashi, Katunobu
Taki, Hiromitsu Hayashi, Daisuke Hashimoto, Akira
Chikamoto, Takatoshi Ishiko, Toru Beppu, Hideo Baba.
8.
4147 Synergistic effect of combined EGFR and Src
inhibitor in colon cancer cell migration. Yi-Che Wu, WanChen Wei, Wei-Ting Chao.
Poster
Board
Abstract
Number
9.
4148 Tankyrase inhibition impairs directional
migration and invasion of lung cancer cells by affecting
microtubule dynamics and polarity signals. Barbara Lupo,
Jorge Vialard, Andrea Bertotti, Letizia Lanzetti, Livio
Trusolino.
10.
4149 Epidermal growth factor-induced
cyclooxygenase-2 enhances head and neck squamous cell
carcinoma metastasis through fibronectin up-regulation.
Jinn-Yuan Hsu, Kwang-Yu Chang, Shang-Hung Chen, ChungTa Lee, Sheng-Tsung Chang, Hung-Chi Cheng, Wen-Chang
Chang, Ben-Kuen Chen.
11.
4150 TNF␣ and TGF␤1 secreted by macrophages
enhance breast cancer cell migration dynamics via the
induction of NF-␬B dependent MMP-1 expression. Ran Li,
Tara Lee, Roger D. Kamm.
12.
4151 Interleukin 17 promotes tumor progression in oral
squamous cell carcinoma. Avadhoot Avadhani, Trudy Milne,
Gregory Seymour, Alison Rich.
13.
4152 NKCC1 regulates migration of glioblastoma tumor
initiating cells by interacting with the actin cytoskeleton.
Paula V. Schiapparelli, Roxana Magaña-Maldonado, Susan
Hamilla, Eric Goulin Lippi Fernandes, Sara Ganaha, ChuanHsiang Huang, Hugo Guerrero-Cazares, Helim ArandaEspinoza, Peter N. Devreotes, Alfredo Quiñones-Hinojosa.
14.
4153 Investigating the role of Fn14 in EGFRvIII-driven
glioblastoma. Alison Roos, Zachary Mayo, Michael Pineda,
Jeffery A. Winkles, Michael E. Berens, Nhan L. Tran.
15.
4154 Large oncosomes derived from the aggressive
prostate cancer sub-line, DU145R80, can modify the
biological behavior of the parental DU145 cells. Chiara
Ciardiello, Valentina R. Minciacchi, Mariana Reis-Sobreiro,
Maria R. Milone, Biagio Pucci, Rita Lombardi, Francesca
Bruzzese, Dolores Di Vizio, Alfredo Budillon.
16.
4155 Interstitial fluid flow-induced hepatocellular
carcinoma cell invasion requires MEK/ERK signaling. Arpit
D. Shah, Michael Bouchard, Adrian C. Shieh.
POSTER SESSION
Tumor Biology
Molecular Mechanisms of Angiogenesis
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
4156 Immunohistochemical study of microvasculature
in penile carcinoma, and its relationship to infection with
the human papillomavirus. Bruno Vilela, Antonio Hugo
Campos, Fernando A. Soares, Rafael M. Rocha, Isabela C.
Werneck, Stenio Zequi, Jose Vassallo.
4157 Heterogeneity of vascular endothelial growth
factor receptors 1, 2, and 3 in human non-small cell lung
carcinomas. Timothy R. Holzer, Angie D. Fulford, Leslie
O’Neill Reising, Drew M. Nedderman, Laura E. Benjamin,
Andrew E. Schade, Aejaz Nasir.
4158 Novel PAK4-mediated regulation of endothelial
CXCL1/CXCR2 signaling and angiogenesis in glioblastoma.
Divya Kesanakurti, Jihong Xu, Alessandro Canella,
Prabhakaran Nagarajan, Balveen Kaur, Vinay K. Puduvalli.
4159 Therapeutic effects of luteolin against progestindependent breast cancer involves induction of apoptosis,
and suppression of both stem-cell-like cells and
angiogenesis. Matthew T. Cook, Yayun Liang, Sandy
Goyette, Benford Mafuvadze, Cynthia Besch-Williford,
Salman Hyder.
4160 SPARC overexpression combined with irradiation
reduces VEGF-A dependent angiogenesis in vitro and in
vivo via up regulation of miR410 in neuroblastoma cells.
Smita Tanpure, Jerusha Boyineni, Reuben Antony, Karen
Fernández, Julian Lin, David Pinson, Christopher S. Gondi.
4161 Differential expression of VEGFR2 Protein in HER2
positive primary human breast cancer: Potential relevance
to newer anti-angiogenic therapies. Aejaz Nasir, Timothy R.
Holzer, Michael Man, Laura E. Benjamin, Allen S. Melemed,
Andrerw E. Schade.
4162 Interleukin– 6 stimulates defective angiogenesis.
Ganga Gopinathan, Carla Milagre, Oliver M. Pearce, Louise
Reynolds, Kairbaan Hodivala-Dilke, Andrew Leinster,
Haihong Zhong, Robert E. Hollingsworth, Richard Thompson,
James R. Whiteford, Frances Balkwill.
4163 Targetting VPAC1 for intestinal cancer
prevention. Shaohua Liu, Yunjie Zeng, Nengtai Ouyang.
4164 uPA modulates angiogenesis through
transcriptional regulation of vascular endothelial growth
factor (VEGF) receptors VEGFR1 and VEGFR2. Victoria
Stepanova, Padma Sheela Jayaraman, Sergei V. Zaitsev,
Tatiana Lebedeva, Rachael M. Kershaw, Douglas B. Cines.
4165 The gain-of-function truncated GLI1 (TGLI1)
promotes glioblastoma angiogenesis by direct
upregulation of VEGF-C and TEM7 expression. Richard L.
Carpenter, Ivy Paw, Sherona Sirkisoon, Fei Xing, Denise Gibo,
Kounosuke Watabe, Waldemar Debinski, Hui-Wen Lo.
4166 Targeting NF-␬B by the curcumin and its analogs
EF-31 and UBS-109 decreases growth and angiogenesis of
colon cancer. Ganji P. Nagaraju, Mamoru Shoji, Bassel E.
Rayes.
4167 Snai2(Slug) regulates tumor angiogenesis
through the induction of EndoMT. Nan Wu, Katrina WelchReardon, Christopher Hughes.
4168 Robo1 promotes angiogenesis through CDC42/
Rho GTPases signaling pathway in hepatocellular
carcinoma. Hui-Chuan Sun, Jian-Yang Ao, Zong-Tao Chai,
Yuan-Yuan Zhang.
4169 Tumor endothelium regulates microenvironmentmediated migration via the proteolysis of extracellular
TFPI-2 by trypsinogen 4. Carmen Ghilardi, Figini Sara,
Monica Lupi, Alessia Anastasia, Raffaella Giavazzi, Mariarosa
Bani.
4170 The role of VEGF-C for cell viability, tumor growth
and bevacizumab resistance in glioblastoma multiforme.
Signe R. Michaelsen, Mette K. Nedergaard, Thomas Urup,
Mette Villingshoej, Andreas Kjaer, Lara Perryman, Janine T.
Erler, Ulrik Lassen, Hans S. Poulsen.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
4171 Novel regulatory role of Neuropilin-1 in
endothelial to mesenchymal transition as a potential
source of carcinoma associated fibroblasts. Pratiek N.
Matkar, Krishna K. Singh, Gerald Prud’homme, Howard
Leong-Poi.
4172 Differential angiogenesis-related cytokines
release in tumor interstitial fluid and plasma in ER-positive
and triple-negative breast cancers overexpressing VEGF.
Louis Dore-Savard, Esak Lee, Aleksander S. Popel, Zaver M.
Bhujwalla.
4173 Endoglin regulation of Smad2/3 function
mediates beclin1 expression and endothelial autophagy
during angiogenesis. Nam Y. Lee, Christopher Pan, Sanjay
Kumar.
4174 Molecular changes in the EGFR pathway and RAS/
RAF genes identify subtypes of metastatic and
nonmetastatic colorectal cancer associated with different
outcomes. Abeer A. Bahnassy, Salem E. Salem, Nehal
Hussein, Hend F. Yousif, Marwa, Iman Al-Desouky,
Abdel-Rahman N. Zekri.
4175 Robust immunohistochemical assay to
characterize human cancer tissues for prevalence of
vascular endothelial growth factor receptor 3 (VEGFR3).
Timothy R. Holzer, Drew M. Nedderman, Aejaz Nasir.
4176 The homeobox gene DLX4 stimulates inducible
nitric oxide synthase-mediated angiogenesis in ovarian
cancer. Bon Q. Trinh, Song Yi Ko, Dhwani Haria, Nicolas
Barengo, Honami Naora.
4177 Simultaneous activation of C-X-C chemokine
receptor 4 and cannabinoid receptor 2 results in decreased
angiogenesis. Kisha A. Scarlett, Brittney Sandifer,
Christopher J. Coke, Cimona V. Hinton.
4178 L1CAM and integrin ␣v␤3 mediate direct cell
contact between cancer stem cells and endothelial cells:
Promotion of endothelial cell migration and survival.
Monica E. Burgett, Justin D. Lathia, Patrick Roth, Amy S.
Nowacki, Ping Huang, Amit Vasanji, Meizhang Li, Tatiana
Byzova, Tom Mikkelsen, Shideng Bao, Jeremy Rich, Michael
Weller, Candece L. Gladson.
4179 Id3 generated cancer stem-like cells: A
microvascular niche for the development of glioma.
Jayanta Das, Quentin H. Felty.
4180 TGF-beta promotes angiogenesis in an RBdeficient, Kras-driven mouse model of pancreatic cancer.
Jesse Gore, Kelly E. Craven, Julie L. Wilson, Murray Korc.
4181 Chronic stress and beta adrenergic signaling
promote angiogenesis and prostate cancer progression
through suppressing the expression of Thrombospondin 1.
Mohit M. Hulsurkar, Meixiang Sang, Haiping Song, Wenliang Li.
4182 Gemcitabine triggers angiogenesis-promoting
molecular signals in pancreatic cancer cells: Therapeutic
implications. Mohammad Aslam Khan, Sanjeev K. Srivastava,
Arun Bhardwaj, Seema Singh, James E. Carter, Ajay P. Singh.
4183 Differential expression of VEGF in breast cancer
cells induced by gp130 cytokines. Danielle S. Hedeen, Ken
Tawara, Madhuri Nandakumar, Ryan Fox, David Chang, Alex
Ide, Andrew Oler, Dollie LaJoie, Cheryl L. Jorcyk.
4184 CAF-derived MFAP5 promotes tumor
angiogenesis and confers paclitaxel resistance in highgrade serous ovarian cancer. Cecilia S. Leung, Tsz-Lun
Yeung, Kay-Pong Yip, Kwong-Kwok Wong, Anil K. Sood,
Michael J. Birrer, Samuel C. Mok.
4185 Role of Cathepsin L in breast cancer angiogenesis.
Dhivya Sudhan, Belen Rabaglino, Charles Wood, Dietmar
Siemann.
19
19
527
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
20
20
Mouse Models of Human Cancer 3
Poster
Board
Poster
Board
Abstract
Number
1.
4186 p120 catenin: A novel regulator of epithelial cell
delamination in early Kras-driven pancreatic cancer.
Audrey M. Hendley, Yue J. Wang, Janivette Alsina, Ishrat
Ahmed, Hao Zhang, Samuel Savidge, Hao Ho, Albert
Reynolds, Anirban Maitra, Michael Goggins, Christine
Iacobuzio-Donahue, Steven D. Leach, Jennifer M. Bailey.
17.
4202 Targeting focal adhesion kinase is a novel
approach to therapy of high-risk, Ikaros-mutant acute
B-cell lymphoblastic leukemia. Nilamani Jena, Ila Joshi,
Toshimi Yoshida, Zhihong Zhang, Zhong-Ying Liu, Prasanthi
Tata, Irina M. Shapiro, Jonathan A. Pachter, David T. Weaver,
Katia Georgopoulos, Richard A. Van Etten.
2.
4187 Expression of ion channels in a cervical cancer
mouse model. ANA RAMIREZ, EUNICE VERA, PAUL
LAMBERT, PATRICIO GARIGLIO, JAVIER CAMACHO.
18.
4203 Retinoic acid signal and annexins: A vicious circle of
breast tumorigenesis. Stefano Rossetti, Wiam Bshara, Johanna
Reiners, Francesca Corlazzoli, Austin Miller, Nicoletta Sacchi.
3.
4188 Conditional epithelial cell-specific knockout of
CCN6/Wisp3 disrupts normal development of the virgin
murine mammary gland. Emily E. Martin, Wei Huang, JunLin Guan, Celina G. Kleer.
19.
4204 The cellular hierarchy of intestinal tumors. Ryoji
Yao, Tetsuo Noda.
20.
4205 Development of peritoneal carcinomatosis by
multicellular structures of high-grade serous ovarian
cancer. Alicia A. Goyeneche, Rekha Srinivasan, Juan M.
Valdez, Carlos M. Telleria.
4.
4189 Analgesic effect of quetiapine on the cancer
induced bone pain animal model. Keon Uk Park, Mi Hwa
Heo, Jin Young Kim, Ilseon Hwang, Hun Mo Ryoo.
5.
4190 A mouse model of pRb2/p130 in prostate cancer.
Silvia Boffo, Andres J. Klein-Szanto, Flavio Rizzolio, Antonio
Giordano.
22.
4207 Secreted proteins from breast cancer cell lines as
a source of cancer biomarkers. Even Birkeland, Monica
Mannelqvist, Lars A. Akslen.
7.
4192 Identification of novel genetic drivers of vulvar
carcinoma in a Sleeping Beauty model of spontaneous
cancer. Amy Guimaraes-Young, Traci Neff, David K.
Meyerholz, Adam J. Dupuy, Michael J. Goodheart.
23.
9.
4194 APC and DIAPH1 collaborate to suppress
myelodysplastic syndrome (MDS) pathogenesis. Julie D.
Turner, Susan M. Kitchen-Goosen, Andrew M. Howard,
Heather L. Schumacher, Arthur S. Alberts.
4208 The castrate resistant PC-3 cell line with
neuroendocrine features is enriched in tumor initiating
cells and is resistant to enzalutamide and abiraterone but
sensitive to antimetabolites. Nitu Bansal, Lisa Wu, Nadine J.
Farley, Philip Tedeschi, Joseph R. Bertino.
24.
4195 GNASR201H and KrasG12D cooperate to promote
murine pancreatic tumorigenesis recapitulating human
intraductal papillary mucinous neoplasm. Toru Furukawa,
Etsuko Tanji, Masaki Ohmuraya, Katsunobu Taki, Kimi Araki.
4209 Development of patient-derived xenograft (PDX)
models for small cell lung cancer (SCLC) as a preclinical
platform for drug development. Chelsea Mullins, Jill Ricono,
Praveen Nair, Cyrus Mirsaidi, Thomas Broudy.
25.
4210 Patient-derived models of human acute myeloid
and lymphoid leukemia in immunocompromised mice for
preclinical drug development. Eva Oswald, Kerstin Klingner,
Benedikt Hammerich, Gabriele Greve, Dorothee Lenhard,
Milena Pantic, Heinz-Herbert Fiebig, Michael Luebbert, Julia
B. Schüler.
26.
4211 The proteomic characterization of HNSCC patientderived xenografts. Hua Li, Sarah E. Wheeler, Yongseok
Park, Zhenlin Ju, Ann Marie Egloff, Michele Fichera, Sufi
Thomas, Gordon B. Mills, Jennifer R. Grandis.
27.
4212 Inhibition of mouse PTEN-deficient prostate
cancer with next generation antisense oligonucleotide
targeting the androgen receptor. Marco A. De Velasco,
Yurie Kura, Naomi Ando, Emiko Fukushima, Barry R. Davies,
Hayley Campbell, Yuji Hatanaka, Yutaka Yamamoto,
Nobutaka Shimizu, Masahiro Nozawa, Kazuhiro Yoshimura,
Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura.
28.
4213 Gene therapy for esophageal squamous cell
carcinoma using SOCS-1 expressing adenoviral vector.
Hisashi Hara, Rie Nakatsuka, Tsuyoshi Takahashi, Satoshi
Serada, Minoru Fujimoto, Yasuhiro Miyazaki, Tomoki Makino,
Yukinori Kurokawa, Makoto Yamasaki, Hiroshi Miyata,
Kiyokazu Nakajima, Shuji Takiguchi, Masaki Mori, Yuichiro
Doki, Tetsuji Naka.
10.
528
Abstract
Number
11.
4196 Neuregulin signaling in development and
transformation of the luminal breast epithelium. David B.
Vaught, Donna Hicks, Violeta Sanchez, Rebecca Cook.
12.
4197 Mutant GATA3 drives precocious lobuloalveolar
mammary development and promotes the growth of
estrogen receptor positive xenograft tumors. Natasha
Chandiramani, Esther A. Peterson, Eric H. Jung, E. Charles
Jenkins, Paraic A. Kenny.
13.
4198 mTORC2 directs breast morphogenesis through
Rictor-dependent PKC␣/Rac1 signaling independent of
Akt. Dana M. Brantley-Sieders, Meghan M. Morrison, Donna J.
Hicks, Rebecca S. Cook.
14.
4199 Developing therapies for rare tumors: Using
mouse models of malignant peripheral nerve sheath
tumors to complement rare human samples in drug
screens. Karlyne M. Reilly, Robert G. Tuskan, Brigitte C.
Widemann.
15.
4200 Novel treatment strategy for pancreatic cancer.
Chintan Chheda, Ramachandran Murali, Paul Grippo, Dale
Uyeminami, Kent Pinkerton, Stephen Pandol, Mouad
Edderkaoui.
16.
4201 Development of a syngeneic metastatic mouse
model of malignant lymphoma. Takuro Matsumoto, Atsushi
Suetsugu, Yuhei Shibata, Nobuhiko Nakamura, Hitomi Aoki,
Takahiro Kunisada, Masahito Shimizu, Hisashi Tsurumi,
Robert M. Hoffman.
POSTER SESSION
Tumor Biology
Therapeutics Targeting Cancer Stem Cells
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Abstract
Number
4214 Quinomycin A affects pancreatic cancer stem cells in
part through suppression of notch signaling pathway.
Dharmalingam Subramaniam, Sivapriya Ponnurangam, Afreen Sayed,
Animesh Dhar, Dan A. Dixon, Ossama Tawfik, Rajashri R. Parab,
Prabhu D. Mishra, Prafull Ranadive, Rajiv Sharma, Girish Mahajan,
Aravind Sugumar, Scott J. Weir, Roy A. Jensen, Arun Balakrishnan,
Shrikant Anant.
4215 Small molecule compounds that destabilize stem cell
factors. Naohiko Ikegaki, Sarah Lomahan, Xao Tang.
4216 Targeting NANOG: genes, proteins and response to viral
RNAi in preclinical models. J. M. Jessup, Abid R. Mattoo, Nikolay
Korokhov.
4217 Targeting head and neck cancer-initiating cells with
combinatorial therapeutics through pharmacological inhibition of
ROS scavenger and conventional chemotherapy. Ching-Wen Chang,
Jeng-Fan Lo.
4218 Phenotypic selection screening reveals cancer stem cell
therapeutic targets. Elaine M. Hurt, Matt Flynn, Suneetha Thomas,
Lilian van Vlerken-Ysla, Alan Sandercock, Steven Rust, Minter Ralph,
Robert Hollingsworth.
4219 Small G protein Rac GTPases regulate the maintenance
of glioblastoma stem-like cells. Yun-Ju Lai, Jui-Cheng Tsai, YingTing Tseng, Etty N. Benveniste.
4220 Silencing DCLK1 prevents breast cancer cell selfrenewal, epithelial mesenchymal transition, circulating tumor cells
and metastasis. PARTHASARATHY CHANDRAKESAN, Nathaniel
Weygant, Vivian Taylor, William Berry, Randal May, Dongfeng Qu,
Meghna Singh, Sripathi Sureban, Naushad Ali, Michael Bronze,
Courtney Houchen.
4221 Inhibition of glioblastoma tumorsphere by combination
of 2-deoxyglucose and metformin. Eui Hyun Kim, Ji-Hyun Lee,
Yoonjee Oh, Jin-Kyoung Shim, Jun Jeong Choi, Jong Hee Chang, Sun
Ho Kim, Jae-Ho Choeng, Pilnam Kim, Seok-Gu Kang.
4222 Targeting HMGA2 suppresses GBM stemness, invasion
and tumorigenicity. Harpreet Kaur, Marianne Hütt-Cabezas, Isabella
Taylor, Laura Asnaghi, Fausto Rodriguez, Brent A. Orr, Charles G.
Eberhart, Eric H. Raabe.
4223 Rapid identification and targeting of chemotherapy
resistant tumor stem cell clones in ovarian high-grade serous
carcinoma. Ting Zhang, Gang Ning, Yusuke Yamamoto, Brooke
Howitt, Xia Wang, Lane Wilson, Yue Hong, Chiea C. Khor, Suzy Torti,
Molly Brewer, Christopher Crum, Frank McKeon, Wa Xian.
4224 CD133 knockdown sensitizes melanoma to kinase
inhibitors. Maryam AbdusSamad, Anirudh Gaur, Hengbo Zhou, John
L. Zapas, Cynthia M. Simbulan-Rosenthal, Edward C. McCarron, Dean
S. Rosenthal.
4225 A novel pharmacological inhibitor CEP1430 for human
pancreatic cancer stem cells. Jitesh Jani, Mandana Amiri, Cristian
Sharma, Joshua Harris, Shruthi Satish, Michael Sharma, Robert
Rodriguez, Miriam Navel, Natalee Amezcua, Shaleekha Sharma, Arun
Sharma, Dhimant Desai, Shantu Amin, Satya Narayan, Rubio
Punzalan, Jay P. Sharma.
4226 Histone deacetylase inhibitors sensitize cancer stem
cells to PARP inhibitors in triple-negative breast cancer. Yajing Liu,
Rachel Martin-Trevino, Li Shang, April Davis, Max Wicha, Suling Liu,
Monika Burness.
4227 PARP inhibitors sensitize glioblastoma stem cells to
oncolytic herpes simplex virus therapy. Jianfang Ning, Hiroaki
Wakimoto, Robert Martuza, Samuel Rabkin.
4228 Identification of distinct mammary cancer stem cells
with differential requirements for the autophagy regulator FIP200.
Syn K. Yeo, Jian Wen, Song Chen, Jun-Lin Guan.
4229 ATP-binding cassette transporter ABCG2/BCRP
inhibition sensitizes CD133+ cells to MEK/BRAF inhibitors. Abrar
Mohamad Pauzi.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
4230 Targeting lung cancer stem cells through fatty acid
metabolism. Alessia Noto, Maria Elena Pisanu, Claudia De Vitis,
Debora Malpicci, Luigi Fattore, Nadia Lobello, Barbara Bonacci,
Gennaro Ciliberto, Rita Mancini.
4231 Combination of epigenetic, differentiation and DNA
damaging agents induce tumor cell death and stem cell depletion
in breast cancer. Vanessa F. Merino, Nguyen Nguyen, Helen Sadik,
Soonweng Cho, Leslie Cope, Xian C. Zhou, Zhe Zhang, Qian Chen,
Duojia Pan, David L. Huso, Syed Ali, Christina Adams, Balázs GyŐrffy,
Saraswati Sukumar.
4232 CAPE (caffeic acid phenethyl ester) induces a mammary
stem cell lineage restriction to a luminal phenotype via chromatin
remodeling. Coral O. Omene, Manan Patel, Kasthuri Kannan, Adriana
Heguy, Mary Helen Barcellos-Hoff.
4233 Wnt pathway antagonist ipafricept (FZD8-Fc, OMP54F28) inhibits tumor growth and reduces tumor-initiating cell
frequency in ovarian patient-derived xenograft models. Marcus M.
Fischer, Wan-Ching Yen, Chun Zheng, Randall Henner, Fiore
Cattaruzza, Tracy Tang, Pete Yeung, Tanuka Biswas, John Lewicki,
Austin Gurney, Ann M. Kapoun, Timothy Hoey.
4234 Targeting cancer stem cell to enhance therapeutic
efficacy of prostate cancer. Eun-Jin Yun, Elizabeth Hernandez, JerTsong Hsieh.
4235 Anti-proliferative effects of ZR2002, a novel combimolecule with EGFR/DNA binary targeting properties compared to
Gefitinib in glioblastoma cell lines and brain tumor stem cells.
Zeinab Sharifi, Jean-Claude Bertrand, Kevin Petrecca, Elliot
Goodfellow, Bassam Abdulkarim, Siham Sabri.
4236 FAK inhibitor VS-6063 (defactinib) targets
mesothelioma cancer stem cells, which are enriched by standard of
care chemotherapy. Jonathan A. Pachter, Vihren N. Kolev, Laurel
Schunselaar, Irina M. Shapiro, Raphael Bueno, Paul Baas, Qunli Xu,
David T. Weaver.
4237 Drug-releasing mesenchymal cells strongly suppress
B16 lung metastasis in a syngeneic murine model. Giulio Alessandri,
Carlo Leonetti, Simona Artuso, Augusto Orlandi, Daniela Passeri,
Anna Benetti, Angiola Berenzi, Enrico Dessy, Luisa Pascucci, Piero
Ceccarelli, Arianna Bonomi, Valentina Coccè, Nazario Portolani,
Valentina Ceserani, Eugenio Parati, Augusto Pessina.
4238 Lung cancer stem cell targets sensitizing tumor cells to
chemo therapy and radiation therapy by exploiting synthetic
lethal relationships in an RNAi high-throughput screen. Kunal R.
Chaudhary, Haiying Cheng, Balaz Halmos, Jose M. Silva, K.S. Clifford
Chao, Tom K. Hei, Simon Cheng.
4239 Epithelial-like breast cancer stem cells are preferentially
sensitive to nanoparticle-mediated hyperthermia. Hayley J.
Paholak, Nicholas O. Stevers, Joseph P. Burnett, Hongwei Chen, Sean
P. McDermott, Miao He, Tahra Luther, Shawn G. Clouthier, Max S.
Wicha, Duxin Sun.
4240 TORC inhibition enriches for a cancer stem cell-like
population with FGFR-dependent Notch1 activation. Neil E. Bhola,
Valerie M. Jansen, Carlos L. Arteaga.
4241 ONC201/TIC10 targets colorectal cancer stem cells and
bulk tumor cells via an Akt-Foxo3a-TRAIL-dependent mechanism.
Varun Vijay Prabhu, Joshua E. Allen, David T. Dicker, Wafik S. ElDeiry.
4242 Metformin suppresses GRP78-dependent PI3-Kinase
activity in clonogenic side population to enhance the antimyeloma benefit of bortezomib. James J. Driscoll, Sajjeev
Jagannathan, Mohamed A. Abdel Malek, Nikhil Vad, Ehsan Malek.
4243 Iron control is a novel therapeutic target of cancer stem
cells. Takayuki Ninomiya, Toshiaki Ohara, Hajime Kashima, Ryoichi
Katsube, Kazuhiro Noma, Yasuko Tomono, Akifumi Mizutani,
Tomonari Kasai, Masaharu Seno, Shinji Kuroda, Hiroyuki Kishimoto,
Hiroshi Tazawa, Yasuhiro Shirakawa, Shunsuke Kagawa, Toshiyoshi
Fujiwara.
21
21
529
POSTER SESSION
Clinical Research
Poster
:LJ[PVU
23
23
Genomics in the Clinic 1
Poster
Board
1.
4244 Comparison of different ALK tests in non-small cell lung
cancer (NSCLC) patients treated with crizotinib and their clinical
outcome. Anthonie J. van der Wekken, Thijo J. Hiltermann, Wim Timens,
Ed Schuuring, Harry J. Groen.
2.
4245 Detection of fusion genes in lung cancer biopsies of
crizotinib resistant patients. Ali Saber, Anthonie van der Wekken, Klaas
Kok, Martijn M. Terpstra, Mirjam F. Mastik, Wim Timens, Ed M. Schuuring,
T. Jeroen Hiltermann, Harry J. Groen, Anke van den Berg.
3.
4246 Comparison of pathology versus IHC-based ovarian
carcinoma histology assignment using gene expression, DNA
methylation, and clinical outcome data. M. A. Earp, S. J. Winham, S. M.
Armasu, B. L. Fridley,
M. C. Larson, Z. C. Fogarty, K. R. Kalli, C. Wang, G. L. Keeney, J. M.
Cunningham, S. Ramus, M. Kobel, E. L. Goode.
4.
4247 BRCAness by MLPA is clinically useful for tailored treatment
in triple-negative breast cancer. Takashi Ishikawa, Kazutaka Narui,
Akimitsu Yamada, Sadatishi Sugae, Yasushi Ichikawa, Mari S. Oba, Saeko
Teraoka, Kumiko Kida, Hidetaka Shima, Itaru Endo.
5.
4248 A long tail of sub-clonal TP53 mutations emerged by ultradeep sequencing of newly diagnosed multiple myeloma (MM). Marina
Martello, Giovanni Martinelli, Angela Flores Dico, Barbara Santacroce,
Enrica Borsi, Mauro Procacci, Torsten Haferlach, Flavio Mignone, Igor
Saggese, Elena Zamagni, Paola Tacchetti, Lucia Pantani, Anna Maria Brioli,
Serena Rocchi, Annalisa Pezzi, Michele Cavo, Carolina Terragna.
6.
4249 High-Frequency of TMPRSS2-ERG fusion gene identifies a
non-random androgen-driven event of chromosomal instability in
BRCA mutated prostate cancer. Elena Castro, Floortje Van de Poll, Elena
Piñeiro, Paz Nombela, Elizabeth Bancroft, Koveela Govindasami, Michelle
Guy, G Kovacs, Steve Ellis, Antonis Antoniu, Douglas Easton, Zsofia KoteJarai, Fatima Al-Sharour, David Olmos, Rosalind Eeles.
7.
4250 5= deletion on ALK break-apart FISH and risk of false
positive results. Xin Gao, Lynette M. Sholl, Mizuki Nishino, Jennifer Heng,
Pasi A. Janne, Geoffrey R. Oxnard.
8.
4251 Paclitaxel is necessary for improved survival in epithelial
ovarian cancers with somatic homologous recombination gene
mutations. Stephanie Jean, Bradley Wubbenhorst, Jiaqi Li, Kara N.
Maxwell, Lauren Fishbein, Michael W. McLane, Nandita Mitra, Lin Zhang,
Katherine L. Nathanson, Janos L. Tanyi.
9.
4252 Accurate site prediction of gastrointestinal cancer by novel
methylated DNA markers: Discovery & validation. John B. Kisiel, William
R. Taylor, Tracy C. Yab, Hassan M. Ghoz, Patrick H. Foote, Mary E. Devens,
Douglas W. Mahoney, Thomas C. Smyrk, Lisa A. Boardman, Gloria M.
Petersen, Navtej S. Buttar, Lewis R. Roberts, Graham P. Lidgard, David A.
Ahlquist.
10.
11.
12.
13.
530
Abstract
Number
4253 A vascular endothelial growth factor gene polymorphism
predicts malignant potential in intraductal papillary mucinous
neoplasm. Suguru Yamada, Norimitsu Yabusaki, Tsutomu Fujii, Mitsuro
Kanda, Hiroyuki Sugimoto, Yasuhiro Kodera.
4254 Changes in PD-L1 expression during cisplatin containing
treatment in patients with head and neck squamous cell carcinoma, and
their association with epithelial-mesenchymal transformation. ChanYoung Ock, Bhumsuk Keam, Sehui Kim, Jong-Yeon Shin, Yong-Oon Ahn,
Tae Min Kim, Yoon Kyung Jeon, Se-Hoon Lee, Dong-Wan Kim, Dae Seog
Heo.
4255 Development and clinical validation of a quantitative mass
spectrometric assay for immuno-oncology targets in FFPE samples.
Sheeno P. Thyparambil, Fabiola Cecchi, Eunkyung An, Wei-Li Liao, Jon
Burrows, Todd Hembrough, Daniel Catenacci.
4256 High programmed cell death ligand 1 expression and low
immune infiltrate score correlate with worse outcome in patients with
lung adenocarcinoma. Edwin R. Parra, Carmen Behrens, Jaime
Rodriguez-Canales, Heather Lin, Barbara Mino, Jorge Blando, Yanyan Lou,
Don L. Gibbons, John V. Heymach, Stephen G. Swisher, Annikka
Weissferdt, Neda Kahlor, Julie Izzo, J. Jack Lee, Humam Kadara, Cesar
Moran, Ignacio Wistuba.
Poster
Board
Abstract
Number
14.
4257 Reducing GC bias and increasing complexity: Clinical
implementation and validation of KAPA library preparation protocol for
Oncopanel, a targeted next generation sequencing panel. Yonghui Jia,
Allison D. Manning, Ruchi A. Joshi, Bernard J. Fendler, Priyanka Shivdasani,
Lawrence P. Chung, Phani K. Davineni, Xin Gong, Matthew D. Ducar,
Lynette M. Sholl, Neal I. Lindeman, Laura E. Macconaill, Elizabeth P. Garcia.
15.
4258 Genetic profiling of breast cancer confirms a pivotal Role of
EGFR pathway in the development of acquired resistance to Tamoxifen
in locally recurrent and metastatic breast cancer patients. AbdelRahman N. Zekri, Abeer Bahnassy, Ibrahim Malash, Mohammad Mansour,
Sabry Shaarawy, Hoda Abdel-Raouf, Rabab Gaafar.
16.
4259 Conversion of the Lung Cancer Risk Test (LCRT) to a next
generation sequencing (NGS) platform. Erin L. Crawford, Thomas M.
Blomquist, James C. Willey.
17.
4260 Clinical testing and implementation of the TruSight Myeloid
Next Generation Sequencing (NGS) panel for identification of clinically
relevant variants in hematological malignancies. Mariam Thomas,
Mahadeo Sukhai, Tong Zhang, Djamel Harbi, Justin De Souza, Katherine
MacDonald, Trevor Pugh, Mark Minden, Andre Schuh, Tracy L. Stockley,
Suzanne Kamel-Reid.
18.
4261 Oncomine® Cancer Panel: simultaneous detection of
clinically relevant hotspot mutations, CNVs, and gene fusions in solid
tumors. Peng Fang, Zhenyu Yan, Weihua Liu, Jennifer Biroschak, Paul
Labrousse, Jennifer Wright, Cindy Spittle, Chad Galderisi, Li Jin.
19.
4262 PRAME as a biomarker for a new molecular subclass of uveal
melanoma. Matthew G. Field, Christina L. Decatur, J. William Harbour.
20.
4263 Concurrent aberrations in the Wnt, MAPK and PI3K pathways
identified through next generation sequencing of relapsed refractory
colorectal adenocarcinoma (CRC): Implications for future therapeutic
trials. Ishwaria M. Subbiah, Filip Janku, Apostolia M. Tsimberidou, Aung
Naing, Vivek Subbiah, Jennifer J. Wheler, Ralph Zinner, Cathy Eng, Michael
J. Overman, Scott Kopetz, David S. Hong.
21.
4264 Clinical targeted sequencing from FFPE tumor tissue
samples for early-phase clinical trials at the National Cancer Center of
Japan. Hitoshi Ichikawa, Mamoru Kato, Kenji Tamura, Noboru Yamamoto,
Yuko Tanabe, Takashi Kohno.
22.
4265 Identification of new NTRK1 gene fusion as oncogene target
in colon cancer. Laurent Creancier, Caroline Dejean, Isabelle
Vandenberghe, Jean-Christophe Blanchet, Yannick Aussagues, Jean
Philippe Annereau, Janick Selves, Anna Kruczynski.
23.
4266 DNA Repair Enzyme Signature as a new strategy to stratify
patients in metastatic melanoma. Sylvie Sauvaigo, Fanny Sarrazy,
Florence de Fraipont, Julie Guy, Marie-Thérèse Leccia.
24.
4267 Integrated genomic analysis of hepatoblastoma identifies
distinct molecular and prognostic subgroups. Dolores H. Lopez-Terrada,
Pavel Sumazin, Yidong Chen, Lisa Trevino, Stephen Sarabia, Oliver
Hampton, Kayuri Patel, Toni-Ann Mistretta, Barry Zorman, Sarah
Comerford, David Wheeler, Murali Chintagumpala, Rebecka M. Meyers,
Milton J. Finegold, Gail Tomlinson, Donald W. Parsons.
25.
4268 DNA copy number variation and driver mutation patterns of
follicular thyroid tumors. Hyun-seok Kim, Kathleen Wilsbach, Aurelien
Marti, Alireza Najafian, Alan K. Meeker, James R. Eshleman, Justin A.
Bishop, Martha Zeiger, Christopher B. Umbricht.
26.
4269 A gene signature defines chromosomal instability (CIN) and
poor survival in liver cancer patients . Sofia Weiler, Thomas Wolf,
Federico Pinna, Stephanie Roessler, Teresa Lutz, Shan Wan, Jens
Marquardt, Hauke Lang, Peter Schirmacher, Kai Breuhahn.
27.
4270 NGS based microhaplotype counting for ultrasensitive
human DNA detection. Marija Debeljak, Donald N. Freed, Jane A. Welch,
Lisa Haley, Katie Beierl, Brian S. Iglehart, Aparna Pallavajjala, Christopher
D. Gocke, Mary S. Leffell, Ming-Tseh Lin, Laura D. Wood, Jonathan Pevsner,
Sarah J. Wheelan, James R. Eshleman.
POSTER SESSION
Clinical Research
Novel Immunomodulators
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
Abstract
Number
4271 Lack of CD47 membrane mobility contributes to
the poor erythrocyte binding of SIRP␣Fc, a novel CD47blocking cancer immunotherapeutic. Penka S. Petrova,
Karen Dodge, Tanya Prasolava, Vien Chai, Xinli Pang, Robert
A. Uger.
4272 Potent in situ cancer immunotherapy with
synthetic human STING-activating cyclic dinucleotides.
Laura H. Glickman, David B. Kanne, Kelsey E. Gauthier,
George E. Katibah, Justin J. Leong, Ken Metchette, Thomas
W. Dubensky, Sarah M. McWhirter.
4273 ROR␥ agonists as a novel immunotherapy
approach for cancer. Xiao Hu, Jacques Moisan, Charles
Lesch, Yahong Wang, Xikui Liu, Rodney Morgan, David Mertz,
Brian Sanchez, Dick Bousley, Clark Taylor, Chad Van Huis,
Thomas Aicher, Peter Toogood, Weiping Zou, Gary Glick,
Laura L. Carter.
4274 Anticancer mechanisms of a small amphipathic
molecule, LTX-401, against B16 melanoma cancer cells.
Liv-Marie Eike, Brynjar Mauseth, Ketil Camilio, Oystein
Rekdal, Baldur Sveinbjornsson.
4275 Agonist OX40 ligand fusion proteins induce
effector T cell proliferation, block regulatory T cell
function and can combine with immune checkpoint
inhibitors to promote antitumor immunity in preclinical
models. Kelly McGlinchey, Kathy Mulgrew, Chad Morris,
Catherine Auge, Nicholas Holoweckyj, Nicholas Durham,
Karen Coffman, James Hair, Terrance O’Day, Nicholas Morris,
Andrew Weinberg, Ching Ching Leow, Michael Oberst, Scott
A. Hammond.
4276 Engineering a trivalent lupus anti-DNA
autoantibody fragment for cancer therapy. Jaymin M.
Patel, Phil W. Noble, Grace Chan, Richard H. Weisbart, James
E. Hansen.
4277 Oral administration of a traditional herbal
remedy, JC001, suppresses pancreatic tumorigenesis in
mice via regulating immune cell functions. Ming-Shiou Jan,
Fong-Rong Hsu, You-Chain Lin, Shu-Han Chuang, Jia-Wei
Lin, Meng-Hsein Chuang, Li-Jin Hsu.
4278 Soy isoflavones and their metabolites modulate
IL-12-induced NK cell IFN-␥ production. Thomas A. Mace,
Samantha King, Matthew Farren, Elizabeth McMichael,
Steven Scoville, William E. Carson, Gregory Young, Jennifer
Thomas-Ahner, Kenneth M. Riedl, Steven Schwartz, Steven K.
Clinton, Gregory Lesinski.
4279 A new class of immunomodulators derivatized
from the Tat protein of HIV-1 in a murine breast cancer
model. Christoph M. Hotz-Behofsits, Sophie J. Hanscom,
Joshua B. Goldberg, Colin B. Bier.
4280 Utilizing a selective agonist of the intermediateaffinity IL-2 receptor with an improved pharmacokinetic
profile leads to an enhanced immunostimulatory response
With reduced toxicity in mice. Heather C. Losey, Jared E.
Lopes, Reginald L. Dean, Heather Flick, Madison Gomes,
Michael R. Huff, Rosemarie A. Moroso, Lei Sun, Chunhua
Wang, Julie F. Waters, Juan C. Alvarez.
4281 Determination of the Relative Potency of a
Selective Agonist of the Intermediate-Affinity IL-2
Receptor on Lymphocytes from Human, Cynomolgus
Monkey and Mouse. Emily E. Rosentrater, Heather Flick,
Jared E. Lopes, Heather C. Losey, Chunhua Wang, Juan C.
Alvarez.
4282 All-trans retinoic acid enhances the effector
functions of the anti-CD38 antibody SAR650984. Lucas
Bush, David Harper, Rita Greco, Zhili Song, Guang Yang,
Francisco Adrian.
Poster
Board
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
Abstract
Number
4283 Anticancer effects obtained against A20
lymphomas following treatment with LTX-315
(Oncopore®) in combination with low-dose
cyclophosphamide. Ketil André Camilio, Liv-Marie Eike,
Øystein Rekdal, Baldur Sveinbjornsson.
4284 The effect of resveratrol and curcumin on the
expression of immune modulatory molecules on colorectal
cancer cells. Donald P. Braun, Bani M. Fagla, Irshad Ali.
4285 Immunomodulatory activity of azapodophyllotoxin derivatives. Ajay Kumar, Eric M. Valentin,
Miguel Otero.
4286 Development of a safe and effective systemically
administered multiple Toll-like receptor (TLR) agonist for
anti-tumor immunotherapy. Michael J. Newman.
4287 Talimogene laherparepvec activates systemic
T-cell-mediated anti-tumor immunity. Julia Piasecki, Jim
Rottman, Tiep Le, Rafael Ponce, Courtney Beers.
4288 A cancer therapeutic nanoparticle vaccine
targeting HAAH significantly inhibits metastasis in a
mouse model of breast cancer. Steven Fuller, Michael
Lebowitz, Solomon Stewart.
4289 Targeting of phosphatidylserine by monoclonal
antibodies enhances the activity of immune checkpoint
inhibitors in breast tumors. Jian Gong, Shen Yin, Van
Nguyen, Jeff Hutchins, Bruce D. Freimark.
4290 Potent and selective next generation inhibitors of
indoleamine-2,3-dioxygenase (IDO1) for the treatment of
cancer. Jay P. Powers, Matthew J. Walters, Rajkumar
Noubade, Stephen W. Young, Lisa Marshall, Jan Melom,
Adam Park, Nick Shah, Pia Bjork, Jordan S. Fridman, Hilary P.
Beck, David Chian, Jenny V. McKinnell, Maksim Osipov,
Maureen K. Reilly, Hunter P. Shunatona, James R. Walker,
Mikhail Zibinsky, Juan C. Jaen.
4291 An optimized therapeutic nanoparticle delivery
platform of miRNA in preclinical murine models of
malignancy. Nasser K. Yaghi, Jun Wei, Ling-Yuan Kong,
Yuuri Hashimoto, Edjah K. Nduom, Neal Huang, Xiaoyang
Ling, Shouhao Zhou, Jonathan M. Levine, Virginia R. Fajt,
Kiyoshi Tachikawa, Padmanabh Chivukula, David C. Webb,
Joseph E. Payne, Amy B. Heimberger.
4292 In vitro kynurenine modulation by novel dualacting and selective tryptophan 2,3-dioxygenase (TDO)
and indoleamine 2,3-dioxygenase (IDO) inhibitors. Alan
Wise, Barry E. McGuinness, Sarah C. Trewick, Phillip M.
Cowley, Nicola Bevan, Clare Szybut, Thomas J. Brown.
4293 Histamine dihydrochloride as an immune
modulator for solid tumors. Kheng Newick, Shaun O’Brien,
Veena Kapoor, Liang-chuan Wang, Edmund Moon, Daniel
Sterman, Steven Albelda.
4294 Cancer immunotherapeutic potential of NKTT320,
a novel human invariant natural killer T-cell activating
monoclonal antibody. Rupali Das, Felix Scheuplein, Peng
Guan, Robert Schaub, Kim E. Nichols.
4295 INT230-6, a novel intratumoral anticancer agent,
is able to eradicate large established tumors and stimulate
potent anti tumor immunity. Ian B. Walters, Lewis H.
Bender, Masaki Terabe, Jay A. Berzofsky.
4296 Dextran sodium sulfate-induced colitis in
dendritic cell deletion mice. Junko Masuda, Atsuhi Kitani,
Ivan Fuss, Masaharu Seno, Warren Strober.
4297 mAbXcite: A novel immunotherapy platform that
initiates a robust anti-cancer immune response by
recruiting and activating neutrophils. Isabelle SansalCastellano, Mark Carlson, Todd Armstrong, Gabriel Reznik,
James Siedlecki, John Kane, Zuzana Dostalova, Hua Miao,
Elizabeth Jaffee, Ifat Rubin-Bejerano.
24
24
531
POSTER SESSION
Clinical Research
Poster
:LJ[PVU
25
25
Predictive Biomarkers 2
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
532
Abstract
Number
4298 Defects in DNA repair genes and sensitivity to cisplatin
based neoadjuvant chemotherapy (NAC) for bladder cancer. Elizabeth
R. Plimack, Roland L. Dunbrack, Timothy A. Brennan, Mark D. Andrake, Yan
Zhou, Ilya Serebriiskii, Essel Dulaimi Al-Saleem, Jean Hoffman-Censits,
Marijo Bilusic, Yu-Ning Wong, Alexander Kutikov, Rosalia Viterbo, Richard
Greenberg, David Chen, Costas D. Lallas, Edouard J. Trabulsi, Roman
Yelensky, Vincent A. Miller, Erica Golemis, Eric Ross.
4299 MicroRNA 200c regulates cytochrome P450 1B1-mediated
docetaxel resistance in renal cell cancers. Inik Chang, Yozo Mitsui,
Shinichiro Fukuhara, Ankurpreet Gill, Darryn K. Wong, Soichiro Yamamura,
Varahram Shahryari, Z. Laura Tabatabai, Rajvir Dahiya, Dong Min Shin,
Yuichiro Tanaka.
4300 Solute carrier family group of membrane transporter gene
alteration in collecting duct renal cell carcinoma. Sreenivasulu Chintala,
Jianmin Wang, Lei Wei, Biao Liu, Eric Ciamporcero, Kiersten Marie Miles,
May Elbanna, Remi Adelaiye, Li Shen, Ashley Orillion, Sheng Yu Ku,
Antonios Papanicolau-Sengos, Carl D. Morrison, Roberto Pili.
4301 Endothelial angiopoietin-2 expression correlates with tumor
angiogenesis and response to sunitinib in metastatic renal cell
carcinoma. Anita Lampinen, Juhana Rautiola, Tuomas Mirtti, Ari Ristimäki,
Heikki Joensuu, Petri Bono, Pipsa Saharinen.
4302 Long term monitoring of circulating regulatory T cells
(Treg), myeloid derived suppressor cella (MDSC) and type I effector T
cells in melanoma patients treated with neoadjuvant ipilimumab. Janet
Retseck, Amanda Gillespie-Twardy, Alexis Nasr, Hui-Min Lin, Yan Lin, John
Kirkwood, Lisa H. Butterfield, Haris Zahoor, Cindy Sander, Ahmad A.
Tarhini.
4303 Programmed death ligand 1 (PD-L1) expression in paired
melanoma tumor samples. Torben Steiniche, Allan Vestergaard
Danielsen, Zhen (Adelle) Wang, Patricia Switten Nielsen, Lars Bastholt,
Henrik Schmidt, Inge Marie Svane, Marisa Dolled-Filhart, Kenneth
Emancipator, Dianna Y. Wu, Michael Busch-Sorensen, Wei Zhou.
4304 MMP-9 as a marker of response to treatment with B-Raf
inhibitors in cutaneous melanoma. Saverio Candido, Grazia Malaponte,
Rossella Salemi, Franca M. Pezzino, Aurora Scalisi, James A. McCubrey,
Massimo Libra.
4305 NMI as a biomarker of response to CDK4/6 inhibition in a
preclinical model of neuroblastoma. JulieAnn Rader, Pichai Raman, Lori
Hart, Mike Russell, Kristina A. Cole, John M. Maris.
4306 A prognostic model for clinical response to bevacizumab in
recurrent glioblastoma multiforme. Thomas Urup, Signe R. Michaelsen,
Camilla B. Holst, Anders Toft, Ib J. Christensen, Kirsten Grunnet, Michael
Kosteljanetz, Helle Broholm, Ulrik Lassen, Hans S. Poulsen.
4307 In vitro drug sensitivity and genetic profile analysis from
primary culture obtained from brain cancer. Franciele C. Kipper, Louise
C. Mendonça, Rafael Becker, Gláucia Confortin, Pítia F. Ledur, André Marc,
Eliseu Paglioli-Neto, Fabiana Viola, Fernanda B. Morrone, Guido Lenz.
4308 Serum ferritin as a predictive marker for increase in infection
and increased mortality in patients with myelodysplastic syndrome.
Anish Konde, Mamta Puppala, Pallavi Srivastava, Stephen T. Wong, Kelty
Baker, Lawrence Rice, Swaminathan P. Iyer.
4309 Description of a scientific treatment approach of mast cell
leukemia, an aggressive orphan hematologic disorder: strategy based
on next-generation sequencing data. Jeonghwan Youk, Youngil Koh,
Ji-Won Kim, Dae-Yoon Kim, Woo June Jung, Kwang-Sung Ahn, Sung-Soo
Yoon, Hye Lim Jung.
4310 Predictive biomarkers of tumor sensitivity to STEAP1
antibody-drug conjugate (ADC) in patients (pts) with metastatic
castration-resistant prostate cancer (mCRPC). Daniel C. Danila, Howard
I. Scher, Edith Szafer-Glusman, Amrita Herkal, Rebecca Suttmann, Martin
Fleisher, Nicole A. Schreiber, Kristen Curtis, Houston Gilbert, Daniel
Maslyar, Bernard Fine, Ron Firestein, Michael Mamounas, Mark R. Lackner,
Omar Kabbarah.
4311 Molecular basis of interaction between ERG and microtubule
inhibitors in CRPC patients. Giuseppe Galletti, Cynthia Cheung, David S.
Rickman, Paraskevi Giannakakou.
4312 A novel miRNA-based predictive model for biochemical
failure following post-prostatectomy salvage radiation therapy. Erica
Hlavin Bell, Simon Kirste, Jessica L. Fleming, Petra Stegmaier, Vaness
Drendel, Xiaokui Mo, Stella Ling, Denise Fabian, Isabel Manring, Cordula A.
Jilg, Wolfgang Schultze-Seemann, Maureen McNulty, Debra L. Zynger,
Douglas Martin, Julia White, Martin Werner, Anca L. Grosu, Arnab
Chakravarti.
Poster
Board
16.
17.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
4313 Abiraterone acetate (AA) treatment of prostate cancer
patient-derived xenografts (PDX) demonstrates heterogeneity of
responses and identifies potential biomarkers of adaptive resistance.
Hung-Ming Lam, Ryan McMullin, Holly M. Nguyen, Michael Gormley,
Roman Gulati, Weimin Li, Deborah Ricci, Karin Verstraeten, Shibu Thomas,
Elahe A. Mostaghel, Peter S. Nelson, Robert L. Vessella, Eva Corey.
4314 Prediction of chemotherapy response and metabolism for
the tailoring of ovarian cancer treatment. Maria L. Bravo, Pamela
Gonzalez, Sumie Kato, Carolina Ibañez, Marcelo Garrido, Jorge Brañes,
Maria I. Barriga, Eva Bustamante, Nicanor Barrena, Catalina Alonso, Leonel
Muñoz, Erasmo Bravo, Clemente Arab, Alejandro Barra, Paula Jimenez,
Patricio Gayan, Fernando Gonzalez, Ignacio Chavez, Alfredo Aguilar,
Joseph Pinto, Mauricio Cuello, Gareth Owen, Jaime Cartagena.
4316 hMENA11a contributes to HER3-mediated resistance to PI3K
inhibitors in HER2 overexpressing breast cancer cells. Paola Trono,
Francesca Di Modugno, Rita Circo, Sheila Spada, Roberta Melchionna,
Belinda Palermo, Mariangela Panetta, Silvia Matteoni, Silvia Soddu,
Ruggero De Maria, Paola Nisticò.
4317 The sialyl-glycolipid SSEA4 marks a subpopulation of
chemotherapy-resistant breast cancer cells with mesenchymal
features. Andrea Aloia, Evgeniya Petrova, Stefan Tomiuk, Ute Bissels,
Sophie Banis, Olivier Deas, Silvia Rüberg, Bernhard Gerstmayer, David
Agorku, Jean-Gabriel Judde, Andreas Bosio, Stefano Cairo, Olaf T. Hardt.
4318 Dexamethasone variably protects triple negative breast
cancer cells against paclitaxel depending on relative cellular levels of
glucocorticoid receptor alpha. Roselyne Labbe, Cecilia Speyer, Miriam
Bukhsh, Austin Belfiori, Rafa Khansa, Mudgha Patki, Manohar Ratnam,
David Gorski.
4319 Clinical significance and possible role of GPNMB in patients
with breast cancer. Manabu Futamura, Masako Kanematsu, Atsuko
Yamada, Kasumi Morimitsu, Akemi Morikawa, Ryutaro Mori, Kazuhiro
Yoshida.
4320 Genomic change in residual triple-negative breast cancers
after neoadjuvant chemotherapy. Adriana Aguilar-Mahecha, Ewa
Przybytkowski, Josiane Lafleur, Cathy Lan, Stephanie Légaré, Najmeh
Alirezaie, Carole Séguin, Federico Discepola, Bojan Kovacina, Catalin
Mihalcioiu, André Robidoux, Elizabeth Marcus, Josée Anne Roy, Manuela
Pelmus, Olga Aleynikova, Sheida Nabavi, Jacek Majewski, Mark Basik.
4321 Biomarkers of platelet activation and coagulation in African
women with breast cancer. HANNAH E. OMUNAKWE.
4322 Kinase activity profiles distinguish papillary thyroid cancers
with and without BRAF V600E mutations. Maria H. Hilhorst, Adrienne van
den Berg, Tom van Wezel, Tim Kievits, Piet J. Boender, Rik de Wijn, Rob
Ruijtenbeek, Wim Corver, Hans Morreau.
4323 ALK overexpression is associated with activation of PI3K/
AKT signaling pathway in PTC. Rong Bu, Sarita Prabhakaran, Shaham
Beg, Zeenath Jehan, Abdul K. Siraj, Maqbool Ahmed, Azhar Hussain, Saif
A. Alsobhi, Fouad Al-Dayel, Shahab Uddin, Khawla S. Al-Kuraya.
4324 Predictive biomarker signatures for IAP inhibitor CUDC-427.
Kaiming Sun, Ze Tian, Qi Zhang, Maria Samson, Ruzanna Atoyan, Mylissa
Borek, Steven Dellarocca, Brian Zifcak, Troy Patterson, Anna W. Ma,
Guangxin Xu, Michael J. Wick, Richard Rickles, Jing Wang.
4325 The role of FGFR fusion genes as novel oncogenic targets.
Gabriela Martinez Cardona, Katherine Bell, Dana Gaffney, Joseph Portale,
Suso Platero, Matthew Lorenzi, Jayaprakash Karkera.
4326 Co-amplification of FGF receptors and ligands in FGFR
inhibitor-sensitive cell lines. Katherine Bell, Dana Gaffney, Gabriela
Martinez-Cardona, Jayaprakash Karkera, Suso Platero.
4327 Nek6 and Hif-1␣ cooperate with the cytoskeletal gateway of
drug resistance to drive outcome in serous ovarian cancer. Marta De
Donato, Mara Fanelli, Marisa Mariani, Giuseppina Raspaglio, Deep Pandya,
Shiquan He, Paul Fiedler, Marco Petrillo, Giovanni Scambia, Cristiano
Ferlini.
POSTER SESSION
Clinical Research
Prognostic Biomarkers 2: Prostate Cancer and Thoracic Malignancies
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Abstract
Number
4328 New perspectives on the use of polo-like kinase 1
as a prognostic biomarker in non-small cell lung cancer.
Jolien Van den Bossche, Filip Lardon, Christophe Hermans,
Christophe Deben, Vanessa Deschoolmeester, Julie Jacobs,
Karlijn van der Ven, Jurgen Del-Favero, Patrick Pauwels,
Marc Peeters, An Wouters.
4329 Expression of serpin B2, neuroserpin and L1CAM
in association with metastasis and survival in non-small
cell lung cancer. Maria Ramnefjell, Lars Helgeland, Lars A.
Akslen.
4330 Immune checkpoint expression score is an
independent prognostic biomarker in resectable nonsmall cell lung cancer. Marta Usó, Eloisa Jantus-Lewintre,
Rafael Sirera, Silvia Calabuig, Enrique Pastor, Jerónimo
Forteza, Carlos Camps.
4331 Menacalc as an independent prognostic factor
and predictor of metastasis in Non-Small Cell Lung Cancer.
Mark Gustavson, Wendy Davis, Oscar Bronsther, Frank
Gertler.
4332 Evaluation of arachidonic acid pathways with
prognosis in patients with surgically resected non-small
cell lung cancer. Yinghao Su, Ming-Zhi Zhang, Wanqing
Wen, Wei Zheng, Rosana Eisenberg, Pierre P. Massion, Qiuyin
Cai.
4333 Association of TP53 mutation status with clinical
outcomes in patients with EGFR mutated non-small cell
lung cancer (NSCLC). Saman Ahmed, Charu Aggarwal,
Rosemarie Mick, Joshua Bauml, Roger Cohen, Stephan
Kadauke, Trisha Sterlicchi, Tracey L. Evans, John C.
Kucharczuk, Charu Desphande, Jennifer J. Morrissette, Robert
Daber, Corey J. Langer.
4334 Elevated lactic acid is a negative prognostic
factor in metastatic lung cancer. Panagiotis J.
Vlachostergios, Nirav Parikh, Katerina Oikonomou, Eugene
Gibilaro, George Apergis.
4335 Role of proton-coupled folate transporter
expression in resistance of mesothelioma patients treated
with pemetrexed. Elisa Giovannetti, Paolo A. Zucali, Yehuda
G. Assaraf, Niccola Funel, Maria Gemelli, Michal Stark, Leticia
G. Leon, Zhanjun Hou, Matteo Perrino, Larry H. Matherly,
Godefridus J. Peters.
4336 Direct genotyping of CYP2A6 whole gene
deletion: A new biomarker for prognosis of lung
adenocarcinoma in Japanese smoking male. Yasuko Okano,
Yasushi Ichikawa, Yohei Miyagi, Takashi Chishima, Yutaka
Natsumeda.
4337 Comprehensive analysis of genetic variations of
genes involved in DNA damage response pathways or cell
cycle checkpoints and treatment outcome in non-small cell
lung cancer patients treated with platinum doublets. Jeong
Seon Ryu, Bo-Rim Yi, Seul-Ki Lee, Soon-Sun Hong.
4338 Clinical significance of soluble CD26 in malignant
pleural mesothelioma. Nobukazu Fujimoto, Kei Ohnuma,
Keisuke Aoe, Osamu Hosono, Taketo Yamada, Takumi
Kishimoto, Chikao Morimoto.
4339 Progranulin (GP88) expression in thoracic
maligancies. Ginette Serrero, Martin J. Edelman, Pablo
Bejarano, Douglas M. Hawkins, David Hicks, David N.
Reisman, Olga Ioffe, Josephine Feliciano, Binbin Yue.
4340 Nuclear expression of antizyme inhibitor is
associated with poor prostate cancer prognosis. Liangzhe
Wang, Yingjie Xu, Shulin Wu, Mary Fergus, Chin-Lee Wu,
Bruce Zetter.
Poster
Board
14.
15.
16.
17.
18.
19.
20.
22.
23.
24.
25.
26.
28.
29.
Abstract
Number
4341 Distinct expression of PMEPA1 and its isoform,
STAG1 in prostate cancer. Hua Li, Lakshmi Ravindranath,
Yongmei Chen, Shashwat Sharad, Allissa Dillman,
Alargarsamy Srinivasan, David G. McLeod, Isabell A.
Sesterhenn, Albert Dobi, Shiv Srivastava, Gyorgy Petrovics.
4342 Differential expression of novel PKD1 related
biomarker panel in African American men with prostate
cancer. Bita Nickkholgh, Xiaolan Fang, Shira M. Winters, Nora
Fino, KC. Balaji.
4343 Prognostic significance of CBP (CREB-binding
protein) in prostatic adenocarcinomas (PACs): CBP is
associated with high grade, advanced stage and
biochemical disease recurrence. Jeffrey S. Ross, Olga
Voronel, Siddhartha Dalvi, Gregory M. Sheehan, Christine E.
Sheehan, Tipu Nazeer, Bhaskar V. Kallakury.
4344 Olfactomedin 4 plays a tumor-suppressor role
and is a novel candidate biomarker in the prostate cancer
progression and independent of PSA. Hongzhen Li, Ye
Chen, Wenli Liu, Jianqiong Zhu, Chin Kay, Xujing Wang,
Griffin P. Rodgers.
4345 FGFR1, a new FISH biomarker, may predict
recurrence of prostate cancer after prostatectomy. Ying
Zhang, Katerina Pestova, Jing Du, Ping Liu, Lela Buckingham,
Tracey Colpitts.
4346 Prognostic gene signature for intermediate risk
prostate cancer. Brian Li, Robin Hallet, Ying Wu, Greg Pong, John
Hassell, Sebastien Hotte, Mark Levine, Himansu Lukka, Anita Bane.
4347 A novel live cell diagnostic platform measuring
phenotypic biomarkers using objective algorithmic
analysis enables further risk stratification for
intermediate-risk prostate cancer patients. Michael S. Manak,
Wendell R. Su, Andrew Min, Brad J. Hogan, Matthew J. Whitfield,
Jonathan S. Varsanik, Delaney Berger, Mani Foroohar, Kimberly M.
Rieger-Christ, Travis B. Sullivan, Naveen Kella, Ray Hernandez,
Vladimir Mouraviev, Kevin B. Knopf, Hani H. Rashid, David M. Albala,
Grannum R. Sant, Ashok C. Chander.
4349 Cancer histologic and cell nucleus architecture
differentiate prostate cancer Gleason patterns 3 from 4.
Robert W. Veltri, Sahirzeeshan Ali, Wen-Chyi Lin, Guangjing
Zhu, Jonathan I. Epstein, Ching-Chung Li, Anant Madabhushi.
4350 Prognostic potential of epithelial to mesenchymal
transition in prostate cancer at first presentation. Ahmad AlSukaini, Claire Hart, Richard Robinson, Mick Brown, Noel Clarke.
4351 Identification of molecular signature associated with
the castration-resistant prostate cancer (CRPC) development by
next-generation sequencing (NGS)-based transcriptomic
profiling. Seon-Kyu Kim, Jeong-Hwan Kim, Pildu Jeong, WunJae Kim, Yong Sung Kim, Seok-Joong Yun, Seon-Young Kim.
4352 Prediction of prostate cancer progression with
biomarkers and tissue morphometry changes. Guangjing
Zhu, George Lee, Christine Davis, Luciane T. Kagohara,
Jonathan I. Epstein, Patricia Landis, H. Ballantine Carter,
Anant Madabhushi, Robert W. Veltri.
4353 Improved prediction of prostate cancer prognosis
by using a multiparametric molecular classifier. Maria
Christina Tsourlakis, Martina Kluth, Thorsten Schlomm,
Ronald Simon, Guido Sauter, Sarah Minner.
4355 Prognostic significance of RUNX2 protein
expression in carcinomas of the prostate (PAC), colon
(CRC), and breast (BC). Bhaskar V. Kallakury, Albert Huho,
Ann B. Boguniewicz, David M. Jones, Tipu Nazeer, Hwa Jeong
Lee, Christine E. Sheehan, Jeffrey S. Ross.
4356 Factors predicting lymph node metastasis in
resected lung adenocarcinoma of 2cm or smaller. Jung-Jyh
Hung, Teh-Ying Chou, Yu-Chung Wu, Wen-Hu Hsu.
Poster
:LJ[PVU
26
26
533
POSTER SESSION
Poster
:LJ[PVU
27
27
New Targets 1
Poster
Board
1.
4357 Key differences revealed in NSD2 kinetics using truncated
versus full-length protein. Melissa B. Pappalardi, Jessica L. Schneck,
Rosalie Matico, Michael Huddleston, Wangfang Hou, Patrick McDevitt,
Roland Annan, Robert Kirkpatrick, Ryan Kruger.
2.
Poster
Board
Abstract
Number
16.
4358 Targeting connexin 43 with ␣-connexin carboxyl-terminal
(ACT1) peptide in breast cancer. Christina Grek, Joshua M. Rhett, Melissa
Abt, Jaclynn Bruce, Gautam Ghatnekar, Elizabeth S. Yeh.
4372 Phosphodiesterase 10A inhibition suppresses lung tumor
cell growth by activating PKG to inhibit ras and Wnt signaling. Bing
Zhu, Kevin Lee, Joshua Canzoneri, Veronica Ramirez-Alcantara, Sara
Sigler, Bernard Gary, Ethan Butler, Adam Keeton, Xi Chen, Michael Boyd,
Gary Piazza.
17.
3.
4359 Characterization of GalNAc-conjugated generation 2.5 ASOs
in DEN and DEN/CCL4-induced HCC tumors. Joanna Schmidt, Minji Jo,
Tianyuan Zhou, Youngsoo Kim, A. R. MacLeod.
4373 Targeting lung cancer stem cells with inhibition of multiple
drug resistance by demethoxylcurcumin-carrying chitosan-antibody
core-shell nanoparticles. Shih-Hwa Chiou.
18.
4.
4360 Validation of phosphodiesterase 10A as a cancer target.
Kevin Lee, Nan Li, Xi Chen, Bing Zhu, Larry Yet, Luciana Madeira da Silva,
Suzanne Russo, Adam B. Keeton, Michael R. Boyd, Gary A. Piazza.
4374 DCLK1 is a broadly dysregulated target against epithelialmesenchymal transition, focal adhesion, and stemness in clear cell
renal carcinoma. Nathaniel Weygant, Dongfeng Qu, Randal May, Ryan M.
Tierney, William L. Berry, Lichao Zhao, Shweta Agarwal, Parthasarathy
Chandrakesan, Sripathi M. Sureban, Michael J. Schlosser, James J.
Tomasek, Courtney W. Houchen.
5.
4361 Efficacy of MET inhibitors in NSCLC with CBL alterations.
Yi-Hung Carol Tan, Cleo Rolle, Li Zhu, Minu K. Srivastava, Sherven Sharma,
Ravi Salgia.
19.
6.
4362 Screening of investigational antimalarials for anticancer
activity in high risk N-MYC amplified neuroblastoma (NB). Don W.
Coulter, Jonathan Vennerstrom, John G. Sharp, Yuxiang Dong, Xiaofang
Wang, Erin McIntyre, Tim McGuire.
4375 Podoplanin (PDPN): novel biomarker and chemotherapeutic
target. Harini Krishnan, Jhon Ochoa-alvarez, Yongquan Shen, Evan Nevel,
David Kephart, Angels Nguyen, Min Han, Nimish Acharya, Robert Nagele,
Maria Ramirez, W. T. Miller, Evelyne Kalyoussef, Soly Baredes, Mahnaz
Fatahzadeh, Lasse Jensen, Alan Shienbaum, Gary Goldberg.
20.
4376 Characterization and targeting of TAF15, a radiationinducible target in multiple cancer types. Lincoln Muhoro, Heping Yan,
Sergey Kaliberov, Jerry Jaboin, David Curiel, Dennis Hallahan.
7.
4363 Selective modulation of IRES-mediated translation in
malignant cells. Christos Vaklavas, Zheng Meng, Hyoungsoo Choi, William
E. Grizzle, Kurt R. Zinn, Scott W. Blume.
21.
8.
4364 Characterization of mucin-like 1 (MUCL1) in breast cancer
and its novel role as a potent activator of cell proliferation. Sarah J.
Conley, Emily Bosco, David Tice, Robert Hollingsworth, Ronald Herbst,
Zhan Xiao.
4377 Biodistribution and therapeutic effects of a monoclonal
antibody against Eph receptor A10 in a breast cancer xenograft model.
Kazuya Nagano, Yuka Maeda, Takuya Yamashita, Yohei Mukai, Haruhiko
Kamada, Kazuma Higashisaka, Yasuo Yoshioka, Yasuo Tsutsumi, Shin-ichi
Tsunoda.
22.
4378 Targeting the embryonic morphogen Nodal reduces viability
of doxorubicin-treated breast cancer cells in vitro. Thomas M.
Bodenstine, Grace S. Chandler, Naira V. Margaryan, Luigi Strizzi, Alina
Gilgur, Elisabeth A. Seftor, Richard E. Seftor, Zhila Khalkhali-Ellis, Andrey
Ugolkov, Andrew P. Mazar, Mary J. Hendrix.
23.
4379 MPT0B292 enhances acetylation of ␣-tubulin through upregulation of acetyltransferase gene, MEC-17 and exhibits potent antitumor, anti-angiogenesis and anti-metastatic effects in vitro and in
vivo. Jang-Yang Chang, Yun-Ching Cheng.
24.
4380 IACS-10759: A novel OXPHOS inhibitor which selectively kill
tumors with metabolic vulnerabilities. Marina Protopopova, Madhavi
Bandi, Jennifer Bardenhagen, Christopher Bristow, Christopher Carroll,
Edward Chang, Ningping Feng, Jason Gay, Mary Geck Do, Jennifer Greer,
Marina Konopleva, Polina Matre, Zhijun Kang, Gang Liu, Florian Muller,
Timothy Lofton, Timothy McAfoos, Yuting Sun, Melinda Smith, Jay Theroff,
Yuanqiang Wu, Lynda Chin, Giulio Draetta, Philip Jones, Carlo Toniatti, M.
Emilia Di Francesco, Joseph R. Marszalek.
25.
4381 High efficacy of T-LAK cell-originated protein kinase
inhibitor in acute myeloid leukemia with FLT3-ITD mutation. Houda
Alachkar, Martin Mutonga, Jae-Hyun Park, Gregory Malnassy, Alex Woods,
Gordana Raca, Olatoyosi M. Odenike, Naofumi Takamatsu, Takashi
Miyamoto, Shoji Hisada, Yo Matsuo, Wendy Stock, Yusuke Nakamura.
26.
4382 Anti-human LSR monoclonal antibody inhibits tumor growth
of ovarian cancer directly. Kosuke Hiramatsu, Satoshi Serada, Takayuki
Enomoto, Satoshi Nakagawa, Akiko Morimoto, Minoru Fujimoto, Takuhei
Yokoyama, Yusuke Takahashi, Yutaka Ueda, Kiyoshi Yoshino, Eiichi Morii,
Tadashi Kimura, Tetsuji Naka.
27.
4383 Vitamin E delta-tocotrienol inhibits metastasis and targets
cancer stem cell signaling in human pancreatic cancer. Kazim Husain,
Said M. Sebti, Mokenge P. Malafa.
28.
4384 TET inhibits phosphorylation of eIF4E-binding protein, in
prostate cancer cells. Sweaty Koul, Qin Dong, Sergey Slepenkov, Hari K.
Koul.
29.
4384A A novel potential therapeutic target for breast,
lung, ovary and colon cancer. Matteo Parri, Alberto Grandi,
Susanna Campagnoli, Elisa De Camilli, Alice Santi, Boquan
Jin, Paolo Sarmientos, Guido Grandi, Giuseppe Viale, Paola
Chiarugi, Luigi Terracciano, Piero Pileri, Renata Maria
Grifantini.
9.
10.
11.
534
Abstract
Number
4365 Targeting the SF3B1 spliceosome protein: Development of a
reporter for HTS screen and pharmacodynamic profiling of small
molecule drug leads. Yihui Shi, Chandraiah Lagisetti Lagisetti, Amanda S.
Joyner, Lidia C. Sambucetti, Thomas R. Webb.
4366
Inhibition of late-stage tumor growth of human pancreatic
and triple-negative breast cancer by blocking the most downstream
“gatekeeper” signaling module, SIAH E3 ligase, in the oncogenic
ERBB/ K-RAS signaling pathway. Minglei Bian, Vasilena Zheleva, Xiaofei
Gao, Justin Odanga, Monica Njogu, Zena Urban, Bruce Knudsen, Richard A.
Hoefer, Roger R. Perry, Amy H. Tang.
4367 Discovery and evaluation of pharmacodynamic and
predictive biomarkers for anti-RSPO3, a treatment that reduces tumor
growth and cancer stem cell frequency in patient derived xenograft
tumor models. Fiore Cattaruzza, Pete Yeung, Wan-Ching Yen, Alayne
Brunner, Min Wang, YuWang Liu, Marcus Fischer, Gilbert O’Young, Cecile
Chartier, Austin Gurney, Tim Hoey, John Lewicki, Ann M. Kapoun.
12.
4368 Targeting of a radiation inducible tax-interaction protein 1
(Tip 1) as a novel molecule for cancer treatment. Heping Yan, Kim
Nguyen, Vaishali Kapoor, Steve Mnich, Jalen Scott, Hua Li, Buck Rogers,
Dinesh Thotala, Dennis Hallahan.
13.
4369
Rearrangements of the erythropoietin receptor are recurrent
in Ph-like acute lymphoblastic leukemia and are sensitive to Jak2
inhibition. Ilaria Iacobucci, Kathryn G. Roberts, Yongjin Li, Jinghui Zhang,
Richard C. Harvey, Debbie Payne-Turner, Marcus Valentine, Kelly
McCastlain, John Easton, I-Ming Chen, Michael Rusch, Steven M. Kornblau,
Marina Konopleva, Elisabeth Paietta, Jacob M. Rowe, Ching-Hon Pui, Julie
M. Gastier-Foster, Shalini Reshmi, Mignon L. Loh, Cheryl Willman, James R.
Downing, Stephen P. Hunger, Charles G. Mullighan.
14.
GSK3␣/␤ inhibition as a drug target in prostate cancer.
Husnain Ali, Amy Burke, Enda O’Connell, Frank Sullivan, Frank Giles,
Sharon Glynn.
15.
4371 Transient receptor potential cation channel 3 (TRPC3)
regulates tumor proliferation and migration of BRAF wild type human
malignant melanoma. Kayoko Oda, Masanari Umemura, Mayumi
Katsumata, Haruki Aoyama, Ayako Makino, Makoto Ohtake, Itaru Sato,
Yukie Yamaguchi, Yoji Nagashima, Michiko Aihara, Yoshihiro Ishikawa,
Akane Nagasako.
4370
POSTER SESSION
Novel Drug Delivery Systems
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
4385 Colorectal cancer lung metastasis treatment with lungselective PI3K pathway inhibition. Piotr G. Rychahou, Younsoo Bae,
Yekaterina Zaytseva, Eun Y. Lee, Heidi L. Weiss, B. Mark Evers.
2.
4386 Docetaxel-trastuzumab stealth immunoliposome: design
and non-clinical study in HER2+ and HER2- breast cancer models.
Raphaelle R. Fanciullino, Jean-Michel Brunel, Florian Correard, Sarah
Giacometti, Joseph Ciccolini.
4399 Utilizing cobalt coordination chemistry as a traceless
prodrug strategy in targeted drug delivery. Robby A. Petros, Duong T.
Nguyen, Ronaldo J. Cavazos, Clifford S. Morrison, Jana B. Lampe, Alesha N.
Harris, Brian K. McFarlin.
16.
4400 Anti-tumor activity of liposomal docetaxel prodrug MNK010 on PC3 human prostate xenografts in mice. Richard M. Fitch, Jolette
K. Wojdyla, James A. Blackledge, William D. McGhee.
18.
4401 Tumor-associated antigen gene-loading polyplex micelle is
a promising platform for anti-cancer DNA vaccine. Lin Cui, Kouichi
Furugaki, Kensuke Osada, Kazunori Kataoka, Kenji Nakano.
19.
4402 Lazaroid formulations for brain delivery in treatment of
glioblastoma multiforme. Prajakta Gadgil, Diana S. Chow, Pamela New,
Jaymin Shah.
20.
4403 Antitumor properties of ouabain in lipid double emulsion
integrated with tumor cell membrane fractions. Jun Wu, Mariele
Mondala, Meng-Yin Hsieh, Eugene Roberts, Richard Ermel.
21.
4390 Metronomic maintenance chemotherapy of orally active
pemetrexed for effective treatment of lung cancer. Foyez Mahmud,
Seho Kweon, Hyo Won Chang, Hae Yoon Nam, Mi Ra Kim, Jung Je Park,
Sang Yoon Kim, Youngro Byun.
4404 A novel chitosan-based hydrogel for intratumoral release of
immunotherapeutic cytokines. Ethan D. Lowry, Christopher Wallace,
Bhanu prasanth Koppolu, Sean Smith, David Zaharoff.
22.
4391 Evaluation of tumor targeting activity by elastin like
polypeptide containing cell penetrating peptide and IL-4 receptor
targeting peptide. Young-Jin Lee, Vijaya Sarangthem, Yun-Jae Kim, Kuen
Hur, Byung-Heon Lee, Rang Woon Park.
4405 Tumor-targeted nanotherapeutics. Olga B. Garbuzenko,
Andriy Kuzmov, Justin E. Sapiezynski, Oleh Taratula, Vatsal Shah, Min
Zhang, Ronak Savla, Shali John, Lorna Rodriguez-Rodriguez, Tamara
Minko.
23.
4406 ROR1 targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in
mantle cell lymphoma in-vitro and in-vivo. Rajeswaran Mani, Chi-Ling
Chiang, Frank W. Frissora, Ribai Yan, Xiaokui Mo, Sivasubramanian Baskar,
Christoph Rader, Mitch Phelps, Ching-Shih Chen, Robert Lee, John Byrd,
Robert Baiocchi, L J. Lee, Natarajan Muthusamy.
24.
4407 Novel mitochondria-targeted Doxorubicin Prodrug for
colorectal cancer and hepatocellular carcinoma: In vitro studies.
Jemianne Jia, Minzhi Xing, Xiaoxi Ling, Mingfeng Bai, Hyun S. Kim.
26.
4409 STA-12-8666: a first-in-class HSP90 inhibitor drug conjugate
(HDC) designed to selectively deliver chemotherapy to tumors. David
A. Proia, Donald L. Smith, Junyi Zhang, Dan Zhou, John-Paul Jimenez, Jim
Sang, Sarah Rippy, Cheryl London, Luisa S. Ogawa, Jun Jiang, Teresa
Przewloka, Manuel Sequeira, Jaime Acquaviva, Suqin He, John Chu,
Chaohua Zhang, Yuan Liu, Josephine Ye, Vladimir Khazak, Igor Astsaturov,
Takayo Inoue, Noriaki Tatsuta, Richard C. Bates, Andrew Sonderfan,
Dinesh Chimmanamada, Weiwen Ying.
27.
4410 An ICAM-1-targeted, Lcn2 siRNA-encapsulating liposome as
a potent anti-angiogenic agent for triple-negative breast cancer. Peng
Guo, Jiang Yang, Marsha Moses, Debra Auguste.
4387 Anti-tumor activity of TNF-gold nanodrugs tagged with
tumor vasculature-homing peptides containing the NGR or isoDGR
motives. Flavio Curnis, AnnaMaria Gasparri, Angelina Sacchi, Martina
Fiocchi, Angelo Corti.
4.
4388
Targeting Ki-67 in the nucleus by light-controlled delivery
of monoclonal antibody constructs. Sijia Wang, Gereon Hüttmann,
Tayyaba Hasan, Ramtin Rahmanzadeh.
5.
4389 Liposomes containing piperazine compounds inhibit tumor
growth in a patient-derived xenograft model of glioblastoma
multiforme. Elden P. Swindell, Andrey Ugolkov, Christian Freguia, Oleksii
Dubrovskyi, Patrick L. Hankins, Jeong Yang, Jeffrey J. Raizer, James P.
Chandler, Charles D. James, Andrew P. Mazar, Thomas V. O’Halloran.
7.
8.
9.
Abstract
Number
15.
3.
6.
Poster
Board
4392 Generation of a novel ormeloxifene nanoparticle
formulation for pancreatic cancer treatment. Sheema Khan, Neeraj
Chauhan, Murali M. Yallapu, Mara C. Ebeling, Swathi Balakrishna, Robert T.
Ellis, Paul A. Thompson, Stephen W. Behrman, Nadeem Zafar, Man M.
Singh, Fathi T. Halaweish, Meena Jaggi, Subhash C. Chauhan.
4393 Design and synthesis of novel conjugates for targeting the
folate receptor: Exploiting cytotoxic GARFTase inhibitors for delivering
additional chemotherapeutic payloads to cancer cells. Iontcho R.
Vlahov, Fei You, Hanna F. Klein, Paul J. Kleindl, Melissa Nelson, Marilynn
Vetzel, Joseph A. Reddy, Christopher P. Leamon, Larry H. Matherly, Aleem
Gangjee.
10.
4394 Selective accumulation and specific tumor damage by folate
receptor-targeted CA-4 prodrug as part of a combination of
photodynamic therapy and site-specific chemotherapy. Nkepang
Gregory, Moses Bio, Pallavi Rajaptura, Samuel G. Awuah, Youngjae You.
11.
4395
Strategy to overcome inherent TRAIL-based therapeutic
limitations. Yumin Oh, Maggie Swierczewska, Seulki Lee.
12.
4396 Nanocarrier for monoclonal antibody delivery. Andrew
Gdowski, Amalendu Ranjan, Anindita Mukerjee, Jamboor Vishwanatha.
28.
4411 Oral drug formulations containing microspheres. Duc P. Do,
Alexander Kar.
13.
4397 Preclinical development of a novel hypoxia-activated EGFR
inhibitor using a cobalt(III)-based prodrug design. Petra Heffeter,
Claudia Karnthaler-Benbakka, Diana Groza, Kushtrim Kryeziu, Walter
Berger, Bernhard K. Keppler, Christian R. Kowol.
29.
4412 Assessing protease inhibition enhanced delivery of prostate
tumor targeted peptide receptor based radiotherapy. Tammy L. Rold,
Nicole E. Bernskoetter, Ashley F. Berendzen, Timothy J. Hoffman.
30.
14.
4398
4413 Zinc-dipicolylamine directed pharmaceutical delivery
system (ZAPS) as an innovative cancer drug delivery platform. Lun K.
Tsou, Yu-Wei Liu, Yun-Yu Chen, Chen-Fu Lo, Teng-Kuang Yeh, ChienHuang Wu, Kak-Shan Shia, Joe C. Shih, Brian D. Gary, Koon Y. Pak, ChiungTong Chen.
Methotrexate derivative with intrinsic magnetism.
MASANARI UMEMURA, Mayumi Katsumata, Itaru Sato, Akane Nagasako,
Haruki Aoyama, Ayako Makino, Makoto Ohtake, Kayoko Oda, Kosuke
Matsuo, Haruki Eguchi, Yoshihiro Ishikawa.
28
28
535
POSTER SESSION
Poster
:LJ[PVU
29
29
Novel Mechanisms of Drug Response, Sensitivity, or Resistance 1
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
536
Abstract
Number
4414 RhoA activation in diffuse type gastric
adenocarcinoma promotes cancer stem cell phenotypes
including chemotherapy resistance. Changhwan Yoon, SooJeong Cho, Bulent A. Aksoy, Do Joong Park, Sam S. Yoon.
4415 Tyrosine phosphorylation is essential for OCT2
function and a target of inhibition by TKIs. Navjotsingh Pabla,
Jason A. Sprowl, Su Sien Ong, Alice A. Gibson, Guoqing Du,
Wenwei Lin, Shuiying Hu, Lie Li, Taosheng Chen, Alex
Sparreboom.
4416 Reversal of chemoresistance in ovarian cancer cells
by the liposomal co-delivery of MDR inhibitors and paclitaxel.
Shravan K. Sriraman, Yilin Zhang, Ed Luther, Ernst Lengyel,
Vladimir Torchilin, Vladimir Torchilin.
4417 Vatalanib targets ABCG2-overexpressing multidrug
resistant colon cancer cells under hypoxia. Kenneth K. To,
Daniel C. Poon, Yuming Wei, Fang Wang, Ge Lin, Li-wu Fu.
4418 Autophagy induction contributes to cisplatin
resistance in ovarian cancer and is independent of AKT
pathway activity. Emma L. Kipps, Mike I. Walton, Udai Banerji,
Stan B. Kaye, Michelle D. Garrett.
4419 Design, synthesis and biological evaluation of Naryl-3,3,3-trifluoro-2-hydroxy-2-methylpropionamide analog
as a promising inhibitor of the multidrug resistance-linked
ABCG2 transporter. Atish S. Patel, Tianwen Li, Nagaraju
Anreddy, Yufen Zhao, Rishil J. Kathawala, Yijun Wang, Suresh V.
Ambudkar, Zhe-Sheng Chen, Changmei Cheng.
4420 Factors potentially contributing to sensitivities of
CD22-targeting agents in B-cell malignancies. Xin Yao, Patricia
Burke, Joyce O. Obidi, Xiaoru Chen, Haifeng Bao, Yihong Yao,
Jiaqi Huang.
4421 GPER-mediated activation of the cAMP response
element-binding protein (CREB) and subsequent IGFBP-1
expression is altered during the development of tamoxifen
resistance. Ali Vaziri-Gohar, Kevin D. Houston.
4422 TTT-28, a newly synthesized thiazole-valine peptide,
antagonizes multidrug resistance by inhibiting the efflux
activity of the ABCB1 transporter. Yi-Jun Wang, Nagaraju
Anreddy, Bhargav A. Patel, Eduardo E. Chufan, Satyakam Singh,
Guan-Nan Zhang, Yun-Kai Zhang, Anna Maria Barbuti, Suresh V.
Ambudkar, Tanaji T. Talele, Zhe-Sheng Chen.
4423 Chemoresistance regulation by COL11A1 in ovarian
cancer. Yi-Hui Wu.
4424 Molecular diagnostics of drug resistant multiple
myeloma cases using targeted next generation sequencing.
Hiroshi Ikeda, Yasushi Sasaki, Tetsuyuki Igarashi, Yuka Aoki,
Toshiaki Hayashi, Tadao Ishida, Takashi Tokino, Yasuhisa
Sinomura.
4425 Multiple -omic analyses of a pair of primary HCC
tumor cell lines with different drug response revealed the
mechanisms of drug resistance. Gang Hu, Alicia Du, Yong
Huang, Kunyan Liu, Fubo Xie, Xuzhen Tang, Xueyan Yang, Qi Gu,
Yixin Zhang, Weikang Tao, Yingjia Zhang, Wei Tang, He Zhou.
4426 A 13 mer LNA miR-221 inhibitor restores drug
sensitivity in melphalan-refractory multiple myeloma cells.
Annamaria Gulla, Maria Teresa Di Martino, Maria Eugenia Gallo
Cantafio, Eugenio Morelli, Nicola Amodio, Cirino Botta, Maria Rita
Pitari, Santo Giovanni Lio, Pierosandro Tagliaferri, Pierfrancesco
Tassone.
4427 Apoptosis, autophagy and ATP: The dynamic
interaction of cellular ATP and drug resistance in MET
amplified gastric cancer. Rebecca Dunbar Schroeder, David
Hong, David J. McConkey.
4428 Metformin effects on ABCB1 expression and
proliferation in pancreatic cancer cell lines with different
ABCB1 genotypes/haplotypes. Beverly D. Lyn-Cook, Taylor
Osborne, Stancy Joseph, Beverly Word, Li Pang, George
Hammons.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
4429 EGR1-MIR152 pathway overcomes acquired cisplatin
resistance in ovarian cancer cells by inhibiting cyto-protective
autophagy via ATG14. Jun He, Jing-Jie Yu, Bing-Hua Jiang.
4430 Loss of the histone methyltransferase EZH2 induces
chemoresistance in acute myeloid leukemia (AML). Stefanie
Göllner, Shuchi Agrawal-Singh, Tino Schenk, Hans-Ulrich Klein,
Christian Rohde, Tim Sauer, Mads Lerdrup, Sigal Tavor, Friedrich
Stölzel, Gerhard Ehninger, Gabriele Köhler, Martin Dugas, Arthur
Zelent, Christian Thiede, Wolfgang E. Berdel, Klaus Hansen,
Carsten Müller-Tidow.
4431 Musashi enhances GS3K-beta and promotes
stemness-related chemoresistance in glioblastoma. Hsiao-Yun
Chen, Shih-Hwa Chiou.
4432 A-803467, a tetrodotoxin-resistant sodium channel
blocker, modulates ABCG2-mediated MDR in vitro and in vivo.
Nagaraju Anreddy, Atish Patel, Yun-Kai Zhang, Yi-Jun Wang,
Suneet Shukla, Rishil J. Kathawala, Priyank Kumar, Pranav Gupta,
Suresh V. Ambudkar, John N. Wurpel, Zhe-Sheng Chen.
4433 P-gp-overexpressing MDR cells shed larger
extracellular vesicles than their drug-sensitive counterparts.
Vanessa Lopes-Rodrigues, Alessio Di Luca, Diana Sousa, Hugo
Seca, Paula Meleady, Michael Henry, Raquel T. Lima, Robert
O’Connor, M. Helena Vasconcelos.
4434 Selinexor and melphalan combination therapy for
the treatment of multiple myeloma. Joel G. Turner, Jana L.
Dawson, Christopher Cubitt, Taiga Nishihori, Claudio Anasetti,
Melissa Alsina, Rachid C. Baz, Michael Kauffman, Sharon
Shacham, William S. Dalton, Daniel M. Sullivan.
4435 Mucolytic agent N-Acetylcysteine breaks resistance
to trastuzumab caused by MUC4 overexpression in human
BC-bearing nude mice. Zena Wimana, Bruno Vanderlinden,
Thomas Guiot, Renato Morandini, Gilles Doumont, Gaetan Van
Simaeys, Serge Goldman, Patrick Flamen, Ghanem Ghanem.
4436 Metformin upregulates hENT1 expression and
enhances gemcitabine efficacy in pancreatic cancer cells.
Stancy J. Joseph, Taylor Osborne, Beverly Word, Beverly LynCook.
4437 The relevance of aberrant FPGS splicing for ex vivo
MTX resistance and clinical outcome in childhood acute
lymphoblastic leukemia. Anna Wojtuszkiewicz, Yehuda G.
Assaraf, Mirthe Hoekstra, Gerrit Jansen, Godefridus J. Peters,
Edwin Sonneveld, Gertjan L. Kaspers, Jacqueline Cloos.
4438 Bevacizumab-induced MIF depletion: A novel
mechanism of bevacizumab resistance in glioblastoma.
Brandyn A. Castro, Arman Jahangiri, Gary Kohanbash, Michael
Delay, Ruby Kuang, Garima Yagnik, Liane Miller, Maxim Sidorov,
Rebecca Chen, Hideho Okada, Manish K. Aghi.
4439 Ero1L is a determinant of resistance to bortezomib
and collateral sensitivity to MTI-101-induced cell death in
myeloma. Michael Emmons, Lori Hazlehurst, Steven Escherich,
Mark McLaughlin, Javier Cuevas, Daniel Sullivan.
4440 The functional role of insulin-like growth factor
binding protein-2 in esophageal adenocarcinoma
chemoresistance. Amy L. Myers, Lin Lin, Derek J. Nancarrow,
Zhuwen Wang, Daysha Ferrer-Torres, David G. Beer, Andrew C.
Chang.
4441 Differential regulation of AP1 components by the
Hedgehog pathway. Lauren Amable, Eddie Reed, Kenji Kudo.
4442 TP53 hot spot mutations in ovarian cancer: Selective
resistance to microtubule stabilizing agents in monoclonal
cells and comparison of clinical outcomes from The Cancer
Genome Atlas data. Brandon-Luke L. Seagle, Gerda Hofstteter,
Chia-Ping Yang, Kevin Eng, Oluwatosin Odunsi-Akanji, Kunle
Odunsi, Shohreh Shahabi.
4443 PB-42: Design and characterization of a glutathione
pro-drug selectively delivered to normal tissue and not tumor
tissue. James P. Thomas, Peter G. Geiger.
POSTER SESSION
Novel Targets 1
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
4444 Small molecule drug Verteporfin inhibits TAZ/YAP-driven
signaling and tumorigenicity of breast cancer cells. Han Sun, Mingyao
Ying.
2.
4445 Selective inhibitor of nuclear exporter CRM1/XPO1,
Selinexor (KPT-330), exhibits remarkable activity against AML
leukemia-initiating cells while sparing normal hematopoietic cells.
Julia Etchin, Bonnie T. Le, Alla Berezovskaya, Amy S. Conway, Weihsu C.
Chen, Alex Kentsis, Marc R. Mansour, Richard M. Stone, Ilene A. Galinsky,
Daniel J. DeAngelo, Dilara McCauley, Michael Kauffman, Sharon Shacham,
Jean C. Wang, Andrew L. Kung, Thomas Look.
3.
4446 Discovery of tumor types highly susceptible to FASN
inhibition and biomarker candidates for clinical analysis. Timothy S.
Heuer, Richard Ventura, Kasia Mordec, Julie Lai, Joanna Waszczuk, Glenn
Hammonds, Marina Fridlib, Russell Johnson, Lily Hu, Allan Wagman, Marie
O’ Farrell, Douglas Buckley, George Kemble.
4.
4447 Targeting SET oncoprotein reactivates the tumorsuppressor PP2A and shows synergy with sorafenib in hepatocellular
carcinoma. Man-Hsin Hung, Chung-Wai Shiau, Chih-Ting Shin, Hui-Chuan
Yu, Wei-Tien Tai, Chun-Yu Liu, Cheng-Yi Wang, Kuen-Feng Chen.
5.
4448 Identification of a small molecule inhibitor of aldolase A for
the targeting of hypoxic cancer cells. Petrus R. de Jong, Geoffrey V.
Grandjean, Ashwini K. Devkota, Eun Jeong Cho, Kevin N. Dalby, Garth
Powis.
6.
4449
A novel Porcupine inhibitor is effective in the treatment of
cancers with RNF43 mutations. Zhiyuan Ke, Babita Madan, Shermaine Q.
Lim, Sifang Wang, Jenefer Alam, Soo Yei Ho, Duraiswamy Athisayamani
Jeyaraj, Kakaly Ghosh, Yun Shan Chew, Li Jun Ding, Vithya Monoharan,
Vishal Pendharkar, Esther Ong, Jeffrey Hill, Kanda Sangthongpitag,
Thomas Keller, May Ann Lee, David M. Virshup.
7.
CB839, an orally bioavailable glutaminase inhibitor, shows
potent antitumor activity in vitro against models of soft tissue sarcoma
and chondrosarcoma. Tahir N. Sheikh, Parag P. Patwardhan, Serge
Cremers, Gary K. Schwartz.
8.
4451
Novel small molecule AG311 induces tumor cell death
through inhibition of mitochondrial electron transport. Anja Bastian,
Lora C. Bailey-Downs, Jessica E. Thorpe, Ravi Kumar Vyas Devambatla,
Aleem Gangjee, Kenneth M. Humphries, Michael A. Ihnat.
9.
4452 Liver selective acetyl-CoA carboxylase inhibition by ND-654
improves survival in cirrhotic rats with hepatocellular carcinoma.
Omeed Moaven, Lan Wei, Geraldine Harriman, Jeremy Greenwood,
Sathesh Bhat, William F. Westlin, H. J. Harwood, Rosana Kapeller, Danielle
K. DePeralta, Kenneth K. Tanabe, Bryan C. Fuchs.
Poster
Board
Abstract
Number
15.
4458 The HIV-derived protein Vpr52-96 has anti-glioma activity in
vitro and in vivo. Jens Kuebler, Stefanie Kirschner, Linda Hartmann, Grit
Welzel, Maren Engelhardt, Carsten Herskind, Marlon R. Veldwijk, Christian
Schultz, Manuela Felix, Gerhard Glatting, Patrick Maier, Frederik Wenz,
Marc A. Brockmann, Frank A. Giordano.
16.
4459 Accelerated drug discovery platform yields synthesis of
novel stearoyl-CoA desaturase 1 inhibitors that demonstrate antitumor efficacy in several models of aggressive cancer. Christina A. Von
Roemeling, Thomas R. Caulfield, Derek C. Radisky, Ilah Bok, Laura A.
Marlow, James Miller, Mojda Sidiqi, Anthony B. Pinkerton, Winston W. Tan,
Amy L. Lane, Han W. Tun, John A. Copland.
17.
4460 Targeting the redox-protective protein MTH1 for cancer
therapy: A novel way to exploit the unique redox status of cancer cells.
Andrea Glasauer, Horst Irlbacher, Anja Richter, Luisella Toschi, Michael
Steckel, Andrea Haegebarth.
18.
4461 New potent AMPK activators against colorectal cancer stem
cells. Dasha Kenlan, Piotr G. Rychahou, Vitaliy Sviripa, David Watt, B. Mark
Evers.
19.
4462 The effects of NT-1044, a novel AMPK activator, on
endometrial cancer cell proliferation and apoptosis. Dario R. Roque,
Weiya W. Wysham, Chunxiao Zhou, Ken Batchelor, Wendy R. Brewster,
Victoria L. Bae-Jump.
20.
4463 Riluzole effectively modulates cell cycle and cell death in a
molecularly diverse set of breast cancer cell lines. Sonia C. Dolfi, Daniel
J. Medina, Shridar Ganesan, Alexei Vazquez, Kim M. Hirshfield.
21.
4464 Effect of bacterial quorum sensing lactones on human
pancreatic carcinoma cells. Senthil R. Kumar, Jeffrey Bryan.
22.
4465 Sequential combination of docetaxel with a novel SHP-1
agonist enhanced anti-tumor effect in triple negative breast cancer
cells. Ling-Min Tseng, Chun-Yu Liu, Shiu-Ping Yang, Wan-Lun Wang,
Jung-Chen Su, Chia-Yun Wu, Chung-Wai Shiau, Kuen-Feng Chen.
23.
4466 New biomarkers to optimize preclinical development of the
PDI inhibitor XCE853. Gregoire P. Prevost, Marine Garrido, Shili Xu, Celine
Lefebvre, Anne Chauchereau, Denis Carniato, Jean François Briand,
Mathieu Gutmann, Maria Serova, Annemilai Tijeras-Raballand, Armand De
Grammont, Eric Raymond, Christian Gespach, Michèle Sabbah, Nouri
Neamati, Marc-Henry Pitty, Paul Foster.
24.
4467 Targeting of chemokine receptor CXCR4 inhibits invasion
and sensitizes melanoma cells to chemotherapeutic agents. Manoj K.
Pandey, Deepkamal Karelia, Vijay P. Kale, Krishne Gowda, Arun K. Sharma,
Rogerio I. Neves, Shantu G. Amin.
4450
10.
4453 The dual CK2/TNIK inhibitor, ON108600 targets cancer stem
cells and induces apoptosis of paclitaxel resistant triple-negative
breast cancer cells. Amol Padgaonkar, Stephen Cosenza, Venkat Pallela,
Venkata Subbaiah DRC, MV Ramana Reddy, E Premkumar Reddy.
25.
4468 Anticancer activity of novel cucurbitacin analogue in
pancreatic cancer. Mohammed Sikander, Sheema Khan, Neeraj Chauhan,
Mohd S. Zaman, Murali M. Yallapu, Fathi T. Halaweish, Bhavin Chauhan,
Shabnam Malik, Meena Jaggi, Subhash C. Chauhan.
11.
4454 Targeting the gp130 receptor in preclinical models of triplenegative breast cancer. Leonel F. Hernandez-Aya, Yajing Liu, Kelsey Kerr,
Shuzo Tamura, Nouri Neamati, Max S. Wicha, Monika L. Burness.
26.
12.
4455 Relapsed/refractory AML responds robustly to IACS-10759,
a novel OXPHOS inhibitor. Marina Protopopova, Madhavi Bandi, Jennifer
Bardenhagen, Christophor Bristow, Christopher Carroll, Edward Chang,
Ningping Feng, Jason Gay, Mary Geck Do, Jennifer Greer, Marina
Konopleva, Polina Matre, Zhijun Kang, Gang Liu, Florian Muller, Timothy
Lofton, Timothy McAfoos, Jay Theroff, Yuting Sun, Yuanqiang Wu, Melinda
Smith, Lynda Chin, Giulio Draetta, Philip Jones, Carlo Toniatti, M. Emilia Di
Francesco, Joseph R. Marszalek.
4469 A novel class of inhibitors of the immunosuppressive
enzyme indoleamine 2,3-dioxygenase 1 (IDO1) with potential for the
treatment of cancer. Lai-Ming Ching, Brian D. Palmer, Petr Tomek, Jack U.
Flanagan, Kimiora Henare.
27.
4470 Targeting autophagy and apoptosis to enhance anticancer
effect on esophageal carcinoma in vitro. Yan Cai, Jiajing Cai, Qiang Ma,
Yuan Xu, Dongsheng Wang, Xiaolan Guo.
28.
4471 The antitumor activity of hyaluronic acid nimuselide-NH2
bioconjugate (CA102N) in human colorectal cancer (CRC). Eskouhie
Tchaparian.
13.
4456 Prevention of MICA shedding from HBV infected hepatocytes
to activate NK cells for better clearance of malignant foci and virusinfected cells. Motoko Ohno, Motoyuki Otsuka, Takahiro Kishikawa,
Takeshi Yoshikawa, Akemi Takata, Kazuhiko Koike.
29.
4472 Plitidepsin shows antitumor activity in patient-derived
tumor xenografts and hematologic malignancies. Armin Maier, Gerhard
Kelter, Vincent Vuaroquaux, Pablo M. Avilés Marin, Carmen Cuevas, Carlos
M. Galmarini, Heinz H. Fiebig.
14.
4457 Novel fatty-acid synthase inhibitor in combination with
platinum-based therapy provides increased tumor killing efficacy in
luminal breast murine model. David Darr, Yazan Alwarawrah, Lucas
Hunter, David Loiselle, Philip Hughes, Timothy Haystead.
30.
4473 WP760, A new highly potent and selective agent against
melanoma including BRAFi resistant melanoma. Aleksandra Rusin, Rafal
Zielinski, Izabela Fokt, Van Nguyen, Stanislaw Skora, Arumugam
Jayakumar, Waldemar Priebe.
30
30
537
POSTER SESSION
Poster
:LJ[PVU
31
31
Novel Targets 2
Poster
Board
Poster
Board
Abstract
Number
1.
4474 Dual targeting of the stress-p53 pathway as a potential anticancer therapy. Hua Lu, Qi Zhang, Shelya X. Zeng, Rui-Zhi Wu, Yiwei
Zhang, Daniel Nguyen, Xiang Zhou, Jun-ming Liao, Bo Cao.
16.
4489 Angiotensin-(1-7) prevents fibrosis in doxorubicin-treated
rats. Omeed A. Rahimi, Sharon M. Castellino, Cheryl E. Cammock, E Ann
Tallant, Patricia E. Gallagher.
2.
4475 In vitro efficacy profiling of ONC201 in cancer cells reveals
sensitivity pattern that is consistent with ER stress response. Joshua E.
Allen, Jo Ishizawa, Wafik S. El-Deiry, Michael Andreeff, Mathew Garnett,
Cyril Benes.
17.
3.
4476 Targeting Wnt5a and STAT3 pathways for the treatment of
prostate cancer. Giacomo Canesin, Susan Evans-Axelsson, Rebecka
Hellsten, Nicholas Don-Doncow, Tommy Andersson, Anders Bjartell.
4490 Selinexor (KPT-330) radio-sensitizes non-small cell lung
cancer cells in vitro and in vivo. Tami Rashal, Sivan Elloul, Marsha
Crochiere, Trinayan Kashyap, William Senapedis, Ryan George, Sharon
Friedlander, Maya Ilouze, Yosef Landesman, Robert Carlson, Nir Peled,
Michael Kauffman, Sharon Shacham, Yaacov Lawrence.
18.
4491 Antiproliferative activity of bacterial proteins against MDAMB-231 human breast adenocarcinoma and HEPG-2 human
hepatocellular carcinoma cells. Asvene K. Sharma, Partha Roy, Pratibha
Vats.
19.
4492 Novel carborane based inhibitors of carbonic anhydrase IX.
Jana Štěpánková, Pavlína Řezáčová, Jiří Brynda, Monika Harvanová,
Vlastimil Mašek, Alice Nová, Michal Šiller, Viswanath Das, Dalibor Doležal,
Bohumír Grüner, Václav Šícha, Petr Konečný, Pawel Znojek, Petr Džubák,
Marián Hajdúch.
20.
4493 Ironing out breast cancer: investigation of a novel iron
chelator. Anna Greenshields, David Hoskin, Melanie Coombs, Taryn Grant.
4.
4477 A 5-nitrobenzoate-derived compound elicits anti-cancer
metastatic activity by inhibition of poloplanin-stimulated tumor cellinduced platelet aggregation. Yao-Wen Chang, Pei-Wen Hsieh, Kowit-Yu
Chong, Ching-Ping Tseng.
5.
4478 6-Phosphofructo-2-Kinase (PFKFB3): At the crossroads of
resistance to targeted cancer therapies. Sucheta Telang, Julie O’Neal,
Yoannis Imbert-Fernandez, Brian Clem, Nadiia Lypova, Gilles H. Tapolsky,
John Trent, Jason Chesney.
6.
4479 ONC201 is non-toxic at efficacious doses in vitro and in vivo.
Joshua E. Allen, Wafik S. El-Deiry.
7.
4480 Evaluation of anti-tumor enone-based bioactive compounds
as specific thioredoxin reductase inhibitors. Kamila K. Kaminska, Joanne
Jia-An Low, Wan-Ying Chua, Esther Woon, Eng-Hui Chew.
21.
4494 Physical and metabolic stability of SH7139, a new drug
candidate for non-Hodgkin’s lymphoma targeting HLA-DR10. Rod
Balhorn, Saphon Hok, Monique C. Balhorn.
8.
4481 Tumor-targeting with novel 6-substituted thienoyl[2,3d]pyrimidine antifolates via cellular uptake by folate receptor ␣, and
inhibition of de novo purine nucleotide biosynthesis. Larry H. Matherly,
Xin Zhang, Adrianne Wallace, Zhanjun Hou, Christina George, Xilin Zhou,
Aleem Gangjee.
22.
4495 Small molecule approach for targeting tumor-associated
macrophages via a functional FR␤. Leroy W. Wheeler, Yingjuan Lu, Vicky
Cross, Alex Lloyd, Nikki Parker, Longwu Qi, Kevin Wang, Ian Wang,
Spencer Hahn, Jeremy Vaughn, Iontcho P. Vlahov, Philip S. Low,
Christopher P. Leamon.
9.
4482 A new quantification method for assessment of plasma
concentrations of pemetrexed and its polyglutamate metabolites.
Marcel Stoop, Sabine Visser, Evert van Dijk, Bruno Stricker, Theo Luider,
Joachim Aerts.
23.
10.
4483 Impact of loss of folate receptor alpha on antitumor effects
of novel 6-substituted pyrrolo[2,3-d]pyrimidine antifolates with
substrate activities for both folate receptors and the proton-coupled
folate transporter. Zhanjun Hou, Steve Orr, Christina George, Adrianne
Wallace, Larry H. Matherly, Lei Wang, Si Yang, Aleem Gandjee.
4496 Genomics-based resistome analysis revealed endogenous
adenosine kinase levels as a chief determinant of specificity for a novel
nucleoside analog lymphoma inhibitor. Utthara Nayar, Jonathan Reichel,
Jouliana Sadek, Denise Hernandez-Hopkins, Gunkut Akar, Hufeng Zhou,
Michelle A. Sahai, Peter Barelli, Ilaria Guasparri, Jennifer Totonchy, Duane
Hassane, Shizuko Sei, Robert H. Shoemaker, J. D. Warren, Olivier
Elemento, Kenneth M. Kaye, Ethel Cesarman.
24.
4497 Design and synthesis of hybrid drugs to target inflammatory
pathways in breast cancer. Irida Kastrati, Marton Siklos, Vladislav Litosh,
Gregory Thatcher, Jonna Frasor.
25.
4498 Assessing the effects of the small molecule cathepsin L
inhibitor, KGP94: combination with radiotherapy and evaluation of
antimetastatic potential in vivo. Thomas R. Wittenborn, Michael R.
Horsman.
26.
4499 Cytotoxicity, biochemical activity, and structural analysis of
ONC201 and comparisons to a biologically inactive isomer. Jessica
Wagner, Christina L. Kline, Richard S. Pottorf, Bhaskara R. Nallaganchu,
Gary L. Olson, David T. Dicker, Joshua E. Allen, Wafik S. El-Deiry.
11.
538
Abstract
Number
4484 BTP-114: An albumin binding cisplatin prodrug with
improved and sustained tumor growth inhibition. Benoit Moreau,
Rossitza Alargova, Adam Brockman, Kerry Whalen, Jamie Quinn, Kristan
Meetze, Patrick Bazinet, Michelle DuPont, Beata Krawiec, Kristina
Kriksciukaite, Charles Lemelin, Patrick LimSoo, Haley Oller, Mike Ramstack,
Danielle Rockwood, Rajesh Shinde, Sukhjeet Singh, Brian White, Tsun
AuYeung, Craig Dunbar, Mark Bilodeau, Richard Wooster.
12.
4485
Anticancer effect of platinum(IV) complex against cisplatinresistant human ovarian cancer. Yoshinori Okamoto, Takao Tobe, Koji
Ueda, Nakao Kojima.
13.
4486 Antiangiogenic platinum through glycan targeting. Erica J.
Peterson, Susan J. Berners-Price, Anna Bezos, Lisa Bohlman, Samantha J.
Katner, A. Gerard Daniel, Chih-Wei Chang, Mark von Itzstein, Christopher
R. Parish, Nicholas P. Farrell.
27.
4500 Nisin ZP, a food preservative, has antitumor potential for
head and neck cancer and extends survival. Pachiyappan Kamarajan,
Takayuki Hayami, Bibiana Matte, Yang Liu, Ayyalusamy Ramamoorthy,
Francis P. Worden, Sunil Kapila, Yvonne Kapila.
14.
4487 Design, synthesis and biological activity of N-phenyl
ureidobenzenesulfonates (PUB-SOs) as new and innovative smallmolecule drugs inhibiting proteins involved in DNA repair/replication
mechanisms. Sébastien Fortin, Hanane Moussa, Mathieu Gagné-Boulet,
Jacques Lacroix, Marie-France Côté, Denis Velic, Joris Pauty, Jean-Yves
Masson.
28.
4501 Development of novel Lithocholic acid carboxamides with
antiproliferative and pro-apoptotic effects on human cancer cells.
Srinivasa R. Ramisetti, Deepkamal Karelia, Melanie Neagley, Shantu Amin,
Arun K. Sharma.
29.
15.
4488
4502 Identification of an aspirin-derived small molecule as a
potential therapeutic for colorectal cancer. Deepkamal Karelia, Manoj
Pandey, Daniel Plano, Satya Narayan, Jitesh Jani, Jay Sharma, Shantu
Amin, Arun K. Sharma.
Folate receptor targeted therapy using small molecule drug
conjugates constructed with high affinity antifolate ligands. Christopher
P. Leamon, Joseph A. Reddy, Iontcho R. Vlahov, Fei You, Hanna F. Klein,
Paul J. Kleindl, Melissa Nelson, Marilynn Vetzel, Patrick J. Klein, Larry H.
Matherly, Aleem Gangjee.
POSTER SESSION
Pharmacokinetics and Pharmacodynamics
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
4503 Pharmacokinetics and pharmacodynamic analysis of eribulin
mesylate and paclitaxel in mouse. Krystyna Wozniak, Ying Wu, Bruce A.
Littlefield, Kenichi Nomoto, Christopher DesJardins, Yanke Yu, George Lai,
Larisa Reyderman, Barbara S. Slusher.
2.
4504 Plasma pharmacokinetics and tumor accumulation in
mice of IMGN779, an antibody-drug conjugate for acute myeloid
leukemia. Katharine C. Lai, Prerak Shah, Surina Sikka, XiuXia Sun, Rassol
LaLeau, Kathleen R. Whiteman, Holly Johnson-Modafferi, Alan Wilhelm,
Charlene Audette, Lintao Wang, Megan E. Bogalhas, Thomas A. Keating,
Ravi Chari.
Poster
Board
Abstract
Number
15.
4517 Plasma and tumor pharmacokinetics of IV LMP744, a novel
indenoisoquinoline topoisomerase I inhibitor, in a canine phase I study.
Julie L. Eiseman, Julianne Holleran, David L. McCormick, Miguel Muzzio,
Joseph M. Covey, Chand Khanna, Christina Mazcko, Yves Pommier, Melissa
Paolini, Amy Leblanc, Jenna H. Burton, James H. Doroshow, Joseph E.
Tomaszewski, Jan H. Beumer.
16.
4518 Model-based integration of pharmacokinetics, efficacy and
safety data for optimizing therapy of inotuzumab ozogamicin in
subjects with indolent non-Hodgkin’s lymphoma. Kenneth Luu, Joseph
Boni.
17.
4519 Development of a whole body physiologically-based
pharmacokinetic (PBPK) model with individualized tumor
compartment for topotecan (TPT) in mice bearing neuroblastoma (NB).
Yogesh T. Patel, Megan O. Jacus, Abbas Shirinifard, Abigail D. Davis,
Suresh Thiagarajan, Stacy L. Throm, Vinay M. Daryani, Andras Sablauer,
Clinton F. Stewart.
3.
4505 Activity and avascular penetration of FTY720 (fingolimod)
and its non-immune suppressant analogue (OSU2S) within three
dimensional tissue culture model of colorectal cancer. Samir A.
Zaahkouk, Serag Eldin I. Elbehairi, Aly F. El-Sayed, Sayed Bakry, Alaa
Khedr, Hany A. Omar, Ahmed M. Al-Abd.
4.
4506 Computational-driven metronomics: application to
gemcitabine in neuroblastoma-bearing mice. Joseph Ciccolini, Eddy
Pasquier, Aurelie Lombard, Sarah Giacometti, Christian Faivre, Raphaelle
Fanciullino, Cindy Serdjebi, Dominique Barbolosi, Nicolas Andre.
18.
4507 Intra-tumoral pharmacokinetic profiling for doxorubicin
within solid tumor micromilieu using multicellular layers culture invitro. Ahmed M. Al-Abd, Fahad A. Al-Abbasi, Alaa Khedr, Salah G. Atteiah.
4520 Biological coupling: Drug synergy, cross-resistance, and
schedule effects in combination therapy. Andrew Chen, Christopher J.
Zopf, Jing-Tao Wu, Wen Chyi Shyu, Arijit Chakravarty.
19.
4521 Evaluation of the relationship between serum exposure,
receptor (GITR) availability and tumor suppression following
administration of the anti-GITR antibody DX400 in mouse syngeneic
tumor models. Ayse Meric Ovacik, Natalie Shinsky-Bjorde, Douglas
Hodges, Svetlana Antonenko, Roanna Ueda, Smita Mauze, Danling Gu,
Derek Wiswell, Shuli Zhang, Amy Beebe, Mohammad Tabrizi.
20.
4522 Pharmacokinetic evaluation of a novel anti-angiogenic
molecule named JFD-WS in Balb/c mice. Manasa Subbarao, Sivanesan
Dhandayuthapani, Mortatha Albassam, Appu Rathinavelu.
21.
4523 Population pharmacokinetic (PPK) modeling of onapristone
in patients (pts) with progesterone receptor (PR)-expressing cancers.
Keyvan Rezai, Paul Cottu, Samuel Huguet, Mario Campone, Antoine
Italiano, Andrea Varga, Jacques Bonneterre, Alexandra Leary, Marie-Paule
Sablin, Stefan Proniuk, Alice Bexon, Erard Gilles, Joseph Bisaha, Alexander
Zukiwski, Francois Lokiec.
22.
4524 A preclinical PKPD modeling & simulation strategy: building
a predictive model of dose, schedule and therapeutic index for small
molecule targeted anticancer agents. Rhys D. Jones, Rajesh Odedra,
James W. Yates, Pablo Morentin Gutierrez, Barry Davies, Kevin Hudson,
Simon T. Barry.
23.
4525 The impact of chemoimmunotherapy dose intensity in
diffuse large b-cell lymphoma. Michael P. Chu, Sunita Ghosh, Andrew
Belch, Neil S. Chua, Amelie Fontaine, Randeep Sangha, Robert Turner,
Christopher Venner, Vickie Baracos, Michael B. Sawyer.
24.
4526 Age dependent disposition of cyclophosphamide (CTX) and
metabolites in infants < 1 year old with brain tumors. Vinay M. Daryani,
Thandranese S. Owens, K. Elaine Harstead, Yogesh T. Patel, David C.
Turner, Stacy L. Throm, John C. Panetta, Amar Gajjar, Clinton F. Stewart.
25.
4527 Dosing schedule effects on combination activity from first
principles. Andrew Chen, Jing-Tao Wu, Wen Chyi Shyu, Arijit Chakravarty,
Christopher J. Zopf.
26.
4528 Characterization of changes in passive permeability and
drug uptake at the blood-tumor barrier in four preclinical models of
brain metastases of breast cancer. Afroz Shareef Mohammad, Chris E.
Adkins, Rajendar K. Mittapalli, Tori B. Terrell-Hall, Mohamed I. Nounou,
Paul R. Lockman.
27.
4529 Pharmacokinetics (PK) of LOXO-101 during the first-inhuman Phase I study in patients with advanced solid tumors: Interim
update. Howard A. Burris, Alice T. Shaw, Todd M. Bauer, Anna F. Farago,
Robert C. Doebele, Steven Smith, Nisha Nanda, Scott Cruickshank, Jennifer
A. Low, Marcia S. Brose.
28.
4530 Tissue distribution, excretion and pharmacokinetics of
the environmental pollutant and the tobacco smoke constituent
dibenzo[a,l]pyrene in mice. Kun-Ming Chen, Yuan-Wan Sun, Cesar
Aliaga, Alaa Awad, Krishne Gowda, Shantu Amin, Karam El-Bayoumy.
5.
6.
4508 Predicting therapeutic monoclonal antibody efficacious
human doses from mouse experimental tumors: a pharmacokinetic/
pharmacodynamic approach. Songmao Zheng, Honghui Zhou, Weirong
Wang.
7.
4509 Comparison of the pharmacokinetics of erlotinib
administered in complete fasting and two hours after a meal in nonsmall cell lung cancer patients. Yuki Katsuya, Yutaka Fujiwara, Kuniko
Sunami, Hirofumi Utsumi, Yasushi Goto, Shintaro Kanda, Hidehito
Horinouchi, Hiroshi Nokihara, Noboru Yamamoto, Yuichiro Ohe, Satoko
Osawa, Akinobu Hamada.
8.
4510 Model-based phase II dose selection of c-Met inhibitor
MSC2156119J. Wenyuan Xiong, Samer El Bawab, Friedhelm Bladt,
Michael Meyring, Manfred Klevesath, Gerald Falchook, David Hong,
Andreas Johne, Pascal Girard.
9.
4511
Pharmacokinetics of OTX015 in a phase Ib dose-finding
study of patients with hematologic malignancies: Preliminary results of
a population PK analysis. Elodie Odore, Francois Lokiec, Maria E. Riveiro,
Fabrice Bourdel, Carmen Kahatt, Patrice Herait, Esteban Cvitkovic, Keyvan
Rezai.
10.
4512 Onapristone in patients (pts) with progesterone receptor
(PR)-expressing cancers: PK results from part 1 of a randomized,
parallel-dose phase 1 study. Francois Lokiec, Antoine Italiano, Andrea
Varga, Jacques Bonneterre, Mario Campone, Alexandra Leary, Keyvan
Rezai, Marie-Paule Sablin, Alice Bexon, Stefan Proniuk, Erard Gilles, Joseph
Bisaha, Alexander Zukiwski, Paul Cottu.
11.
12.
4513 Pharmacokinetics and pharmacodynamics of
indenoisoquinoline LMP400 (Indotecan) in BALB/c female mice bearing
CT-26 colon tumors. Jianxia Guo, Julianne Holleran, John C. Schmitz,
Kenneth Czambel, Jan H. Beumer, Julie L. Eiseman.
4514 PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR
inhibitor with excellent oral bioavailability and tolerability. Vladimir
Cmiljanovic, Robert A. Ettlin, Florent Beaufils, Walter Dieterle, Petra
Hillmann, Juergen Mestan, Anna Melone, Thomas Bohnacker, Marc Lang,
Natasa Cmiljanovic, Bernd Giese, Paul Hebeisen, Matthias P. Wymann,
Doriano Fabbro.
13.
4515 A phase 1 randomized, open-label, fixed-sequence, 2period study of the effect of multiple doses of rifampin on palbociclib
(PD-0332991) pharmacokinetics in healthy volunteers. Justin T.
Hoffman, Anna Plotka, Melissa O’Gorman, Andrew Chang, Maha Kosa,
Cho-Ming Loi, Corrado Gallo-Stampino, Diane D. Wang.
14.
4516 The effects of microbeam radiation therapy on the
pharmacokinetics of PEGylated liposomal doxorubicin in a triple
negative breast cancer GEM model. Xiao S. Chang, Andrew J. Madden,
Judith Rivera, Charlene Santos, David Darr, Lucas Hunter, William C.
Zamboni.
32
32
539
POSTER SESSION
Chemistry
Poster
:LJ[PVU
33
33
Drug Discovery, Drug Targeting, and Drug Delivery
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
540
Abstract
Number
4531 Effects of drug load on therapeutic index for
antibody-maytansinoid conjugates. Xiuxia Sun, Jose F.
Ponte, Nicholas C. Yoder, Jennifer Coccia, Leanne Lanieri,
Rassol Laleau, Qifeng Qiu, Rui Wu, Erica Hong, Megan
Bogalhas, Lintao Wang, Erin K. Maloney, Olga Ab, Hans K.
Erickson, Thomas A. Keating, Ravi Chari, John M. Lambert.
4532 Functional evaluation of novel Tubulysin analogs
as payloads for antibody-drug conjugates. Junxiang Jia,
Xiaomai Zhou, Yuanyuan Huang, Hongsheng Xie, Huihui Guo,
Shun Gai, Lan Qu, Wenjun Li, Lin Chen, Xing Li, Sanxing Sun,
Qingliang Yang, Xiaotao Zhuo, Hangbo Ye, Robert Zhao.
4533 New antimicrotubule phenyl 4-(2-oxo-3alkylimidazolidin-1-yl)benzenesulfonate prodrugs
bioactivated selectively in breast cancer cells by CYP1A1:
An innovative approach for the personalized treatment of
breast cancer. René C.-Gaudreault, Mathieu Gagné-Boulet,
Xavier Charest-Morin, Jacques Lacroix, Marie-France Côté,
Stéphane Gobeil, Sébastien Fortin, Coraline Lauvaux.
4534 Cyclooxygenase inhibitors as delivery vehicles for
histone deacetylase inhibitors. Idris O. Raji, Emily Janeira,
Fatima Yadudu, Fathi Shaghayegh, James Kornacki, Milan
Mrksich, Adegboyega Oyelere.
4535 Graphene/Pectin-NaCl based gel-biosensor for
tracing skin cancer and delivery of anticancer drug
paclitaxel. Sharif M. Shaheen, Daniel Gromadzki, Amor
Abdelkader, Stanislav Rangelov.
4536 Biomimetic carriers modulate tumor vascular
barrier function. Alessandro Parodi, Roberto Palomba,
Michael Evangelopoulos, Claudia Corbo, Ennio Tasciotti.
4537 Geranyloxy-ifosfamide: A pre-activated
ifosfamide analogue showing an increased therapeutic
index. Charles SKARBEK, Didier Desmaele, Alain Deroussent,
Lea Lesueur, Estelle Daudigeos-Dubus, Ludivine Le Dret,
Michael Rivard, Thierry Martens, Gilles Vassal, Patrick
Couvreur, Angelo PACI.
4538 Multivalent targeting based delivery of
therapeutic peptide using AP1-ELP carrier for effective
cancer therapy. Sarangthem V. Devi, Yun Jae Kim, YoungJin Lee, Kuen Hur, Byung-Heon Lee, Rang Woon Park.
4539 Nitroxide-aspirin conjugates: A new class of
NSAIDs. Terry W. Moody, Robert T. Jensen, Komba Thomas,
Kathryn E. Fairfull-Smith, Steven E. Bottle, Lisa Ridnour,
David A. Wink.
4540 Development of orally bioavailable formulation
of WP1066 and its evaluation in vivo. Rafal Zielinski,
Aleksandra Rusin, Timothy Madden, Charles Conrad, Mary
Johansen, Izabela Fokt, Stanislaw Skora, Arumugam
Jayakumar, Amy Heimberger, Waldemar Priebe.
4541 Tumor-selective bioactivation of duocarmycin
bioprecursors by cytochrome P450 enzymes provides an
opportunity to treat drug-resistant breast cancer cells.
Steven D. Shnyder, Paul M. Loadman, Mark Sutherland, Helen
M. Sheldrake, Mark Searcey, Laurence H. Patterson, Klaus
Pors.
4542 Targeting KRAS4b plasma membrane localization
in cells. Alla Brafman, Prabhakar Gudla, Kaustav Nandy, John
Columbus, De Chen, Karen Worthy, Stephen Lockett, Thomas
Turbyville.
4543 Characterization of the liposomal formulation of
eribulin mesylate (E7389) in mice. Makoto Asano, Kenji
Hyodo, Yanke Yu, Edgar Schuck, Junji Matsui, Hiroshi
Ishihara, Hiroshi Kikuchi, Kenichi Nomoto.
4544 Synthesis and biological evaluation of novel 6substituted pyrrolo[2,3-d]pyrimidines as targeted
antifolates. Aleem Gangjee, Lalit Golani, Adrianne Wallaceb,
Larry H. Matherly.
Poster
Board
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
Abstract
Number
4545 Development of a synthetic organic peroxide,
RA1, that overcomes p53 and Bcl-2 resistance
mechanisms. Rachel P. Abrams, K. A. Woerpel, William L.
Carroll.
4546 Depleting cysteine: A novel approach to tumor
therapy. Marie H. Hanigan, Anthony W. Burgett, Nancy
Wakeham, Simon S. Terzyan.
4547 Preparation of peptide-based Shp2 substrates
with phosphatase activity-dependent fluorescence. Steven
Gunawan, Yunting Luo, Yuan Ren, Harshani R. Lawrence,
Jerry Wu, Nicholas J. Lawrence.
4548 Simultaneous hyperthermic-chemotherapy for
glioblastoma using a single anti-cancer compound with
intrinsic magnetism. Makoto Ohtake, Masanari Umemura,
Itaru Sato, Kayoko Oda, Akane Nagasako, Ayako Makino,
Haruki Aoyama, Mayumi Katsumata, Haruki Eguchi,
Nobutaka Kawahara, Yoshihiro Ishikawa.
4549 A comparative efficacy study of Saquinavir in
combination with cisplatin or paclitaxel in platinumresistant ovarian cancer cells. Terry-Ann E. Waite, Monique
Reboe, Arkene Levy, Sivanesan Dhandayuthapani, Appu
Rathinavelu.
4550 Antiproliferative activity of 8-methoxypsoralen
without UV light irradiation: A new perspective for cancer
therapy. Diêgo M. de Oliveira, Rute M. Lima, Eudes S. Velozo,
Ilza A. Amorim, Tales H. Mota, Silvia L. Costa, Fabio P. Silva,
Ramon S. El-Bachá.
4551 Impairment of c-kit expression in human cancer
cell lines by a novel pharmacophoric unit selected for the
recognition of the proto-oncogene KIT promotorial region.
Claudia Sissi, Silvia Da Ros, Eleonora Zorzan, Caterina
Musetti, Lara Z. Shahidian, Manlio Palumbo, Mery Giantin,
Mauro Dacasto.
4552 Apatorsen enhances 5-FU sensitivity in colon
cancer cell SW480. Takehiro Shimada, Masashi Tsuruta,
Shingo Akimoto, Kaoru Koishikawa, Koji Okabayashi,
Hirotoshi Hasegawa, Yuko Kitagawa.
4553 Substituted monocyclic pyrimidines as potent
tubulin inhibitors that circumvent P-glycoprotein
mediated resistance. Rishabh Mohan, Aleem Gangjee, Ruoli
Bai, Ernest Hamel.
4554 An evaluation of the role of Mucin in drug
resistant ovarian cancer. Steven M. Richards, Robert B.
Campbell.
4555 C8-linked pyrrolobenzodiazepine (PBD)benzofused hybrids as transcription factor inhibitors.
David B. Corcoran, Paul J. Jackson, Ambereen Ajaz, Thomas
Lewis, Chris Pepper, David E. Thurston, Khondaker M.
Rahman.
4556 Identification of novel agent for HCC treatment by
GNMT-promoter orientated cell-based drug screening
platform. Rajni Kant, Lucas Tung, Chung-Kuang Lu, Yi-Ming
Chen, Chia-Hung Yen.
4557 Assessment of a humanized CXCR4 monoclonal
antibody for therapeutic monitoring and intervention in
experimental NSCLC and TNBC mouse models. Babak
Behnam Azad, Samit Chatterjee, Ala Lisok, Mrudula
Pullambhatla, Wojciech G. Lesniak, Zaver M. Bhujwalla,
Martin Pomper, Sridhar Nimmagadda.
4557A Development of the proteasome deubiquitinase
inhibitor VLX1570 for treatment of multiple myeloma . Xin
Wang, Chitralehka Mohanty, Padraig D’Arcy, Maria H.
Olofsson, Felicitas Bossler, Asher Chanan-Khan, Stig Linder.
POSTER SESSION
Carcinogenesis
Prevention, Intervention, and Modulation of Carcinogenic Risk
Poster
Board
Abstract
Number
Poster
Board
Abstract
Number
13.
4570 Genetic deletion of TNF␣ in mice inhibits UVRinduced development of cutaneous squamous cell
carcinomas via suppression of its own receptors and
associated signals to epidermal cell survival. Ashok Singh,
Anupama Singh, Samuel J. Bauer, Ajit K. Verma.
14.
4571 Chronic oxidative stress increases resistance in
renal carcinoma cells to doxorubicin-induced cytotoxicity
potentially through epigenetic mechanism. Logeswari
Ponnusamy, PrathapKumar S. Mahalingaiah, Kamaleshwar P.
Singh.
15.
4572 Western diet enhances benzo(a)pyrene [B(a)P]induced colon tumorigenesis in the PIRC rat model via
cytochrome P450 drug metabolizing enzymes. Kelly Harris,
Mohammad Niaz, Mary Washington, Aramandla Ramesh.
4561 Cancer preventive effect of antioxidants for
spontaneous liver cancer in XPA(-/-) mice. Ying Fu, Shana
Silverstein, Marcin Dyba, Heidi Coia, Elizabeth Sinclair, Jishen
Pan, Bhaskar Kallakury, Michael D. Johnson, Fung-Lung
Chung.
16.
4573 6-C-(E-phenylethenyl)-naringenin suppresses
colorectal cancer growth by inhibiting cyclooxygenase-1.
Haitao Li, Feng Zhu, Hanyong Chen, Ka Wing Cheng, Tatyana
Zykova, Naomi Oi, Ronald A. Lubet, Ann M. Bode, Mingfu
Wang, Zigang Dong.
5.
4562 Slug knockdown suppresses malignant
phenotype of nanomaterial-transformed human lung
epithelial cells. Maria Voronkova, Sudjit Luanpitpong, Liying
Wang, Yon Rojanasakul.
17.
4574 Genomic copy number variations characterize
prognosis of oropharyngeal squamous cell carcinoma,
including p16 positive subset, after surgery-based
treatment. Yuh-S. Jung, Arang Rhie, Jong-Il Kim, Jin Soo
Lee, Junsun Ryu, Weon Seo Park.
6.
4563 Muscadine grape extract reduces lung
carcinogenesis in female mice exposed to 3methylcholanthrene in utero. Brooke E. Porter, Joseph E.
Moore, Mark S. Miller, E. Ann Tallant, Patricia E. Gallagher.
18.
4575 Açaí intake reduces the aberrant crypt foci
development in a colitis-associated carcinogenesis model
in male Wistar rats. MARIANA F. FRAGOSO, GUILHERME R.
ROMUALDO, CLAUDIA H. PELLIZZON, LUIS F. BARBISAN.
7.
4564 TCF4 is a molecular target of resveratrol-induced
apoptosis in colon cancer. Jin Boo Jeong, Kui-Jin Kim,
Seong-Ho Lee.
19.
8.
4565 ATM genotyping modulates the risk of radiationassociated breast cancer among atomic-bomb survivors.
Tomonori Hayashi, Yiqun Hu, Kengo Yoshida, Waka Ohishi,
Ayumi Hida, Ikue Hayashi, Seishi Kyoizumi, Yoichiro
Kusunoki, Kei Nakachi.
4576 Early-in-life dietary zinc supplementation or
deficiency and susceptibility to mammary carcinogenesis
in female Sprague-Dawley rat. Flávia R. Silva, Lucas T.
Bidinotto, Robson F. Carvalho, Luis F. Barbisan.
20.
4566 Differential reactivation of fetal/neonatal genes
in mouse liver tumors induced in cirrhotic and noncirrhotic conditions. Xi Chen, Masahiro Yamamoto, Kiyonaga
Fujii, Yasuharu Nagahama, Bing Xin, Takako Ooshio, Yoko
Okada, Yuji Nishikawa.
4577 Mitagation of potassium dichromate micronuclei
induction and kidney damage by ethanol extract of
Moringa oleifera in Swiss albino rats. Kazeem A. Akinwum,
Ayobami W. Adedoja, Osifeso O. Osifeso, Adenike M.
Adegboyega, Deborah O. Aralamo, Olaitan O. David, Kazeem
A. Akinwumi.
21.
4567 Activation of T-cell protein tyrosine phosphatase
suppresses keratinocyte survival and proliferation
following UVB irradiation. Hyunseung Lee, Mihwa Kim, Liza
D. Morales, Thomas J. Slaga, Dae Joon Kim.
4578 Excision DNA repair: a biomarker of colorectal
cancer onset and its chemotherapy. Pavel E. Vodicka,
Ludmila Vodickova, Miroslav Svoboda, Jana Slyskova,
Barbara Pardini, Alessio Naccarati, Kari Hemminki.
22.
4579 The role of carnosol in reducing skin cancer
development and progression. Lingying Tong, Shiyong Wu.
23.
4580 Expression of ␥H2AX as a biomarker of genotoxic
carcinogen in the urinary bladder of rats. Takeshi Toyoda,
Young-Man Cho, Jun-ichi Akagi, Yasuko Mizuta, Kumiko
Ogawa.
24.
4580A Metabolic activation of 3-nitrobenzanthrone by
human aldo-keto reductases (AKR1C1-AKR1C4). Jessica R.
Murray, Meng Huang, Tianzhu Zang, Volker M. Arlt, Heinz H.
Schmeiser, Trevor M. Penning.
1.
4558 Using reduction mammoplasty tissues from
healthy young women living in USA’s high breast cancer
(BC) risk posing environment to open up to study the
“black box” of latent stages of breast carcinogenesis; a
key to develop strategies for BC prevention. Judith Weisz,
Debra Shearer, Anna C. Salzberg.
2.
4559 Phosphodeficient NRF1 mutant suppresses the
susceptibility of the breast epithelial cells to develop
tumors when exposed to estrogen - a major breast cancer
risk factor. Lazaro Mesa, Jayanta Das, Alok Deoraj, Victor
Okoh, Deodutta Roy.
3.
4560 Targeting chronic lymphocytic leukemia with p53
deficiency with phenethyl isothiocyanate. Jinyun Liu, Gang
Chen, Helen Pelicano.
4.
9.
10.
11.
4568 Inhibition of autophagy in EBV-positive Burkitt’s
lymphoma cells enhances EBV lytic genes expression and
replication. Alessandra De Leo, Francesca Colavita, Fabiola
Ciccosanti, Gian Maria Fimia, Paul Lieberman, Elena Mattia.
12.
4569 A simple method to screen patients for SNPs in
NAT1 gene for prostate cancer risk. James Gomes, Melody
Emaimem, Maja Zuric, Maitland Long.
Poster
:LJ[PVU
34
34
541
POSTER SESSION
Epidemiology
Poster
:LJ[PVU
35
35
Molecular and Genetic Epidemiology of Cancer 2: Colorectal, Lung, and Prostate
Poster
Board
1.
4581 Genetic variations in CDKN1A and RHPN2 associated with
prognosis for patients with colorectal cancer. Byung Woog Kang, Jong
Gwang Kim, Yee Soo Chae, Shin Yup Lee, Soo Jung Lee, Shinkyo Yoon.
2.
4582 Enrichment of colorectal cancer and inflammatory bowel
disease risk variants in colon expression quantitative trait loci in
African Americans. Sonia S. Kupfer, Imge Hulur, Eric Gamazon, Andrew
Skol, Xavier Llor, Kenan Onel, Nathan A. Ellis.
3.
4583 Computational analysis predicts unbalanced IDH1/IDH2
expression associate with 2-HG-inactivating beta-oxygenation
pathway in colorectal cancer. Jun Koseki, Hugh Colvin, Takahito
Fukusumi, Naohiro Nishida, Masamitsu Konno, Koichi Kawamoto, Kenta
Tsunekuni, Yuichiro Doki, Masaki Mori, Hideshi Ishii.
4.
5.
4584 VDR genotype modifies vitamin D efficacy for colorectal
adenoma prevention in a randomized controlled trial. Elizabeth L. Barry,
Leila A. Mott, Judith R. Rees, Dennis J. Ahnen, Roberd M. Bostick, Robert S.
Bresalier, Douglas J. Robertson, Robert W. Summers, John A. Baron.
4585 Folate-mediated one-carbon metabolism polymorphisms
associated with risk and survival of colorectal cancer. Akke Botma,
Katharina Buck, Yesilda Balavarca, Dominique Scherer, Nina Habermann,
Reka Toth, Lina Jansen, Michael Hoffmeister, Hermann Brenner, Elisabeth
J. Kap, Petra Seibold, Axel Benner, Alexis Ulrich, Barbara Burwinkel, Jenny
Chang-Claude, Cornelia M. Ulrich.
6.
4586 Association of FUT2 gene variant, gut bacteria and
colorectal adenomas. Winifred Okunola, Amber McCoy, Santosh Dulal,
Temitope O. Keku.
7.
4587
Genome-wide copy number analysis identified a copy
number polymorphism at chromosome 8p11 associated with sporadic
colorectal cancer risk in Singapore Chinese. Peh Y. Cheah, Lai Fun Thean,
Yik Ying Teo, Woon-Puay Koh, Jian-Min Yuan, Min Hoe Chew, Choong
Leong Tang.
8.
4588 Whole genome hypo- and hyper-methylation sequencing
among Africa American patients with colorectal cancer. Hassan
Ashktorab, Afnan Shakoori, Shatha Zarnogi, Xueguang Sun, Sudhir Varma,
Edward Lee, Babak Shokrani, Adeinko O. Laiyemo, Kareem Washington,
Hassan Brim.
9.
4589
10.
542
Abstract
Number
Association of genes, pathways, and haplogroups of the
mitochondrial genome with the risk of colorectal cancer: The
Multiethnic Cohort. Yuqing Li, Kenneth Beckman, Christian Caberto, Remi
Kazma, Annette Lum-Jones, Christopher A. Haiman, Loic Le Marchand,
Daniel O. Stram, Richa Saxena, Iona Cheng.
4590 Polymorphisms in cell-cycle related genes modify the
effect of NSAIDs on the risk of colorectal cancer. Reka Toth, Yesilda
Balavarca, Dominique Scherer, Nina Habermann, Katharina Buck, Akke
Botma, Elisabeth J. Kap, Axel Benner, Alexis Ulrich, Michael
Hoffmeister, Hermann Brenner, Barbara Burwinkel, Jenny ChangClaude, Cornelia M. Ulrich.
11.
4591 Differential expression of tight junction polarity genes in
human colon cancer. Kathryn E. Royse, Liang Chen, Jocelyn Uriostegui,
Michael Ittmann, David Y. Graham, Hashem El-Serag, Li Jiao.
12.
4592 Integrating tumor and stromal gene expression signatures
with clinical indices for survival stratification of early-stage non-small
cell lung cancer. Andrew J. Gentles, Scott V. Bratman, Luke J. Lee, Jeremy
P. Harris, Weiguo Feng, Ramesh V. Nair, David B. Shultz, Viswam S. Nair,
Chuong D. Hoang, Robert B. West, Sylvia K. Plevritis, Ash A. Alizadeh,
Maximilian Diehn.
13.
4593
Telomere length measured prior to lung cancer diagnosis
and survival by histologic type. Jennifer A. Doherty, John Houck, Matt J.
Barnett, Jean D. Tapsoba, Liberto Julianto, Mark D. Thornquist, Ching-Yun
Wang, Chu Chen, Gary E. Goodman.
14.
4594 Serum microRNA signatures predict recurrence and survival
in Caucasian patients with early stage non-small cell lung cancer. Liren
Zhang, Jack A. Roth, Jie Lian, Yuanqing Ye, Jian Gu, Xifeng Wu.
15.
4595 The impact of CYP2A6 genetic polymorphisms on nicotine
metabolism and lung cancer risk in two prospective cohorts of smokers.
Jian-Min Yuan, Heather H. Nelson, Lesley M. Butler, Steven G. Carmella,
Renwei Wang, Jennifer Adams-Haduch, Stephen S. Hecht, Woon-Puay
Koh, Yu-Tang Gao, Sharon E. Murphy.
Poster
Board
Abstract
Number
16.
4596 Genetic variants associated with longer telomere length are
associated with increased lung cancer risk among never-smoking
women in Asia: A report from the Female Lung Cancer Consortium in
Asia. Mitchell J. Machiela, Chao A. Hsiung, Xiao-Ou Shu, Wei J. Seow,
Zhaoming Wang, Keitaro Matsuo, Yun-Chul Hong, Adeline Seow, Chen
Wu, H Dean Hosgood, Kexin Chen, Jiu-Cun Wang, Wanqing Wen,
Tangchun Wu, Maria P. Wong, Yi-Long Wu, Pan-Chyr Yang, Baosen Zhou,
Min-Ho Shin, Joseph F. Fraumeni, Wei Zheng, Dongxin Lin, Stephen
J. Chanock, Nathaniel Rothman, Qing Lan.
17.
4597 A novel variant in DNA repair gene GTF2H4 is associated
with lung cancer risk: A reanalysis of GWAS datasets from the TRICL
consortium. Qingyi Wei, Hongliang Liu, Zhensheng Liu, Christopher I.
Amos, Jennifer A. Doherty, Heike Bickeboller, Rayjean J. Hung, Paul
Brennan, Richard Houlston, Maria Teresa Landi, Neil E. Caporaso, David
Christiani.
18.
4598 Low-frequency coding variants in BAT2, HIST1H1E and
BPIFB1 are associated with lung cancer risk in Chinese populations.
Guangfu Jin, Meng Zhu, Rong Yin, Wei Shen, Lin Xu, Zhibin Hu, Dongxin
Lin, Hongbing Shen.
19.
4599 Somatic mutation profile differences of “driver” mutations
in 26 oncogenic lung cancer genes between African American and
European American non-small cell lung cancer patients. Sarah H.
Stephens, Patrice J. Fleming, Braxton D. Mitchell, Nicholas Ambulos, Joan
E. Bailey-Wilson, Christy Chang, Josephine L. Feliciano, Edward A.
Sausville, Martin J. Edelman.
20.
4600 Target exome sequencing for disease-causing rare
mutations in familial and sporadic lung cancer. Yanhong Liu, Farrah
Kheradmand, Michael Scheurer, Caleb Davis, David Wheeler, Edwin
Silverman, Shete Sanjay, Spiridon Tsavachidis, Georgina Armstrong, Elena
Kupert, Marshall Anderson, Yafang Li, Claudio Pikielny, Joan E. BaileyWilson, Ming You, Colette Gaba, Mariza DeAndrade, Diptasri Mandal, Claire
Simpson, Susan Pinney, Christopher Amos, Margaret Spitz.
21.
4601 Genetic polymorphisms in the vitamin D pathway in relation
to lung cancer risk and survival. Jinyu Kong, Fangxiu Xu, Jinli Qu, Yu
Wang, Ming Gao, Herbert Yu, Biyun Qian.
22.
4602 Exome sequencing of UKLS lung cancer CT screened early
stage cancers. Russell Hyde, Michael Davies, Martin Ledson, John A.
Holemans, Richard D. Page, John Gosney, David R. Baldwin, Anand
Devaraj, David M. Hansell, Stephen W. Duffy, John K. Field.
23.
4603 Male pattern baldness in relation to prostate cancer-specific
mortality: A prospective analysis in the NHANES I Epidemiologic
Followup Study (NHEFS). Cindy Ke Zhou, Paul H. Levine, Sean D. Cleary,
Heather J. Hoffman, Barry I. Graubard, Michael B. Cook.
24.
4604 DNA methylation at chromosome 8q24 in peripheral blood
and prostate cancer risk. Kathryn H. Barry, Lee E. Moore, Joshua
Sampson, Stella Koutros, Liying Yan, Ann Meyer, Mahitha Reddy, Michael
B. Cook, Joseph F. Fraumeni, Meredith Yeager, Laufey Amundadottir,
Sonja I. Berndt.
25.
4605 Variation in genes involved in the immune response and
prostate cancer risk in the placebo arm of the Prostate Cancer
Prevention Trial. Danyelle A. Winchester, Cathee Till, Phyllis J. Goodman,
Catherine M. Tangen, Regina M. Santella, Teresa L. Johnson-Pais, Robin J.
Leach, Jianfeng Xu, S. Lilly Zheng, Ian M. Thompson, M. Scott Lucia, Scott
M. Lippmann, Howard L. Parnes, Paul J. Dluzniewski, William B. Isaacs,
Angelo M. De Marzo, Charles G. Drake, Elizabeth A. Platz.
26.
4606 Fine mapping of 64 prostate cancer GWAS regions identifies
multiple novel association signals. Zsofia Kote-Jarai, Ali Amin Al Olama,
Tokhir Dadaev, Dennis Hazelett, Qiuyan Li, Daniel Leongamornlert, Ed
Saunders, Matthew Feedman, David Conti, Douglas Easton, Gerhard
Coetzee, Rosalind Eeles, The PRACTICAL Consortium.
27.
4607 Integration of multiethnic fine-mapping and genomic
annotation to prioritize candidate functional SNPs at prostate cancer
susceptibility regions. Ying Han, Dennis J. Hazelett, Brian E. Henderson,
David V. Conti, Gerhard A. Coetzee, Christopher A. Haiman, on behalf of
the GAME-ON/ELLIPSE Consortium.
28.
4608 Racial differences in the distribution of prostate tumor
biomarkers and treatment failure: The SCORE study. Priti Lal*, Kosj
Yamoah*, Amy Ziober, Amy Walker, Wenting Zhou, Elaine Spangler,
Charnita Zeigler-Johnson, Michael Feldman, Timothy R. Rebbeck.
POSTER SESSION
Epidemiology
Molecular and Genetic Epidemiology of Cancer 3
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Abstract
Number
4609 Risk loci in telomere structure and maintenance genes across five
cancer types: GAME-ON Consortium. Sara Karami, Younghun Han, Fredrick R.
Schumacher, Zsofia Kote-Jarai, Sara Lindstrom, John S. Witte, Iona Cheng,
Shenying Fang, Jiali Han, Peter Kraft, Fengju Song, Rayjean J. Hung, James
McKay, Stephen J. Chanock, Mala Pande, Angela Risch, Hongbing Shen,
Christopher A. Haiman, Lisa Boardman, Cornelia M. Ulrich, Graham Casey, Ulrike
Peters, Nilanjan Chatterjee, Brandon Pierce, Wei Zheng, Christopher I. Amos,
Jennifer A. Doherty.
4610 Functional characterization of a multicancer risk locus on
chr5p15.33 reveals regulation of TERT by ZNF148. Kevin M. Brown, Jun Fang,
Jinping Jia, Zhaoming Wang, Matthew Makowski, Tongwu Zhang, Jason
Hoskins, Jiyeon Choi, Younghun Han, Mingfeng Zhang, Mai Xu, Peter Kanetsky,
Andresson Thorkell, Gloria M. Petersen, Katherine L. Nathanson, Christopher I.
Amos, Maria T. Landi, Stephen J. Chanock, Michiel Vermeulen, Laufey T.
Amundadottir.
4611 Quantification and functional characterization of the shared
heritability across multiple cancer sites: results from the GAME-ON
Consortium. Sara Lindstrom, Hilary Finucane, Brendan Bulik-Sullivan, Fredrick
Schumacher, Christopher Amos, Stephen Gruber, Brian Henderson, David
Hunter, Thomas Sellers, Benjamin Neale, Alkes Price, Peter Kraft, GAME-ON
Consortium.
4612 Genetic variants in epigenetic pathways and risk of multiple
cancer types in the GAME-ON consortium. Dominique Scherer, Reka Toth,
Linda Kelemen, Angela Risch, Aditi Hazra, Jean Pierre Issa, Victor Moreno,
Rosalind A. Eeles, John Quackenbush, Ellen L. Goode, Shuji Ogino, Rayjean
Hung, Cornelia M. Ulrich.
4613 MDM4 SNP 34091 (rs4245739) effect on risk of breast, colon,
lung, prostate, endometrial and ovarian cancer. Liv B. Gansmo, Merete
Bjørnslett, Anne Dørum, Helga Salvesen, Pål Romundstad, Kristian Hveem, Lars
Vatten, Per Eystein Lønning, Stian Knappskog.
4614 Mutation detection in urine from bladder cancer patients as noninvasive prognostic tool. Rossana Critelli, Francesca Fasanelli, Manuela B.
Assumma, Ellen C. Zwarthoff, Marco Oderda, Silvia Polidoro, Carlotta Sacerdote,
Paolo Vineis, Giuseppe Matullo, Alessio Naccarati.
4615 H2AX phosphorylation assays, gene expression and epigenomic
profiles as markers in bladder cancer: an integrated approach. Barbara
Pardini, Alessandra Allione, Simonetta Guarrera, Valentina Turinetto, Giovanni
Fiorito, Clara Viberti, Alessia Russo, Paolo Vineis, Carlotta Sacerdote, Claudia
Giachino, Giuseppe Matullo.
4616 Genome wide association analysis identified 15q24 as a bladder
cancer susceptibility locus. Koichi Matsuda, Atsushi Takahashi, Chizu Tanikawa,
Michiaki Kubo, Yusuke Nakamrua.
4617 An alternatively spliced isoform of TMEM129 shows association
with bladder cancer GWAS marker rs798766. A. Rouf Banday, Ashley Paquin,
Candace Middlebrooks, Eniko Kiss, Ludmila Prokunina-Olsson.
4618 The risk prediction for esophageal cancer by drinking, smoking,
and the polymorphisms of ALDH2 and ADH1B. Hidemi Ito, Isao Oze, Satoyo
Hosono, Miki Watanabe, Hideo Tanaka, Keitaro Matsuo.
4619 DNA adductome analyses at multiple sites of human gastric
mucosa, resected for gastric cancer. Nobuya Kurabe, Ippei Ohnishi, Masako
Suzuki, Yusuke Inoue, Tomoaki Kahyo, Moriya Iwaizumi, Yoshitaka Matsushima,
Yukari Totsuka, Hitoshi Nakagama, Masako Kasami, Hideto Ochiai, Keigo
Matsumoto, Shioto Suzuki, Fumihiko Tanioka, Haruhiko Sugimura.
4620 Somatic mutation profile of gastric cancer cases from the
Hispanic population. Rodrigo Prieto-Sanchez, Ruta M. Sahasrabudhe, Paul Lott,
Mabel Bohorquez, Jhon Jairo Suarez, Gilbert Mateus, Javier Torres, Magdalena
Echeverry, Luis Carvajal-Carmona.
4621 Validation and calibration of next-generation sequencing to
identify Epstein-Barr Virus-positive gastric cancer. M. C. Camargo, Reanne
Bowlby, Andy Chu, Chandra S. Pedamallu, Vesteinn Thorsson, Sandra Elmore,
Andrew Mungall, Adam Bass, Margaret L. Gulley, Charles S. Rabkin.
4622 Common genetic variants in epigenetic machinery genes and risk
of upper gastrointestinal cancers. Hyuna Sung, Howard H. Yang, Han Zhang, Qi
Yang, Nan Hu, Ze-Zhong Tang, Hua Su, Lemin Wang, Chaoyu Wang, Ti Ding,
Jin-Hu Fan, You-Lin Qiao, William Wheeler, Carol Giffen, Laurie Burdett,
Zhaoming Wang, Maxwell P. Lee, Stephen J. Chanock , Sanford M. Dawsey, Neal
D. Freedman, Christian C. Abnet, Alisa M. Goldstein , Kai Yu, Philip R. Taylor ,
Paula L. Hyland.
4623 piRNA and glioma risk: Evidence from a post-GWAS analysis of
the GliomaScan Cohort. Daniel I. Jacobs, Michael C. Lerro, Alan Fu, Qin Qin,
Andrew T. DeWan, Robert Dubrow, Elizabeth B. Claus, Yong Zhu.
4624 Clinical impact of telomere shortening in normal and leukemia
cells in chronic lymphocytic leukemia. Lin Yang, Sara Beiggi, Yunli Zhang,
Robert Schmidt, Spencer B. Gibson, James B. Johnston.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
4625 Influence of intrinsic apoptotic pathway gene polymorphisms on
the development and progression of acute myeloid leukemia: Case-control
study. Anuradha Cingeetham, Sugunakar Vuree, Nageswara R. Dunna, Manjula
Gorre, Raghunadharao Digumarti, Sudha Sinha, Vishnupriya Satti.
4626 Genetic susceptibility to diffuse large B-cell lymphoma in a
pooled study of three Eastern Asian populations. Nathaniel Rothman, Bryan A.
Bassig, James R. Cerhan, Wing-Yan Au, Hee Nam Kim, Suleeporn Sangrajrang,
Wei Hu, Jovic Tse, Sonja Berndt, Tongzhang Zheng, Heping Zhang, Pattarapong
Pornsopone, Je-Jung Lee, Hyeoung-Joon Kim, Christine F. Skibola, Joseph Vijai,
Laurie Burdette, Meredith Yeager, Paul Brennan, Min-Ho Shin, Raymond Liang,
Stephen Chanock, Qing Lan.
4627 A novel computational re-analysis of published GWAS data
suggests new risk loci for melanoma susceptibility. Rachel M. Cymerman,
Benedetta Bigio, Martin P. Seybold, David Polsky, Knut M. Wittkowski.
4628 Analysis of melanoma GWAS data suggests specific risk loci
influencing age of onset of melanoma. Rachel M. Cymerman, Benedetta Bigio,
Martin P. Seybold, David Polsky, Knut M. Wittkowski.
4629 Multiple myeloma susceptibility loci examined in African and
European ancestry populations. Kristin A. Rand, Chi Song, Eric Dean, Daniel
Serie, Karen Curtin, Dennis Hazelett, Amie E. Hwang, Xin Sheng, Alex Stram,
David J. Van Den Berg, Carol Ann Huff, Leon Bernal-Mizrachi, Michael H.
Tomasson, Sikander Ailawadhi, Anneclaire De Roos, Seema Singhal, Karen
Pawlish, Edward Peters, Catherine Bock, David V. Conti, Graham Colditz, Todd
Zimmerman, Scott Huntsman, John Graff, African Ancestry Prostate Cancer
GWAS Consortium,African Ancestry Breast Cancer GWAS Consortium, Stephen
J. Chanock, Michael Lieber, Jayesh Mehta, Eric A. Klein, Nalini Janakiraman,
Richard K. Severson, Angela R. Brooks-Wilson, Vincent Rajkumar, Elizabeth E.
Brown, Laurence Kolonel, Susan Slager, Brian E. Henderson, Graham G. Giles,
John J. Spinelli, Brian Chiu, Kenneth C. Anderson, Jeffrey Zonder, Robert Z.
Orlowski, Sagar Lonial, Nicola Camp, Celine Vachon, Elad Ziv, Dan O. Stram,
Christopher A. Haiman, Wendy Cozen.
4630 Heterogeneity revealed through meta-analysis might link
geographical differences with nasopharyngeal carcinoma incidence in Han
Chinese. Wen-Hui Su, Chi-Cking Chiu, Yin Y. Shugart.
4631 AKAP12 is elevated in paclitaxel-resistant ovarian cancer cells
and correlates with poor ovarian cancer patient survival. Nicholas Bateman,
Elizabeth Jaworski, Guisong Wang, Elizabeth Dubil, Charlotte Marcus, Kelly
Conrads, Pang-ning Teng, Brian Hood, Chad Hamilton, Larry Maxwell, Kathleen
Darcy, Thomas Conrads.
4632 Poor survival associated with NUAK1 overexpression in serous
ovarian cancer may be explained by chemotherapy resistance. Neil T.
Phippen, Nicholas W. Bateman, Guisong Wang, Chad A. Hamilton, George L.
Maxwell, Kathleen M. Darcy, Thomas P. Conrads.
4633 Evidence that long non-coding RNA variants associate with
epithelial ovarian cancer risk. Thomas A. Sellers, Brett M. Reid, Y. Ann Chen,
Hui-Yi Lin, Edward Richards, Jamie Teer, Alvaro Monteiro, Zhihua Chen, Andrew
Berchuck, Georgia Chenevix-Trench, Jennifer Doherty, Ellen Goode, Edwin
Iverson, Leigh Pearce, Paul Pharoah, Catherine Phelan, Susan Ramus, Mary Anne
Rossing, Joellen Schildkraut, Jin Cheng, Simon Gayther, Jennifer Permuth-Wey,
on behalf of the Ovarian Cancer Association Consortium.
4634 Variants within super-enhancer regulatory elements associate
with epithelial ovarian cancer risk. Brett M. Reid, Jennifer Permuth-Wey, Y.
Ann Chen, Hui-Yi Lin, Alvaro Monteiro, Zhihua Chen, Andrew Berchuck, Georgia
Chenevix-Trench, Jennifer Doherty, Simon Gayther, Ellen L. Goode, Edwin
Iversen, Leigh Pearce, Paul Pharoah, Catherine Phelan, Susan Ramus, Mary Anne
Rossing, Joellen Schildkraut, Thomas Sellers, on behalf of the Ovarian Cancer
Association Consortium.
4635 Inherited variants affecting RNA editing may contribute to
ovarian cancer susceptibility. Jennifer Permuth-Wey, Brett M. Reid, Y. Ann
Chen, Hui-Yi Lin, Alvaro Monteiro, Zhihua Chen, Andrew Berchuck, Georgia
Chenevix-Trench, Jennifer Doherty, Simon Gayther, Ellen Goode, Edwin Iversen,
Leigh Pearce, Paul D. Pharoah, Catherine Phelan, Susan Ramus, Mary Anne
Rossing, Joellen Schildkraut, Thomas Sellers, on behalf of the Ovarian Cancer
Association Consortium.
4636 Investigation of exome variants associated with overall survival
in ovarian cancer. Stacey J. Winham, Brooke L. Fridley, Melissa C. Larson,
Zachary Fogarty, Andrew Berchuck, Yian A. Chen, Hui-Yi Lin, Georgia ChenevixTrench, Jenny Permuth-Wey, Thomas A. Sellers, Ailith Pirie, Ellen L. Goode,
Ovarian Cancer Association Consortium.
4637 The effect of height, BMI and serum lipid levels on ovarian cancer
prognosis in over 12,000 women: a Mendelian randomization study. Ailith
Pirie, Suzanne C. Dixon, Penelope M. Webb, Wei Zheng, Paul D. Pharoah, on
behalf of the Ovarian Cancer Association Consortium.
4638 Fine mapping of two GWAS at 9q22 and 14q13 associated with
differentiated thyroid cancer risk. catherine TCHEANDJIEU, Fabienne
LESUEUR, Marie Sanchez, Therese TRUONG, Pascal GUENEL.
36
36
543
POSTER SESSION
Prevention Research
Poster
:LJ[PVU
37
37
Chemoprevention 2
Poster
Board
1.
4639 Metformin decreases cellular ceramides in MCF-7
and MDA-MB 231 breast cancer cell lines by inhibition of
ceramide synthetic enzymes. Daniel Wann, Victoria Palau,
Janet Lightner, Marianne Brannon, William Stone,
Koyamangalath Krishnan.
2.
4640 Andrographolide modulates cell cycle, cell
migration and tumor growth in prostate cancer. Ingrid
Forestier-Roman, Maria Sánchez, Joseph Casillas, Krizia
Rohena, Magaly Martínez-Ferrer.
3.
4641 Crucial role of c-Jun phosphorylation at Ser63/73
mediated by PHLPP protein degradation in the
Cheliensisin A (Chel A) inhibition of cell transformation.
Chuanshu Huang, Junlan Zhu, Jingxia Li.
4.
4642 Quercetin inhibits prostate cancer by modulating
molecules involved in apoptosis and cell proliferation.
Ashely B. Ward, Hina Mir, Neeraj Kapur, Shailesh Singh.
5.
6.
7.
8.
4643 Effect of resveratrol-zinc combination on
prostate tumor growth in transgenic adenocarcinoma of
mouse prostate (TRAMP) model. Chandra K. Singh,
Minakshi Nihal, Jasmine George, Imtiaz A. Siddiqui, Hasan
Mukhtar, Nihal Ahmad.
4644 Curcumin C3 ® prevents ultraviolet B radiationinduced acute damage in JB6 keratinocytes and mouse
skin via FGF-2/mTOR/NF-⌲B pathway. Alok R.
Khandelwal, Arun Anandharaj, Ekshyyan Oleksandr, Tara
Moore-Medlin, Abreo Fleurette, Cherie-Ann O. Nathan.
4645 Decursin, a coumarin compound, inhibits the
growth of human hepatoma cells involving cell cycle
arrest, apoptosis, and autophagy. Praveen K. Kujur,
Dongsool Yim, Rana P. Singh.
4646 Cumin extract prevents estrogen-associated
breast cancer in ACI rats. Farrukh Aqil, Jeyaprakash
Jeyabalan, Radha Munagala, Ramesh C. Gupta.
Poster
Board
Abstract
Number
15.
4653 Modulation of mTOR and p53 signaling using
rapamycin plus CP-31398 inhibits growth and progression
of urothelial carcinoma in-vivo. Venkateshwar Madka, Altaf
Mohammed, Qian Li, Yuting Zhang, Laura Biddick, Jagan M.
Patlolla, Stanley Lightfoot, Xue-Ru Wu, Vernon Steele, Levy
Kopelovich, Chinthalapally V. Rao.
16.
4654 Antitumorigenic activity of trans-chalcone in
osteosarcoma. Gabriel D. Silva, Mozart Marins, Ana L. Fachin,
Seung J. Baek.
17.
4655 Plant polyphenols inhibit cellular 24-hydroxylase
(CYP24A1) expression and elevate serum 25hydroxyvitamin D levels. Ehud Sharony, Ze’ev Barvish,
Victoria Novik, Marina Khanin, Merav Cohen-Lahav, Doron
Amichay, Yoav Sharoni, George P. Studzinski, Michael
Danilenko.
18.
4656 Phytochemicals target epigenetic signaling to
block cancer stem cell-driven colon carcinogenesis. Shahid
Umar, Ishfaq Ahmed Ahmed, Dharmalingam Subramaniam.
19.
4657 Targeting STAT3 for mammary cancer prevention
in MMTV/Neu mice employing the antagonist GLG-302.
Robert H. Shoemaker, Michael W. Lovell, John J. Whalen,
Fariba Moeinpour, Clinton J. Grubbs.
20.
4658 Resveratrol aspirinate derivatives as novel
chemopreventive agents for colon cancer. Shengmin Sang,
Yingdong Zhu, Junsheng Fu, Kelly Shurlknight.
21.
4659 Hyaluronan: A novel target of dietary flavonoid
fisetin in prostate cancer. Rahul K. Lall, Mohammad Imran
Khan, Deeba N. Syed, Vaqar M. Adhami, Hasan Mukhtar.
22.
4660 Association of longer telomere length with
increased risk of chronic hepatitis B and hepatocelluar
carcinoma. Qiang Ma, Jiajing Cai, Yan Cai, Yuan Xu, Fan
Chang, Lei Xu, Xiaolan Guo.
23.
4661 Preventive effects of branched-chain amino acid
supplementation on the spontaneous development of
hepatic preneoplastic lesions in C57BL/KsJ-db/db obese
mice. Takayasu Ideta.
9.
4647 Bioactive tanshinones and tea polyphenols inhibit
prostate cancer stem cells by targeting bmi1. Jin-Rong
Zhou, Yi Gong, Hamid Abdolmaleky.
24.
10.
4648 Differential regulation of estrogen metabolizing
CYP1A1 and CYP1B1 enzymes by novel resveratrol analogs
in breast cancer cells. Amruta M. Ronghe, Anwesha
Chatterjee, Subhash Padhye, Hari K. Bhat.
4662 Framework for clinical evaluation of
chemopreventive agents: Defining criteria for future
assessment. Naomi Walsh, David S. Alberts, Powel Brown,
Paul Limburg, Mark Sherman, Eva Szabo.
25.
11.
4649 Apigenin increases maspin expression and
suppresses invasiveness in prostate cancer cells. Sanjeev
Shukla, Ata Abbas, Sanjay Gupta.
12.
4650 Novel resveratrol-analog HPIMBD inhibits breast
cancer cell metastasis by reversal of epithelialmesenchymal transition. Anwesha Chatterjee, Amruta
Ronghe, Subhash Padhye, Hari K. Bhat.
4663 Identification of germline variants in cancer
susceptibility genes in patients with multiple primary
cancers. Brandon Wenz, Kara N. Maxwell, Bradley
Wubbenhorst, Kurt D’Andrea, Bradley Garman, Jessica M.
Long, Jacquelyn Powers, Jill E. Stopfer, Angela R. Bradbury,
Angela DeMichele, Susan M. Domchek, Katherine L.
Nathanson.
26.
4664 Impact of TP53 mutations, single nucleotide
variants and global methylation patterns on premenopausal breast cancer risk. Nardin Samuel, Mathieu
Lemire, Ana Novokmet, Thomas J. Hudson, David Malkin.
27.
4665 Pre-diagnostic smoking, alcohol and obesity and
risk of second primary cancer in female keratinocyte
carcinoma survivors. Sang Min Park, Tricia Li, Shaowei Wu,
Wen-Qing Li, Abrar A. Qureshi, Eunyoung Cho.
13.
14.
544
Abstract
Number
4651 Urolithin A (UA) inhibits both androgen receptor
and AKT signaling and prevents the progression of
castration resistant prostate cancer. Manicka V. Vadhanam,
Trinath P. Das, Suman Suman, Lakshmanan Annamalai,
Chendil Damodaran.
4652 Wide antiproliferative and proapoptotic activity
of the natural prenyl-flavonoid Xanthohumol and its
derivatives on cancer cells, peripheral blood mononuclear
cells, and human primary endothelial cells. Katiuscia
Dallaglio, Valentina Fragliasso, Cristina Gallo, Raffaele Frazzi,
Clara Maccari, Armando Rossello, Adriana Albini.
LATE-BREAKING POSTER SESSIONS
Tuesday, 1:00 p.m.-5:00 p.m.
Halls B-E, Pennsylvania Convention Center
Abstracts will be available online and in the Proceedings Part 2.
Section 39
Section 40
Late-Breaking Research: Immunology
Late-Breaking Research: Experimental and Molecular Therapeutics 2
545
Tuesday, 1:30 p.m.-3:00 p.m.
Research Priorities for NCI’s Center for Global Health
Moderators: Lisa M. Stevens and Paul C. Pearlman, National Cancer Institute-CGH, Rockville, MD
The NCI Center for Global Health (CGH) is committed to strengthening cancer research and cancer
control planning in a manner that is sustainable beyond the NCI funding. Our research efforts have been
focused on a limited number of topics that are relevant to international investigators. These areas
include cancers associated with chronic infection, ecological-niche cancers (cancers with a high
incidence in a region or country), high-burden cancers, tobacco control, and implementation science.
CGH recently funded projects to study the application of low-cost technologies in specific settings
via a translational research program to adapt, engineer, and apply low-cost and point-of-care cancer
technologies in Low- and Middle-Income Countries (LMICs) settings.
During the three years that the Center has existed, there have been a limited number of funding
opportunities to develop this type of capacity in LMICs. The intention is to grow the funding
opportunities for research within these LMIC settings (through partnerships) and to increase the
mentoring of scientists in grant and scientific writing, experimental design, and utilization of data to
inform policy (where appropriate). CGH staff work across NCI to engage scientific experts and intend
to continue to increase the engagement of the scientific community in our efforts. We hope to tap into
the scientific expertise of our Cancer Centers, University partners, and AACR members as our
programs continue to grow.
Program highlights include:
1) Low-Cost Technology Request for Applications: status and organization of the program, projects
funded in the first round, evaluation plan, focus for round two;
2) Pilot Projects for Cancer Centers in Research, Training, and Capacity Building: projects funded and
regions served, plans for round two, evaluation plan;
3) Bilateral funding initiatives: U.S.-China, U.S.-South Africa, U.S.-Brazil and future opportunities;
activities funded to date and scope of planned re-issuances;
Speakers:
Lisa M. Stevens, National Cancer Institute-CGH, Rockville, MD
Paul C. Pearlman, National Cancer Institute, Rockville, MD
Wael El-Rifai, Vanderbilt University, Nashville, TN
Ricky Lu, Johns Hopkins University, Baltimore, MD
Kathleen Schmeler, The University of Texas MD Anderson Cancer Center, Houston, TX
546
Tuesday, 2:30 p.m.-3:30 p.m.
AACRcentral, AACR Amphitheater, Halls B-E, Booth #725
Meet the Mentor: Undergraduate Focus
Chairperson: Kathleen W. Scotto, Rutgers, The State University of New Jersey, New
Brunswick, NJ
Mentor:
Patricia M. LoRusso, DO
Yale Cancer Center, New Haven, CT
Dr. Patricia M. LoRusso will engage undergraduate students in an informal discussion about cancer
research. Key answers will also be provided to important questions to help guide students in their
professional development throughout their cancer research career. All undergraduate student
attendees at the Annual Meeting are invited to participate in this session.
Dr. LoRusso is the Associate Center Director for Innovative Medicine at Yale University. She is also the
co-leader of the Stand Up to Cancer (SU2C)/Melanoma Research Alliance (MRA)-funded Melanoma
Dream Team.
Dr. LoRusso serves as co-chair of the NCI Cancer Therapy Evaluation Program (CTEP) Investigational
Drug Steering Committee. She has also served on the education and scientific committees of the
American Society of Clinical Oncology (ASCO), the scientific committee of the American Association
for Cancer Research (AACR), and as a parent member of the NCI’s Quick Trials Clinical Subcommittee.
She has served either ad hoc or as an appointed member on multiple study sections, including
Subcommittee D of the Program Projects Grants, and Small Business Innovation Research (SBIR) and
Department of Defense (DOD) study sections. She has reviewed for Komen Promise grants, numerous
SPORE and P01 study sections and translational research grants.
In 1999, Dr. LoRusso was awarded the Hero of Breast Cancer award and in 2004 the Bennett J. Cohen
Educational Leadership Award for Medical Research. She received the Marygrove College
Distinguished Alumni Award and was named one of Crain’s Detroit Business Health Care Heroes. She
was also recognized with the 2008 Michaele C. Christian Oncology Drug Development Award and
Lectureship from NCI CTEP. In 2013, she received the Hope on the Hill award for her service to the
patients in the state of Michigan.
547
AACR-CICR AWARD LECTURE
Tuesday, 3:00 p.m.-4:00 p.m.
Terrace Ballroom II-III (400 Level), Pennsylvania Convention Center
Ninth Annual AACR Award for Outstanding Achievement in
Chemistry in Cancer Research
Ligand-Targeted Imaging and Therapeutic Agents for Cancer
Philip S. Low, PhD
Director of the Purdue Center for Drug Discovery
Ralph C. Corley Distinguished Professor
Purdue University, West Lafyette, IN
The AACR and its Chemistry in Cancer Research Working Group established the Outstanding
Achievement in Chemistry in Cancer Research Award in 2007 to recognize the importance of
chemistry in advancing cancer research. The Award is presented for outstanding, novel chemistry
research that has led to significant contributions to the fields of basic or translational cancer research,
cancer diagnosis, prevention, or clinical cancer treatments and therapeutics.
Dr. Philip S. Low, currently the R.C. Corley Distinguished Professor of Chemistry at Purdue University
and the Director of the Purdue University Center for Drug Discovery, is recognized for his pioneering
use of low-molecular-weight targeting ligands for selective delivery of attached therapeutic and
imaging agents into cancer cells. His contributions to the development of these drugs have led to
dramatic improvements in therapeutic potency, reductions in drug toxicity, and increased companion
diagnostic applications such as whole body imaging and fluorescence-guided surgery. This work has
motivated fundamental changes in the practice of surgery and medicine. Dr. Low’s accomplishments
epitomize the importance of chemistry in cancer research.
Dr. Low and coworkers discovered the ability of folate to carry attached payloads into cancer cells that
express folate receptors (FR) in 1989. After characterizing the intracellular trafficking of FR in cancer
cells, and determining expression levels of FR in various tumors, Dr. Low and coworkers developed
folate-linked imaging agents for identification of patients with FR+ tumors and folate-linked cytotoxic
drugs for treatment of patients with FR+ cancers. In contrast to classical drugs that distribute
indiscriminately into all cells of the body, Dr. Low’s small molecule targeting approach concentrates
the attached cargo (chemotherapeutic agent, liposome, siRNA, enzyme-activated prodrug, gene
therapy vector, imaging agent (PET, MRI, SPECT), etc.) specifically in the diseased tissue, thereby
avoiding collateral toxicity to normal tissues. Development of the tumor-targeted drugs to date has
led to eight drugs in current human clinical trials for ovarian, lung, kidney, and prostate cancers, and
additional ligand-targeted drugs in preclinical development for treatment of other cancers and
inflammatory/autoimmune diseases. Ligand-targeted therapies for viral and other infectious diseases
are also undergoing preclinical development.
Dr. Low earned his BS degree from Brigham Young University in 1971 and his PhD from the University
of California, San Diego in 1975. After postdoctoral work at the University of Massachusetts he joined
the faculty at Purdue in 1976. Dr. Low has won multiple awards including this year’s American
Chemical Society’s Award for cancer research (Sosnovsky Award) and is the founder of Endocyte Inc.,
On Target Laboratories LLC, and HuLow LLC, which have advanced discoveries around receptor
targeting to clinically useful drugs.
548
AACR-ACS AWARD LECTURE
Tuesday, 3:00 p.m.-4:00 p.m.
Grand Ballroom (300 Level), Pennsylvania Convention Center
Twenty-Fourth Annual AACR-American Cancer Society Award for Research Excellence
in Cancer Epidemiology and Prevention
Risk Models and Cancer Prevention
Mitchell H. Gail, MD, PhD
Senior Investigator, Biostatistics Branch
Division of Cancer Epidemiology and Genetics
National Cancer Institute, National Institutes of Health, Rockville, MD
The AACR and the American Cancer Society established this Award in 1992 to honor outstanding
research accomplishments in the fields of cancer epidemiology, biomarkers, and prevention.
Dr. Mitchell H. Gail is honored for his exceptional career in molecular cancer epidemiology, cancer
biomarkers, and cancer prevention.
Dr. Gail is recognized for work in statistical modeling and the validation of cancer risk prediction
models that are applicable in a generalized population setting. Aptly named the “Gail” model,
Dr. Gail’s development of cancer risk prediction modeling for breast cancer has revolutionized cancer
assessment for this patient population. Likewise, his continued efforts in incorporating genome-wide
association studies into the model will undoubtedly have a profound impact on cancer prevention.
Dr. Gail is a Senior Investigator at the Biostatistics Branch of the Division of Cancer Epidemiology and
Genetics, National Cancer Institute (NCI). He received an MD from Harvard Medical School and a PhD in
statistics from George Washington University. His work at NCI has included studies on the motility of
cells in tissue culture, clinical trials of lung cancer treatments and of preventive interventions for gastric
cancer, assessment of cancer biomarkers, AIDS epidemiology, and models to project the risk of breast
cancer. Dr. Gail’s current research interests include statistical methods for the design and analysis of
epidemiologic studies, including studies of genetic factors, and models to predict the absolute risk of
disease. He is also working on methods of calibration and seasonal adjustment for multicenter
molecular-epidemiologic studies.
Dr. Gail is a Fellow and former President of the American Statistical Association, and a member of the
Institute of Medicine of the National Academy of Sciences. He received the Spiegelman Award from
the American Public Health Association, the Snedecor Award from the American Statistical
Association, the Marvin Zelen Leadership Award in Statistical Science, and the Nathan Mantel Lifetime
Achievement Award from the American Statistical Association.
549
CLINICAL TRIALS MINISYMPOSIUM
Tuesday, 3:00 p.m.-4:40 p.m.
Clinical Trials of Agents Targeting Breast and Prostate Cancers
Co-Chairpersons: Nicholas C. Turner, Institute of Cancer Research, London, United Kingdom, and
Helen X. Chen, National Cancer Institute-CTEP, Rockville, MD
3:00 p.m.
Introduction
3:10 p.m.
CT328: Exploratory genetic analysis of tumors from a phase I/II dose escalation study
of GSK2636771 in patients with PTEN-deficient advanced tumors
Johann de Bono, Hendrik-Tobias Arkenau, Joaquin Mateo, Jeffrey R. Infante, Howard A.
Burris, Yung-Jue Bang, Joseph Eder, Sunil Sharma, Hyun C. Chung, Shaun Decordova,
Karen E. Swales, Michelle D. Garrett, Desamaparados Roda-Perez, Meichun Ding, Mark
Russo, Li Yan, Ben Suttle, Jerry M. Tolson, Wendy S. Halsey, Ganji Gopi, Harjeet K. Van
Der Keyl, Shanker Kalyana-Sundaram, Ganesh M. Sathe, Monica Motwani, Rakesh Kumar.
3:30 p.m.
CT329: Phase I study of the PI3Kβ/δ inhibitor AZD8186 in patients with advanced
castration-resistant prostate cancer, triple-negative breast cancer, squamous nonsmall cell lung cancer, or PTEN-deficient solid tumors: Update from dose-finding
Lillian L. Siu, Johann De Bono, Kari B. Wisinski, Celestia S. Higano, Natalie Cook,
Maria Jose De Miguel Luken, Rajiv Kumar, Joshua Lang, Gurkamal S. Chatta, Sara M.
Tolaney, Stefan M. Symeonides, Gilmour Morrison, Patrick D. Mitchell, David G. Brooks,
Geoffrey I. Shapiro.
3:50 p.m.
CT330: Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor in patients with
hormone receptor-positive metastatic breast cancer
Payal D. Shah, Mary E. Moynahan, Shanu Modi, Nicola Hamilton, Betty Ann Caravella,
Stephen Zamora, Chau Dang, Theresa Gilewski, Tiffany Traina, Elizabeth Comen, Steven
M. Sugarman, Gabriella D'Andrea, Diana Lake, Shari Goldfarb, Sujata Patil, Anne Covey,
Michael Berger, Mario Lacouture, Larry Norton, Clifford A. Hudis, Jose Baselga, Sarat
Chandarlapaty, Maura Dickler.
4:10 p.m.
CT331: “BEECH,” a phase I/II study of the AKT inhibitor AZD5363 combined with
paclitaxel in patients with advanced or metastatic breast cancer: Results from the
dose-finding study, including quantitative assessment of circulating tumor DNA as a
surrogate for response/resistance
Nicholas C. Turner, Mafalda Oliveira, Anne Armstrong, Marie-Paule Sablin, José A.
Perez-Fidalgo, Sarah Herebien, Isaac Garcia-Murillas, Stan Johnson, Andrew Foxley,
Adnan Mahmood, Justin P. Lindemann.
4:30 p.m.
Discussion
550
MAJOR SYMPOSIA
Tuesday, 3:00 p.m.-5:00 p.m.
AACR-CIMM-CIMT Joint Session on
Immune-Informatics and the
Tumor Microenvironment to Boost
Cancer Immunotherapy
AACR-CSCO Joint Session: Using Genome
Sequencing to Identify Responders to
Targeted and Immune Therapeutics
Co-Chairpersons: Sjoerd H. Van Der Burg, Leiden
University Medical Center, Leiden, The Netherlands; Cedrik
M. Britten, GlaxoSmithKline, Stevenage, United Kingdom
The aim of this session that is jointly organized by the
AACR Cancer Immunology (CIMM) Working Group and the
Association for Cancer immunotherapy (CIMT) is to cover
two innovative areas of immune-oncology that bear the
potential to give rise to next waves of treatments in the
coming years. The session will provide insight into how the
adaption of clinical-grade genomics and bioinformatics
tools into translational oncology may open the stage for
novel concepts for personalized medicine. The second part
of the session will focus on the topic of local immunity
which may play a critical role in determining whether
pharmacologically active immune-therapeutic treatments
will be able to induce killing of tumor cells in vivo. The
promise is that a greater understanding of the hurdles and
druggable switches within the tumor microenvironment
will enable development of novel treatments or rational
combinations of compounds with increased efficacy.
3:00 p.m.
An integrative network approach for
genomic discovery and personalized
therapy in relapsed multiple myeloma
Joel Dudley, Icahn School of Medicine at
Mount Sinai, New York, NY
3:25 p.m.
Discussion
3:30 p.m.
Characterization of cancer
immunophenotypes and antigenomes using
NGS data and bionformatics methods
Zlatko Trajanoski, Innsbruck Medical
University, Innsbruck, Austria
3:55 p.m.
Discussion
4:00 p.m.
Building effective immunotherapy: Lessons
learned from ovarian cancer
George Coukos, University Hospital of
Lausanne, Lausanne, Switzerland
4:25 p.m.
Discussion
4:30 p.m.
The role of the p53 protein in epigenetic
regulation and the innate immune response
Arnold J. Levine, Institute for Advanced
Study, Princeton, NJ
4:55 p.m.
Discussion
Co-Chairpersons: Lillian L. Siu, University Health Network
Princess Margaret Hospital, Toronto, ON, Canada; Xuchao
Zhang, Guangdong Academy of Medical Sciences,
Guangzhou, P.R. China
The identification of valid predictive biomarkers is a key step
to unravel the biological complexity of cancer. Predictive
biomarkers form the basis of precision medicine by
providing information related to the effects of specific
treatments, and thus enabling the selection of patients who
are most or least likely to benefit. Advances in massive
parallel sequencing of cancer genomes have revealed that
individual tumors frequently harbor driver somatic mutations
and other molecular aberrations that confer growth
advantage and positive selection. Some of these aberrations
represent therapeutic targets of approved or investigational
anticancer agents, and may ultimately become predictive
biomarkers of sensitivity or resistance to these compounds if
antitumor activity can be demonstrated. Numerous national
and international efforts are actively ongoing to elucidate
the value of genotype-matching with molecularly targeted
agents. In addition to targeted therapeutics, recent evidence
reveals that genome sequencing can also provide insight to
identify responders to immune checkpoint inhibitors such as
CTLA and PD-1/PD-L inhibitors through the identification of
neoantigen signature, analysis of TCR repertoire, etc. This
session will highlight the use of genome sequencing
technologies to identify predictive biomarkers for targeted
and immune therapeutics.
3:00 p.m.
Clinical application of genome sequencing
to identify genotype-matching therapy
Lillian L. Siu, University Health Network
Princess Margaret Hospital, Toronto, ON,
Canada
3:25 p.m.
Discussion
3:30 p.m.
Genome sequencing based molecular
profiling efforts in China
Xuchao Zhang, Guangdong Academy of
Medical Sciences, Guangzhou, China
3:55 p.m.
Discussion
551
MAJOR SYMPOSIA
Tuesday, 3:00 p.m.-5:00 p.m.
Molecular identification and application of
the malignant and reactive T cell clones in
leukemia
Yangqiu Li, Jinan University Medical College,
Guangzhou, China
3:00 p.m.
Introduction
3:05 p.m.
A CTD2 pipeline for precision cancer
medicine
Andrea Califano, Columbia University, New
York, NY
4:25 p.m.
Discussion
3:25 p.m.
4:30 p.m.
Mutational landscapes and response to
immune checkpoint blockade
Timothy A. Chan, Memorial Sloan Kettering
Systematic interrogation of cancer alleles
and dependencies
William C. Hahn, Dana-Farber Cancer
3:45 p.m.
Targeting a dependency of high
mesenchymal-state cancer cells with small
molecules
Stuart L. Schreiber, Broad Institute of MIT
and Harvard, Cambridge, MA
4:05 p.m.
CDK9-mediated transcription elongation is
required for MYC addiction in hepatocellular
carcinoma
Scott W. Lowe, Memorial Sloan Kettering
4:25 p.m.
Functional oncogene validation in primary
organoid cultures
Calvin J. Kuo, Stanford University,
Stanford, CA
4:45 p.m.
Discussion
4:00 p.m.
4:55 p.m.
Discussion
CTD2 Network: Accelerates Translation of
Patient Genomic Data to Improved Patient
Outcomes
Chairperson: Daniela S. Gerhard, National Cancer Institute,
Bethesda, MD
The goals of the NCI’s Cancer Target Discovery and
Development (CTD2) Network are to bridge the gap
between the enormous volumes of data generated by
multiple efforts for the genomic characterization of cancer
and the ability to use these data for the development of
human cancer therapeutics. It specializes in computational
and functional genomics approaches critical for translating
next-generation sequencing data, including those
generated by the TCGA, TARGET, and ICGC consortia.
Specifically, the CTD2 network deploys a variety of
innovative high-throughput and integrative approaches
that combine the power of computational systems biology,
functional screens, and large-scale chemical profiling
approaches to discover, characterize, and validate novel
cancer drug targets, including novel genetic drivers and
non-oncogene dependencies that can be targeted by small
molecules or immunotherapy. This includes targets for
combination therapy and for the development of
compounds that rescue sensitivity to existing standard of
care oncology drugs. These approaches are designed to
match targets to relevant cancer phenotypes and
genotypes, thus providing companion biomarkers
supporting efficient patient stratification for more targeted
clinical trials. The presentations highlight the breadth of
approaches and translational potential employed by
Network Centers. The session starts with a brief
introduction to CTD2 and its mission and resources.
http://ctd2.nci.nih.gov/
552
MINISYMPOSIUM
Tuesday, 3:00 PM-5:00 PM
Terrace Ballroom IV (400 Level), Pennsylvania Convention
Center
Clinical Research
Precision Medicine in the Clinic
Molecular Endocrinology of Breast and
Prostate Cancer
Chairpersons: Pasi A. Jänne and David B. Solit
Chairperson: Lesley-Ann Martin
Endocrinology
3:00 Introduction
3:00 Introduction
3:05 4666 Revolutionizing clinical care using prospective,
institution-wide tumor sequencing. Lynette M. Sholl, Elizabeth
Garcia, Yonghui Jia, Matthew Ducar, Bernard Fendler, Priyanka
Shivdasani, Frank C. Kuo, Azra H. Ligon, Barrett J. Rollins, Neal I.
Lindeman, Laura E. MacConaill.
3:05 4673 Parity and short-term estradiol treatment confers
protection against breast cancer by suppressing cell survival and
migration. Arunkumar Arumugam, Ramadevi Subramani, Sushmita
Nandy, Duy Do, Rajkumar Lakshmanaswamy.
3:20 4667 The complex genomic landscape of glial tumors reveals
distinct subclasses and potential therapeutic targets associated
with clinical responses to targeted inhibitors. Juliann Chmielecki,
Michael E. Goldberg, Alex Fichtenholtz, Julia Elvin, Garrett M.
Frampton, Siraj M. Ali, Jeffrey S. Ross, Deborah Morosini, Vincent A.
Miller, David Piccioni, Santosh Kesari, Philip J. Stephens.
3:35 4668 Targeted, massively parallel sequencing identifies novel
genetic subsets of cutaneous melanoma. Bradley Garman,
Clemens Krepler, Katrin Sproesser, Patrica Brafford, Melissa Wilson,
Bradley Wubbenhorst, Ravi Amaravadi, Joseph Bennett, Marilda
Beqiri, Michael Davies, David Elder, Keith Flaherty, Dennie
Frederick, Tara C. Gangadhar, Michael Guarino, David Hoon, Giorgos
Karakousis, Nandita Mitra, Nicholas J. Petrelli, Lynn Schuchter,
Batool Shannan, Jennifer Wargo, Min Xiao, Wei Xu, Xaiowei Xu,
Meenhard Herlyn, Katherine Nathanson.
3:50 4669 Druggable oncogene fusions in lung invasive mucinous
adenocarcinoma. Takashi Nakaoku, Koji Tsuta, Hitoshi Ichikawa,
Kouya Shiraishi, Hiromi Sakamoto, Masato Enari, Koh Furuta, Yoko
Shimada, Hideaki Ogiwara, Shun-ichi Watanabe, Hiroshi Nokihara,
Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Young Hak Kim,
Michiaki Mishima, Jun Yokota, Teruhiko Yoshida, Takashi Kohno.
4:05 4670 A novel companion diagnostic predicts response to the
PARP inhibitor rucaparib in ovarian cancer. James Sun, Iain
McNeish, Robert L. Coleman, Amit Oza, Clare Scott, David M.
O’Malley, Kevin K. Lin, Christine Burns, Christine Vietz, Philip J.
Stephens, Murtaza Mehdi, Matthew Hawryluk, Heidi Giordano, Mitch
Raponi, Lindsey Rolfe, Jeff Isaacson, Vincent A. Miller, Andrew
Allen, Elizabeth Swisher, Roman Yelensky.
3:20 4674 Localization of estrogen receptor ␣(ER␣) at the
centrosome and its regulation by protein kinases in breast cancer
cells. Yingfeng Zheng, Christine Bruce, Shihua He, Kirk McManus,
Jim Davie, Leigh Murphy.
3:35 4675 GR activation modifies ER transcriptional activity and
results in decreased estrogen-mediated breast cancer cell
proliferation. Diana C. West, Charles F. Pierce, Deng Pan, Kyle
Hernandez, Masha Kocherginsky, Suzanne D. Conzen.
3:50 4676 In silico and in vitro analyses of androgen receptor
splicing variants with a special focus on human patient samples.
Takuma Uo, Heidi Dvinge, Cynthia C. Sprenger, Shihua Sun, Robert
K. Bradley, Peter S. Nelson, Stephen R. Plymate.
4:05 4677 Control of androgen receptor function by the genomic
action of the cochaperone Bag-1L. Laura Cato, Antje Neeb,
Guillaume Adelmant, Scott Ficarro, Thomas Westerling, Jarrod A.
Marto, Andrew C. Cato, Myles Brown.
4:20 4678 A novel nuclear transporter for androgen receptor and
AR-variant-7 in castration resistant prostate cancer: Ideal
therapeutic target. Aijaz Parray, Hifzur R. Siddique, Alyssa
Langfald, Pooja Singh, Mikihiko Naito, Robert Matusik, Ingo Schmitz,
Shahriar Koochekpour, Badrinath R. Konety, Mohammad Saleem.
4:35 4679 Silencing of PMEPA1, a NEDD4 E3 ubiquitin ligase
binding protein, stabilizes androgen receptor and confers
resistance to AR inhibitors. Hua Li, Elizabeth Umeda, Yingjie Song,
Denise Young, Lakshmi Ravindranath, Ahmed Mohamed, Shashwat
Sharad, Gyorgy Petrovics, David McLeod, Isabell Sesterhenn, Taduru
Sreenath, Albert Dobi, Shiv Srivastava.
4:50 Discussion.
4:20 4671 Identification of novel drugs for glioblastoma using
chemical biology fingerprinting. Darren Finlay, Harshil Dhruv, Lisa
Evers, Sen Peng, Jeff Kiefer, Seungchan Kim, Jeffrey Raizer, Michael
Berens, Kristiina Vuori.
4:35 4672 Development of 2D - cell strain and 3D - tumor spheroid
models for Precision Medicine. Chantal Pauli, Jonathan Pauwels,
Myriam Kossai, Nikolai Steklov, Andrea Sboner, Rema Rao, Kenneth
Hennrick, Brian Robinson, Juan Miguel Mosquera, Himisha Beltran,
Mark A. Rubin.
4:50 Discussion.
553
MINISYMPOSIUM
Epidemiology
Molecular and Genetic Epidemiology of
Cancer 4: New Insights
Exploiting the MAPK Pathway in Cancer
Chairperson:
Chairperson: Brandon L. Pierce
3:00 Introduction
3:00 Introduction
3:05 4680 Efficacy of the HPV16/18 vaccine against cervical, anal,
and oral HPV infection among women with and without previous
HPV16/18 exposure. Daniel C. Beachler, Aimee R. Kreimer, Mark
Schiffman, Rolando Herrero, Sholom Wacholder, Ana Cecilia
Rodriguez, Douglas R. Lowy, Carolina Porras, John T. Schiller, Silvia
Jimenez, Linda Struijk, John Schussler, Allan Hildesheim, Paula
Gonzalez, Costa Rica Vaccine Trial Group.
3:20 4681 Reducing overdiagnosis by polygenic risk-stratified
screening: findings from the Finnish arm of the European
randomised study of screening for prostate cancer (ERSPC). Nora
Pashayan, Paul D. Pharoah, Johanna Schleutker, Kirsi Talala, Teuvo
L. Tammela, Liisa Määttänen, Patricia Harrington, Jonathan Tyrer,
Rosalind Eeles, Stephen W. Duffy, Anssi Auvinen.
3:35 4682 Standardized measures of lobular involution and
subsequent breast cancer risk among women with benign breast
disease. Jonine D. Figueroa, Ruth Pfeiffer, Maya Palakal, Amy C.
Degnim, Derek Radisky, Lynn C. Hartmann, Marlene Frost, Melody L.
Stallings Mann, Louise A. Brinton, Daphne Papathomas, Daniel
Visscher, Mark E. Sherman.
3:50 4683 Smoking is associated with mosaic loss of chromosome
Y. Jan P. Dumanski, Chiara Rasi, Mikael Lönn, Hanna Davies, Martin
Ingelsson, Vilmantas Giedraitis, Lars Lannfelt, Patrik K. Magnusson,
Cecilia M. Lindgren, Andrew P. Morris, David Cesarini, Magnus
Johannesson, Eva Tiensuu Janson, Lars Lind, Nancy L. Pedersen,
Erik Ingelsson, Lars A. Forsberg.
4:05 4684 Assessment of multifactor gene-environment
interactions and ovarian cancer risk: SNPs, obesity, and
hormone-related risk factors. Joseph Usset, Brooke Fridley, Ellen
Goode, Joellen Schildkraut, Paul Pharoah.
4:20 4685 Characterization of variants of uncertain significance
(VUS) in breast and ovarian cancer predisposition genes. Fergus
J. Couch, Hermela Shimelis, Andreas Schroeder, Chunling Hu, Emily
Hallberg, Gary Lipton, Edwin Iversen, Noralane M. Lindor.
4:35 4686 Identifying obesity-linked gene expression changes in
prostate cancer. Ericka M. Ebot, Travis Gerke, Svitlana Tyekucheva,
David P. Labbé, Giorgia Zadra, Rachel S. Kelly, Michaela Bowden,
Jennifer R. Rider, Kathryn M. Wilson, Neil E. Martin, Myles Brown,
Matthew G. Vander Heiden, Edward L. Giovannucci, Massimo Loda,
Lorelei A. Mucci.
3:05 4687 A novel alkylating pyrrol-imidazole polyamide, KR12,
specifically recognizes mutant KRAS genes and potently induces
cell death. Kiriko Hiraoka, Takahiro Inoue, Hiroyuki Yoda, Atsushi
Takatori, Takayoshi Watanabe, Nobuko Koshikawa, Toshinori Ozaki,
Hiroki Nagase.
3:20 4688 Overcoming drug resistance and stemness in oncogenic
kras driven pancreatic ductal adenocarcinoma through PAK4
inhibition. Asfar S. Azmi, William Senapedis, Erkan Baloglu, Yosef
Landesman, Michael Kauffman, Sharon Shacham, Jack Wu, Amro
Aboukameel, Irfana Muqbil, Ramzi M. Mohammad.
3:35 4689 Targeting constitutive GLI activation in colon
carcinomas and cancers with oncogenic KRAS signaling. Tapati
Mazumdar, Babal K. Jha, Akwasi Agyeman, Janet A. Houghton.
3:50 4690 Next-generation screen for integrative subtyping and
target discovery for KRAS-mutant cancer. Tina L. Yuan, Rachel
Bagni, Ming Yi, Arnaud Amzallag, Shervin Afghani, Katie Beam,
William Burgan, Nicole Fer, Leslie Garvey, Brian Smith, Andrew
Waters, Robert Stephens, Cyril Benes, Frank McCormick.
4:05 4691 KRAS mutation specific alkylating pyrrole-imidazole
polyamide (KR12) suppresses mutant KRAS expression and
inhibits tumor growth by showing accumulation in KRAS mutant
xenografts. Takahiro Inoue, Kiriko Hiraoka, Yusei Suzuki, Hiroyuki
Yoda, Takayoshi Watanabe, Atsushi Takatori, Nobuko Koshikawa,
Toshinori Ozaki, Hiroki Nagase.
4:20 4692 BGB-283, a novel RAF kinase and EGFR dual inhibitor,
displays potent antitumor activity in B-RAF mutated colorectal
cancers. Zhiyu Tang, Xi Yuan, Rong Du, Shing-Hu Cheung, Guoliang
Zhang, Jing Wei, Yuan Zhao, Yingcai Feng, Yi Zhang, Yunguang Du,
Xiaoxia Hu, Wenfeng Gong, Yong Liu, Yajuan Gao, Rui Hao, Jiafu Ji,
Lianhai Zhang, Shuangxi Li, David Sutton, Min Wei, Changyou Zhou,
Lai Wang, Lusong Luo.
4:35 4693 The selective ERK inhibitor BVD-523 is active in models
of MAPK pathway-dependent cancers, including those with
intrinsic and acquired drug resistance. Ursula Germann, Brinley
Furey, Jeff Roix, William Markland, Russell Hoover, Alex Aronov,
Michael Hale, Guanjing Chen, Gabriel Martinez-Botella, Rossitza
Alargova, Bin Fan, David Sorrell, Kay Meshaw, Paul Shapiro, Michael
J. Wick, Cyril Benes, Mathew Garnett, Gary DeCrescenzo, Mark
Namchuk, Saurabh Saha, Dean J. Welsch.
4:50 Discussion.
4:50 Discussion.
554
MINISYMPOSIUM
Terrace Ballroom I (400 Level), Pennsylvania Convention
Center
Refined Targeting of the PI3K Pathway in
Cancer
Immunology
Chairperson:
Chairperson: Nabil Ahmed
Adoptive Immunotherapy
3:00 Introduction
3:00 Introduction
3:05 4694 Whole-exome sequencing of gastric cancer identifies
germline PIK3R1 variant as a novel genetic biomarker for a PI3K
beta-isoform selective inhibitor, GSK2636771. Chan Kim, Woo
Sun Kwon, Sun Young Rha, Sun Kyung Kang, Hyoki Kim, Carolyn
Buser-Doepner, Li Yan, Rakesh Kumar, Hyun Cheol Chung.
3:05 4701 NY-ESO T cells administered post ASCT for MM exhibit
extended functionality without exhaustion in a natural pattern of
effector and memory programming. Aaron Rapoport, Edward
Stadtmauer, Luca Melchiori, Ryan Wong, Eduardo Davila,
Gwendolyn Binder-Scholl, Tom Holdich, Dan Vogl, Brendan Weiss,
Jeffrey Finkelstein, Simon Lacey, Sarah Bond, Marylene Fortin, Yoav
Peretz, Joanna Brewer, Alan Bennett, Andrew Gerry, Nick
Pumphrey, Helen Tayton-Martin, Lilliam Ribeiro, Ashraf Badros,
Saul Yanovich, Nancy Hardy, Jean Yared, Naseem Kerr, Sunita
Philip, Sandra Wesphal, Bruce L. Levine, Carl June, Michael Kalos,
Bent Jakobsen.
3:20 4695 Dual targeting of MEK and PI3K pathways can act via
tumor-intrinsic mechanisms to overcome resistance and tumorextrinsic mechanisms to modulate immunity and limit cancer
cachexia. Jennifer Yang, Erin Talbert, Omar Elnaggar, Priyani
Rajasekera, Thomas Mace, Matthew Farren, Zheng Che, Benjamin
Swanson, Gregory Young, Ericka Haverick, Cynthia Timmers, Mark
Bloomston, Tanios Bekaii-Saab, Denis Guttridge, Gregory Lesinski.
3:35 4696 Combining AZD8186, an inhibitor of PI3Kbeta, with
inhibitors of PI3Kalpha and mTORC1/2 gives comprehensive
pathway suppression and enhanced antitumor activity in PTEN
null tumors. Urs Hancox, Urszula Polanska, James T. Lynch, Carol
Lenaghan, Cath Trigwell, Oona Depuelch, Phillippa Dudley, Juliana
Maynard, Lara Ward, Kevin Hudson, Jon Curwen, Francisco
Cruzalegui, Stephen Green, Klinowska Teresa, Simon T. Barry.
3:50 4697 The PI3K/mTOR pathway is a potential therapeutic
target in cancers with ARID1A mutations. Suet-Yan Kwan, Daisy I.
Izaguirre, Xuanjin Cheng, Suet-Ying Kwan, Yvonne T. Tsang, HoiShan Kwan, Kwong-Kwok Wong.
4:05 4698 Combination of ceritinib (LDK378) with PI3K inhibitors
(buparlisib [BKM120] and alpelisib [BYL719]) demonstrates
synergistic preclinical antitumor activity in ALK-rearranged nonsmall cell lung cancer (NSCLC). Emmanuelle Di Tomaso, Ronald
Linnartz, Fang Li, Cristian Massacesi, Samit Hirawat.
4:20 4699 Preclinical activity of the AKT inhibitor AZD5363 in
PTEN-deficient mouse models of prostate cancer. Marco A. De
Velasco, Yuji Hatanaka, Yurie Kura, Emiko Fukushima, Naomi Ando,
Barry R. Davies, Yutaka Yamamoto, Takashi Oki, Nobutaka Shimizu,
Kazuhiro Yoshimura, Masahiro Nozawa, Kazuhiro Yoshikawa,
Kazuto Nishio, Hirotsugu Uemura.
4:35 4700 The novel and selective PI3K␦ inhibitor, RV1001,
displays single agent biologic activity in spontaneous canine
NHL. Cheryl A. London, Sarah B. Rippy, Misty D. Bear, Kim Cronin,
Andrew H. Abbo, Kumar V. Penmetsa, Srikant Viswanadha,
Swaroop Vakkalanka.
4:50 Discussion.
3:20 4702 4-1BB costimulation ameliorates exhaustion and
prolongs in vivo persistence of chimeric antigen receptor (CAR)
expressing T cells. Adrienne H. Long, Waleed M. Haso, Jillian P.
Smith, Alec J. Walker, Terry J. Fry, Rimas J. Orentas, Crystal L.
Mackall.
3:35 4703 Improving CAR T cell function by reversing the
immunosuppressive tumor microenvironment of pancreatic
cancer. Somala Mohammed, Sujita Sukumaran, Pradip Bajgain,
Usanarat Anurathapan, Helen E. Heslop, Cliona M. Rooney, Malcolm
K. Brenner, Ann M. Leen, Juan F. Vera.
3:50 4704 Neo-antigen enriched TIL therapy mediates superior
tumor eradication in a patient-derived xenograft model of
human melanoma. Sander Kelderman, Laura Bies, Marit M. Van
Buuren, Nienke Van Rooij, John Haanen, Pia Kvistborg, Ton
Schumacher.
4:05 4705 Late ALL relapse following CD19 CAR immune-pressure
demonstrates reversible pan-antigen loss. Elad Jacoby, Yinmeng
Yang, Chris D. Chien, Waleed Haso, Haiying Qin, Terry J. Fry.
4:20 4706 TCR engineered adoptive T-cell therapy for lung cancer
is augmented by combined PD1 and TIM3 antibody blockade.
Edmund K. Moon, Raghuveer Ranganathan, Xiaojun Liu, Raluca
Verona, Linda Snyder, Carl H. June, Yangbing Zhao, Steven M.
Albelda.
4:35 4707 Genetically engineered NY-ESO-1-specific T cells in
HLA-A2+ patients with synovial sarcoma. Melinda S. Merchant,
Sandra P. D’Angelo, Hua Zhang, Donna Bernstein, Gwen BinderScholl, Tom Holdich, Luca Melchiori, Dan Williams, Marylene Fortin,
Yoav Peretz, Jason Howe, Michael Mehler, Bruce A. Hug, Matthew
Wright, Stephen Grupp, Paul A. Meyers, William Tap, Bent
Jakobsen, Crystal L. Mackall.
4:50 Discussion.
555
MINISYMPOSIUM
Metabolism and Cancer 3
Targeting Signaling Pathways in Cancer
Chairperson: Nabil Ahmed
Chairperson: Lloyd C. Trotman
3:00 Introduction
3:00 Introduction
3:05 4708 Mammalian glutamine metabolism controls circadian
rhythm through regulation of reactive oxygen species. Brian J.
Altman, Zachary E. Stine, Annie L. Hsieh, Ralph J. Deberardinis, Chi
V. Dang.
3:05 4714 Targeting p53 mutant cancers through inhibition of the
phosphatidylinositol-5-phosphate 4-kinases. Brooke M. Emerling,
Zhiwei Yang, Ryan Loughran, T.Jonathan Yang, Jared Johnson,
Rajan Pragani, Mindy Davis, Min Shen, Matthew Boxer, Anton
Simeonov, Lewis C. Cantley.
3:20 4709 Compartmental flexibility in mammalian folate
metabolism. Gregory S. Ducker, Li Chen, Xin Teng, Joshua D.
Rabinowitz.
3:35 4710 Evaluation of the glutaminase inhibitor CB-839 in nonsmall cell lung cancer. Lindsey K. Boroughs, Pei-Hsuan Chen, Ling
Cai, Mirna Rodriguez, Winter Zhang, Kenneth E. Huffman, Lauren A.
Byers, Luc Girard, Adi F. Gazdar, John V. Heymach, Michael A.
White, John D. Minna, Ethan Emberley, Alison Pan, Frank Parlati,
Ralph J. DeBerardinis.
3:50 4711 CB-839, a selective glutaminase inhibitor, synergizes
with signal transduction pathway inhibitors to enhance antitumor activity. Mirna Rodriguez, Winter Zhang, Mark Bennett,
Ethan Emberley, Mathew Gross, Julie Janes, Andrew MacKinnon,
Alison Pan, Susanne Steggerda, Melissa Works, Francesco Parlati.
4:05 4712 Targeting the arginine-nitric oxide pathway to arrest
development and progression of invasive bladder cancer. Divya
Sahu, Sounak Gupta, Andrew M. Hau, Paul Elson, John Bomalaski,
Gerry R. Boss, Donna E. Hansel.
4:20 4713 Targeting the mitochondria for the treatment of MLH1deficient disease. Sukaina Rashid, Gemma Bridge, Zhi Yao, Gyorgy
Szabadkai, Sarah A. Martin.
4:35 Discussion.
3:20 4715 Regulation of the PI3K pathway through a p85␣
monomer-homodimer equilibrium. Lydia W. Cheung, Katarzyna
W. Walkiewicz, Tabot Besong, David Hawke, Stefan T. Arold,
Gordon B. Mills.
3:35 4716 Tumor-specific regulation of receptor tyrosine kinases
by Grp94. Pengrong Yan, Hardik Patel, Pallav Patel, Stefan Ochiana,
Weilin Sun, Smit Shah, Paola Finotti, Cynthia Leifer, Zihai Li, Daniel
Gewirth, Tony Taldone, Gabriela Chiosis.
3:50 4717 In vitro potency of dual PI3K/mTORC1/C2 inhibitor,
GDC-0980 in ER+ and HER2 overexpressing breast cancer cells.
Yuliang Sun, Pradip De, Jennifer H. Carlson, Lori Friedman, Nandini
Dey, Brian Leyland-Jones.
4:05 4718 Inositol polyphosphate 4-phosphatase II activates
PI3K/SGK3 signaling to promote proliferation of human
melanoma cells. Chen Chen Jiang, Meng Na Chi, Su Tang Guo,
James S. Wilmott, Xiang Yun Guo, Xu Guang Yan, Chun Yan Wang,
Xiao Ying Liu, Lei Jin, Hsin-Yi Tseng, Amanda Croft, Hubert
Hondermarck, Tao Liu, Richard A. Scolyer, Xu Dong Zhang.
4:20 4719 Targeting interdependent signaling pathways to
increase the durability and magnitude of response: promising
combination therapy with dual mTORC1/2 inhibitors and CDK4/6
inhibitors. Claire Crafter, Jon Curwen, Oona Delpuech, Lenka
Oplustilova, Stephen Green, Henry Brown, Cath Trigwell, Sabina
Cosulich.
4:35 4720 Protein kinase C alpha (PKC␣) regulates PI3K/AKT
signaling in endometrial cancer. Alice H. Hsu, Kathryn J. Curry,
Kang-Sup Shim, Peter Frederick, Carl Morrison, Baojing Chen,
Subodh M. Lele, Takiko Daikoku, Sudhansu K. Dey, Gustavo Leone,
Adrian R. Black, Jennifer D. Black.
4:50 Discussion.
556
MINISYMPOSIUM
Tumor Biology
Tumor Biology
Clonal Evolution, Epithelial-Mesenchymal
Transition, and Metastatic Colonization
Pediatric Cancer: Basic Science 3
Chairpersons: A. Thomas Look and Rani E. George
Chairperson: Filippo G. Giancotti
3:00 Introduction
3:00 Introduction
3:05 4721 Epithelial to mesenchymal transition is not required for
breast to lung metastasis but contributes to chemoresistance.
Kari R. Fischer, Anna Durrans, Sharrell Lee, Jianting Sheng, Hyejin
Choi, Fuhai Li, Stephen Wong, Nasser K. Altorki, Vivek Mittal,
Dingcheng Gao.
3:20 4722 Inactivation of neogenin promotes castration resistance
and bone metastasis in prostate cancer models. Goutam
Chakraborty, Mayur Gadiya, Myriam Kossai, Dong Gao, Weijing Su,
Hua Gao, Yu Chen, Howard I. Scher, Mark A. Rubin, Filippo Giancotti.
3:35 4723 Mesenchymal status promotes metastatic colonization
via a cancer cell-stroma crosstalk which uncouples EMT and
stemness. Yaiza Del Pozo Martin, Danielle Park, Erik Sahai, Ilaria
Malanchi.
3:50 4724 Targeting matrix metalloproteinases (MMP) for antimetastatic therapy: Blocking active MMP9 abrogates metastatic
niche formation and prevents metastatic seeding in a breast
cancer model. Vicki Plaks, Jonathan Chou, Carrie Maynard, Nguyen
H. Nguyen, Niwen Kong, Inna Solomonov, Dalit Talmi-Frank,
Caroline Bonnans, Irit Sagi, Zena Werb.
4:05 4725 Hematopoietic stem cell niche activation and progenitor
mobilization mediate cancer-associated immunosuppression
and metastasis. Amber J. Giles, Meera Murgai, Yorleny Vicioso,
Steven Highfill, Miki Kasai, Linda Vahdat, Leonard Wexler, Crystal
Mackall, David Lyden, Rosandra Kaplan.
4:20 4726 Gene expression signatures of isolated circulating
tumor cells from metastatic breast cancer patients reveal
presence of breast cancer stem cells with EMT or MET
phenotypes. Shamileh Fouladdel, Hyeun Joong Yoon, Eric Lin, Tae
Hyun Kim, Yadwinder S. Deol, Tahra K. Luther, Shawn G. Clouthier,
Hui Jiang, Monika L. Burness, Sunitha Nagrath, Ebrahim Azizi, Max
S. Wicha.
4:35 4727 Genomic characterization of brain metastases reveals
divergent evolution and metastasis specific mutations. Priscilla K.
Brastianos, Scott L. Carter, Sandro Santagata, Amaro TaylorWeiner, Robert T. Jones, Eli Van Allen, Keith L. Ligon, Josep
Tabernero, Joan Seoane, Elena Martinez-Saez, Daniel Cahill, William
T. Curry, Ian F. Dunn, Sun Ha Paek, Paul Van Hummelen, Aaron R.
Thorner, Bruce E. Johnson, Nancy U. Lin, Toni K. Choueiri, Michael S.
Rabin, Rameen Beroukhim, Anat Stemmer-Rachamimov, Matthew
Meyerson, Levi Garraway, Tracy Batchelor, Jose Baselga, David N.
Louis, William C. Hahn, Gad Getz.
4:50 Discussion.
3:05 4728 Apoptotic priming is regulated by a developmental
program and predisposes children to therapy-induced toxicity.
Kristopher A. Sarosiek, Michael Ziller, Cameron Fraser, Patrick
Bhola, Jeremy Ryan, Jing Deng, Brian Jian, Marti Goldenberg,
Joseph Madsen, Ruben Carrasco, Shenandoah Robinson, Javid
Moslehi, Anthony Letai.
3:20 4729 Frequency of actionable gene fusions in patients with
Philadelphia chromosome-like (Ph-like) B-acute lymphoblastic
leukemia (ALL): A retrospective study from the Children’s
Oncology Group (COG). Shalini C. Reshmi, Richard C. Harvey, Amy
Smith, I-Ming Chen, Marc Valentine, Yu Liu, Yongjin Li, Jinghui
Zhang, Kathryn G. Roberts, Ying Shao, John Easton, Debbie PayneTurner, Meenakshi Devidas, Nyla Heerema, Andrew J. Carroll,
Elizabeth A. Raetz, Michael J. Borowitz, Brent L. Wood, Anne L.
Angiolillo, Michael M. Burke, Wanda L. Salzer, Patrick A. ZweidlerMcKay, Karen R. Rabin, William L. Carroll, Mignon L. Loh, Stephen P.
Hunger, Charles G. Mullighan, Cheryl L. Willman, Julie M. GastierFoster.
3:35 4730 Molecular analysis of the pediatric cancer fibrolamellar
hepatocellular carcinoma. Elana P. Simon, Joshua N. Honeyman,
David G. Darcy, Brad R. Rosenberg, Iris I. Lim, Jennifer M. Murphy,
Ben Farber, Gadi Lalazar, Catherine Freije, Michael P. La Quaglia,
Sanford M. Simon.
3:50 4731 Targeting super-enhancer induced gene expression
with the novel BRD4 inhibitor OTX015 in preclinical models of
MYCN-amplified neuroblastoma. Anton Henssen, Kristina Althoff,
Richard Koche, Andrea Odersky, Anneleen Beckers, Frank
Speleman, Simon Schäfers, Katleen De Preter, Alexandra Florin,
Lukas Heukamp, Annika Spruessel, Kathy Astrahanseff, Natalie
Sadowski, Alexander Schramm, Angelika Eggert, Lucile AstorguesXerri, Eugenia Riveiro, Esteban Cvitkovic, Johannes H. Schulte.
4:05 4732 Efficacy of focal adhesion kinase inhibition in IKZF1altered BCR-ABL1 acute lymphoblastic leukemia. Michelle L.
Churchman, Irina M. Shapiro, Jonathan A. Pachter, David T. Weaver,
Charles G. Mullighan.
4:20 4733 Notch signaling increases the number of relapse-driving
tumor propagating cells in embryonal rhabdomyosarcoma.
Myron Ignatius, Riadh Lobbardi, Madeline Hayes, Eleanor Chen,
Karin McCarthy, G. Petur Nielsen, Brian Beleyea, Corinne Linardic,
Javed Khan, Charles Keller, David M. Langenau.
4:35 4734 A LIN28B/RAN/AURKA signaling network promotes
neuroblastoma tumorigenesis. Robert W. Schnepp, Priya Khurana,
Edward F. Attiyeh, Sara Chodosh, Pichai Raman, Derek A. Oldridge,
Maria E. Gagliardi, Karina Conkrite, Shahab Asgharzadeh, Robert C.
Seeger, Blair Madison, Anil Rustgi, John M. Maris, Sharon J. Diskin.
4:50 Discussion.
557
REGULATORY SCIENCE AND POLICY SESSIONS
Tuesday, 3:00 p.m.-5:00 p.m.
Clinical Trial Enrichment Strategies: Designing a Prospectively Defined
Retrospective Analysis Study
Chairperson: Eric H. Rubin, Merck Research Laboratories, North Wales, PA
Given our improving understanding of the genetic and molecular underpinnings driving cancer
growth, it is often possible to hypothesize that a specific population of patients will be uniquely
responsive to a new drug. However, development of companion diagnostic assays often lags behind
development of new therapeutics, and there may be uncertainty in key aspects of an assay, such as
the cutoff defining a “positive” test. The U.S. Food and Drug Administration (FDA) guidance
“Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological
Products” includes a discussion of an approach in which a predictive biomarker is identified during
(not before) a phase III trial. This approach involves the enrollment of “all comers” without
stratification, but with a prospectively defined retrospective analysis that controls type I error. Use of
this approach has the potential to accelerate development of optimal diagnostic tests that can be
used to identify uniquely responsive patients.
This session will discuss:
• The criteria for designing a prospectively defined retrospective study,
• Potential modification of a trial to enrich for a specific population,
• The statistical considerations for study design, as well as
• Developing companion assays for biomarker identification.
The session will also include the FDA’s perspective on Agency expectations for conducting such
studies. A panel discussion moderated by Eric H. Rubin, Merck Research Laboratories, and audience Q
and A will follow the presentations.
Speakers:
Eric H. Rubin, Merck Research Laboratories, North Wales, PA
Geoffrey S. Kim, U.S. Food and Drug Administration, Silver Spring, MD
Richard M. Simon, National Cancer Institute, Bethesda, MD
Lisa M. McShane, National Cancer Institute, Bethesda, MD
Cyrus R. Mehta, Cytel Inc., Cambridge, MA
Yun-Fu Hu, U.S. Food and Drug Administration, Silver Spring, MD
558
Regulatory Strategies to Expedite Oncology Drug Development
Co-Chairpersons: Mace L. Rothenberg, Pfizer, Inc., New York, NY; Tatiana M. Prowell, U.S. Food and
Drug Administration, Silver Spring, MD, and Johns Hopkins Kimmel Cancer Center, Baltimore, MD
The U.S. Food and Drug Administration (FDA) has a number of programs intended to hasten the
development and approval of safe and effective therapies for patients, including fast track
designation, breakthrough therapy designation, priority review, and accelerated approval. The Agency
recently issued final guidance on the differences and applicability of each of these programs, titled
“Expedited Programs for Serious Conditions – Drugs and Biologics.” These programs impact drugs at
virtually every stage of development and are designed to streamline the process by which safe and
effective new agents receive regulatory approval and may be made available as quickly as possible to
treat patients with serious and life-threatening diseases. It is recognized that under these conditions,
new drugs will be introduced into the market based on compelling data generated by clinical trials
that may have been relatively small in size, conducted without a concurrent control arm, and/or
lacking long term follow up. The impact of expedited development and the level of clinical evidence
available at the time of approval will be discussed from various perspectives including those of
patients, clinicians, regulators, industry, and others. This session will use case studies to illustrate the
scientific and regulatory considerations to strategically employ expedited programs in oncology drug
development. Discussion topics will include:
I. Expedited approval and the impact on patient care: a) How ready are practicing oncologists to
embrace new drugs that are approved via expedited pathways; b) How does expedited approval
impact payment and reimbursement; c) What are the concerns of clinicians (private practice and
academic); patients and payers regarding uptake of drugs approved via expedited pathways?
II. Expedited approval and the impact on drug development:
a) Impact on the development of other agents in class; b) Impact on the drug’s development for other
indications; c) Impact on other drugs in development (other sponsors and sponsor’s own pipeline)
III. Secondary Impacts of expedited approvals:
a) Criteria for expedited approval in other parts of the world; b) Impact on the drug’s development in
regions with differing standards for approval; c) Perception of unmet need and level of urgency for
new drug approval in different parts of the world
Speakers:
Mace L. Rothenberg, Pfizer, Inc., New York, NY
Tatiana M. Prowell, U.S. Food and Drug Administration, Silver Spring, MD, and Johns Hopkins Kimmel
Cancer Center, Baltimore, MD
Julia Beaver, U.S. Food and Drug Administration, Silver Spring, MD
Deborah K. Armstrong, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
Hans Loland, Cancer Survivor and Patient Advocate, Seattle, WA
Jorge Martinalbo, European Medicines Agency, London, United Kingdom
Erling T. Donnelly, Pfizer, Inc., Cambridge, MA
John M. Burke, Rocky Mountain Cancer Center, Aurora, CO
559
Tuesday, 3:30 p.m.-4:30 p.m.
AACRcentral, MICR Networking and Resource Center, Halls B-E, Booth #725
Meet the Director and Staff of the NCI Center to
Reduce Cancer Health Disparities
Sanya A. Springfield, PhD
NCI Center to Reduce Cancer Health Disparities, Bethesda, MD
The Center to Reduce Cancer Health Disparities (CRCHD) is central to NCI’s efforts to reduce the
unequal burden of cancer in our society and train the next generation of competitive researchers in
cancer and cancer health disparities research. All MICR members and Annual Meeting attendees are
invited to this informal meet and greet to talk with the director and staff on topics such as:
• Funding Opportunities – Disparities Research and Diversity Training
• Disparities Research Initiatives
• Diversity Training Programs
• and More
Speakers:
Nelson Aguila, Deputy Director
Peter Ogunbiyi, Chief, Diversity Training Branch
Jason Liu, Program Director
John Ojeifo, Program Director
Liz Perruccio, Program Director
Tiffany Wallace, Program Director
560
Tuesday, 4:00 p.m.-5:00 p.m.
Booth #725 (AACR Central), Halls B–E
Meet the Editors-in-Chief of Cancer Discovery
Lewis C. Cantley, PhD, FAACR
Meyer Director, Sandra and Edward Meyer Cancer Center at Weill Cornell Medical
College/Ronald P. Stanton Clinical Cancer Program at NewYork-Presbyterian
Margaret and Herman Sokol Professor in Oncology Research
Professor of Cancer Biology in Medicine
Weill Cornell Medical College
José Baselga, MD, PhD, FAACR
Physician-in-Chief, Memorial Sloan-Kettering Cancer Center
Join us at Booth #725 (AACR Central) at AACR Annual Meeting 2015 to meet the editors of Cancer
Discovery. The Editors-in-Chief will explain the mission and scope of the journal, recent submission
trends, and other topics of interest for researchers looking to publish their work in this highly
esteemed AACR publication. Learn what the Editors look for in manuscripts and participate in a
unique Q&A session.
Cancer Discovery publishes high-impact, peer-reviewed articles describing major advances in research
and clinical trials. As the premier cancer information resource, the journal presents Review Articles,
Perspectives and Commentaries, News stories, and Research Watch summaries of important journal
articles to its readers to keep them informed about the latest findings in the field. Topics span the
spectrum of cancer research and medicine from the laboratory to the clinic and epidemiologic studies.
561
AACR AWARD LECTURE
Tuesday, 4:15 p.m.-5:15 p.m.
Terrace Ballroom II-III (400 Level), Pennsylvania Convention Center
Thirty-Fifth Annual AACR Award for Outstanding Achievement in Cancer Research
Chromatin Regulators as Cancer Dependencies
Christopher R. Vakoc, MD, PhD
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Since 1979, the AACR Award for Outstanding Achievement in Cancer Research has been given to a young
investigator no more than 40 years of age to recognize his or her meritorious achievements within the
field of cancer research.
Dr. Christopher R. Vackoc is honored for his groundbreaking discoveries in the areas of epigenetics
and cancer biology. More specifically, Dr. Vakoc’s work on the basic molecular mechanisms that
control leukemias has revealed an essential connection between epigenetic regulation and
oncogenesis, and has subsequently led to development of new therapeutic approaches. He brings a
high level of precision, creativity, and intensity to his research, and we applaud his efforts in bringing
new fundamental insights to the clinic.
Dr. Vakoc is recognized for having found that the BET bromodomain protein BRD4 is a specific
vulnerability of aggressive forms of acute myeloid leukemia (AML). His work also provided for the first
time an opportunity to drug the hitherto undruggable MYC pathway in cancer, as BRD4 is an upstream
regulator of MYC. Chris found that an existing BRD4 drug, JQ1, could inhibit MYC and thereby have a
therapeutic effect on MYC driven leukemia mouse models. These findings have now progressed into
the clinic, where multiple BET domain inhibitors are tested in MYC driven cancers.
Earlier in his career, Dr. Vakoc worked in the lab of Gerd Blobel at the University of Pennsylvaina, were
he studied members of the mixed-lineage leukemia (MLL) family of proteins – histone modifying
enzymes responsible for generating epigenetic marks on chromatin. Chris identified a persistent
histone mark he thought could be contributing to the epigenetic reprogramming of these leukemias,
an early example of the emerging significance that epigenetics has had in cancer biology.
In 2008 Dr. Vakoc joined Cold Spring Harbor Laboratories as a fellow where he followed up on his
work at University of Pennsylvania, finding that MLL acts as a “bookmark” to tell daughter cells which
genes to express after mitosis. This was a significant finding, as it not only provided a clearer picture
of what MLL normally does in healthy cells to promote inheritance of gene expression information, it
also provided the basis for future studies directed at understanding how MLL mutations impact these
mechanisms in leukemia.
Dr. Vakoc received both his PhD and MD degrees from the University of Pennsylvania (in 2005 and
2007, respectively). He joined Cold Spring Harbor Laboratories in 2008, where he currently is an
assistant professor. He has received several awards and honors for his work, including the 2011
Burroughs Wellcome Fund Career Award for Medical Scientists, the 2011 Sass Foundation Fellowship
and the 2011 Forbeck Scholar Award.
562
AACR-BURCHENAL AWARD LECTURE
Tuesday, 4:15 p.m.-5:15 p.m.
Twentieth Annual AACR Joseph H. Burchenal Memorial Award for
Outstanding Achievement in Clinical Cancer Research
Immunologic Treatments for Pancreatic Cancer:
Current and Future Strategies
Elizabeth M. Jaffee, MD
Johns Hopkins University, Baltimore, MD
The Joseph H. Burchenal Memorial Award was established in 1996 to recognize outstanding
achievements in the field of clinical cancer research. It is named for the late Dr. Joseph H. Burchenal,
honorary member and past president of the American Association for Cancer Research and pioneer in
the development of chemotherapeutics for the treatment of cancer.
Elizabeth M. Jaffee, MD, is honored for her outstanding contributions to cancer immunology in both
the preclinical and early clinical settings. Her pioneering work in immunotherapies for breast and
pancreatic cancers has been tremendously influential to the discovery and development of new and
effective cancer treatments, providing renewed hope for those afflicted with these terrible diseases. In
addition to her remarkable scientific accomplishments, we also applaud her efforts as a mentor for the
next generation of researchers and clinicians.
Dr. Jaffee is credited with opening the door to immunotherapy as a potential treatment for pancreatic
cancer. Her numerous clinical research successes include testing one of the earliest therapeutic
pancreatic cancer vaccines (GVAX) in 1997. She has also shown that mesothelin is a viable target for
therapeutic vaccines and adoptive therapy for pancreatic cancer. Dr. Jaffee recently led a phase II trial
that showed that a GVAX prime and Listeria monocytogenes vaccine boost improved overall survival
for patients with pancreatic cancer; this approach was recently granted breakthrough status by the
U.S. Food and Drug Administration.
Dr. Jaffee is currently leader of the Stand Up To Cancer-Lustgarten Foundation Dream Team:
Transforming Pancreatic Cancer to a Treatable Disease. The Dream Team is conducting combination
clinical trials and establishing biomarkers of tumor microenvironment reprogramming. The trials focus
on novel immune-suppressive pathways within the tumor, either in combination with a T cellactivating vaccine or chemotherapy.
Dr. Jaffee is an active AACR member, currently serving on the board of directors, as chair of the
Cancer Immunology Working Group, and as co-chair of the Immunology Program Committee at this
year’s AACR Annual Meeting. Additionally, she is deputy editor of Cancer Immunology Research and
has been active in AACR mentoring programs, including those as part of the Women in Cancer
Research Working Group.
Dr. Jaffee received her medical degree from New York Medical College in Valhalla and completed an
internship and residency at the University of Pittsburgh’s Presbyterian University Hospital. She first
came to Johns Hopkins to complete a postdoctoral fellowship in 1989 and joined the faculty in 1992.
563
FORUMS
Tuesday, 5:00 p.m.-6:30 p.m.
Convention Center
David Sidransky, Johns Hopkins Medical Institutes,
Baltimore, MD
Are Cancer Stem Cells Relevant to the
Success of Human Cancer Therapy?
Moderator: Benjamin G. Neel, University of Toronto Ontario
Cancer Institute, Toronto, ON, Canada
The cancer stem cell model of tumor heterogeneity holds
that only certain cells within tumors or hematologic
neoplasms, termed “cancer stem cells” (CSCs) or “leukemia
stem cells” (LSCs), respectively, have the capacity to
indefinitely self-renew and generate the remaining bulk
tumor. Because CSCs and LSCs are proposed to have distinct
properties, they also could have unique vulnerabilities, as
well as manifest resistance to conventional agents.
Substantial evidence supports a CSC/LSC organization in
many malignancies, yet in other cases (e.g., melanoma) all
tumor cells appear to have self-renewal/differentiation
potential. This session will consider the role of CSC/LSC in
leukemia, breast cancer and glioblastoma, with particular
focus on therapeutic implications.
Panel:
Ross L. Levine, Memorial Sloan Kettering Cancer Center,
New York, NY
Convention Center
Challenges in Trial Design for the Genomic Era
Moderator: Donna S. Neuberg, Dana-Farber Cancer
The ability to test patient samples for mutations and other
anomalies in a timely fashion, coupled with the availability
of agents targeted to mutations and aberrant expression,
offers great promise in cancer therapy. There are many
ways to implement such studies and to measure effect.
One can restrict the study population to a particular
disease type, but one can also offer treatment based on
biology to a more heterogeneous population. Biomarkers
are critical for assigning treatment and assessing
specificity of effect. Participants will highlight some of the
challenges in reworking our established paradigms to
address the needs of modern trials in the genomic era.
5:00 p.m.
Introduction
Donna S. Neuberg, Dana Farber Cancer
5:05 p.m.
Gideon Blumenthal, U.S. Food and Drug
Administration, Silver Spring, MD
5:20 p.m.
Susan Geyer, University of South Florida,
Tampa, FL
5:35 p.m.
Lisa M. McShane, National Cancer Institute,
Bethesda, MD
5:50 p.m.
David P. Schenkein, Agios Pharmaceuticals
Inc., Cambridge, MA
6:05 p.m.
Panel Discussion
Jenny C. Chang, Houston Methodist Hospital, Houston, TX
Peter B. Dirks, University of Toronto Hospital for Sick
Children, Toronto, ON, Canada
Avatar Mouse Models for Personalized
Cancer Treatment
Moderator: Manuel Hidalgo, Centro Nacional de
Investigaciones Oncológicas (CNIO), Madrid, Spain
Strategies to personalize cancer treatment are very
important and highly needed. Currently, several biomarkers
are routinely used for that goal. For most tumors types and
drugs, however, there are no methods for personalized
treatment. Over the last few years, there has been interest
in using patient-derived xenograft models, aka Avatar
mouse models, for this goal. Earlier studies suggest the
promise of this approach but important scientific, technical,
and logistic issues remain to be solved for broader
application of this method. In this session, the current status
and future directions of this approach will be discussed.
Panel:
Giorgio Inghirami, Weill Cornell Medical College, New YorkPresbyterian, New York, NY
564
Role of Autophagy in Cancer Development,
Progression, and Therapy
Moderator: Eileen P. White, Rutgers-The Cancer Institute of
New Jersey, New Brunswick, NJ
Autophagy is a catabolic process that captures, degrades,
and recycles intracellular components to maintain
metabolism and survival in starvation and the function and
quality of intracellular proteins and organelles. The discovery
that autophagy inactivation can selectively compromise the
growth and survival of some RAS- and BRAF-driven and
other cancers has prompted interest in inhibiting autophagy
for cancer therapy. Autophagy has also been implicated as a
therapy resistance mechanism suggesting that addition of
autophagy inhibitors may provide clinical benefit. We will
discuss the mechanisms by which autophagy contributes to
tumorigenesis, how the role of autophagy differs between
tumor types, whether the functional status of autophagy
influences treatment response, and the degree to which
autophagy inactivation is selectively detrimental to tumor
rather than normal tissues.
Panel:
Alec C. Kimmelman, Dana-Farber Cancer Institute,
Boston, MA
Jayanta Debnath, University of California, San Francisco, CA
Value-Based Drug Development
Moderator: Ellen V. Sigal, Friends of Cancer Research,
Washington, DC
Health care has become increasingly complex with the
advent of genomic medicine and the downward pressure
on costs. As a result, pharmaceutical companies must
continue to adapt the drug development process to ensure
that, in this complex environment, the drugs produced
provide maximum value to consumers. Value-based
medicine is at the core of ongoing discussions within the
health care community, particularly within the field of
oncology, as quality of care, patient outcomes and survival,
and access to treatments are of increasing importance. This
forum, which will build on the larger discussion about
quality and value taking place at the national level, will
highlight current research, initiatives, and policy needs to
move towards a healthcare system with high-quality care
and improved outcomes for patients. The forum will foster
a dialogue with leaders in academia, industry, and the
patient community to discuss the important role and need
for innovation and define the value components necessary
for innovative development of targeted therapies that
improve patient outcomes.
5:00 p.m.
Introduction
Ellen V. Sigal, Friends of Cancer Research,
Washington, DC
5:05 p.m.
Richard L. Schilsky, American Society of
Clinical Oncology, Alexandria, VA
5:20 p.m.
Mace L. Rothenberg, Pfizer, Inc., New York, NY
5:35 p.m.
Andrea S. Ferris, LUNGevity Foundation,
Potomac, MD
5:50 p.m.
Louis J. DeGennaro, The Leukemia and
Lymphoma Society, White Plains, NY
6:05 p.m.
Panel Discussion
What Is the Real Target of Bromodomain
Inhibitors?
Moderator: Johnathan R. Whetstine, Harvard Medical
School and Massachusetts General Hospital Cancer,
Charlestown, MA
Bromodomain inhibition has shown tremendous clinical
promise. This session is aimed at asking some key
questions about bromodomains and their therapeutic
potential. For example, “Are all bromodomains created
equal?” and “Are all bromodomain inhibitors acting the
same or impacting one universal pathway?” Discussing
these types of fundamental questions will foster interactive
and thoughtful dialog that will impact our understanding
of this area of epigenetic therapy. The discussions within
this session will address which bromodomains should be
targeted and explore the impact of pan-inhibition versus
site-selectivity. The session will also interrogate
mechanisms of action. Specifically, discussions will be
centered on Myc-dependent and -independent roles
between and within tumor types. These discussions are
designed at creating a dialog and exchange. The two
speakers that are leading this session are Drs. Panagis
Filippakopoulos (Wellcome Trust Research Career
development Fellow and Principal Investigator at the
University of Oxford) and Chris Carpenter (VP-DPU Head
Cancer Epigenetics, GlaxoSmithKline). The session
will be moderated by Dr. Johnathan Whetstine
(Tepper Family Research Scholar, Associate Professor of
Medicine at Massachusetts General Hospital and Harvard
Medical School).
Panel:
Panagis Filippakopoulos, University of Oxford, Headington,
Oxford, United Kingdom
Chris Carpenter, GlaxoSmithKline, Collegeville, PA
565
Tuesday, 5:00 p.m.-6:30 p.m.
The NCI RAS Initiative at the Frederick National Laboratory
for Cancer Research
In the fall of 2013, the National Cancer Institute launched the RAS Initiative with the goal to unravel
the role of mutant RAS proteins in order to solve the challenges of treating RAS-driven cancers and to
build an open model or collaboration among government, academic, and industry researchers. The
initiative is operated as a research hub based at the Frederick National Laboratory of Cancer Research
in Frederick, MD, with spokes reaching into the extramural community. This session will cover the RAS
Initiative development, research progress in the areas of structural biology and biochemistry, RAS
pathway analysis, assay development, and opportunities for collaborative efforts to target KRAS.
Speakers:
Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Rachel K. Bagni, Frederick National Laboratory for Cancer Research, Frederick, MD
Tina L. Yuan, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Matthew Holderfield, Frederick National Laboratory for Cancer Research, Frederick, MD
John C. Hunter, UT Southwestern Medical Center, Dallas, TX
Lynn McGregor, University of California, San Francisco, CA
566
REGULATORY SCIENCE AND POLICY SESSION
Tuesday, 5:00 p.m.-6:30 p.m.
FDA’s Proposed Framework to Regulate
Laboratory-Developed Tests (LDTs)
Chairperson: Laura J. van ‘t Veer, UCSF Helen Diller Family Comprehensive Cancer Center,
San Francisco, CA
In the era of precision cancer medicine, safe and effective diagnostic tests are a crucial tool to tailor
treatments for individual patients based on their unique tumor molecular profile. Molecular diagnostic
tests can take two paths to market – via review and approval by the U.S. Food and Drug
Administration (FDA) as in vitro diagnostic (IVD) tests or “kits” or as laboratory-developed tests
(LDTs). LDTs are tests that are designed, manufactured, and offered within a single laboratory. While
the FDA has authority over all diagnostic tests, the agency had historically chosen not to enforce its
authority in the case of LDTs because traditionally these were simple, well-established tests. However,
LDTs being developed today can be complicated tests that pose a high risk to the patient. Therefore,
the FDA has recently proposed a framework detailing a risk-based, phased-in approach to oversee
high- and moderate-risk LDTs. This proposal raises many concerns within the laboratory community
and the American Association for Cancer Research (AACR) is committed to engaging with the FDA in
a constructive dialogue to protect patients, instill physician confidence in the validity of the test
results, incentivize innovation, and advance the practice of precision medicine. This town hall session
will provide an opportunity for AACR members to interact with the FDA’s leadership on the proposed
framework to regulate LDTs.
A panel discussion moderated by Laura J. van ‘t Veer, UCSF Helen Diller Family Comprehensive Cancer
Center, and audience Q and A will follow the presentations.
Speaker:
Laura J. van ‘t Veer, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Elizabeth Mansfield, U.S. Food and Drug Administration, Rockville, MD
Curtis A. Hanson, Mayo Clinic Cancer Center, Rochester, MN
567
SPECIAL SESSION (not eligible for CME credit)
Tuesday, 5:00 p.m.-6:30 p.m.
Please Note: The time of this session has been changed.
The new time is 3:15 p.m.-4:45 p.m. on Tuesday, April 21.
Liberty Ballroom (Level 3), Philadelphia Marriott Downtown
MYC Pathway Social Interactome
Following upon the success of the RAS Interactome sessions held at the 2013 and 2014 Annual
Meetings, the AACR and Sage Bionetworks are collaborating to offer a session focused on community
building for MYC pathway researchers. Through text mining of abstracts and a survey sent to AACR
attendees, the interactome application will provide a visual map of research on MYC and highlight
areas of interest within this community—enabling attendees of this session to identify potential
collaborators working in adjacent areas. Following a brief demonstration of the interactome, attendees
will participate in roundtable discussions on key MYC topics to foster future collaborations.
5:00 p.m.
Interactome application: Networking of MYC researchers
Justin Guinney, Sage Bionetworks, Seattle, WA
5:10 p.m.
Progress and prospects in MYC research
Rodrigo Dienstmann, Sage Bionetworks, Seattle, WA
5:25 p.m.
Roundtable discussions with experts
Roundtable Moderators
Laura Soucek, Vall d'Hebron Institute of Oncology, Barcelona, Spain
Carla Grandori, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
Rosalie C. Sears, Oregon Health and Science University, Portland, OR
568
AACR-CRI AWARD LECTURE
Tuesday, 5:30 p.m.-6:30 p.m.
Third Annual AACR-Cancer Research Institute
Lloyd J. Old Award in Cancer Immunology
CAR T Cells: Can We Move Beyond B Cells?
Carl H. June, MD
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
The AACR-CRI Lloyd J. Old Award in Cancer Immunology was established in honor of the late
Lloyd J. Old, MD, who is considered the “Founding Father of Modern Tumor Immunology.” Dr. Old’s
outstanding research in the field of cancer immunology, as well as his decades of leadership in
fostering the field, have had a far-reaching impact on cancer. This award is intended to recognize an
active cancer immunologist who, like Dr. Old, has done outstanding, innovative, and impactful research
in cancer immunology.
Dr. Carl H. June is recognized for his important contributions to cancer immunology, specifically his
pioneering efforts related to the development of chimeric antigen receptor (CAR) T cell therapy. His
work with CAR T cell therapy has significantly enhanced the promise of cancer immunotherapy,
evidenced by the recent licensing of this therapeutic by Novartis. This investigational therapy, now
called CTL019, has received breakthrough therapy designation from the U.S. Food and Drug
Administration for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic
leukemia (ALL). This work will not only have a profound impact on the treatment of leukemia but is
paving the way for the development of CAR T therapies for other types of cancer.
Dr. June has been recognized with numerous honors throughout his career, including the Taubman Prize
for Excellence in Translational Medical Science, the Karl Landsteiner Memorial Award from the American
Association of Blood Banks, the Steinman Award for Human Immunology Research from the American
Association of Immunologists, the Richard V. Smalley Award from the Society of Immunotherapy of
Cancer, the Paul Ehrlich and Ludwig Darmstaedter Prize, the Legion of Merit from the U.S. Navy, and
election to the Institute of Medicine and the American Academy of Arts and Sciences.
A graduate of the United States Naval Academy in Annapolis, MD, Dr. June served as a U.S. Navy
Medical Officer from 1975 to 1996. He received his medical degree from Baylor College of Medicine in
Houston and completed a research fellowship in immunology with the World Health Organization in
Geneva, Switzerland, and a fellowship in oncology at the Fred Hutchinson Cancer Research Center in
Seattle. Dr. June performed his internship and residency at the National Naval Medical Center in
Bethesda, after which he was appointed professor in the Department of Medicine at the Uniformed
Services University of the Health Sciences in Bethesda, MD. He is currently the Richard W. Vague
professor in immunotherapy at the Perelman School of Medicine and director of the Translational
Research Program at the Abramson Cancer Center of the University of Pennsylvania.
569
TOWN MEETING (not eligible for CME credit)
Tuesday, 6:30 p.m.-8:30 p.m.
Grand Ballroom Salons C-D (Level 5), Philadelphia Marriott Downtown
Tumor Microenvironment (TME) Working Group Town Hall Meeting
This is an opportunity for all interested to hear an update from our colleagues on “The Future of
Cancer Science.” Dr. Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, will speak on
“Stromal reengineering to treat cancer”; Dr. Valerie Lebleu, The University of Texas MD Anderson
Cancer Center, will speak on “Targeting vascular pericytes in hypoxic tumors increases lung metastasis
via angiopoietin-2”; and Dr. Johanna A. Joyce, Memorial Sloan Kettering Cancer Center, will speak on
“Exploring and exploiting the tumor microenvironment.” Come learn about these and other important
TME initiatives, meet members of the working group and steering committee, in addition to taking
advantage of the opportunity to join the TME Working Group. A networking reception will follow.
6:30 p.m.
Chairperson: Opening Remarks
Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, TX
6:45 p.m.
Chairperson-Elect: Remarks
Morag Park, Canadian Institutes of Health Research, Montréal, QC, Canada
7:00 p.m.
Stromal reengineering to treat cancer
Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, WA
7:20 p.m.
Targeting vascular pericytes in hypoxic tumors increases lung metastasis
via angiopoietin-2
Valerie LeBleu, The University of Texas MD Anderson Cancer Center, Houston, TX
7:40 p.m.
Exploring and exploiting the tumor microenvironment
Johanna A. Joyce, Memorial Sloan Kettering Cancer Center, New York, NY
8:00 p.m.
Closing Remarks
Morag Park, Canadian Institutes of Health Research, Montréal, QC, Canada
570

poster session - American Association for Cancer Research

Transcription

Similar documents

Leaving Cert Craft Exam-Poster Question By Ruth Graydon

poster packs - Oxford SA Blog

tumor marker`s

Exsanguination - Northern Health

AMPULLA OF VATER STAGING FORM

Johnny Tremain by Esther Forbes Objectives

Tumor Antigens and Cancer Vaccines

Analyzing Music Posters

Karaoke Contest Information

Evolutionary optimization in (deformable) registration of medical